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Abstract 
 
167 patients with the recessive repeat expansion disorder Friedreich’s ataxia (FRDA) 
were recruited as part of the European FRDA Consortium for Translational Studies 
(EFACTS) and underwent longitudinal clinical assessment including validated and 
standardized clinical and functional rating scales. The mean age at onset was 13.7±9.6 
years (range 1-55) and disease duration 20.5±11.2 years (range 3-55). The smaller 
repeat expansion (GAA1 size) correlated with age at onset, Activities of Daily Living 
(ADL), Scale for the Assessment and Rating of Ataxia (SARA), Inventory of Non-Ataxic 
Symptoms (INAS) count & Spinocerebellar Degeneration Functional Score (SDFS). 125 
patients were seen after 1 year, and 116 after 2 years. Disease progression could be 
measured using these rating scales: SARA increased over 2 years by 1.3±3.1, ADL by 
2.0±3.2 and SDFS by 0.3±0.6. There was no statistical difference in INAS count. A 
majority of patients could not complete the Spinocerebellar Ataxia Functional Index 
(SCAFI) which was deemed inappropriate in FRDA. Two novel FXN mutations were 
identified, as well as a probable macrodeletion. No compound heterozygous exonic 
deletions were found amongst 1768 cases referred with a possible diagnosis of FRDA, 
indicating that these deletions are extremely rare. 
Twenty-six patients with autosomal recessive spastic ataxia of Charlevoix-Saguenay 
(ARSACS) were recruited (mean age onset 15.0±17.4, range 0-51); mean disease 
duration 28.5±12.9, range 8-56). Loss of mobility, dysarthria, dysphagia, ataxia, sensory 
loss, square wave jerks and saccadic dysmetria were less common in ARSACS 
compared to FRDA; nystagmus, spasticity and hyperreflexia were more common. Nine 
novel SACS mutations were identified. Retinal Nerve Fibre Layer (RNFL) thickening on 
ocular coherence tomography (OCT) was found to be a specific (99.4%) and sensitive 
(100%) marker of ARSACS with positive predictive value of 94.4%, amongst 191 
patients with ataxia, using a cut-off thickness of 119μm. 
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Chapter 1 :  Friedreich’s Ataxia   
 
1.1 Introduction 
2013 marked the 150th anniversary of the seminal description by Nikolaus Friedreich of 
the ataxic syndrome which now bears his name (Friedreich 1863c, Friedreich 1863a, 
Friedreich 1863b). Since then, descriptions of its clinical phenotype have evolved and 
extended, but it was not until the 1970s and 1980s that systematic phenotypic 
descriptions allowed the development of reliable diagnostic clinical criteria (Geoffroy 
et al. 1976, Harding 1981) (see Table 1). However, these cases were not genetically 
proven. The discovery in 1996 of the genetic abnormality responsible for FRDA 
(Campuzano et al. 1996) allowed genotype-phenotype correlations, and expanded 
further the previously understood phenotypic spectrum. Since then, there have been 
few natural history studies performed on large, genetically confirmed series of patients 
with FRDA, which are so vital in illuminating underlying molecular mechanisms, in 
planning and directing interventional trials and in providing prognostic information for 
patients (see Table 2). 
The European Friedreich’s Ataxia Consortium for Translational Studies (EFACTS) was 
formed in 2010 with the intention of assembling a body of expertise in clinical 
neurology, biochemistry, molecular biology, genetics and bioinformatics which could 
apply a translational approach to the study of FRDA. Central to this objective was the 
recruitment of a large pan-European cohort of patients with genetically proven FRDA 
whose presentation and progression would be systematically and prospectively 
recorded, and who would form part of a patient registry linked to a repository of 
biological samples collected during the study which would enable patients’ 
participation in therapeutic trials and studies of fundamental pathological 
mechanisms. The UK contribution to this project forms the core of this thesis. This 
introductory chapter reviews the history and chronology of our developing 
understanding of this condition, describes current concepts of pathogenic mechanisms 
and summarizes current knowledge of its clinical features. 
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Table 1: Diagnostic criteria for FRDA 
 Geoffroy, et al. (1976) Harding (1981) 
Primary criteria (essential 
for diagnosis) 
 Onset before end of 
puberty and never 
after age 20 
 Ataxia of gait 
 Progression of ataxia 
within last 2 years to 
all extremities without 
remission 
 Dysarthria 
 Decreased position 
and/or vibration sense 
in lower limbs 
 Muscle weakness 
 Lower limb deep 
tendon areflexia 
 Onset before age 25 
 Progressive 
unremitting ataxia of 
limbs and gait 
 Absent knee and ankle 
jerks 
Secondary criteria  Extensor plantar 
responses 
 Pes cavus 
 Scoliosis 
 Cardiomyopathy 
 Dysarthria 
 Extensor plantar 
responses 
Additional criteria  Decrease in visual 
acuity 
 Nystagmus 
 Paresthesiae 
 Partial deafness 
 Essential type tremor 
 Vertigo 
 Spasticity 
 Pain 
 Decrease in IQ 
If secondary features not 
present, then must have : 
 An affected sibling 
with both secondary 
criteria ; or 
 Median motor nerve 
conduction velocities > 
40m/s 
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Table 2: Frequencies of clinical features in published cases series of FRDA 
 Geoffroy et 
al. 1976; 
Andermann 
et al 1976 
Harding 
1981 
Ackroyd et 
al. 1984 
Filla et al. 
1990 
Dürr et al. 
1996 
Schöls et al. 
1997 
Lamont et 
al. 1997 
Delatycki et 
al. 1999 
McCabe et 
al. 2000 
Origin Canada UK UK Italy France & 
Réunion 
Germany UK Australia Ireland 
Genetic diagnosis No No No No Yes Yes Yes Yes Yes 
No. of patients 36
b
 ; 58 115 12 80 140 38 56 51 58 
Male:female 1 : 2.0 1 : 1.2 1 : 1.0 1 : 0.7 1 : 1.1 1 : 1.4 - 1 : 0.8 - 
Age at onset (years)
a 
7.97±3.07 
10.52±7.4 
(1.7-27) 
5.8              
(3-9) 
11.6±4.5    
(2-23) 
15.5±8       
(2-51) 
14.15±5.03 
(5-36) 
(3-30) 
10.5±6.4    
(1-26) 
- 
Disease duration 
(years)
a 11.72±7.04 
22.00±12.76 
(2-61) 
4.7 (1-10) 13.4 15.5 
19.69±8.75 
(5-42) 
13.6±9.9    
(6-50) 
- - 
Age when 
wheelchair-bound 
(years)
a 
- 
25.14±15.5 
(11-58) 
- 
26.3±7.8  
(15-42) 
26.3 
23.98±5.66 
(15-44) 
- 
19.0±6.4    
(8-33) 
- 
Age at onset to age 
at wheelchair-bound  
(years)
a 
- 
15.51±7.41 
(3-44) 
- 13.8±5.8 
10.8±6       
(1-25) 
11.29±4.09 
(5-26) 
- 
10.1±4.4    
(1-20) 
- 
Wheelchair-bound 
(%) 
- 72 - 43 - 78 - 55 - 
Age at death 
(years)
a 
30.6±1.3 
(4.5-40) 
37.54±14.35 
(21-69) 
- 
13.5±3.5  
(10-17) 
- - - - - 
Gait ataxia (%)
c 
100 100 100 100 100 100 - 100 100 
Limb ataxia (%) - 99 100 94 99 100 100 100 - 
Dysarthria (%) 100 97 75 84 91 100 91 95 93 
Dysphagia (%) - - - 30 27 76 - - - 
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Nystagmus (%) 42 20 25 29 40 39 - - 40 
Broken pursuit eye 
movements (%) 
- 12 - - 30 - - - 52 
LL areflexia (%) 
 
100 99 100 100 87 84 87 98 86 
Extensor plantar 
responses (%) 
94 89 42 75 79 95 96 74 93 
Loss of vibration 
sense (%) 
- 73 67 91 78 83 87 88 89 
LL muscle weakness 
(%) 
100 88 92 80 67 69 - - 72 
UL amyotrophy (%) - 49 42 49 25 - - - 29 
LL amyotrophy (%) - 39 92 61 39 50 - - 67 
Scoliosis (%) 92 79 33 94 60 84 - 78 84 
Foot deformity (%)
d 
89 55 83 90 55 82 - 74 79 
Cardiomyopathy 
(%)
e 97 - 100 28 63 75 - 65 67 
Diabetes (%)
f
 19 10 - 14 32 6 - 8 7 
Sphincter 
disturbance (%) 
7 - - 18 23 12 - 41 - 
Hearing loss (%) 22 8 - 9 13 39 - -  
Visual loss (%) 50 18 - - 13 6 - - - 
a Expressed as mean±SD (range) 
b ‘Typical’ FRDA with complete or incomplete picture 
c Gait ataxia present or not testable due to weakness 
d Pes cavus, talipes equinovarus or other foot abnormality 
e Cardiomyopathy or left ventricular hypertrophy (definitions vary between papers) f Diabetes or 
impaired glucose tolerance (definitions vary between papers) 
- Not known or not recorded 
UL=upper limb ; LL=lower limb 
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1.2 History 
 
Figure 1: Nikolaus Friedreich (1825-1882) 
(Universitätsbibliothek Heidelberg, http://heidicon.ub.uni-heidelberg.de/id/33455) 
 
Nikolaus Friedreich was born in Würzburg on 31 July 1825, the son of Johannes Baptist 
Friedreich (1796-1862), Professor of Surgery in the Medical Faculty of the University of 
Würzburg, and grandson of Nikolaus Anton Friedreich (1761-1836), also Professor of 
Surgery at Würzburg, who had described idiopathic facial nerve paralysis in 1798 some 
23 years before Sir Charles Bell in a paper named De paralysis musculorum faciei 
rheumatica (Bird 1979). Nikolaus Friedreich (1825-1882; see Figure 1) began his 
medical studies in Würzburg in 1844 and graduated in 1850 completing a thesis on 
tumours within the skull (Beiträge zur Lehre von den Geschwülsten innerhalb der 
Schedelhöhle). He was strongly influenced by Rudolf Virchow (1821-1902) who worked 
in Würzburg from 1849 and whom Friedreich succeeded as Professor of Pathological 
Anatomy when Virchow returned to Berlin in 1856. Two years later, Friedreich was 
appointed chief of the medical clinic in Heidelberg where he took up the Chair of 
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Pathology and Therapy. His main interest was diseases of the nervous system. He 
remained in Heidelberg for the rest of his career, teaching such luminaries as Adolf 
Kussmaul (1822-1902) and Wilhelm Erb (1840-1921), the latter succeeding him as 
Professor of Pathology and Therapy in 1882 (Koehler 2000). 
The term ataxia meaning disorder, irregularity or confusion (ατάξις – lack of order) had 
been used since the time of Hippocrates in the description of disease as well as more 
generally but it was not until the nineteenth century that its present meaning of 
incoordination of neurological origin was adopted. Guillaume Duchenne de Boulogne 
(1806-1875) used the term ataxie locomotrice progressive to describe a distinct 
condition characterized by incoordination of movement. At the time, a wide variety of 
conditions causing functional impairment attracted the epithets ‘palsy’, ‘paralysis’ or 
‘paraplegia’ such as the ‘shaking palsy’ now known as Parkinson’s disease. Duchenne 
drew the distinction between true weakness found on testing individual muscle groups 
and the apparent weakness resulting from incoordination of movement (‘Abolition 
progressive de la coordination des mouvements et paralysie apparente, contrastant 
avec l’intégralité de la force musculaire’) (Duchenne 1858). 
Ataxic disorders remain to the present day defined by their principal symptom, but the 
term progressive locomotor ataxia was insufficiently linked to a single pathological 
entity and hence this appellation and the term Duchenne’s disease are no longer used. 
Indeed, by 1895, William Gowers commented in his Clinical Lectures at the National 
Hospital for the Paralysed and Epileptic, that the term was no longer considered 
accurate as, ‘The disease in a large number of cases is not progressive’ and ‘the term 
“locomotor ataxy” is itself somewhat redundant, because the disorder is one of 
movement in general, and not merely that which causes change of place.’ (Gowers 
1895). Cases of the locomotor ataxia described by Duchenne and extensively in the 
medical literature of the nineteenth century, were probably predominantly caused by 
tabes dorsalis (syphilitic myeloradiculopathy). It was not until the 1880s that the 
epidemiological link between syphilis and tabes was firmly established through the 
works of Jean-Alfred Fournier (1832-1914), Gowers and Erb, having previously been 
thought to be caused by a number of environmental and hereditary factors including 
excessive drinking and sexual activity. Fritz Schaudinn (1871-1906) and Erich Hoffman 
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(1868-1959) finally discovered the underlying infective agent of syphilis in 1905, 
describing it as Spirochaeta pallida, later known as Treponema pallidum (Goetz 1987, 
Nitrini 2000, Waugh 2005).  
Friedreich began his studies of ataxia in the 1850s. His critical observation was to 
realize that a subgroup of his patients were not suffering from Duchenne’s progressive 
locomotor ataxia, but from a hereditary form associated with early age at onset, long 
duration and absence of sensory loss in the early stages. He also felt there was a 
female predominance, although this was not borne out by subsequent studies. Other 
typical symptoms of tabes such as pupillary disorders (Argyll-Robertson pupils), 
shooting lancinating pains, joint disorders and onset in later life, were not present. He 
presented his initial findings at the meeting of the Society of German Natural Scientists 
and Physicians (Versammlung Deutscher Naturforscher und Ärzte) in Speyer close to 
Heidelberg, on the 18th September 1861. He subsequently published the cases of six 
named patients (Andreas and Charlotte Lotsch; Justine, Salome, Lisette and Friedrich 
Süss) from two families including three autopsies in a series of monographs in 1863 
(Friedreich 1863c, Friedreich 1863a, Friedreich 1863b): 
The clinical characters of the disease are impairment in the coordination and 
harmony of movements, developing gradually and spreading from the lower to 
the upper half of the body, and always involving finally the organs of speech; 
sensibility and the functions of the special senses, and of the brain, being 
intact…Less common phenomena are curvature of the spine, sensations of 
vertigo, and nystagmus. From a clinical point of view we must regard the 
disease as a progressive paralysis of the faculty of the combination of 
movements; from the point of view of pathological anatomy, as a chronic 
degenerative atrophy of the posterior columns of the cord.  
Die Affection ist klinisch ausgezeichnet durch eine, in sehr allmäligem Verlaufe 
sich entwickelnde, von der unteren auf die obere Körperhälfte forterstreckende, 
constant zuletzt auch die Sprachorgane betheiligende Störung in der 
Association und Harmonie der Bewegungen, bei ungestörter Sensibilität und bei 
vollständiger lntegrität der Sinnesorgane und cerebralen Functionen… Als 
weniger constante Erscheinungen sind Verkrümmungen der Wirbelsäule, 
Schwindelgefühle und Nystagmus zu nennen. Die Krankheit dürfte vom 
klinischen Gesichtspunkte aus als chronische progressive Lähmung der 
Combination der Bewegungen, vom pathologisch-anatomischen Standpunkte 
aus als chronische degenerative Atrophie der spinalen Hinterstränge zu 
bezeichnen sein (Friedreich 1863a). 
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His proposition that he had described a discreet nosological entity was disputed for 
many years.  Most authors, such as Wilhelm Erb (1840-1921), Adolph Strümpell (1853-
1925), Paul Topinard (1830-1911), Albert Eulenburg (1840-1917), Paul Julius 
Möbius (1853-1907) and Sigismond Jaccoud (1830-1913), felt that it represented a 
hereditary or juvenile form of tabes dorsalis. Jean-Martin Charcot (1825-1893) and 
Désiré-Magloire Bourneville (1840-1909) felt it was caused by multiple sclerosis (la 
sclerose en plaques disséminées) which Charcot and Alfred Vulpian (1826-1887) had 
described in 1868 (Keppel Hesselink 1986). Bourneville specifically re-examined two of 
Friedreich’s cases commenting about that of Justine Süss that: 
A careful reading of this observation easily proves that, from the clinical point 
of view, the picture is far from being completely that of progressive locomotor 
ataxia. The nature of the onset described is not that normally seen in ataxia, 
while it is much more in line with that of multiple sclerosis. The impairment of 
speech, the tremor of the head, the nystagmus, are morbid phenomena foreign 
to the classical type of ataxia. Finally, contrary to what takes place so 
frequently in this disease, cutaneous sensibility and vision, were not affected. 
La lecture attentive de cette observation prouve sans peine que, au point de vue 
clinique, le tableau est loin d'être complètement celui de l'ataxie locomotrice 
progressive. Le mode de début indiqué n'est pas celui qui se voit d'ordinaire 
dans l'ataxie, tandis qu'il est beaucoup plus conforme à celui de la sclérose en 
plaques. L'embarras de la parole, le tremblement de la tête, le nystagmus, sont 
des phénomènes morbides étrangers au type classique de l'ataxie. Enfin, 
contrairement à ce qui a lieu si fréquemment dans cette maladie, la sensibilité 
cutanée, la vision n'étaient point affectées (Bourneville & Guérard 1869). 
and of his sister Salome Süss that: 
The value of this result will not escape anyone. The reality of the sclerotic 
lesions, even though they escape the naked eye, confirming what we said in a 
previous chapter, has given a considerable contribution to the opinion we 
stated, namely the coexistence in this case, of progressive locomotor ataxia and 
multiple sclerosis. 
La valeur de ce résultat n'échappera à personne. La réalité des lésions 
scléreuses, alors qu'elles échappent à l'oeil nu, en confirmant ce que nous avons 
dit dans un chapitre précédent, vient donner un appoint considérable à l'opinion 
que nous avons émise, à savoir, la coexistence, dans ce cas, de l'ataxie 
locomotrice progressive et de la sclérose en plaques disséminées  (Bourneville & 
Guérard 1869). 
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In 1876 and 1877 Friedreich published the cases of three more sisters (Louise, 
Katharina and Marie Schulz) and further information on those previously described 
(Friedreich 1876, Friedreich 1877). In particular, he countered Bourneville’s and 
Charcot’s assertion that his cases represented mixed forms with multiples sclerosis and 
that Bourneville had not discussed his most characteristic case: 
Bourneville in fact says that the cases described by me were not pure ataxias 
but mixed forms with multiple sclerosis, and Charcot agrees with this opinion… 
Bourneville has reproduced in detail in his work, cases III and IV described by 
me (Justine and Salome Süss), while my case I (Andreas Lotsch), although it 
showed most clearly the clinical and anatomical features of posterior column 
degeneration, strangely remained unrecorded. Charcot thinks that the speech 
disturbance and the nystagmus observed in my cases are mainly symptoms 
characteristic of multiple sclerosis and, on the other hand, are not seen or only 
in exceptional cases in degeneration of the posterior columns, the evidence 
provided that the cases were not pure ataxias. I have no hesitation in 
recognizing the rarity of both symptoms mentioned in the common forms of 
ataxic tabes; but I must explain that I am firmly against the idea that this cannot 
also occur in pure and uncomplicated degeneration of the posterior columns, 
and in particular the hereditary forms of ataxia described by me are 
characterized by the existence of those symptoms in the common forms, as I 
emphasized repeatedly. 
 
Bourneville spricht sich nehmlich dahin aus, dass die von mir geschilderten Fälle 
keine reinen Ataxien, sondern Mischformen mit multipler Sclerose gewesen 
seien, und auch Charcot schliesst sich dieser Meinung an…. Bourneville hat in 
seiner Arbeit die von mir geschilderten Fälle III und IV (Justine und Salome Süss) 
ausführlich wiedergegeben, während mein Fall 1 (Andreas Lotsch), obgleich 
gerade bei diesem die klinischen und anatomischen Verhältnisse der 
Hinterstrangdegeneration am Reinsten hervortraten, sonderbarer Weise 
unberücksichtigt geblieben ist. Charcot meint, dass die in meinen Fällen 
beobachtete Störung der Sprachbewegungen und der Nystagmus, welche 
Symptome vorwiegend der multiloculären Sclerose eigenthümlich seien, 
dagegen nicht oder nur ausnahmsweise der Degeneration der Hinterstränge 
zukämen, den Beweis lieferten, dass dieselben nicht reine Ataxien gewesen 
seien. Ich nehme keinen Anstand, die Seltenheit der genannten beiden 
Symptome für die gewöhnlichen Formen atactischer Tabes anzuerkennen; allein 
ich muss mich eben so entschieden dagegen erklären, dass dieselben nicht auch 
bei reiner und uncomplicirter Degeneration der Hinterstränge vorkommen 
können, und gerade die von mir geschilderten Formen hereditärer Ataxie sind, 
wie ich dies wiederholt betonte, durch das Vorhandensein jener Symptome von 
den gewöhnlichen Formen ausgezeichnet (Friedreich 1876). 
 
He concluded: 
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I find it incomprehensible that anyone can still speak of multiple sclerosis, when 
I have given the results of 3 carefully made autopsies… I have not given up 
hope that Charcot in the vast record of observations at his disposal, would 
sooner or later have the opportunity of finding cases analogous to those 
described by me. 
 
(I)ch finde es für unbegreiflich, wie man Angesichts der von mir mitgetheilten 3 
Sectionsergebnisse von multipler Sclerose sprechen kann… (I)ch gebe die 
Hoffnung nicht auf, dass Charcot bei dem ihm zu Gebote stehenden grossen 
Beobachtungsmateriale früher oder später einmal analoge Fälle, wie die von 
mir beschriebenen, zu sehen Gelegenheit finden werde (Friedreich 1876). 
It was not until 1882 however that the French neurologist Auguste Brousse working in 
Montpellier definitively acknowledged Friedreich’s hereditary ataxia as a distinct 
nosological entity for which he proposed the term ‘la maladie de Friedreich.’ (Brousse 
1882):   
The disease studied by Friedreich under the name hereditary ataxia, is a 
specific disease with an aetiology, symptomatology and pathological anatomy 
of its own ... As for the term hereditary ataxia, it seems quite inappropriate, 
given the nature of the disease. We would prefer FRIEDREICH’S DISEASE, as we 
should give the name Duchenne’s disease to classic progressive locomotor 
ataxia. 
La maladie étudiée par Friedreich sous le nom d’ataxie héréditaire est une 
maladie spéciale ayant une étiologie, une symptomatologie et une anatomie 
pathologique propres…Quant au terme d’ataxie héréditaire, il nous paraît assez 
impropre, étant donné la nature spéciale de la maladie. Nous préférerions celui 
de MALADIE DE FRIEDREICH, de même qu’on devrait donner le nom de Maladie 
de Duchenne à l’ataxie locomotrice progressive classique (Brousse 1882). 
He summarized the 31 cases in the literature he felt represented cases of Friedreich’s 
disease and added a further case with autopsy findings, a 32-year old domestic maid 
named Marie R employed by a baker to deliver bread. Onset was eight years before, 
when she noticed her legs became progressively weaker and less coordinated and her 
gait more hesitant. After four years, she could not walk. 
Brousse defined the disease’s origin as being in childhood or adolescence under direct 
or indirect genetic influence with the sexes affected equally. Symptomatically, it was 
characterized by ataxia of all four limbs, beginning in the lower limbs and progressing 
until it caused almost complete functional loss of power. Speech was affected but 
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sensory loss occurred only later. The progression was slow and long but was inevitably 
fatal with death occurring because of intercurrent illness: 
Au point de vue symptomatique, par l'ataxie des quatre membres, débutant par 
les membres inférieurs et se généralisant ensuite au point de réduire les 
malades à une impotence fonctionnelle à peu près absolue, par l'embarras delà 
parole, par l'absence ou l'apparition tardive des troubles de sensibilité ,par 
l'absence de troubles trophiques et la conservation de la tonicité des sphincters, 
par une marche lente et constamment progressive, par une durée très longue, 
enfin par une terminaison toujours fatale se produisant le plus souvent par une 
maladie intercurrente (Brousse 1882) 
 
Pathologically, it was characterized by degeneration of the posterior columns up to the 
bulbar region with more diffuse degeneration in the lateral and anterior columns. He 
underlined the importance of distinguishing it from progressive locomotor ataxia, 
multiple sclerosis and other forms of ataxia (‘elle doit être distinguée de l'ataxie 
locomotrice progressive, de la sclérose en plaques disséminées’). 
The term Friedreich’s disease quickly caught on with Charles Féré later that year using 
the term ‘la maladie de Friedreich’ to describe the by that time 48 cases appearing in 
the literature consistent with Friedreich’s original description (Féré 1882). Over the 
next few years, the term appeared in the German, British, French, Italian, American 
and Russian literature (Bury 1886). Significantly, Charcot presented a young patient at 
the Salpêtrière in 1884 with a hereditary ataxia which he realized was not caused by 
multiple sclerosis or tabes dorsalis (Goetz 1987, Keppel Hesselink 1986). He 
subsequently presented several cases at length (Charcot 1888).  
Freidreich died on 6 July 1882 at the age of 57 of a ruptured thoracic aortic aneurysm. 
The British Medical Journal published an editorial the following March, commenting: 
It is just twenty years since Professor Friedreich, whose recent death has 
deprived the University of Heidelberg of one of its greatest ornaments, first 
drew attention to a peculiar form of degenerative atrophy of the posterior 
columns of the spinal cord, to which he and others after him have applied the 
name “hereditary ataxy” (Anon 1883). 
They, like others, favoured the term Friedreich’s disease over hereditary ataxia as the 
cases were typically familial rather than hereditary. This concept must have been 
difficult to disentangle before there was a full understanding of genetics or the 
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infective aetiology of tabes dorsalis given that syphilis can be transmitted vertically 
whereas Friedreich’s ataxia  rarely appears in consecutive generations. 
Further case series appeared with Dr Everett Smith of Framingham, Massechusetts 
identifying 57 cases including six of his own in 1885 (Smith 1885). Gowers described 65 
cases from 19 families in his famous Manual of Diseases of the Nervous System in 1886 
(Gowers 1886). Kinnier Wilson in his textbook of neurology describes 73 cases of 
Friedreich’s disease from 15,923 admissions to the National Hospital between 1909 
and 1925 (Wilson 1940). Although Friedreich described thickening of the left 
ventricular wall and fatty degeneration of the heart tissue in his original cases, and 
sporadic reports of cardiac involvement and ECG changes in Friedreich’s ataxia 
appeared in the first half of the twentieth century, Loiseau is accredited with bringing 
these reports together systematically in 1938 (Loiseau 1938). The occurrence of 
diabetes was clearly linked with FRDA for the first time by Thorén in 1962 in his 
description of a cohort of 50 patients (Thorén 1962). The presence of neurological and 
non-neurological manifestations in FRDA made this condition a truly multisystem 
disorder. The causative gene was mapped to chromosome 9p22 in 1988 (Chamberlain 
et al. 1988) and fully elucidated in 1996 (Campuzano et al. 1996). 
1.3 Genetics & Pathology 
FRDA is now recognized as the commonest hereditary form of ataxia, caused by an 
autosomally recessively inherited unstable GAA expansion situated in intron 1 of the 
FXN gene on the proximal long arm of chromosome 9. This causes decreased 
production of frataxin (see Figure 2), probably through transcriptional silencing 
because of heterochromatin formation. Frataxin is a mitochondrial protein essential 
for life but whose function is not fully understood. It is thought to be important in the 
biogenesis of iron-sulphur clusters which, amongst other roles, act as cofactors in the 
mitochondrial respiratory chain. Iron-sulphur-cluster-containing enzymes include 
aconitase and mitochondrial complexes I to III (Martelli et al. 2012, Lill 2009). A small 
minority of cases (about 4%) carry a compound heterozygous GAA expansion with a 
point mutation or large deletion in the FXN gene (Campuzano et al. 1996, Cossée et al. 
1999, Gellera et al. 2007). No homozygous point mutations or deletions have hitherto 
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been described. The molecular biology of frataxin and the clinical and genetic nature of 
compound heterozygotes with point mutations or large deletions are discussed more 
extensively in Chapter 3. 
 
Figure 2: Schematic representation of GAA expansion in FXN intron 1 causing 
decreased frataxin production.  
From (Gatchel & Zoghbi 2005) 
The prevalence of the condition has been estimated in a variety of Western European 
populations at between 1:20,000 and 1:125,000 (Filla et al. 1992). Carrier frequency is 
estimated at between 1:60 and 1:110 (Epplen et al. 1997, Cossée et al. 1997, Harding 
& Zilkha 1981). The GAA expansion appears only to exist in individuals of European, 
North African, Middle-Eastern or Indian origin and is not described in those of Sub-
Saharan African, Amerindian or East Asian origin (Labuda et al. 2000). Male to female 
distribution is equal. Families usually consist of an isolated individual or multiple 
siblings, although pseudo-dominance has been described (Harding & Zilkha 1981). 
Heterozygous carriers of the GAA expansion without any other abnormality of the FXN 
gene are not thought to be clinically affected (Harding 1981, Andermann et al. 1976) 
although they are known to produce significantly less frataxin than normal controls 
(Willis et al. 2008, Deutsch et al. 2010, Saccà et al. 2011).  
The clinical phenotype of FRDA is thought to be largely determined by the effect of the 
GAA repeat expansion on gene transcription. The expansion size has been shown to be 
inversely correlated with age at onset and confinement to wheelchair, and positively 
correlated with the incidence of cardiomyopathy (Dürr et al. 1996, Filla et al. 1996, 
Montermini et al. 1997). The closest genotype-phenotype relationship is with the 
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smaller of the two alleles (GAA1), probably because large expansions produce very 
little frataxin, and so the smaller expansion produces the majority of the frataxin. The 
size of the smaller expansion therefore has a much greater influence over the total 
amount of frataxin produced and therefore over clinical severity. GAA1 size has been 
correlated with both frataxin mRNA (Pianese et al. 2004) and protein levels 
(Campuzano et al. 1997), with expansions of approximately 800 to 1000 GAA repeats 
producing approximately 10% of the normal amount of frataxin mRNA, whereas 
expansions of approximately 400 repeats produce approximately 40% of normal 
(Pianese et al. 2004). Exceptionally small or large GAA repeat sizes and compound 
heterozygotes with point mutations are responsible for most atypical presentations.  
The smallest symptomatic non-interrupted GAA1 expansion so far described involved 
44 repeats, whereas normal chromosomes have fewer than 33 repeats (Pandolfo 
2001). Patients with FRDA usually have between 70 and 1500 repeats, most commonly 
600 to 900 (Pandolfo 2001). Late-onset atypical FRDA phenotypes commonly have 
between 100 and 500 repeats in GAA1, comparable to the smaller of the two alleles in 
classical FRDA (Schöls et al. 1997, Dürr et al. 1996, Bhidayasiri et al. 2005). Compound 
heterozygotes with a missense mutation on one allele located near the amino end of 
the carboxy-terminal domain of frataxin may also result in an atypically mild FRDA 
phenotype (Cossée et al. 1999, Bhidayasiri et al. 2005). 
Marked variability in symptoms between individuals and within families is seen in 
FRDA related to intergenerational instability of the GAA expansion (Monros et al. 
1997). It is estimated than GAA expansion size accounts for approximately 50% of the 
variability in age at onset (Filla et al. 1996). Other contributory factors may include 
somatic mosaicism, interruptions in the repeat sequence, changes in expansion size 
over life and other modifying genes or environmental factors (Pandolfo & Pastore 
2009). Of note, almost all human studies measure white cell GAA expansion size which 
is a tissue not affected clinically in FRDA. 
Friedreich published detailed pathological descriptions of the spinal cord, dorsal spinal 
roots and medulla in his paper of 1877 (Friedreich 1877). Although he recognized that 
the dorsal root ganglia nerve fibres were abnormally thin, he placed more emphasis on 
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the degeneration of the spinal cord as well as the medulla oblongata and hypoglossal 
nuclei (Koeppen & Mazurkiewicz 2013) (see Figure 3). Modern analysis shows that 
macroscopically, the dorsal columns and dorsal root ganglia (DRG) are thin and grey, 
with reduced calibre of the spinal cord at all levels, particularly in the thoracic region 
where the transverse diameter is often less than 10mm (Koeppen 2011). There is loss 
of myelin and axons in the dorsal columns, as well as the spinocerebellar and 
corticospinal tracts. In the DRG, ganglion cell size is reduced and very large neurones 
are absent leaving behind residual nodules of Nageotte comprising degenerating 
neurones surrounded by an abnormally thickened rim of satellite cells. These show 
increased immunoreactivity for the iron storage and transporter proteins ferritin and 
ferroportin, supporting the idea that cellular iron excess may be significant in the 
pathology of FRDA. Axonal density is unchanged in the DRG but there is a decrease in 
large myelinated fibres (Koeppen et al. 2009). Peripheral sensory nerves show loss of 
myelinated fibres and a shift to thinner axons (Morral et al. 2010). In the cerebellum, 
atrophy of the dentate nucleus and its efferent fibres is seen with relatively preserved 
cerebellar cortex and white matter. Microscopically, there is grumose degeneration 
and loss of large neurones, particularly with γ-aminobutyric acid (GABA)-containing 
terminals implying impaired corticonuclear connections (Koeppen 2011).  
 
Figure 3: Serial cross sections of the spinal cord from rostral (a) to caudal (g) with the 
dorsal columns shown inferiorly.  
Friedreich commented that ‘Das ganze Rückenmark ist dünner und schmächtiger’ : the 
whole spinal cord is thin and slight (Friedreich 1877) 
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1.4 Clinical Features 
1.4.1 Neurological Features 
Typical age at symptom onset is around or before puberty with large case series 
showing mean age at onset of 10.5±7.4 years (Harding 1981), 11.6±4.5 years (Filla et 
al. 1990) and 15.5±8 years (Dürr et al. 1996). Harding showed modal age at onset of 
10-12 years and Filla et al. (1990) 12-15 years. Age at symptom onset is always studied 
retrospectively and as such may be subject to significant variability in recall. Earlier 
non-genetic studies may also be skewed to earlier age at onset because of the use of 
clinical criteria requiring early age at onset. Gait ataxia and general clumsiness are the 
commonest presenting symptoms (Harding 1981, Filla et al. 1990, Dürr et al. 1996, 
Delatycki et al. 1999). A small proportion of patients present via orthopaedic clinics 
with scoliosis in which additional neurological signs may have been observed.  
Gait and limb ataxia, dysarthria and lower limb (LL) areflexia are found in almost all 
cases, although early cases series may have overestimated their frequency because 
they were required clinical features in the pre-genetic diagnostic criteria (see Table 2). 
The ataxia is of mixed origin, resulting from spinocerebellar degeneration, peripheral 
sensory neuropathy, cerebellar and vestibular pathology (Delatycki & Corben 2012). 
Pyramidal involvement later adds to the disability.  
Gait becomes unsteady and ataxic with increasing falls. Walking on uneven terrain or 
in poor light becomes problematical. Difficulty with tandem standing and walking is an 
early sign. Many patients in retrospect describe a long history of clumsiness, trips or 
inability to participate in sports. There is increasing dependence on aids to walking, 
initially furniture, walls and other people, and ultimately sticks, crutches and wheeled 
walkers. Harding (1981) found the mean age from symptom onset to dependence on 
wheelchair was 15.5 years (range 3-44). Truncal ataxia results in swaying on sitting and 
may necessitate back support. Romberg’s test becomes positive or there may be 
difficulty early in disease progression with standing in tandem. Limb ataxia causes 
increasing difficulty with daily activities which require fine manual dexterity, and is an 
early feature of the disease. This causes difficulty with handwriting, washing, dressing, 
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use of cutlery and carrying drinks or food. Progression of weakness may mask ataxia as 
a clinical sign. 
Pyramidal weakness is a relatively late sign and is much more prominent in the lower 
limbs compared to the upper limbs (ULs) : indeed, patients often have very well 
preserved UL power even when wheelchair-bound and profoundly disabled, and may 
only ever develop mild distal UL weakness. However, this can contribute significantly 
to difficulties with fine manual dexterity. Progression of weakness also may mask 
ataxia as a clinical sign. Wasting is noted in a significant proportion of cases although in 
patients who develop the disease in early life, muscle bulk may never be fully 
developed without significant loss thereafter (Harding 1981, Filla et al. 1990, Dürr et al. 
1996).  
Areflexia, particularly of the LLs, is an early sign present in almost all patients and 
reflects the underlying peripheral neuropathy. Extensor plantar reactions, reflecting 
pyramidal pathology, are a relatively early sign present in 73-89% of cases (Harding 
1981, Dürr et al. 1996, Delatycki et al. 1999). Muscle tone is typically normal or 
reduced, particularly in the early stages of the disease. Spasticity, particularly in the 
lower limbs, can become a significant management problem in the advanced stages of 
the disease, especially in wheelchair-bound patients. It can cause pain, discomfort, 
positioning problems and ultimately contractures if left untreated. It can be associated 
with muscle cramps and spasms, which can often keep patients awake at night.  
Distal sensory loss is virtually universal, with the dorsal column modalities of vibration 
and joint position sense preferentially lost, contributing to the sensory ataxia (Harding 
1981, Dürr et al. 1996, Schöls et al. 1997, Delatycki et al. 1999). Neurophysiological 
studies show a severe axonal neuropathy with severely reduced or absent sensory 
action potentials (SAPs) which do not appear to change significantly over time. 
Peripheral nerve biopsy shows an increase in proportion of large myelinated fibres. 
Both of these findings correlate with GAA expansion size (Santoro et al. 1999). It is 
thought that the sensory neuropathy in FRDA results from a combination of inefficient 
myelination and superimposed slowly progressive axonopathy (Koeppen & 
Mazurkiewicz 2013, Morral et al. 2010). 
42 
 
Abnormalities of eye movement are a common early sign in FRDA. Probably the 
commonest feature is fixation instability interrupted by involuntary saccades, or 
square wave jerks (SWJs), which can occur in primary position, horizontal or vertical 
fixation (Furman et al. 1983, Fahey et al. 2008, Schöls et al. 1997). Square wave jerks 
can also interrupt smooth pursuit movements and be so prominent that they inhibit 
assessment of smooth pursuit and nystagmus. Nystagmus is less common but still 
frequent. It is typically horizontal gaze-evoked nystagmus on lateral gaze, and less 
commonly on vertical gaze (Harding 1981, Dürr et al. 1996, Schöls et al. 1997). Despite 
these commonly observed abnormalities, patients are usually only troubled by 
transient ‘focusing’ difficulties on gaze deviation. Fahey et al. (2008) found only 20% of 
patients had symptomatic oscillopsia.  
Smooth pursuit movements typically have normal or only slightly reduced velocity, but 
are commonly interrupted by saccadic intrusions (Harding 1981, Dürr et al. 1996). 
Saccadic velocities are often normal but dysmetria is very common, often with a mix of 
hypo- and hyper-metria (Furman et al. 1983). Fahey et al. (2008) estimated that 54% of 
saccades were accurate to within 10% of the saccadic amplitude, 37% were 
hypermetric and 9% were hypometric. Ptosis is found in a small but significant 
proportion of cases, perhaps 5-10% (Filla et al. 1990, Schöls et al. 1997, Arnold et al. 
2006). 
Decreased visual acuity is less commonly seen than eye movement abnormalities and 
the majority of patients are asymptomatic. Approximately 20% of patients have 
decreased visual acuity (Harding 1981, Dürr et al. 1996, Fortuna et al. 2009) including 
occasional patients who have sudden bilateral loss of vision, mimicking Leber’s 
hereditary optic atrophy. 30% of patients have disc pallor visible on fundoscopy 
(Harding 1981). In symptomatic patients, field loss may show generalized concentric 
field loss, concentric superior-inferior arcuate defects or isolated paracentral field loss. 
Despite the lack of symptoms, all patients show reduced retinal nerve fibre layer 
thickness throughout all four quadrants on optical coherence tomography (Fortuna et 
al. 2009). Pattern visual-evoked potentials show increased latency in 34-70% of 
patients (Carroll et al. 1980, Dürr et al. 1996, Fortuna et al. 2009). Apparent diffusion 
coefficients on diffusion-weighted magnetic resonance imaging of the optic radiations 
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were significantly higher than controls (Fortuna et al. 2009). Taken together, these 
findings suggest that the entirety of the visual system is involved in FRDA, although a 
minority of patients are clinically affected. 
Dysarthria is a common and early sign present in more than 90% of individuals which 
progresses with disease duration. Speech becomes slow and slurred, impairing 
intelligibility in advanced cases. A study of 38 individuals with FRDA showed that 68% 
had mild dysarthria characterized by consonant imprecision, decreased pitch variation, 
impaired loudness maintenance, reduced phrase length, hypernasality and impaired 
breath support for speech (Folker et al. 2010). Cluster analysis revealed two further 
subgroups with increased laryngeal dysfunction (13%) and increased velopharyngeal 
involvement (11%).  
Mild dysphagia is also a common symptom and can become problematical in advanced 
disease, occasionally requiring percutaneous endoscopic gastro-oesophageal tube 
insertion. Patients may cough or choke on solids or liquids including saliva. Dry dusty 
foods, small particulate foods such as peanuts or fruits which produce large amounts 
of juice on chewing are particularly difficult. Chewing may also be compromised 
requiring avoidance of tough foods or cutting of food into small pieces. Estimates of 
dysphagia frequency vary between 27 and 74% (Filla et al. 1990, Dürr et al. 1996, 
Schöls et al. 1997).  
Hearing difficulties due to auditory neuropathy are a common and understated 
problem which can be very socially disabling even in the early stages of disease. 
Reported prevalences of hearing loss in case series vary widely from 8 to 39% 
(Geoffroy et al. 1976, Harding 1981, Dürr et al. 1996, Schöls et al. 1997) with Harding 
(1981) finding mild deafness in 5.2%, moderate in 1.7% and severe in 0.9%. Sound 
perception, as measured by hearing thresholds across audiometric frequencies in a 
quiet room (250-8000Hz) is typically normal in FRDA (Rance et al. 2008) or there may 
be minor deficiencies at different frequencies (Satya-Murti et al. 1980, López-Díaz-de-
Leóna et al. 2003). However, almost all patients show disordered neural conduction in 
the central auditory pathways which functionally results in impaired speech 
understanding in conditions of background noise typical of everyday listening 
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conditions. This can lead patients to be able to access only 50% of information 
available compared to unaffected individuals (Rance et al. 2010). Peripheral auditory 
(outer and middle ear) function is generally unaffected, as shown by normal 
tympanometry and equal air and bone conduction in pure tone audiometry (Satya-
Murti et al. 1980). Pre-neural cochlear responses, such as oto-acoustic emissions, are 
also normal (López-Díaz-de-Leóna et al. 2003). However, retrocochlear and brainstem 
responses, such as acoustic reflexes, synthetic sentence identification with ipsilateral 
competing message and brainstem-evoked auditory potentials, are abnormal (Satya-
Murti et al. 1980, Jabbari et al. 1983, López-Díaz-de-Leóna et al. 2003). In particular, 
there appears to be impairment of temporal resolution of complex acoustic signals as 
shown by temporal discrepancies between oto-acoustic emissions, cochlear 
microphonics and brainstem-evoked auditory potentials (Rance et al. 2008). Such 
auditory neuropathy dys-synchrony grossly impairs the ability to perceive rapidly 
changing auditory signals which is vital for phoneme discrimination and so speech 
perception.  
Sphincter disturbance is poorly studied in FRDA but its prevalence is said to range from 
7 to 41% in case series (Andermann et al. 1976, Filla et al. 1990, Dürr et al. 1996, Schöls 
et al. 1997, Delatycki et al. 1999). Urinary urgency with secondary urinary incontinence 
is the commonest problem encountered, with urodynamic studies showing uninhibited 
contractions and altered bladder capacity (Vezina et al. 1982, Nardulli et al. 1992). 
Such symptoms of bladder hyperactivity are common in FRDA and are functionally 
exacerbated by mobility and transfer problems; however, suprapubic or transurethral 
catheterization is rarely required. Bowel problems have not been systematically 
studied in FRDA but are generally less troublesome than urinary problems. 
Although ‘decrease in I.Q.’ was specifically mentioned in the first clinical criteria for 
FRDA (Geoffroy et al. 1976), most early studies concluded that cognition was not 
affected other than slowed information processing (Corben et al. 2006). Assessment of 
cognitive function can be significantly hampered by motor, speech and auditory 
impairments influencing reaction times, fluency and comprehension. Clinicians’ 
general experience is that cognitive deficits do not impede participation in education, 
employment or social activities. Mantovan showed impairments in tasks related to 
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visuoconstructive and visuoperceptual capacity, verbal fluency and motor and mental 
reaction times (Mantovan et al. 2006). The intelligence proﬁle of FRDA patients was 
characterized by concrete thinking and poor capacity in concept formation and 
visuospatial reasoning. De Nóbrega found that patients with FRDA performed 
significantly worse in tests of phonemic and action fluency but not semantic fluency, 
when compared to controls (De Nóbrega et al. 2007). They postulated that this might 
represent primary prefrontal or cerebello-prefrontal dysfunction. More recent studies 
provide evidence in the growing field of cerebellar cognitive function and suggest that 
interruptions of the cerebro-cerebellar circuits may be functionally important in FRDA 
(Corben et al. 2010, Corben et al. 2011a, Corben et al. 2011b, Corben et al. 2011c, 
Klopper et al. 2011, Neito et al. 2012). 
A variety of other features have been reported in the presence of FRDA although not 
necessarily related. As with all chronic disorders, depression is more prevalent than in 
the unaffected population. Flood and Perlman found that 92% of patients with FRDA 
showed an affective disorder ranging from mild mood disturbances to major 
depression (8%) (Flood & Perlman 1987). Epstein and colleugues found the Modified 
Fatigue Impact Scale was significantly worse in FRDA patients than controls. This can 
be a significant problem in some patients which often limits attempts at rehabilitation 
or ongoing exercises to maintain physical function (Epstein et al. 2008). Autonomic 
changes have gained little attention in the literature. Of these, a particularly 
troublesome and intractable symptom for a large number of patients is vasomotor 
disturbance, especially cold feet. Filla found vasomotor disturbance or hyperhydrosis 
of the extremities in 48% of patients (Filla et al. 1990).  
1.4.2 Non-Neurological Features 
Evidence of cardiac complications is found if sought in probably the majority of cases 
of FRDA although the patients are very often asymptomatic. Palpitations are 
sometimes reported but overt symptoms of heart failure are uncommon. It is rare for 
cardiomyopathy to develop before neurological features, and even if the patient is 
initially referred to a cardiologist, on detailed history or examination, neurological 
features are usually found which preceded the cardiac complications. Ischaemic heart 
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disease is also rare.  In large cases series, hypertrophic cardiomyopathy or evidence of 
left ventricular hypertrophy (LVH) was found in 28-100% (Geoffroy et al. 1976, Ackroyd 
et al. 1984, Filla et al. 1990, Dürr et al. 1996, Schöls et al. 1997, Delatycki et al. 1999, 
McCabe et al. 2000) although definitions vary widely between studies. Asymmetric 
septal hypertrophy or dilated cardiomyopathy is less commonly seen and may 
represent progression from hypertrophic cardiomyopathy (Casazza & Morpurgo 1996). 
Blood pressure is typically normal or low, and hypertension is rarely a problem. 
Absence of correlation between the presence of cardiac complications and severity of 
neurological involvement has been reported (Weidemann et al. 2012). The disjunction 
between cardiac and neurological features may result from tissue-specific somatic 
instability and mosaicism of the GAA expansion.   
The electrocardiogram (ECG) is abnormal in almost all cases, the commonest anomaly 
being inferolateral or widespread T-wave inversion. Other non-specific ST segment and 
T-wave abnormalities, including ST-segment depression or elevation and flattening of T 
waves, are also seen (Dutka et al. 1999, Schadt et al. 2012). ECG evidence of LVH is 
seen less frequently and if present is usually accompanied by echocardiographic 
evidence of LVH.  QRS axis deviation is variable but most commonly to the right (Dutka 
et al. 1999, Weidemann et al. 2012, Kipps et al. 2008, Schadt et al. 2012). Conduction 
abnormalities are very rare (Weidemann et al. 2012, Schadt et al. 2012). Sinus rhythm 
or sinus tachycardia is usually found, although patients may be troubled with 
paroxysmal or sustained arrhythmias, particularly atrial fibrillation, and only rarely 
require pacemaker or defibrillator insertion (Bourke & Keane 2011).  
Echocardiographic studies again show very variable results between patients. LVH is 
usually seen which is most commonly concentric but can show asymmetric septal 
hypertrophy (Dutka et al. 1999). There is impaired systolic function but with relatively 
preserved ejection fraction. In a longitudinal study including 113 echocardiograms in 
children, median ejection fraction was 61% (Kipps et al. 2008). Systolic function shows 
a slow non-linear decline with ejection fraction decreasing more rapidly with 
increasing age (Kipps et al. 2008, Regner et al. 2012).The cardiac valves are generally 
normal but hypertrophied papillary muscle may be seen (Dutka et al. 1999). In a large 
study of 204 patients with FRDA, 140 (69%) had evidence of cardiomyopathy, of which 
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58.5% were classified as mild, 23.5% intermediate and 18% severe. The mean 
interventricular septal thickness at diastole across these groups was 12.0mm, whilst 
left ventricular posterior wall thickness at diastole was 10.8mm and ejection fraction 
63.2% (Weidemann et al. 2012). A study of 173 patients showed evidence of diastolic 
dysfunction in 84% of cases with pseudonormalization and impaired relaxation being 
the commonest descriptions (Regner et al. 2012). Cardiac magnetic resonance imaging 
studies have broadly confirmed the echocardiographic studies (Weidemann et al. 
2012, Meyer et al. 2007) with increased left ventricular mass seen in FRDA, especially 
with short disease duration and greater GAA size. There seems to be a tendency to left 
ventricular thinning with longer disease duration (Rajagopalan et al. 2010). 
The association between FRDA and diabetes mellitus, although suspected for many 
years, was only confirmed relatively late (Thorén 1962, Hewer & Robinson 1968). The 
mechanism of this is unclear but may relate to a combination of both insulin resistance 
of peripheral tissues such as muscle, and also decreased insulin secretion resulting 
from pancreatic beta cell dysfunction (Finocchiaro et al. 1988). These abnormalities in 
turn are likely to result from mitochondrial dysfunction. There does not appear to be 
an underlying immune pathology driving these changes (Schoenle et al. 1989). There is 
some evidence that heterozygous carriers of the GAA expansion in the frataxin gene 
may have increased incidence of insulin resistance (Fantus et al. 1991, Hebinck et al. 
2000). In case series, diabetes mellitus was found in 6-19% of cases (Andermann et al. 
1976, Harding 1981, Filla et al. 1990, Schöls et al. 1997, Delatycki et al. 1999, McCabe 
et al. 2000).  
Scoliosis is common although may be mild and not require surgery especially if disease 
onset is relatively late. Scoliosis is a relatively common initial presentation of FRDA 
particularly when there is poor recovery from scoliosis surgery requiring prolonged 
rehabilitation, or the presence of subtle neurological signs at or after surgery, both of 
which may warrant further neurological investigations which uncover the underlying 
diagnosis. Labelle and coworkers found scoliosis of more than 10 degrees in 100% of 
patients and hyperkyphosis in 66% (Labelle et al. 1986). Most cases showed double 
thoracic and lumbar curves. Of those that were followed up long-term, roughly equal 
numbers progressed or were non-progressive. Milbrandt and colleagues in a series of 
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77 patients found that 63% had scoliosis and 24.5% hyperkyphosis. 33% had a double 
major curve (Milbrandt et al. 2008). 20% were treated with braces and 33% underwent 
spinal fusion. In other case series, 33 to 94% of patients had scolioisis, most series 
finding a prevalence of more than 75% (Geoffroy et al. 1976, Harding 1981, Ackroyd et 
al. 1984, Filla et al. 1990, Dürr et al. 1996, Schöls et al. 1997, Delatycki et al. 1999, 
McCabe et al. 2000).  
Foot abnormalities are common. Case series show foot deformities in 55 to 90% of 
cases (Geoffroy et al. 1976, Harding 1981, Ackroyd et al. 1984, Filla et al. 1990, Dürr et 
al. 1996, Schöls et al. 1997, Delatycki et al. 1999, McCabe et al. 2000). Friedreich 
observed that both pes cavus and talipes equinovarus occur, either singly or in 
combination. Although more recent literature has concentrated on pes cavus, talipes 
equinovarus is probably more common. Pes planus is sometimes also seen (Harding 
1984). Talipes equinovarus is a progressive condition found in advanced disease and 
can be very disabling to mobility, transfers and seating. If the patient is still ambulant, 
it can prevent proper placement of the foot on the floor and so contribute to instability 
and requirement for walking aids or orthotic devices. If the patient is wheelchair-
bound, it can impede positioning and transfers (Delatycki et al. 2005). It can therefore 
increase carer demand and affect independence and quality of life.  
1.4.3 Progression and Mortality 
There is no accepted measure of progression in FRDA and a variety of rating scales and 
performance measures have been employed which include combinations of 
neurological and other parameters, or more specific measures of particular signs or 
symptoms. At a more basic level, Harding found that 72% of patients in her series were 
wheelchair-bound (Harding 1981). The mean duration from age at onset to age at 
wheelchair-bound was 15.5 years (range 3-44) which represented a mean age of 25 
(range 11-58). The distribution of age at wheelchair-bound was not parametric with a 
prolonged upper tail. Half of cases were wheelchair-bound 16 years after onset of 
symptoms (age 26 years) and 95% 23 years after onset (age 44). Various clinical 
parameters progressed at different rates, with dysarthria present in 100% of cases by 
10-15 years since onset, LL pyramidal weakness by 25-30 years since onset and distal 
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UL wasting and loss of vibrational and joint position sense by 45-50 years since onset. 
Schöls and coworkers found the mean time from onset to wheelchair-bound to be 11 
years (range 5-26) representing a mean age of 24 (range 15-44) (Schöls et al. 1997). 
Mean age at onset of dysarthria was 20.8 years in a group whose mean age at onset of 
any symptom was 14.2 years. These measures correlated with the length of the 
shorter GAA expansion. Mean age at onset of UL ataxia was 19.8 years. De Michele 
and colleagues found the median time to loss of independent gait was 8 years (range 
2-25), and to wheelchair-bound 15 years (range 6-29) (De Michele et al. 1996). 
Symptom onset before 20 years of age and the presence of LVH, predicted increased 
rate of progression. 17% developed diabetes with a median time from symptom onset 
of 16 years (range 4-27) corresponding to a median age of 29 (range 9-42). 
Fahey and colleagues studied different rating scales to determine which best captured 
disease progression in FRDA (Fahey et al. 2007), comparing the Friedreich’s Ataxia 
Rating Scale (FARS) (Subramony et al. 2005), the International Co-operative Ataxia 
Rating Scale (ICARS) (Trouillas et al. 1997) and other less specific measures. They found 
a mean change of 9.5 points in the FARS and 5 points in the ICARS over 12 months. 
They suggested the FARS required fewer patients for an equivalently powered study, 
although the ICARS requires less time to administer (Schulz et al. 2009). Friedman and 
coworkers studied 236 patients with FRDA, 159 of whom returned for follow-up after 1 
year and 124 after 2 years (Friedman et al. 2010). They used a variety of clinical rating 
scales and performance measures to monitor disease progression including those 
relating to specific symptoms (9-hole peg test, timed 25-foot walk, PATA speech test, 
low-contrast letter acuity vision charts) and more general scales (FARS, functional 
disability scale, activities of daily living). These measures and various composite 
versions captured disease progression although with differing sensitivities, linearity 
and subjection to bias, ceiling and floor effects.  In particular, they noted that the 
results of the 9-hole peg test changed linearly over time, whereas the timed 25-foot 
walk and the low-contrast letter acuity test were more susceptible to floor and ceiling 
effects caused by asymptomatic and maximally affected individuals respectively. The 
PATA speech test did not change over time making it unrepresentative of disease 
progression. The FARS and a composite measure called Z3 (combining the 9-hole peg 
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test, the timed 25-foot walk and the low-contrast acuity test) captured change in both 
ambulatory and non-ambulatory patients, whereas a more restricted composite 
measure (Z2) combining only the 9-hole peg test and the timed 25-foot walk was more 
liable to ceiling effect.  
The same group in an expanded cohort of 259 patients found the annual rate of 
change of the FARS to be 2.66 points over the first year and 6.20 points over the first 
two years of follow-up. Assessment over the subsequent four years showed marked 
ceiling effect, as demonstrated by a diminution in the annual rate of change of the 
FARS for those with a baseline FARS of greater than 89 (ie those with more severe 
ataxia). The feature was particularly apparent in those with GAA repeat sizes of greater 
than 600 (Regner et al. 2012).  
Metz and colleagues carried out a cross-sectional study which provides a detailed 
characterization of the ICARS in 603 FRDA patients (Metz et al. 2013). Interestingly the 
analysis showed different rates of progression for patients with early and late disease 
onset, 2.5 ± 0.18 points and 1.8 ± 0.27 points per year respectively. It is noteworthy for 
future trials that ceiling effects in the posture, gait and lower limb scale items lead to 
reduced sensitivity of the scale in the severely affected population with a total score of 
>60 points. Bürk and coworkers rated 96 patients using three different clinical scales, 
the FARS, ICARS, and the Scale for the Assessment and Rating of Ataxia (SARA) (Bürk et 
al. 2009). Although these rating scales have very different structures from each other, 
total SARA scores were significantly correlated with ICARS and FARS making the SARA, 
which is shorter and quicker, suited for trials. However a ceiling effect is also seen in 
the use of the SARA in patients in late stages of the disease.  
Cardiac complications are the commonest cause of death in FRDA. Andermann found 
mean age at death of 30.6 years (range 4.5 to 40) in the 15 patients who died as part 
of their study of 58 Canadian patients (Andermann et al. 1976). Leone found median 
age at death of 34.5 (range 19-54) amongst the 14 patients who died in their cohort of 
59 North-west Italian patients (Leone et al. 1988). Recorded causes of death included 
diabetic coma, myocardial infarction, bronchopneumonia and wheelchair accident. 
Females had better prognosis than males. In a further Italian study, De Michelle found 
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median age at death of 41 (range 10-65) amongst 11 patient who died in their study of 
119 individuals (De Michele et al. 1996). The presence of diabetes and left ventricular 
hypertrophy decreased survival time. The largest study of mortality in FRDA looked 
retrospectively at the notes of 61 individuals who had died. Mean age at death was 
36.5 years (range 12-87) with cardiac or probable cardiac dysfunction accounting for 
62% of cases (Tsou et al. 2011). Of these, the majority resulted from congestive cardiac 
failure or arrhythmia. Other causes of death included stroke, ischaemic heart disease 
and pneumonia. Increased GAA expansion size, presence of arrhythmia and dilated 
cardiomyopathy were greater in deceased compared to live patients, but there was no 
difference in hypertrophic cardiomyopathy.   
1.4.4 Clinical Subtypes: Early & Late Onset Disease 
Since the discovery of the genetic mechanism underlying FRDA, cases with later onset, 
usually with milder or less typical symptoms, slower progression and a lower 
prevalence of non-neurological features, have been described, forming the majority of 
atypical cases. Onset may be in the sixth or seventh decades of life in which case 
symptoms may be mistaken for alternative diagnoses (Berciano et al. 2005, Galimanis 
et al. 2008). It is now felt that up to 25% of patients do not fulfil the original clinical 
criteria proposed by Geoffroy or Harding (Harding 1981, Dürr et al. 1996, Schöls et al. 
1997, Filla et al. 2000, Barbeau 1984, Geoffroy et al. 1976). In the literature there are 
two main late-onset atypical presentations of FRDA described: (i) late-onset FRDA 
(LOFA) or very late onset FRDA (VLOFA); and (ii) FRDA with retained reflexes (FARR) 
(Klockgether et al. 1996, Coppola et al. 1999, Verma & Gupta 2012). LOFA and VLOFA 
are defined as FRDA with onset after the age of 25 years and after 40 years 
respectively.  
Gait and limb ataxia are the presenting clinical features in several series of LOFA 
(Bhidayasiri et al. 2005, Montermini et al. 1997, De Michele et al. 1994, Gellera et al. 
1997, Ragno et al. 1997, Klockgether et al. 1993, Coppola et al. 1999). Dysarthria 
remains a consistent feature, but is found later in the course of disease and correlates 
with disease duration. Pyramidal involvement with or without increased tendon 
reflexes or muscle tone is considerably less prominent in LOFA. The presence of 
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spasticity in LOFA ranges between 30 and 40% but does not correspond to extensor 
plantar responses which are found in 40 to 100% of atypical cases.  In VLOFA, spastic 
tetraparesis has been reported without marked ataxia (Labauge 2002, Lhatoo et al. 
2001, Berciano et al. 2002). Data on the presence of lower limb neuropathy in LOFA 
patients is sparse. Bhidayasiri and colleagues reported only one out of 13 patients with 
atypical FRDA not having sensory neuropathy (Bhidayasiri et al. 2005). De Michele and 
coworkers reported abnormal peripheral sensory and motor neuropathy conduction 
studies in 16 atypical FRDA cases, mainly sensory axonal neuropathy (De Michele et al. 
1994). Subtle sensory neuropathy, a hallmark of classical FRDA, has also been reported 
in VLOFA (Berciano et al. 2005, Lhatoo et al. 2001). Oculomotor abnormalities may be 
absent in LOFA. 
Non-neurologic manifestations such as scoliosis, pes cavus, cardiomyopathy and 
diabetes are considerably less frequent in LOFA. While the presence of pes cavus 
varies between 33 and 45%, scoliosis may be subtle and present in less than 40% of 
cases (Dürr et al. 1996, Bhidayasiri et al. 2005, De Michele et al. 1994, Gellera et al. 
1997, Coppola et al. 1999, Klockgether et al. 1993, Ragno et al. 1997, Schöls et al. 
1997). Cardiomyopathy may be absent in the atypical phenotype. Two recent large 
studies on heart involvement in more than 350 FRDA patients revealed no 
cardiomyopathy in up to 40% of patients and a correlation of cardiac abnormalities 
with GAA1 (Weidemann et al. 2012, Regner et al. 2012). Abnormal findings on 
echocardiogram in atypical FRDA range between 0 and 57% (Schöls et al. 1997, Dürr et 
al. 1996, Gellera et al. 1997, De Michele et al. 1994, Bhidayasiri et al. 2005, Coppola et 
al. 1999) Abnormal electrocardiogram with T-wave inversion, left axis deviation, and 
repolarization abnormalities, however, is found in almost all FRDA patients.  
The ability to measure FXN gene dosage levels, frataxin mRNA expression levels and 
frataxin protein levels seems likely to allow the identification of further atypical cases 
which are not diagnosed by current genetic techniques. In one study, mean residual 
levels of frataxin were 65.6% in LOFA and 35.8% in classical FRDA, compared to 100% 
in controls, with a direct correlation between frataxin protein levels, age at onset and 
GAA repeat size (Saccà et al. 2011). Messenger RNA expression in LOFA has been 
shown to have reduced levels, from 20 to 50% of controls (Pianese et al. 2004, Saccà et 
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al. 2011). Surprisingly however, the latter study showed that frataxin protein and 
mRNA expression levels overlapped in LOFA patients, controls and carriers (Saccà et al. 
2011). The measurements were performed on peripheral blood mononuclear cells 
which may not be representative of affected tissues because of somatic mosaicism or 
mitotic instability, but it may be that there are as yet undiscovered determinants of 
disease in FRDA other than frataxin protein and mRNA levels, such as genetic modifiers 
outside the FXN gene.  
Early-onset cases have been little studied. Harding found that less than 20% of cases 
had onset before the age of 5 (Harding 1981). She commented that patients with onset 
before the age of 10 who deteriorate rapidly are often short in stature and have short 
limbs, unless they are ambulant throughout the growth period (Harding 1984). Kinnear 
Wilson was struck by ‘by the general undersized, almost infantile physique of a 
Friedreich patient.’ (Wilson 1940). Early age at onset is associated with larger GAA1 
size (Dürr et al. 1996, Schöls et al. 1997) which is associated with more severe 
phenotype, faster progression of disability and higher incidence of cardiomyopathy, 
pes cavus and scoliosis. Dürr et al. (1996) found that patients with GAA1 sizes of 
greater than 780 repeats had a mean age at onset of 9.7 years, compared to those 
with GAA1 of less than 520 repeats who had a mean age at onset of 22.5 years. More 
recently, the identification of exonic deletions in the frataxin gene has suggested that 
these may cause a more severe and earlier presentation, and may contribute more to 
the clinical picture of FRDA than is currently appreciated (Anheim et al. 2012). This 
subject is explored in Chapter 3. 
 
54 
 
1.5 References for Chapter 1 
Ackroyd, R. S., Finnegan, J. A. and Green, S. H. (1984) Friedreich's ataxia. A clinical 
review with neurophysiological and echocardiographic findings. Archives of 
Disease in Childhood, 59, 217-221. 
Andermann, E., Remillard, G. M., Goyer, C., Blitzer, L., Andermann, F. and Barbeau, A. 
(1976) Genetic and family studies in Friedreich's ataxia. Can. J. Neurol. Sci., 3, 
287-301. 
Anheim, M., Mariani, L.-L., Calvas, P. et al. (2012) Exonic Deletions of FXN and Early-
Onset Friedreich Ataxia. Archives of neurology, 69, 912-916. 
Anon (1883) Friedreich's Disease. British Medical Journal, i, 627-628. 
Arnold, P., Boulat, O., Maire, R. and Kuntzer, T. (2006) Expanding view of phenotype 
and oxidative stress in Friedreich's ataxia patients with and without idebenone. 
Schweizer Archiv für Neurologie und Psychiatrie, 157, 169-176. 
Barbeau, A. (1984) The Quebec Cooperative Study of Friedreich's Ataxia: 1974-1984--
10 years of research. Can J Neurol Sci, 11, 646-660. 
Berciano, J., Infante, J., Garcia, A., Polo, J. M., Volpini, V. and Combarros, O. (2005) 
Very late-onset Friedreich's ataxia with minimal GAA1 expansion mimicking 
multiple system atrophy of cerebellar type. Mov Disord, 20, 1643-1645. 
Berciano, J., Mateo, I., De Pablos, C., Polo, J. M. and Combarros, O. (2002) Friedreich 
ataxia with minimal GAA expansion presenting as adult-onset spastic ataxia. J 
Neurol Sci, 194, 75-82. 
Bhidayasiri, R., Perlman, S. L., Pulst, S. M. and Geschwind, D. H. (2005) Late-onset 
Friedreich ataxia: phenotypic analysis, magnetic resonance imaging findings, 
and review of the literature. Arch Neurol, 62, 1865-1869. 
Bird, T. D. (1979) Nicolaus A. Friedreich’s Description of Peripheral Facial Nerve 
Paralysis in 1798. . Journal of Neurology, Neurosurgery & Psychiatry, 42, 56-58. 
Bourke, T. and Keane, D. (2011) Friedreich’s Ataxia: a review from a cardiology 
perspective. Irish Journal of Medical Science, 180, 799-805. 
Bourneville, D.-M. and Guérard, L. (1869) De La Sclérose en Plaques Disséminées, pp. 
222 & 235. Paris. 
Brousse, A. (1882) De l’Ataxie Héréditaire (Maladie de Friedreich). Paris. 
Bürk, K., Malzig, U., Wolf, S., Heck, S., Dimitriadis, K. and Schmitz-Hübsch, T. (2009) 
Comparison of three clinical rating scales in Friedreich ataxia (FRDA). 
Movement disorders : official journal of the Movement Disorder Society, 24, 
1779-1784. 
Campuzano, V., Montermini, L., Lutz, Y. et al. (1997) Frataxin is reduced in Friedreich 
ataxia patients and is associated with mitochondrial membranes. Human 
molecular genetics, 6, 1771 - 1780. 
Campuzano, V., Montermini, L., Molto, M. et al. (1996) Friedreich's ataxia: autosomal 
recessive disease caused by an intronic GAA triplet repeat expansion. Science, 
271, 1423 - 1427. 
Carroll, W. M., Kriss, A., Baraitser, M., Barrett, G. and Halliday, A. (1980) The incidence 
and nature of visual pathway involvement in Friedreich's ataxia. A clinical and 
visual evoked potential study of 22 patients. Brain, 103, 413-434. 
Casazza, F. and Morpurgo, M. (1996) The varying evolution of Friedreich’s Ataxia 
cardiomyopathy. Am. J. Cardiol., 77, 895-898. 
55 
 
Chamberlain, S., Shaw, J., Rowland, A., Wallis, J., South, S., Nakamura, Y., von Gabain, 
A., Farrall, M. and Williamson, R. (1988) Mapping of mutation causing 
Friedreich's ataxia to human chromosome 9. Nature, 334, M248 - 250. 
Charcot, J.-M. (1888) Leçons du Mardi à la Salpêtrière, Professeur Charcot. Policlinique 
1887-1888. Notes de Cours de MM. Blin, Charcot et Colin, pp. 253-263 (13 Mars 
1888) & pp. 326-329 (10 Avril 1888): Bureaux du Progrès Médical. Paris. 
Coppola, G., De Michele, G., Cavalcanti, F. et al. (1999) Why do some Friedreich's 
ataxia patients retain tendon reflexes? A clinical, neurophysiological and 
molecular study. J Neurol, 246, 353-357. 
Corben, L. A., Akhlaghi, H., Georgiou-Karistianis, N., Bradshaw, J. L., Egan, G. F., Storey, 
E., Churchyard, A. J. and Delatycki, M. B. (2011a) Impaired inhibition of 
prepotent motor tendencies in Friedreich ataxia demonstrated by the Simon 
interference task. Brain and Cognition, 76, 140-145. 
Corben, L. A., Delatycki, M. B., Bradshaw, J. L., Churchyard, A. J. and Georgiou-
Karistianis, N. (2011b) Utilization of advance motor information is impaired in 
Friedreich ataxia. Cerebellum (London, England), 10, 793-803. 
Corben, L. A., Delatycki, M. B., Bradshaw, J. L., Horne, M. K., Fahey, M. C., Churchyard, 
A. C. and Georgiou-Karistianis, N. (2010) Impairment in motor reprogramming 
in Friedreich ataxia reflecting possible cerebellar dysfunction. J. Neurol., 257, 
782-791. 
Corben, L. A., Georgiou-Karistianis, N., Bradshaw, J. L., Hocking, D. R., Churchyard, A. J. 
and Delatycki, M. B. (2011c) The Fitts task reveals impairments in planning and 
online control of movement in Friedreich ataxia : reduced cerebellar-cortico 
connectivity? Neuroscience, 192, 382-390. 
Corben, L. A., Georgiou-Karistianis, N., Fahey, M., Storey, E., Churchyard, A., Horne, M., 
Bradshaw, J. L. and Delaytcki, M. B. (2006) Towards an understanding of 
cognitive function in Friedreich ataxia. Brain Research Bulletin, 70, 197-202. 
Cossée, M., Campuzano, V., Koutnikova, H. et al. (1997) Frataxin fracas. Nature 
genetics, 15, 337 - 338. 
Cossée, M., Dürr, A., Schmitt, M. et al. (1999) Friedreich's ataxia: point mutations and 
clinical presentation of compound heterozygotes. Ann Neurol, 45, 200 - 206. 
De Michele, G., Filla, A., Cavalcanti, F. et al. (1994) Late onset Friedreich's disease: 
clinical features and mapping of mutation to the FRDA locus. J Neurol 
Neurosurg Psychiatry, 57, 977-979. 
De Michele, G., Perrone, F., Filla, A., Mirante, E., Giordano, M., De Placido, S. and 
Campanella, G. (1996) Age of onset, sex, and cardiomyopathy as predictors of 
disability and survival in Friedreich’s disease : a retrospective study on 119 
patients. Neurology, 47, 1260-1264. 
De Nóbrega, E., Nieto, A., Barrosso, J. and Montón, F. (2007) Differential impairment in 
semantic, phonemic, and action fluency performance in Friedreich's ataxia: 
Possible evidence of prefrontal dysfunction. Journal of the International 
Neuropsychological Society, 13, 944-952. 
Delatycki, M. B. and Corben, L. A. (2012) Clinical Features of Friedreich Ataxia. Journal 
of child neurology, 27, 1133-1137. 
Delatycki, M. B., Holian, A., Corben, L., Rawicki, H. B., Blackburn, C., Hoare, B., Toy, M. 
and Churchyard, A. (2005) Surgery for Equinovarus Deformity in Friedreich’s 
56 
 
Ataxia Improves Mobility and Independence. Clin. Orthopaed. Rel. Res., 430, 
138-141. 
Delatycki, M. B., Paris, D. B. B. P., Gardner, R. J. M. et al. (1999) Clinical and genetic 
study of Friedreich ataxia in an Australian population. American Journal of 
Medical Genetics, 87, 168-174. 
Deutsch, E. C., Santani, A. B., Perlman, S. L., Farmer, J. M., Stolle, C. A., Marusich, M. F. 
and Lynch, D. R. (2010) A rapid, noninvasive immunoassay for frataxin: Utility in 
assessment of Friedreich ataxia. Molecular Genetics and Metabolism, 101, 238-
245. 
Duchenne, G. B. A. (1858) De l’Ataxie Locomotrice Progressive. Arch. Gén. Méd., 12, 
641-652. 
Dürr, A., Cossée, M., Agid, Y., Campuzano, V., Mignard, C., Penet, C., Mandel, J., Brice, 
A. and Koenig, M. (1996) Clinical and genetic abnormalities in patients with 
Friedreich's ataxia. N Engl J Med, 335, 1169 - 1175. 
Dutka, D., Donnelly, J., Nihoyannopoulos, P., Oakley, C. and Nunez, D. (1999) Marked 
variation in the cardiomyopathy associated with Friedreich's ataxia. Heart 
(British Cardiac Society), 81, 141-147. 
Epplen, C., Epplen, T. J., Frank, G., Miterski, B., Santos, M. E. J. and Schöls, L. (1997) 
Differential stability of the (GAA)n tract in the Friedreich ataxia (STM7) gene. 
Human genetics, 99, 834-836. 
Epstein, E., Farmer, J. M., Tsou, A. et al. (2008) Health related quality of life measures 
in Friedreich Ataxia. Journal of the neurological sciences, 272, 123-128. 
Fahey, M. C., Corben, L., Collins, V., Churchyard, A. J. and Delatycki, M. B. (2007) How is 
disease progress in Friedreich's ataxia best measured? A study of four rating 
scales. Journal of neurology, neurosurgery, and psychiatry, 78, 411-413. 
Fahey, M. C., Cremer, P. D., Aw, S. T., Millist, L., Todd, M. J. and White, O. B. (2008) 
Vestibular, saccadic and fixation abnormalities in genetically confirmed 
Friedreich ataxia. Brain, 131, 1035-1045. 
Fantus, I. G., Janjua, N., Senni, H. and Andermann, E. (1991) Glucose intolerance in first 
degree relatives of patients with Friedreich’s ataxia is associated with insulin 
resistance : evidence for a closely linked inherited trait. Metabolism, 40, 788-
793. 
Féré, C. (1882) Ataxie Héréditaire, Maladie de Friedreich, Sclérose Diffuse de la Moelle 
et du Bulbe. Progrès Médical. , 10, 890-892. 
Filla, A., De Michele, G., Cavalcanti, F., Perretti, A., Santoro, L., Barbieri, F., D'Arienzo, 
G. and Campanella, G. (1990) Clinical and genetic heterogeneity in early onset 
cerebellar ataxia with retained tendon reflexes. Journal of neurology, 
neurosurgery, and psychiatry, 53, 667 - 670. 
Filla, A., De Michele, G., Cavalcanti, F., Pianese, L., Monticelli, A., Campanella, G. and 
Cocozza, S. (1996) The relationship between trinucleotide (GAA) repeat length 
and clinical features in Friedreich ataxia. American journal of human genetics, 
59, 554 - 560. 
Filla, A., De Michele, G., Coppola, G. et al. (2000) Accuracy of clinical diagnostic criteria 
for Friedreich's ataxia. Movement disorders : official journal of the Movement 
Disorder Society, 15, 1255 - 1258. 
57 
 
Filla, A., Michele, G., Marconi, R. et al. (1992) Prevalence of hereditary ataxias and 
spastic paraplegias in Molise, a region of Italy. Journal of neurology, 239, 351-
353. 
Finocchiaro, G., Baio, G., Micossi, P., Pozza, G. and Donato, S. D. (1988) Glucose 
metabolism alterations in Friedreich's ataxia. Neurology, 38, 1292. 
Flood, M. K. and Perlman, S. L. (1987) The mental status of patients with Friedreich’s 
ataxia. J. Neurosci. Nurs. , 19, 251-255. 
Folker, J., Murdoch, B., Cahill, L., Delatycki, M., Corben, L. and Vogel, A. (2010) 
Dysarthria in Friedreich’s ataxia : a perceptual analysis. Folia Phoniatr Logop., 
62, 97-103. 
Fortuna, F., Barboni, P., Liguori, R., Valentino, M. L., Savini, G. and Gellera, C. (2009) 
Visual system involvement in patients with Friedreich's ataxia. Brain, 132, 116-
123. 
Friedman, L. S., Farmer, J. M., Perlman, S., Wilmot, G., Gomez, C. M. and Bushara, K. O. 
(2010) Measuring the rate of progression in Friedreich ataxia: implications for 
clinical trial design. Movement disorders : official journal of the Movement 
Disorder Society, 25, 426-432. 
Friedreich, N. (1863a) Ueber Degenerative Atrophie der Spinalen Hinterstränge. Archiv. 
Path. Anat. Physiol. Klin. Med., 26, 433-459. 
Friedreich, N. (1863b) Ueber Degenerative Atrophie der Spinalen Hinterstränge. Archiv. 
Path. Anat. Physiol. Klin. Med. , 27, 1-26. 
Friedreich, N. (1863c) Ueber Degenerative Atrophie der Spinalen Hinterstränge. . 
Archiv. Path. Anat. Physiol. Klin. Med., 26, 391-419. 
Friedreich, N. (1876) Ueber Ataxie mit besonderer Berücksichtigunug der hereditären 
Formen. Archiv. Path. Anat. Physiol. Klin. Med. , 68, 145-245. 
Friedreich, N. (1877) Ueber Ataxie mit besonderer Berücksichtigunug der hereditären 
Formen: Nachtrag. Archiv. Path. Anat. Physiol. Klin. Med., 70, 140-152. 
Furman, J. M., Perlman, S. and Baloh, R. W. (1983) Eye movements in Friedreich's 
ataxia. Archives of neurology, 40, 343-346. 
Galimanis, A., Glutz, L., Spiegel, R., Burgunder, J.-M. and Kaelin-Lang, A. (2008) Very-
late-onset Friedreich ataxia with disturbing head tremor and without spinal 
atrophy : a case report. Movement Disorders, 23, 58-59. 
Gatchel, J. R. and Zoghbi, H. Y. (2005) Diseases of Unstable Repeat Expansion: 
Mechanisms and Common Principles. Nat Rev Genet, 6, 743-755. 
Gellera, C., Castellotti, B., Mariotti, C., Mineri, R., Seveso, V., DiDonato, S. and Taroni, F. 
(2007) Frataxin Gene Point Mutations in Italian Friedreich Ataxia Patients. 
Neurogenetics, 8, 289-299. 
Gellera, C., Pareyson, D., Castellotti, B., Mazzucchelli, F., Zappacosta, B., Pandolfo, M. 
and Di Donato, S. (1997) Very late onset Friedreich's ataxia without 
cardiomyopathy is associated with limited GAA expansion in the X25 gene. 
Neurology, 49, 1153-1155. 
Geoffroy, G., Barbeau, A., Breton, G., Lemieux, B., Aube, M., Leger, C. and Bouchard, J. 
(1976) Clinical description and roentgenologic evaluation of patients with 
Friedreich's ataxia. The Canadian journal of neurological sciences. Le journal 
canadien des sciences neurologiques, 3, 279 - 286. 
Goetz, C. G. (1987) Charcot The Clinician: The Tuesday Lessons, p. 18. Raven Press, New 
York. 
58 
 
Gowers, W. R. (1886) A Manual of Diseases of the Nervous System, I. Diseases of the 
Spinal Cord and Nerves. Churchill, London. 
Gowers, W. R. (1895) Clinical Lectures on Diseases of the Nervous System, p. 130. Vol. 
Chapter IX: Locomotor Ataxy. Blakiston Son & Co., Philadelphia. 
Harding, A. (1981) Friedreich's ataxia: a clinical and genetic study of 90 families with an 
analysis of early diagnostic criteria and intrafamilial clustering of clinical 
features. Brain, 104, 589 - 620. 
Harding, A. E. (1984) The Hereditary Ataxias and Related Disorders: Clinical Neurology 
& Neurosurgery Monographs. Churchill Livingstone, Edinburgh. 
Harding, A. E. and Zilkha, K. J. (1981) 'Pseudo-dominant' inheritance in Friedreich's 
ataxia. Journal of Medical Genetics, 18, 285-287. 
Hebinck, J., Hardt, C., Schols, l. and Vorgerd, M. (2000) Heterozygous expansion of the 
GAA tract of the X25/frataxin gene is associated with insulin resistance in 
humans. Diabetes, 49, 1604-1607. 
Hewer, R. L. and Robinson, N. (1968) Diabetes mellitus in Friedreich's ataxia. Journal of 
neurology, neurosurgery, and psychiatry, 31, 226-231. 
Jabbari, B., Schwartz, D. M., MacNeil, D. M. and Coker, S. B. (1983) Early abnormalities 
of brainstem auditory evoked potentials in Friedreich’s ataxia : evidence of 
primary brainstem dysfunction. Neurology, 33, 1071-1074. 
Keppel Hesselink, J. M. (1986) Een Discussie uit de Vorige Eeuw: Multipele Sclerose of 
tabes dorsalis; of ziekte van Freidreich? . Ned. Tijdschr. Geneeskd, 130, 2353-
2356. 
Kipps, A., Alexander, M., Colan, S. D., Gauvreau, K., Smoot, L., Crawford, L., Darras, B. 
T. and Blume, E. D. (2008) The Longitudinal Course of Cardiomyopathy in 
Friedreich’s Ataxia During Childhood. Pediatric Cardiology, 30, 306-310. 
Klockgether, T., Chamberlain, S., Wullner, U., Fetter, M., Dittmann, H., Petersen, D. and 
Dichgans, J. (1993) Late-onset Friedreich's ataxia. Molecular genetics, clinical 
neurophysiology, and magnetic resonance imaging. Arch Neurol, 50, 803-806. 
Klockgether, T., Zühlke, C., Schulz, J. B., Bürk, K., Fetter, M., Dittmann, H., Skalej, M. 
and Dichgans, J. (1996) Friedreich's ataxia with retained tendon reflexes: 
Molecular genetics, clinical neurophysiology, and magnetic resonance imaging. 
Neurology, 46, 118-121. 
Klopper, F., Delatycki, M. B., Corben, L. A., Bradshaw, J. L., Rance, G. and Georgiou-
Karistianis, N. (2011) The Test of Everyday Attention Reveals Significant 
Sustained Volitional Attention and Working Memory Deficits in Friedreich 
Ataxia. Journal of the International Neuropsychological Society, 17, 196-200. 
Koehler, P. J. (2000) Friedreich’s Ataxia, In: Neurological Eponyms. Oxford University 
Press, Oxford. 
Koeppen, A., Morral, J., Davis, A., Qian, J., Petrocine, S., Knutson, M., Gibson, W., 
Cusack, M. and Li, D. (2009) The dorsal root ganglion in Friedreich’s ataxia. Acta 
Neuropathol, 118, 763-776. 
Koeppen, A. H. (2011) Friedreich’s ataxia: Pathology, pathogenesis, and molecular 
genetics. Journal of the neurological sciences, 303, 1-12. 
Koeppen, A. H. and Mazurkiewicz, J. E. (2013) Friedreich Ataxia: Neuropathology 
Revised. Journal of Neuropathology and Experimental Neurology, 72, 
10.1097/NEN.1090b1013e31827e35762. 
59 
 
Labauge, P. (2002) Very late onset Friedreich's presenting as spastic tetraparesis 
without ataxia or neuropathy. Neurology, 58, 1136. 
Labelle, H., Tohme, S., Duhaime, M. and Allard, P. (1986) Natural history of scoliosis in 
Friedreich’s ataxia. J. Bone Joint Surg. Am., 68, 564-572. 
Labuda, M., Labuda, D., Miranda, C., Poirier, J., Soong, B.-W., Barucha, N. E. and 
Pandolfo, M. (2000) Unique origin and specific ethnic distribution of the 
Friedreich ataxia GAA expansion. Neurology, 54, 2322-2324. 
Leone, M., Rocca, W. A., Rosso, M. G., Mantel, N., Schoenberg, B. S. and Schiffer, D. 
(1988) Friedreich’s disease : survival analysis in an Italian population. 
Neurology, 38, 1433-1438. 
Lhatoo, S. D., Rao, D. G., Kane, N. M. and Ormerod, I. E. (2001) Very late onset 
Friedreich's presenting as spastic tetraparesis without ataxia or neuropathy. 
Neurology, 56, 1776-1777. 
Lill, R. (2009) Function and biogenesis of iron–sulphur proteins. Nature, 460, 831-838. 
Loiseau, J. (1938) Les Troubles Cardiaques dans la Maladie de Friedreich. Thèse, Paris. 
Cited in Boyer S.H., Chisholm A.W. and McKusick V.A. (1962) Cardiac Aspects of 
Friedreich’s Ataxia. Circulation. 25, 493-505. 
López-Díaz-de-Leóna, E., Silva-Rojasa, A., Ysunzab, A., Amaviscac, R. and Riverad, R. 
(2003) Auditory neuropathy in Friedreich ataxia: A report of two cases. Int. J. 
Ped. Otorhinolaryng., 67, 641-648. 
Mantovan, M. C., Martinuzzi, A., Squarzanti, F. et al. (2006) Exploring mental status in 
Friedreich's ataxia: a combined neuropsychological, behavioral and 
neuroimaging study. European Journal of Neurology, 13, 827-835. 
Martelli, A., Napierala, M. and Puccio, H. (2012) Understanding the genetic and 
molecular pathogenesis of Friedreich’s ataxia through animal and cellular 
models. Disease Models & Mechanisms, 5, 165-176. 
McCabe, D. J. H., Ryan, F., Moore, D. P., McQuaid, S., King, M. D., Kelly, A., Daly, K., 
Barton, D. E. and Murphy, R. P. (2000) Typical Friedreich’s ataxia without GAA 
expansions and GAA expansions without typical Friedreich’s ataxia. J. Neurol., 
247, 346-355. 
Metz, G., Coppard, N., Cooper, J. M. et al. (2013) Rating disease progression of 
Friedreich’s ataxia by the International Cooperative Ataxia Rating Scale: analysis 
of a 603-patient database. Brain, 136, 259-268. 
Meyer, C., Schmid, G., Görlitz, S. et al. (2007) Cardiomyopathy in Friedreich's ataxia-
assessment by cardiac MRI. Movement Disorders, 221615-1622. 
Milbrandt, T. A., Kunes, J. R. and Karol, L. A. (2008) Friedreich’s ataxia and scoliosis : 
the experience at two institutions. J. Pediatr. Orthop., 28, 234-238. 
Monros, E., Molto, M., Martinez, F., Canizares, J., Blanca, J., Vilchez, J., Prieto, F., de 
Frutos, R. and Palau, F. (1997) Phenotype correlation and intergenerational 
dynamics of the Friedreich ataxia GAA trinucleotide repeat. American journal of 
human genetics, 61, 101 - 110. 
Montermini, L., Richter, A., Morgan, K. et al. (1997) Phenotypic variability in Friedreich 
ataxia: role of the associated GAA triplet repeat expansion. Ann Neurol, 41, 
675-682. 
Morral, J., Davis, A., Qian, J., Gelman, B. and Koeppen, A. (2010) Pathology and 
pathogenesis of sensory neuropathy in Friedreich’s ataxia. Acta Neuropathol, 
120, 97-108. 
60 
 
Nardulli, R., Monitillo, V., Losavio, E., Fiore, P., Nicolardi, G. and Megna, G. (1992) 
Urodynamic evaluation of 12 ataxic subjects : neurophysiopathologic 
considerations. Functional neurology, 7, 223-225. 
Neito, A., Correia, R., de Nóbrega, E., Montón, F., Hess, S. and Barroso, J. (2012) 
Cognition in Friedreich ataxia. Cerebellum (London, England), 11, 834-844. 
Nitrini, R. (2000) The history of tabes dorsalis and the impact of observational studies 
in neurology. Archives of neurology, 57, 605-606. 
Pandolfo, M. (2001) Molecular basis of Friedreich ataxia. Mov Disord, 16, 815-821. 
Pandolfo, M. and Pastore, A. (2009) The pathogenesis of Friedreich ataxia and the 
structure and function of frataxin. Journal of neurology, 256, 9-17. 
Pianese, L., Turano, M., Lo Casale, M. S., De Biase, I., Giacchetti, M., Monticelli, A., 
Criscuolo, C., Filla, A. and Cocozza, S. (2004) Real time PCR quantification of 
frataxin mRNA in the peripheral blood leucocytes of Friedreich ataxia patients 
and carriers. Journal of Neurology, Neurosurgery & Psychiatry, 75, 1061-1063. 
Ragno, M., De Michele, G., Cavalcanti, F. et al. (1997) Broadened Friedreich's ataxia 
phenotype after gene cloning. Minimal GAA expansion causes late-onset 
spastic ataxia. Neurology, 49, 1617 - 1620. 
Rajagopalan, B., Francis, J. M., Cooke, F., Korlipara, L. V. P., Blamire, A. M., Schapira, A. 
H. V., Madan, J., Neubauer, S. and Cooper, J. M. (2010) Analysis of the factors 
influencing the cardiac phenotype in Friedreich's ataxia. Movement Disorders, 
25, 846-852. 
Rance, G., Corben, L. A., Du Bourg, E., King, A. and Delatycki, M. B. (2010) Successful 
treatment of auditory perceptual disorder in individuals with Friedreich ataxia. 
Neuroscience, 171, 552-555. 
Rance, G., Fava, R., Baldock, H., Chong, A., Barker, E., Corben, L. and Delatycki, M. B. 
(2008) Speech perception ability in individuals with Friedreich ataxia. Brain, 
131, 2002-2012. 
Regner, S. R., Wilcox, N., Friedman, L. S. et al. (2012) Friedreich Ataxia Clinical Outcome 
Measures: Natural History Evaluation in 410 Participants. Journal of child 
neurology, 27, 1152-1158. 
Saccà, F., Puorro, G., Antenora, A. et al. (2011) A combined nucleic acid and protein 
analysis in Friedreich ataxia: implications for diagnosis, pathogenesis and 
clinical trial design. PloS one, 6, e17627-e17628. 
Santoro, L., De Michele, G., Perretti, A. et al. (1999) Relation between trinucleotide 
GAA repeat length and sensory neuropathy in Friedreich’s ataxia. Journal of 
Neurology, Neurosurgery & Psychiatry, 66, 93-96. 
Satya-Murti, S., Cacace, A. and Hanson, P. (1980) Auditory dysfunction in Friedreich 
ataxia : result of spiral ganglion degeneration. Neurology, 30, 1047-1053. 
Schadt, K. A., Friedman, L. S., Regner, S. R., Mark, G. E., Lynch, D. R. and Lin, K. Y. (2012) 
Cross-Sectional Analysis of Electrocardiograms in a Large Heterogeneous 
Cohort of Friedreich Ataxia Subjects. Journal of child neurology, 27, 1187-1192. 
Schoenle, E. J., Boltshauser, E. J., Baekkeskov, S., Olsson, M. L., Torresani, T. and Felten, 
A. (1989) Preclinical and manifest diabetes mellitus in young patients with 
friedreich's ataxia: no evidence of immune process behind the islet cell 
destruction. Diabetologia, 32, 378-381. 
61 
 
Schöls, L., Amoiridis, G., Przuntek, H., Frank, G., Epplen, J. and Epplen, C. (1997) 
Friedreich's ataxia. Revision of the phenotype according to molecular genetics. 
Brain, 120, 2131 - 2140. 
Schulz, J. B., Boesch, S., Burk, K. et al. (2009) Diagnosis and treatment of Friedreich 
ataxia: a European perspective. Nat. Rev. Neurol., 5, 222-234. 
Smith, W. E. (1885) Hereditary or Degenerative Ataxia. Bost. Med. Surg. J., 113, 361-
368. 
Subramony, S. H., May, W., Lynch, D. et al. (2005) Measuring Friedreich ataxia: 
Interrater reliability of a neurologic rating scale. Neurology, 64, 1261-1262. 
Thorén, C. (1962) Diabetes Mellitus in Friedreich's Ataxia. Acta Paediatrica, 51 (Suppl. 
135), 239-247. 
Trouillas, P., Takayanagi, T., Hallett, M. et al. (1997) International Cooperative Ataxia 
Rating Scale for pharmacological assessment of the cerebellar syndrome. 
Journal of the neurological sciences, 145, 205-211. 
Tsou, A. Y., Paulsen, E. K., Lagedrost, S. J., Perlman, S. L., Mathews, K. D., Wilmot, G. R., 
Ravina, B., Koeppen, A. H. and Lynch, D. R. (2011) Mortality in Friedreich Ataxia. 
J. Neurol. Sci., 307, 46-49. 
Verma, R. and Gupta, M. (2012) Freidreich’s ataxia with retained reflexes: a phenotype 
and genotype correlation. BMJ Case Reports, doi:10.1136/bcr-2012-007496. 
Vezina, J. G., Bouchard, J. P. and Bouchard, R. (1982) Urodynamic evaluation of 
patients with hereditary ataxias. Can. J. Neurol. Sci., 9, 127-129. 
Waugh, M. (2005) The centenary of Treponema pallidum: on the discovery of 
Spirochaeta pallida. International Journal of STD & AIDS, 16, 594-595. 
Weidemann, F., Rummey, C., Bijnens, B. et al. (2012) The Heart in Friedreich Ataxia: 
Definition of Cardiomyopathy, Disease Severity, and Correlation With 
Neurological Symptoms. Circulation, 125, 1626-1634. 
Willis, J. H., Isaya, G., Gakh, O., Capaldi, R. A. and Marusich, M. F. (2008) Lateral-flow 
immunoassay for the frataxin protein in Friedreich’s ataxia patients and 
carriers. Molecular Genetics and Metabolism, 94, 491-497. 
Wilson, S. A. K. (1940) Neurology, Vol II. Chapter LIX: Spinocerebellar Types, p. 944. (A. 
N. Bruce ed.). Edward Arnold, London. 
 
 
 
 
62 
 
 
63 
 
Chapter 2 :  Natural History of Friedreich’s Ataxia  
 
2.1 Introduction 
This chapter describes clinical data collected at the National Hospital for Neurology 
and Neurosurgery (NHNN) as part of the European Friedreich’s Ataxia Consortium for 
Translational Studies (EFACTS) natural history study of FRDA. The EFACTS consortium 
comprises 18 centres in 7 European Union (EU) member states, of which 11 are 
involved in the clinical project and 10 in basic sciences projects (see Figure 4). The aim 
of the clinical project was to recruit 600 patients with FRDA across Europe and assess 
them at yearly intervals over a four year period and beyond. Participating patients 
undergo a comprehensive clinical assessment including a panel of assessment tools 
allowing their validation in a large longitudinal cohort of clinically and genetically well-
defined patients.  
Each patient provides a blood and urine sample allowing the generation of a central 
biological sample repository. These samples are used to confirm the genetic diagnosis 
and permit further genetic and epigenetic characterization. Frataxin mRNA and protein 
expression will be determined on peripheral blood samples. Serum and plasma 
samples will be used for proteomic analysis. These measures will therefore allow the 
identification of novel biomarkers and genetic modifiers. 
The clinical, genetic and biochemical results are entered into a central anonymized 
database, allowing data modelling and specialized computational and statistical 
analysis. These may permit the identification of new pathways to facilitate greater 
understanding of the underlying pathogenesis of FRDA and potential new drug targets. 
The validation of clinical assessment tools will enable their use in clinical trials and 
other studies, and provide essential data for power calculations for such studies. More 
widely, the EFACTS project also encompasses basic scientific studies on frataxin 
structure and function, genetic and epigenetic mechanisms, cellular and animal 
models, and therapeutic trials.   
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Figure 4: Clinical centres (blue) and basic science centres (red) participating in EFACTS 
2.2 Method 
2.2.1 Ethics, Recruitment & Funding 
The project was approved by the Central London Research Ethics Committee 
(reference 10/H0716/51) and is funded by a Framework Project 7 grant from the EU 
(reference HEALTH-F2-2010-242193). Patients with FRDA were identified from the 
records of the NHNN and contacted initially using a standard letter enclosing the 
Participant Information Sheet (PIS). Telephone contact was subsequently made if 
necessary, or the project was discussed during the patients’ routine appointment at 
the NHNN. An advertisement was also placed in The Ataxian  ̶  the newsletter of Ataxia 
UK – which is circulated to members of Ataxia UK, the UK’s leading charity concerned 
with all forms of ataxia, as well as being available on their website 
(www.ataxia.org.uk). A further advertisement was placed in the electronic newsletter 
of the Association of British Neurologists (ABN) which is read by members of that 
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organization who are primarily neurologists practising in the UK. In addition, the 
website of EFACTS (www.e-facts.eu) contains contact details by which patients can 
contact the NHNN research group directly, and a facility for patients to obtain further 
information about the project centrally and if appropriate be put in contact with the 
local research groups. Further patients were identified via Ataxia Ireland (formerly the 
Friedreich’s Ataxia Society of Ireland) who also provided funding for the travel 
expenses of patients. The establishment of a Participant Identification Centre (PIC) at 
the Ataxia Centre of the Royal Hallamshire Hospital, Sheffield (Prof. Mario 
Hadjivassiliou) enabled the recruitment of a further tranche of patients. 
2.2.2 Clinical Assessment 
Patients were invited to attend a research clinic at the NHNN. Each patient provided 
signed informed consent after having received the PIS. Travel expenses were paid from 
the EFACTS funding. A small number of patients were seen as part of home visits. The 
clinical assessment lasted approximately two hours. Each patient provided basic 
demographic details including country of birth, ethnic origin, level of educational 
achievement, occupational history, marital and family status. Education was graded 
according to the International Standard Classification of Education (ISCED) formulated 
by the United Nations Educational, Scientific and Cultural Organization (UNESCO) to 
ensure comparability between different countries.  
A structured history of the disease was elicited including age and nature of first 
symptoms, date of clinical and genetic diagnosis, and significant disability milestones 
such as age of first falls, and intermittent or permanent use of aids to mobility or 
wheelchair. Details of associated symptoms were recorded such as visual impairment, 
hearing loss, cardiac involvement, scoliosis and pes cavus. A detailed family history was 
recorded including the relation, age, age at onset and age at death of family members 
diagnosed with FRDA and other causes of ataxia. A detailed structured past medical 
history was recorded. A detailed history was recorded of present and past use of 
medications, vitamins, supplements, alcohol, smoking and recreational drugs, as well 
as involvement in current or previous clinical trials.  
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Patients were requested to bring details of their most recent cardiac investigations 
including echocardiogram and electrocardiogram (ECG) and if these were not available, 
consent was obtained to request these from their cardiologist or General Practitioner. 
Three parameters were recorded from the echocardiogram, namely interventricular 
septal thickness at diastole (IVSd), left ventricular posterior wall thickness at diastole 
(LVPWd) and left ventricular ejection fraction (EF). These data were therefore not 
measured prospectively as part of the study and were undertaken in multiple centres 
by many different operators. The measurements were often not taken at the same 
time as the baseline clinic visit. In the case of echocardiograms, the data were 
obtained from the echocardiogram report or clinic letter. Because of the different 
protocols used in different centres, and because echocardiography is often technically 
difficult in wheelchair-bound patients for reasons of positioning, incomplete data sets 
were often found. Where a range of values was quoted for ejection fraction (eg 40-
50%), the median value was used (ie 45%). In the case or ECGs, the original recording 
was usually acquired and directly assessed, although in a number of cases, the results 
were obtained from clinic letters. The latter practice may serve to overestimate 
abnormalities, as abnormal results are more commonly recorded in clinic letters than 
normal results. Where the ECG was directly scrutinized, it was adjudged to show 
voltage criteria of left ventricular hypertrophy (LVH) if the R wave in leads V5 or V6 
exceeded 26mm or the sum of the R wave in V6 and the S wave in V1 exceeded 35mm 
(Sokolow & Lyon 1949). Blood pressure, pulse rate, weight and height were measured 
and recorded at each assessment. 
Functional disability was assessed using the 9-field Activities of Daily Living (ADL) 
section of the Friedreich’s Ataxia Rating Scale (FARS) (Subramony et al. 2005) which 
has previously been validated for use in FRDA (Lynch et al. 2006, Friedman et al. 2010). 
This covers speech, swallowing, use of cutlery, dressing, washing, falls, walking, sitting 
and bladder function, giving a maximum score of 36 points (thus, higher scores 
represent greater disability). Functional disability was further assessed using the 7-
point Spinocerebellar Degeneration Functional Score (SDFS) which has been used in 
FRDA previously (Anheim et al. 2012). This is a 7-point scale in which higher scores 
represent greater disability, as follows: 
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1. No functional handicap but signs at examination 
2. Mild, able to run, walking unlimited 
3. Moderate, unable to run, limited walking without aid 
4. Severe, walking with one stick 
5. Walking with two sticks 
6. Unable to walk, requiring wheelchair 
7. Confined to bed. 
Quality of life and health status were assessed using the EuroQoL 5-dimension (EQ-5D) 
scale (EuroQol-Group 1990). This is a self-reported questionnaire covering mobility, 
self-care, usual activities (work, study, housework, family or leisure activities), 
pain/discomfort and anxiety/depression. Higher scores represent greater disability or 
disease involvement. In addition, there is a visual-analogue scale (VAS ; the 
‘thermometer’) rating health state on a scale of 0 to 100, in which 0 represents the 
worst imaginable health state and 100 represents the best imaginable heath state. 
There are also background questions covering demographics, previous experience of 
serious illness, employment, education and smoking. This has been validated in FRDA 
although the study found limited discriminant ability and responsiveness to 
progression (Riazi et al. 2006). There were also high levels of missing data particularly 
in the section on mobility. 
Ataxic signs were assessed using the 8-field Scale for the Assessment and Rating of 
Ataxia (SARA) which covers gait, stance, sitting, speech, finger chase, nose-finger test, 
fast alternating hand movements and the heel-shin test. The scale gives a score from 
zero (no ataxia) to a maximum of 40 and has been validated in groups of patients with 
spinocerebellar ataxias (Schmitz-Hübsch et al. 2006), mixed ataxias (Weyer et al. 2007) 
and FRDA (Bürk et al. 2009). 
Ataxic signs were further assessed by two performance measures, the Spinocerebellar 
Ataxia Functional Index (SCAFI) and the Composite Cerebellar Functional Severity 
Score (CCFS). The latter is not presented in this thesis. The SCAFI includes the three 
functional performance measures taken with modifications from the FARS (Subramony 
et al. 2005) which has been validated in the spinocerebellar ataxias (Schmitz-Hübsch et 
al. 2008). The index assesses gait, manual dexterity and speech using an 8-metre timed 
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walk (8mTW) with or without assistive devices; the time taken to place and retrieve 
nine pegs in nine holes for each hand using the Rolyan plastic one-piece 9-hole peg 
test apparatus (9-hole peg test, 9HPT); and the number of vocalized repetitions of the 
two syllables ‘pa-ta’ in 10 seconds (PATA test). Higher scores on the 8mTW and 9HPT 
(ie the patient takes longer to undertake each task) and lower scores on the PATA test 
(ie the patient utters fewer repetitions in 10 seconds) represent greater disability.  
Each test is performed twice. The raw data can be used and a Z score calculated as 
follows: 
Z 𝑠𝑐𝑜𝑟𝑒 =  
(𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 𝑏𝑜𝑡ℎ 𝑡𝑟𝑖𝑎𝑙𝑠)−(𝑚𝑒𝑎𝑛 𝑜𝑓 𝑠𝑡𝑢𝑑𝑦 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛)
(𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑠𝑡𝑢𝑑𝑦 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛)
 
The reciprocal of the 8mTW and 9HPT results are used so that greater values always 
represent better function. The maximal allowable values of the 8mTW and 9HPT are 
set at 180s and 300s respectively. In order to calculate the Z score, if a patient is 
unable to perform a test for reasons of physical disability, the values are set at 10 
times the maximal value for the 8mTW and 9HPT (ie 1800s and 3000s respectively), 
and zero for the PATA test. 
Non-ataxic signs were assessed using the Inventory of Non-Ataxic Symptoms (INAS). 
The INAS was first described for use in the SCAs for assessing additional non-ataxic 
symptoms (Jacobi et al. 2013) and subsequently used as part of the EUROSCA natural 
history study of SCAs 1,2,3 & 6 (Jacobi et al. 2015). The INAS assesses by examination 
the presence, absence or severity of a number of non-ataxic signs including spasticity, 
paresis, muscle atrophy, fasciculations, myoclonus, rigidity, chorea/dyskinesia, 
dystonia and resting tremor. These are assessed using a semi-quantitative scale 
(none/mild/moderate/severe). Reflexes are assessed as normal, hyperreflexic or 
areflexic, and extensor plantar reflexes as absent, unilateral or bilateral. Vibration 
sense is assessed using a Rydel-Seiffer graduated tuning fork at the external malleolus 
of the ankle (Whitton et al. 2005). A range of ophthalmological features are assessed 
as either present or absent (pursuit, square wave jerks, nystagmus, ophthalmoparesis, 
saccades, visual acuity). The INAS further assesses the presence, absence, severity or 
frequency of a number of non-ataxic symptoms as reported by the patient, including 
diplopia, dysphagia, urinary dysfunction, cognitive impairment, vertigo, speech 
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problems, problems with handwriting and muscle cramps which are assessed using a 
similar semi-quantitative scale. Thirty-three separate items are assessed providing a 
large amount of directly analyzable data relating to patients’ symptoms and signs. The 
extracerebellar items are grouped into 16 areas. The presence or absence of signs in 
each area is scored as zero or one, and the total of these provides the INAS count 
ranging from zero (no non-ataxic signs) to a maximum of 16. Both in the raw data for 
the INAS and the INAS count, higher values represent greater disability. 
All patients in the study underwent a thorough neurological examination at every 
presentation, but not all details of this were captured in the validated rating scales and 
other data recorded as part of the EFACTS assessment. Details of the remainder of the 
neurological examination were therefore recorded in the Structured Neurological 
Examination (SNE). This is a tool devised by the author as a formal record of the 
neurological examination using a variety of traditional bedside assessment techniques 
and semi-quantitative scales. These data were therefore not recorded centrally as part 
of the EFACTS Registry. Amongst the cranial nerve examination, the presence, absence 
and nature of the following features was recorded: pupillary abnormalities, ptosis, 
ophthalmoparesis, facial sensory loss, masticatory muscle weakness, facial weakness, 
hearing abnormalities, palatal movement abnormalities, sternocleidomastoid 
weakness, trapezius weakness, tongue atrophy, abnormalities of lingual tone. As part 
of the limb examination, the severity or extent of the following features was recorded: 
power, reflexes, sensation, muscle atrophy, tone. Power was evaluated using the 
modified Medical Research Council (MRC) scale (Guarantors-of-Brain 1986) as follows: 
0. No contraction (MRC 0/5) 
1. Flicker or trace of contraction (MRC 1/5) 
2. Active movement with gravity eliminated (MRC 2/5) 
3. Active movement against gravity (MRC 3/5) 
4. Active movement against gravity and slight resistance (MRC 4-/5) 
5. Active movement against gravity and moderate resistance (MRC 4/5) 
6. Active movement against gravity and strong resistance (MRC 4+/5) 
7. Normal power (MRC 5/5) 
In order to present the results concisely, the individual power ratings were grouped as 
follows: 
70 
 
1. Upper limb proximal : shoulder abduction/adduction, elbow flexion/extension 
2. Upper limb distal: wrist flexion/extension, finger flexion/extension, index finger 
abduction, little finger abduction, thumb abduction 
3. Lower limb proximal: hip flexion/extension, Hip abduction/adduction, knee 
flexion/extension 
4. Lower limb distal: ankle flexion/extension, ankle inversion/eversion, toe 
flexion/extension 
Deep tendon reflexes (biceps, supinator, triceps, patellar, ankle) were recorded 
according to the following scale: 
0. Absent (-) 
1. Present with reinforcement only ([+]) 
2. Present but hyporeflexic (+) 
3. Normal (++) 
4. Hyperreflexic (+++) 
5. Hyperreflexic with clonus (++++) 
The plantar reflexes were recorded as being extensor, flexor, mute or withdrawal. 
Muscle atrophy was recorded using the following scale: 
0. No atrophy 
1. Mild atrophy 
2. Moderate atrophy 
3. Severe atrophy 
Muscle tone was recorded according to the following scale: 
1. Highly flaccid 
2. Flaccid 
3. Normal 
4. Spastic 
5. Highly spastic 
If other variants of muscle tone were present, these were recorded. Upper limb 
sensation (pin prick, joint position sense, vibration) was recorded by extent of 
involvement according to the following scale on the presumption that the sensory loss 
was length-dependent in nature and predominantly distal in distribution: 
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0. Normal 
1. Fingertips only affected 
2. Affected to knuckles 
3. Affected to wrists 
4. Affected to elbows 
5. Affected to shoulders 
6. Other (specifiy) 
Lower limb sensation was recorded using the following scale: 
0. Normal 
1. Toes only affected 
2. Affected to ankles 
3. Affected to knees 
4. Affected to hips 
5. Affected to lower costal margin 
6. Affected to sternum 
7. Other (specify) 
Various other features such as skeletal foot abnormalities were also recorded as part 
of the SNE.  
The EFACTS clinical assessment proforma and copies of all rating scales can be found in 
the Appendix. 
2.2.3 Data Handling 
All EFACTS data were entered into a central database (the ‘EFACTS Registry’) managed 
by 2mt Software GmbH (Ulm, Germany) after generation of a 9-digit anonymous code, 
the key to which was stored in each participating centre. Only clinicians and approved 
data management personnel in each centre had access to patient-identifiable records 
and data. The data were recorded in separate fields (eg demographics, onset, 
examination, cardiology, ADL, EQ-5D, SARA, INAS, SCAFI, etc.). Once the data were 
entered into the EFACTS Registry and finalized at each centre, they were then formally 
‘signed off’ and underwent a process of data monitoring during which they were 
deemed either ‘under editing’ or ‘plausible’. If individual data were missing, these 
could be recorded as such. If whole fields were not undertaken and the data would 
never become available, these could be ‘deactivated’. The data monitoring process 
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generated data queries which were addressed by each participating centre, in order to 
eliminate internal inconsistencies in the data, implausible and missing results, and 
potential errors of data entry. Once this process was complete, the data were said to 
be ‘checked’ and were available anonymously to all participating centres. Difficulties, 
problems and queries concerning the Registry and clinical assessment generally, were 
discussed at monthly web-conferences to which all participating centres and senior 
members of the EFACTS Steering Committee contributed. Subsequent statistical 
analysis was performed using Excel and SPSS. 
2.2.4 Biological Samples & Genetic Analysis 
At the baseline and first year follow-up visits, 70ml of whole blood was taken and a 
urine sample given. All samples were processed within 30 minutes of withdrawal from 
the patient. 10ml of whole blood was taken into EDTA tubes for DNA extraction, 
genetic analysis and GAA size determination. On processing, the samples were frozen 
at -20°C and subsequently transferred to a -80°C freezer for long-term storage. 2.5ml 
of whole blood was taken into a Paxgene tube for frataxin mRNA analysis, inverted ten 
times and stored upright at room temperature for 24 hours to ensure cell lysis. It was 
then transferred to a -20°C for 48 hours before transferring to a -80°C freezer for long-
term storage. The genetic and frataxin expression samples were repeated at the 
second year follow-up visit. 57.5ml of whole blood was taken in a 2:2:1 ratio into 
serum, EDTA and citrate blood tubes, respectively. These were centrifuged at 1,600G 
for 15 minutes at room temperature and the resulting supernatant fluid transferred to 
a pre-cooled matrix box on wet ice so that 16ml of serum, 16ml of EDTA-derived 
plasma and 8ml of citrate-derived plasma were obtained in 1ml sample tubes. The 
urine sample was also transferred to the matrix box in 1ml sample tubes. The matrix 
box was immediately transferred to a -80°C freezer. The resulting four blood tubes and 
matrix box were labelled anonymously with individual 8-digit codes issued by the 
Aachen biobank which were logged on the central EFACTS Registry.  
The processed frozen blood and urine samples were stored at -80°C and periodically 
shipped under dry ice by temperature-controlled courier in batches to collaborating 
centres in Europe. Analysis of the blood samples for GAA size estimation, FXN gene 
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sequencing and measurement of frataxin expression were undertaken by collaborators 
at the Université Libre de Bruxelles (Dr. Myriam Rai & Pr. Massimo Pandolfo). Genomic 
DNA from peripheral blood lymphocytes was extracted using standard procedures and 
GAA expansion size estimated according to previously published methods (Pandolfo 
2006) using primers as previously described (Campuzano et al. 1996). In short, this 
involved PCR using primers flanking the GAA expansion. The PCR products were 
subjected to electrophoresis on a standard agarose gel and the band size estimated by 
comparison with a standard DNA size ladder. The number of triplet repeats (n) was 
calculated according to the following formula: n=(bp-457)/3 where bp represents the 
size of the PCR product in base pairs. The smaller band is by convention denoted 
GAA1, and the larger, GAA2. The GAA size data are used in this thesis.  
Where the results of genetic analysis performed centrally as part of the EFACTS group 
were not available at the time of data analysis, it was then performed locally in the 
accredited Neurogenetics laboratory of the NHNN which used triplet-primed and long 
PCR techniques to confirm the presence of two GAA expansions (protocols available 
locally). These techniques did not provide data concerning the GAA expansion size.  In 
fact, the majority of patients in the study (who were recruited from local clinics at the 
NHNN) already had a genetic diagnosis provided by these techniques which allowed 
corroboration of the results produced by the EFACTS collaborators. Central EFACTS 
data were not available largely for phase 2 patients who entered the project at a later 
stage than phase 1 patients (see Section 1.3.1 below for an explication). Frataxin 
mRNA levels were also not available at the time of preparation of this thesis. The 
remaining blood samples will be stored in a central biobank at the Universitätsklinikum 
Aachen (Prof. Jörg B Schulz) who will coordinate proteomic and biomarker analysis of 
these samples between different collaborating centres. 
2.2.5 Author’s Contribution 
The project was conceived by a working party of European research groups headed by 
Pr. Massimo Pandolfo of the Université Libre de Bruxelles which put together a funding 
application to the Seventh Framework Programme of the European Commission in 
2009. This was successful and provided funding from 1.5.2010 to 30.4.2015. The 
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specific components of the clinical assessment and plans for the ascertainment, 
storage and processing of biological samples were discussed and agreed at the 
inaugural meeting of EFACTS at the European Commission, Brussels on 3-4 May 2010. 
Local Ethics Committee approval was obtained by Dr Suran Nethisinghe & Dr Paola 
Giunti, although the author fully formulated a successful substantive amendment to 
the application in 2013. The author first participated in the project at the EFACTS 
Research Meeting, Brunel University on 25-26 November 2010 and joined full-time at 
UCL on 4 April 2011. The author actively participated in the monthly pan-European 
web-conferences which discussed recruitment and data entry, as well as identifying 
ongoing problems with the project, devising solutions and proposing new sub-projects. 
Prospective participants were identified by the author from records held in the 
Department and from other sources. Participants were contacted by the author in 
writing, by email or by telephone and research clinic appointments made by the 
author. Clinic facilities, laboratory space and clinical materials were obtained by the 
author. Approximately 90% of the patients were seen and fully assessed by the author, 
the remainder being seen by Dr Paola Giunti. All home visits were undertaken by the 
author. At each assessment the history, examination and rating scales were 
undertaken by the author as well as obtaining blood and urine samples. The vast 
majority of these were processed in the laboratory by the author, with help from Dr 
Vittoria Ercolani and Susan Green. Genetic analysis was performed by Dr Myriam Rai of 
the Université Libre de Bruxelles. Participants from the Republic of Ireland were 
identified by Barbara Flynn and Annette Kelly of Ataxia Ireland. Travel for the patients 
to London, or for the author and Dr Giunti were organized by Ataxia Ireland and Sarah 
Green of DeNDRoN. 
Follow-up appointments were organized by the author and by Selina Paul of 
DeNDRoN, with approximately 90% seen and fully assessed by the author; the 
remainder were seen by Dr Paola Giunti. Data entry was performed by a variety of 
individuals including the author, with all data queries answered by the author and 
overall responsibility for quality control of data undertaken by the author. 
Management of the data centrally in the EFACTS Registry was undertaken by Kathrin 
Fesodov geb Osterholt. All local data handling, downloading, processing and statistical 
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analysis were undertaken by the author. The author left the project full-time on 5 
August 2014 but has continued to participate in various elements of the study since 
then. Further details of the author’s contribution are given in the Acknowledgements. 
2.3 Results 
2.3.1 Recruitment 
Recruitment across the 11 European sites began on 15 September 2010 and by 30 April 
2013 the 600 patient recruitment target had been attained. Baseline data for 592 of 
these cases for which a genetic diagnosis and full clinical data were available, was 
published in 2015 including 149 cases from the UK and Ireland (Reetz et al. 2015). 
These patients constitute phase 1 of the study. Recruitment continued and by 1 August 
2014, 637 patients had been recruited across Europe including 169 from the UK and 
Ireland. The additional participants constitute phase 2 of the study. Thus, this centre 
provided 26.5% of the European total (see Figure 5). The distinction between phases 1 
and 2 of the project is largely artificial and determined by internal recruitment and 
publication deadlines within the project. The only differences between the two groups 
were the funding rewarded to recruiting centres and the nature of biological samples 
taken for the central biobank. The clinical assessment was identical and so for the 
purposes of this thesis, the two are combined. However, because the phase 2 patients 
were recruited later than the phase 1 patients, there are almost no follow-up data on 
the former as they had not reached their follow-up appointments by the time the data 
were collated for this thesis. These data continue to be collected within the group as 
the project is ongoing but are not included in this thesis. 
Recruitment in the UK for the purposes of this thesis took place between 1 August 
2011 and 1 August 2014 and included 21 cases from the Republic of Ireland. 169 
patients were recruited in total, for two of which genetic analysis subsequently 
showed no GAA expansions, point mutations or macrodeletions within the FXN gene. 
They were therefore excluded from all subsequent analyses. These two patients had 
been given a clinical diagnosis of FRDA before the discovery of the FXN gene in 1996 
and had never subsequently undergone genetic testing. They were informed of the 
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genetic result and offered further investigations in the Ataxia Clinic. In neither case has 
this revealed a genetic diagnosis. 
Figure 5: EFACTS patient recruitment by centre 15.9.2010-1.8.2014 
2.3.2 Demographics 
The basic demographic details at the baseline assessment of the 167 patients recruited 
at the London centre are given in Table 3, including gender, ethnicity, weight, height, 
country of birth, marital status, offspring, education and employment. Figure 6 and 
Figure 7 show the location of the patients, showing that, although the recruiting centre 
was in London, participants were recruited from throughout the UK and Ireland. 
Although 21 patients were recruited via the charity Ataxia Ireland, a further four were 
born in Ireland but recruited as part of the UK cohort (including one from Northern 
Ireland). The study included 15 pairs of siblings and 1 pair of cousins. 159 patients 
(95.2%) carried two GAA expansions. Of the remaining eight patients, all were 
compound heterozygotes. Seven had a point mutation, including five cases of the 
p.Gly130Val variant, and one each of the p.Met1Thr and p.Arg165Asp variants. There 
was one example of a macrodeletion. The compound heterozygotes are discussed 
more extensively in Chapter 3.  
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Table 3: Basic demographic details of UK EFACTS patients at baseline 
  Number (%) 
Gender Male : Female 72a : 95 (43.1 : 56.9) 
Age (years) Range 16 – 68 
 Mean ± SD 34.3 ± 13.2 
 Median 31 
Disease duration Range 3 – 55 
(years) Mean ± SD 20.5 ± 11.2 
 Median 19 
Weight (kg)b Mean ± SD 68.7 ± 16.1 
 Range 40 – 120 
Height (cm)c Mean ± SD 168.2 ± 10.6 
 Range 128 – 196 
BMI (kg/m2)d Mean ± SD 24.3 ± 5.0 
 Range 15.7 – 40.2 
Ethnicity Caucasian 155 (92.8) 
 Asian 9 (5.4) 
 S American 2 (1.2) 
 Mixed 1 (0.6) 
Country of birth UK 125 (74.8) 
 Eire 25 (15.0) 
 South Africa 3 (1.8) 
 Afghanistan 2 (1.2) 
 France 2 (1.2) 
 Italy 2 (1.2) 
 Othere 9 (5.4) 
Marital status Single 106 (63.5) 
 Married/in relationship 52 (31.1) 
 Divorced/separated/widowed 9 (5.4) 
Offspring Children 47 (28.1) 
 No children 120 (71.9) 
Education (ISCED)f 1 : Primary school 1 (0.6) 
 2 : ‘O’ level/GCSE 40 (24.0) 
 3 : ‘A’ level 39 (23.3) 
 4 : BTEC/NVQ/HND 32 (19.2) 
 5 : BSc/MSc 48 (28.7) 
 6 : PhD 6 (3.6) 
 Not known 3 (1.8) 
Employment Not in employment 111 (66.5) 
 In employment 56 (33.5) 
     Full time 32 (19.2) 
     Part time 24 (14.4) 
Sibling pairs  15 
Cousin pairs  1 
Mutation Homozygous GAA expansion 159 (95.2) 
 Compound heterozygousg 8 (4.8) 
  a
 Includes 1 pre-operative transsexual living as female                                                   cont… 
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  b
n=145; 
c
n=150; 
d
n=140 (incomplete dataset due to immobility) 
  e
Canada, Colombia, Mauritius, New Zealand, Norway, Pakistan, Switzerland, Turkey, USA  
(1 each) 
 
f
ISCED=International Standard Classification of Education 
  g
G130V (5), M1T (1), R165D (1), macrodeletion (1) 
 
 
 
Figure 6: Location of EFACTS patients in the British Isles 
Red dots indicate the current residence of patients participating in the study, showing 
their spread throughout the British Isles but concentration in the South-East of England 
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Figure 7: Location of EFACTS patients in the South-East of England 
Red dots indicate the current residence of patients participating in the study from the 
South-East of England 
 
The range of ages at which patients were examined at baseline as part of the study is 
illustrated in Figure 8 ranging from 16 to 68. Of note, only patients of 16 years and 
older were permitted by the local ethics permission, and so younger patients were not 
studied as part of this project. Figure 9 shows the disease duration since symptom 
onset for the EFACTS patients at their baseline visit, ranging from 3 to 55 years. 
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Figure 8: Age at examination of EFACTS patients at baseline 
Patients were seen in the adult clinic from age 16 upwards. The oldest patient was 68 
at baseline examination. The commonest age at baseline examination was 18, with the 
majority of patients below the age of 45 
 
Figure 9: Disease duration of EFACTS patients at baseline 
Patients seen at baseline examination had disease duration of between 3 and 55 years, 
with the commonest duration of 12 years and the majority less than 30 years 
2.3.3 Genetic Features 
GAA expansion size results were available for 153 patients, principally from phase 1 of 
the study. This included six compound heterozygotes. Results for the remaining 14 
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patients were not available by the time of data analysis. Therefore, 147 results were 
available for patients with two GAA expansions. Analysis of the compound 
heterozygotes is presented in Chapter 3. By convention, the shorter of the two 
expansions is denoted by the term GAA1 and the longer, by GAA2. GAA1 sizes ranged 
from 100 to 1200 repeats with a mean value of 658.1 and mode of 700. GAA2 values 
varied from 200 to 1500 repeats with a mean value of 952.8 (see Table 4). The range of 
GAA expansion sizes is illustrated in Figure 10. There is a significantly longer tail of 
smaller GAA repeats amongst the GAA1 results below about 600 repeats when 
compared to the GAA2 results. This is perhaps because patients with two short 
expansions would have very mild symptoms and late onset or atypical presentations, 
and hence there is a negative ascertainment bias for these values. The distribution of 
GAA2 sizes is shifted approximately 200-400 repeats toward greater values, but is 
rather more skewed in the case of the GAA2 alleles. Thus, the maximum value for both 
alleles is roughly 1200 apart from a single outlier at 1500. It may be that values greater 
than this so disrupt the structure of the gene that they are not compatible with life. 
 
Table 4: GAA expansion sizes for EFACTS patients (excluding compound 
heterozygotes) 
 GAA1 GAA2 
Mean 658.1 952.8 
SD 254.2 186.2 
Median 700 967 
Range 100 - 1200 200 - 1500 
n 147 147 
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Figure 10: GAA expansion sizes for EFACTS patients with two GAA expansions  
GAA1 (top graph) is defined as being the shorter of the two expansions, whereas GAA2 
(middle graph) is the longer. The two sets of expansion sizes are merged in the bottom 
graph. 
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2.3.4 Onset & Disease Progression Recorded at Baseline 
The mean age at onset of the FRDA patients in the study was 13.7, ranging from 1 to 
55 years. 85.0% of the cohort used some aid for walking at least intermittently, from a 
mean age of 20. 74.9% of the cohort permanently used an aid for walking which 
occurred at a mean age of 22.1. Eighty-six of the patients in the study (51.5%) 
permanently used a wheelchair. Progression to permanent use of a wheelchair 
occurred at a mean age of 21.9 years. Further details of these milestones in disease 
progression are given in Table 5. 
Table 5: Significant milestones in disease progression of EFACTS patients 
  Age (years) 
Age at onset  Mean ± SD 13.7 ± 9.6 
(n=167) Median 12 
 Range 1-55 
Age at intermittent support for walking Mean ± SD 20.0 ± 10.5 
(n=142) Median 17 
 Range 2-64 
Age at permanent support for walking Mean ± SD 22.1 ± 10.1 
(n=125) Median 19 
 Range 2-65 
Age at wheelchair-bound Mean ± SD 21.9 ± 8.7 
(n=86) Median 19 
 Range 5-48 
 
The range of ages at symptom onset of the participating EFACTS patients is depicted in 
Figure 11 showing that the majority of patients have disease onset before the age of 
20 but a small number have late-onset disease up to age 55. Figure 12 shows the range 
of ages at which patients become wheelchair-bound which most commonly occurs in 
teenage years or early twenties. 
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Figure 11: Age at onset of EFACTS patients 
Age at onset varied from birth to age 55 but with the vast majority below the age of 25 
as defined in Harding’s diagnostic criteria 
 
Figure 12: Age at wheelchair-bound for EFACTS patients 
55% of the cohort required a wheelchair: the majority became wheelchair-bound 
between the ages of 15 and 25 
The majority of patients present with instability, falls or clumsiness but a significant 
proportion (9.6%) first present with scoliosis. Initial presentation with other known 
non-neurological manifestations of FRDA such as skeletal foot abnormalities (2.4%), 
cardiomyopathy (1.2%) or diabetes (1.2%) is rare. A number of other rare 
presentations are recorded including pain (3%), fatigue (2.4%), dysarthria (1.2%), 
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postural dizziness (1.2%), stiffness (1.2%), urinary urge (0.6%), poor growth (0.6%) and 
cold intolerance (0.6%). Patients described several practical situations in which 
functional ability was first compromised such as problems with sport, carrying liquids 
or handwriting, which probably represent a combination of gait instability and loss of 
manual dexterity. Note, in this analysis, patients may present with more than one 
initial symptom, hence values add up to greater than 100%. The results are detailed in 
Table 6 and depicted in Figure 13. 
Table 6: Symptoms at onset of EFACTS patients 
Symptom at onset Number (%) 
Instability 112 (67.1) 
Falls 26 (15.6) 
Clumsiness 21 (12.6) 
Scoliosis 16 (9.6) 
Difficulty with sport 8 (4.8) 
Difficulty carrying liquid 7 (4.2) 
Altered gait 5 (3.0) 
Leg/foot pain 5 (3.0) 
Skeletal foot abnormality 4 (2.4) 
Problem with handwriting 4 (2.4) 
Fatigue 4 (2.4) 
Cardiomyopathy 2 (1.2) 
Dysarthria 2 (1.2) 
Stiff limbs 2 (1.2) 
Postural dizziness 2 (1.2) 
Diabetes mellitus 1 (0.6) 
Urinary urgency 1 (0.6) 
Poor growth 1 (0.6) 
Arrhythmia 1 (0.6) 
Extreme reaction to alcohol 1 (0.6) 
Episodic sensory symptoms 1 (0.6) 
Cold intolerance 1 (0.6) 
Not known 1 (0.6) 
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Figure 13: Common symptoms at onset of EFACTS patients 
Instability is by far the commonest presenting feature followed by falls & clumsiness. 
Scoliosis is the only common non-neurological presenting feature 
The level of disability of the EFACTS patients at baseline examination based on mobility 
was classified using the Spinocerebellar Degeneration Functional Scale (SDFS) which is 
a 7-point scale described in the Method above. The descriptions of the stages and 
proportion of patients with each stage are given in Table 7 and illustrated in Figure 14. 
129 patients in the study complained of falls (77.2%) which started at a mean age of 
17.1 ± 1.2 years (range 1 to 64 years). These figures show the heavy disease burden of 
FRDA at an early age. 
Table 7: Spinocerebellar Degeneration Functional Score (SDFS) for EFACTS patients at 
baseline 
Disability Stage Number (%) 
1: No functional handicap but signs at examination 1 (0.6) 
2: Mild, able to run, walking unlimited 8 (4.8) 
3: Moderate, unable to run, limited walking without aid 26 (15.6) 
4: Severe, walking with one stick 14 (8.4) 
5: Walking with two sticks 26 (15.6) 
6: Unable to walk, requiring wheelchair 92 (55.1) 
7: Confined to bed 0 (0) 
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Figure 14: Spinocerebellar Degeneration Functional Score (SDFS) for EFACTS patients 
at baseline 
2.3.5 Associated Clinical Features 
Associated clinical features of FRDA were recorded in various parts of the EFACTS 
assessment at baseline. Visual and hearing problems, scoliosis, pes cavus and diabetes 
mellitus were recorded within the history section of the EFACTS Registry. Cardiac 
problems were recorded in this section and as part of a separate cardiology section. 
Further details were also recorded as part of the SNE which will be discussed later.  
Table 8 summarizes the medical problems recorded in the Registry for all the 167 
EFACTS patients at baseline.  
 
Table 8: General medical features seen in EFACTS patients at baseline 
System Diagnosis Number (%) 
Metabolic Dysthyroid 7 (4.2) 
 Hypercholesterolaemia 2 (1.2) 
Cardiovascular Cardiomyopathy/ventricular hypertrophy 72 (43.1) 
 Hypertension 14 (8.4) 
 Heart murmur  9 (5.4) 
 Atrial fibrillation 8 (4.8) 
 Supraventricular tachycardia 4 (2.4) 
 Other arrhythmia/tachycardia 2 (1.2) 
 Ischaemic heart disease/myocardial 
infarction 
2 (1.2) 
 Viral cardiomyositis 1 (0.6) 
 Intracardiac thrombus 1 (0.6) 
Stage 1 
0.6% 
Stage 2 
4.8% 
Stage 3 
15.6% 
Stage 4 
8.4% 
Stage 5 
15.6% 
Stage 6 
55.1% 
88 
 
Respiratory Asthma 18 (10.8) 
 Obstructive sleep apnoea 5 (3.0) 
 Pulmonary embolus 1 (0.6) 
Gastrointestinal Gastritis/GORD/Hiatus hernia 24 (14.4) 
 Chronic constipation 11 (6.6) 
 Chronic diarrhoea 2 (1.2) 
 Coeliac disease 2 (1.2) 
 Irritable bowel syndrome 2 (1.2) 
 Haemorrhoids 2 (1.2) 
 Pyloric stenosis 2 (1.2) 
 Abdominal hernia 1 (1.2) 
Urological Urinary 
frequency/urge/incontinence/retention 
36 (21.6) 
 Suprapubic catheter 3 (1.8) 
 Frequent urinary tract infections 3 (1.8) 
 Haematuria 1 (0.6) 
 Prostatic enlargement 1 (0.6) 
 Erectile dysfunction 1 (0.6) 
 Hypospadias 1 (0.6) 
 Nephrolithiasis 1 (0.6) 
Gynaecological Dysmenorrhoea 3 (1.8) 
 Hysterectomy/ovariectomy 1 (0.6) 
 Ovarian malignancy 1 (0.6) 
Ophthalmological Myopia 48 (28.7) 
 Hypermetropia 18 (10.8) 
 Nystagmus/oscillopsia 15 (9.0) 
 Optic neuropathy  9 (5.4) 
 Strabismus (operated) 3 (1.8) 
 Astigmatism  3 (1.8) 
 Keratoconus 2 (1.2) 
 Amblyopia  1 (0.6) 
 Presbyopia 1 (0.6) 
 Corneal ulceration 1 (0.6) 
 Epiretinal membrane 1 (0.6) 
 Glaucoma 1 (0.6) 
 Diabetic retinopathy 1 (0.6) 
 Mears-Irlen syndrome 1 (0.6) 
Otorhinolaryngological Tonsillectomy/adenoidectomy 4 (2.4) 
 Grommets/multiple ear infections 2 (1.2) 
 Mastoid perforation/abscesses/ear infections 1 (0.6) 
 Small external meati/dewaxing/ear infections 1 (0.6) 
 Chronic otitis externa 1 (0.6) 
 Skull fracture with hearing loss 1 (0.6) 
 Rhinoplasty with sinusitis 1 (0.6) 
 Prominent epistaxis 1 (0.6) 
 Bruxism 1 (0.6) 
 Post-nasal drip 1 (0.6) 
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Rheumatological Osteoporosis 4 (2.4) 
 Arthritis 2 (1.2) 
Orthopaedic Bony fracture 14 (8.4) 
 Meniscectomy 3 (1.8) 
 Hip replacement 2 (1.2) 
 Joint dislocation 1 (0.6) 
 Avascular necrosis of the scaphoid 1 (0.6) 
Dermatological Eczema 12 (7.2) 
 Chronic pruritis 3 (1.8) 
 Psoriasis 2 (1.2) 
 Acne 1 (0.6) 
 Shingles 1 (0.6) 
 Cutaneous sarcoidosis 1 (0.6) 
Haematological Iron deficiency anaemia 7 (4.2) 
 B12/folate deficiency 4 (2.4) 
 Haemolytic anaemia (glandular fever) 1 (0.6) 
 Anaemia, cause unknown 2 (1.2) 
 Deep vein thrombosis 2 (1.2) 
 Superficial thrombophlebitis 1 (0.6) 
 Thombophilia/Factor V Leiden 2 (1.2) 
 Beta-thalassaemia 1 (0.6) 
Psychiatric Depression 15 (9.0) 
 Anxiety/panic attacks 11 (6.6) 
 Adjustment disorder 1 (0.6) 
 Tourette’s syndrome 1 (0.6) 
Neurological Migraine 8 4.8) 
 Epilepsy 6 (3.6) 
 Multiple sclerosis 2 (1.2) 
 Parkinson’s disease 1 (0.6) 
 Subarachnoid haemorrhage 1 (0.6) 
GORD=Gastro-oesophageal reflux disease 
Cardiac, ophthalmological & otorhinolaryngological diagnoses are discussed in the text 
 
The measures of visual impairment and hearing loss recorded in the EFACTS Registry 
do not discriminate between visual and hearing loss primarily caused by FRDA, and 
those of different origin. Given that the majority of participants are young, most 
hearing loss recorded is likely to be a direct result of FRDA. General medical problems 
are recorded as part of the EFACTS assessment. The ear, nose and throat section 
documents only six alternative causes of hearing loss, viz. grommets and/or multiple 
ear infections (2 cases); mastoid perforation and abscesses (1 case); small external 
auditory meati/frequent dewaxing/multiple ear infections (1 case); chronic otitis 
externa (1 case); and hearing loss caused by skull fracture (1 case). The number of 
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cases directly attributable to be FRDA is therefore likely to be around 54 or 32.3% of 
the total cohort. Twenty-three patients (13.8%) are recorded as currently or previously 
using a hearing aid (including four of the above six patients). Only three patients felt 
that their hearing aid was effective (all cases attributable to FRDA). One patient had a 
cochlear implant inserted as a child. 
A high proportion of patients are recorded in the EFACTS Registry as having visual 
impairment (116 cases or 69.5% of the total cohort). However, this figure includes all 
cases of visual impairment including such common ophthalmic problems as myopia (48 
cases), hypermetropia (18 cases), presbyopia (1 case) and astigmatism (3 cases) which 
are unlikely to be directly caused by FRDA. Ninety-six patients (57.5%) are recorded in 
the Registry as using spectacles; in 75 cases these are recorded as being effective. The 
Registry formally records nine patients as having optic neuropathy and fifteen patients 
as having visual problems related to nystagmus, oscillopsia or abnormalities of visual 
fixation. There are also eleven patients with other causes of visual impairment (3 cases 
of strabismus, 2 cases of keratoconus and 1 case each of corneal ulceration, epiretinal 
membrane, amblyopia, Mears-Irlen syndrome, glaucoma and diabetic retinopathy). 
None of the above categories is mutually exclusive and so that patients may have 
multiple causes of visual impairment. Visual impairment in FRDA is caused by 
degeneration of both the anterior (optic nerve) and posterior (optic radiation and 
visual cortex) visual pathways, as well as oculomotor problems (Fortuna et al. 2009, 
Noval et al. 2012). There are 24 cases (14.4%) in the EFACTS Registry in which the 
cause of visual impairment is formally attributed to one of these or not recorded as 
having an alternative cause which is unrelated to FRDA. This figure is therefore likely to 
represent the prevalence of visual impairment in FRDA which is directly attributable to 
the condition itself. 
116 patients in the Registry have scoliosis (69.5%), of which 75 are recorded as mild, 
25 moderate, 10 severe and 6 of unknown severity. Thirty-eight have undergone 
corrective surgery at a mean age of 15.2 (range 6-21). Ninety-seven patients have pes 
cavus (58.1%), of which 30 are recorded as mild, 42 moderate, 20 severe and 5 of 
unknown severity. Twelve patients have undergone corrective surgery on their feet at 
a mean age of 23.8 (range 10-40). 
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Fifteen patients are recorded in the Registry as having diabetes mellitus, including ten 
with type 1 diabetes, four with type 2 and one of unknown type. The mean age at 
onset of diabetes mellitus was 25.5 (range 4-53). 
Dysuria was seen in 36 patients (21.6%) and frequent urinary tract infections in three 
(1.8%). Gastritic symptoms or hiatus hernia were described in 24 patients (14.4%) 
whilst chronic constipation was seen in 11 (6.6%). Fourteen patients had sustained a 
bony fracture (8.4%). Fifteen patients (9.0%) gave a history of depression and 11 
(6.6%) a history of anxiety or panic attacks. Asthma was seen in 18 patients (10.8%). 
The common associated clinical features of FRDA are shown in Table 9 and depicted in 
the Discussion in Figure 36. 
Table 9: Frequency of associated clinical features for EFACTS patients at baseline 
 Number (%) 
Visual impairment 116 (69.5) 
-attributable to FRDAa 24 (14.4) 
Hearing loss 60 (35.9) 
-attributable to FRDAa 54 (32.3) 
Scoliosis 116 (69.5) 
Pes cavus 97 (58.1) 
Cardiomyopathy 72 (43.1) 
Diabetes mellitus 15 (9.0) 
Urinary dysfunction 36 (21.6) 
Gastritic symptoms 24 (14.4) 
                                                
a
see explanation in text 
 
Seventy-two of the participants in the study (43.1%) had a history of cardiomyopathy. 
Twenty-six (15.6%) had a history of arrhythmia of which eight were known to have 
atrial fibrillation and four supraventricular tachycardia. The precise diagnosis was 
unclear in the remainder. Three patients (1.8%) had a permanent cardiac pacemaker in 
situ. Fourteen patients (8.4%) suffered with hypertension. Nine patients (5.4%) had a 
history of a heart murmur either currently or in the past (including childhood). Two 
patients (1.2%) had a diagnosis of ischaemic heart disease. One patient had previously 
had an intracardiac thrombus diagnosed during pregnancy. One patient previously had 
viral cardiomyositis. 
Table 10 shows the results of cardiac investigations of the EFACTS patients at baseline. 
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In total, echocardiographic data were available for 104 patients, and ECG data for 91. 
Results are recorded as a percentage of values obtained rather than of the whole 
cohort which may overestimate the prevalence of abnormal findings as patients with 
evidence of cardiac involvement are more likely to be referred for cardiac assessment. 
The seven cases of conduction abnormality included three cases of incomplete right 
bundle branch block, two cases of incomplete left bundle branch block, one case of 
long QT interval and one case of a non-specific intraventricular conduction delay.  
Table 10: Results of cardiac investigations at baseline for EFACTS patients 
Investigation  Value (%) n 
Systolic BP (mmHg) Mean ± SD 116.7 ± 17.9 164 
 Range 66 – 182  
Diastolic BP (mmHg) Mean ± SD 78.6 ± 14.5 164 
 Range 45 – 168  
Pulse (bpm) Mean ± SD 77.9 ± 12.3 164 
 Range 52 - 112  
IVSd (mm) Mean ± SD 10.6 ± 2.6 91 
 Range 6 - 20  
LVPWd (mm) Mean ± SD 10.0 ± 2.6 86 
 Range 6 - 17  
LVEF (%) Mean ± SD 63.2 ± 10.9 87 
 Range 29 - 89  
ECG  Repolarization changes 59 (69.4%) 88 
 Voltage criteria for LVH 28 (40.0%) 70 
 Pathological Q waves 7 (11.1%) 63 
 Conduction abnormalities 7 (10.6%) 66 
 Arrhythmia (all AF) 3 (3.4%) 89 
 Paced rhythm 3 (3.3%) 90 
 
Reference valuesa Normal Mild Moderate Severe 
IVSd (mm) 6 – 12 13 - 15 16 - 19 ≥20 
LVPWd (mm) 6 – 12 13 - 15 16 - 19 ≥20 
LVEF (%) ≥55% 45-54% 36-44% ≤35% 
IVSd=intraventricular septal thickness at diastole 
LVPWd=left ventricular posterior wall thickness at diastole 
LVEF=left ventricular ejection fraction 
ECG=electrocardiogram   BP=Blood pressure 
LVH=left ventricular hypertrophy   AF=atrial fibrillation 
a
 from (Steeds et al. 2011) 
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2.3.6 Activities of Daily Living (ADL) 
164 participants completed the ADL questionnaire at baseline, as described in the 
Method at 2.2.2. The individual questions of the ADL questionnaire can be found in the 
Appendix. Figure 15. The mean value was 15.6 ± 8.4 out of a possible total of 36. The 
walking and falls parameters were most severely affected, with swallowing and 
bladder function least affected. Higher values represent greater disability. 
Table 11 shows the results by subscore of the questionnaire which are shown 
graphically in Figure 15. The mean value was 15.6 ± 8.4 out of a possible total of 36. 
The walking and falls parameters were most severely affected, with swallowing and 
bladder function least affected. Higher values represent greater disability. 
Table 11: Subscores of the Activities of Daily Living section of the FRDA Rating Scale 
for EFACTS patients at baseline 
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0 18 45 41 35 42 29 1 42 96 349 
1 52 60 48 44 48 41 19 33 37 382 
2 76 55 34 34 29 16 13 37 14 308 
3 13 2 27 32 27 8 43 34 9 195 
4 5 2 14 19 18 70 88 18 8 242 
Mean 1.6 1.1 1.5 1.7 1.6 2.3 3.2 1.7 0.8 15.6 
SD 0.9 0.9 1.3 1.3 1.3 1.6 1.0 1.3 1.1 8.4 
Mode 2 1 1 1 1 4 4 0 0 1 
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Figure 15: Subscores of the Activities of Daily Living section of the FRDA rating scale 
for EFACTS patients at baseline 
Most subscores show a broad range of values except falls and walking which are 
skewed to higher values, and bladder function which is skewed to lower values 
2.3.7 Scale for the Assessment & rating of Ataxia (SARA) 
The SARA was assessed on 166 FRDA patients at baseline, as described in the Method 
at 2.2.2. The individual subscores can be found in the Appendix. The results are shown 
in Table 12 and depicted graphically in Figure 16. The mean SARA was 22.5±10.0. The 
gait, stance, sitting and heel-shin test subscores had the greatest proportion in the 
highest scores, indicating severe involvement of these parameters. The speech, finger 
chase, finger-nose test and fast alternating hand movement results were more evenly 
spread, indicating less severe involvement of these functions. Fractional values appear 
for the finger chase, finger-nose test, fast alternating hand movements and heel-shin 
test subscores as these parameters are assessed for each limb independently and a 
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mean calculated. Fractional values are much less common than integral values as 
patients often have symmetrical signs. Higher values represent more prominent ataxia. 
Table 12: SARA subscores for FRDA patients at baseline 
Score Gait Stance Sitting Speech Finger Chase 
Nose-
Finger 
Test 
Fast 
Alternating 
Hand 
Movements 
Heel-
Shin Test 
0 0 4 44 29 15 16 24 5 
0.5 - - - - 7 10 11 9 
1 10 17 31 33 73 46 46 25 
1.5 - - - - 4 14 12 4 
2 16 20 12 57 46 33 15 26 
2.5 - - - - 1 4 6 0 
3 8 11 1 33 11 36 43 25 
3.5 - - - - 0 0 0 1 
4 3 3 78 10 9 7 9 71 
5 10 16 - 1 - - - - 
6 16 95 - 3 - - - - 
7 7 - - - - - - - 
8 96 - - - - - - - 
Mean 6.3 4.5 2.2 1.9 1.5 1.7 1.7 2.7 
SD 2.4 2.0 1.8 1.3 1.0 1.1 1.2 1.3 
Mode 8 6 4 2 1 1 1 4 
 
 
Figure 16: SARA subscores for FRDA patients at baseline 
All the subscores involved in LL function are skewed toward higher values. Those for 
UL function and speech are more broadly spread 
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2.3.8 Inventory of Non-Ataxic Symptoms (INAS) 
The INAS was completed at baseline for 166 patients in the study, as described in the 
Method at 2.2.2. The individual features of the INAS can be found in the Appendix. 
Higher values represent greater disease involvement. The mean INAS count was 5.0 ± 
1.6. The number and proportion of participants having each of the INAS count values 
are displayed in Table 13 and illustrated in Figure 17. Areflexia, sensory loss and 
weakness are seen in more than 75% of cases. Extensor plantar reactions, spasticity, 
amyotrophy, urinary dysfunction and brainstem oculomotor signs are seen in between 
a quarter and three quarters of patients. Hyperrefexia and cognitive dysfunction are 
seen in less than 10% of cases, whilst dystonia, myoclonus, chorea and parkinsonism 
were seen in less than 3%. Indeed, the only cases of resting tremor and rigidity were 
observed in a 50-year old patient who was compound heterozygous for a p.Gly130Val 
mutation and who was felt to have an independent diagnosis of Parkinson’s disease 
(see Chapter 3, Patient 2 for further details).  
Table 13: INAS count values for EFACTS patients at baseline 
 No. of 
patients (%) 
Hyperreflexia 11 (6.6) 
Areflexia 156 (94.0) 
Extensor plantar 104 (62.7) 
Spasticity 80 (48.2) 
Paresis 129 (77.7) 
Muscle atrophy 76 (45.8) 
Fasciculations 1 (0.6) 
Myoclonus 2 (1.2) 
Rigidity 1 (0.6) 
Chorea/dyskinesia 3 (1.8) 
Dystonia 4 (2.4) 
Resting tremor 1 (0.6) 
Sensory symptoms 146 (88.0) 
Urinary dysfunction 63 (38.0) 
Cognitive dysfunction 13 (7.8) 
Brainstem oculomotor signs 47 (28.3) 
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Figure 17: INAS count values for EFACTS patients at baseline 
Table 14 details the pattern of non-ataxic signs and symptoms as recorded in raw data 
from the INAS for the EFACTS cohort at the baseline assessment. The pattern of 
weakness, spasticity and vibrational sensory loss is illustrated in Figure 18; symptoms 
reported by the patients as part of the INAS (diplopia, dysphagia, episodic vertigo, 
dysarthria, handwriting problems and muscular cramps) are shown in Figure 19; the 
results of deep tendon reflexes are shown in Figure 20; finally, the ophthalmological 
features of the EFACTS cohort at baseline are represented in Figure 21. 
Table 14: Non-ataxic symptoms & signs from INAS at baseline for EFACTS patients 
[Number (%)] 
  None Mild Moderate Severe 
Weakness UL proximal 131 (78.9) 27 (16.3) 3 (1.8) 5 (3.0) 
 UL distal 98 (59.0) 41 (24.7) 14 (8.4) 13 (7.8) 
 LL proximala 51 (30.7) 45 (27.1) 34 (20.5) 34 (20.5) 
 LL distalb 48 (28.9) 33 (18.1) 24 (14.5) 59 (35.5) 
Spasticity ULc 121 (72.9) 41 (24.7) 3 (1.8) 0 (0) 
 LLd 99 (59.6) 33 (19.9) 24 (14.4) 6 (3.6) 
Impaired vibration LL distale 24 (14.5) 38.5 (23.2) 46.5 (28.0) 54 (32.5) 
 
 None Mild Moderate Severe 
Diplopia 143 (86.1) 17 (10.2) 3 (1.8) 3 (1.8) 
Dysphagia 52 (31.3) 64 (38.6) 46 (27.7) 4 (2.4) 
Episodic vertigo 142 (85.5) 9 (5.4) 9 (5.4) 6 (3.6) 
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Speech problems 18 (10.8) 64 (38.6) 62 (37.3) 22 (13.3) 
Handwriting problems 18 (10.8) 24 (14.5) 72 (43.4) 52 (31.3) 
Muscle cramps 58 (34.9) 37 (22.3) 17 (10.2) 54 (32.5) 
 
 Normal Hyperreflexic Areflexic 
Biceps reflex 10 (6.0) 6 (3.6) 150 (90.4) 
Patellar reflex 15 (9.0) 10 (6.0) 141 (84.9) 
Achilles reflex 13 (7.8) 3 (1.8) 150 (90.4) 
 None Unilateral Bilateral 
Extensor Plantarf 62 (37.3) 10 (6.0) 92 (55.4) 
 
 Number (%) 
Broken smooth pursuits 131 (78.9) 
Square wave jerks on fixation 108 (65.0) 
Downbeat nystagmus on fixation 1 (0.6) 
Gaze-evoked nystagmus on horizontal testing 61 (36.7) 
Gaze-evoked nystagmus on vertical testing 14 (8.4) 
Ophthalmoparesis on horizontal gazeg 4 (2.4) 
Ophthalmoparesis on vertical gazeh 8 (4.8) 
Slowing of saccades 44 (26.5) 
Hypometric saccadesi 94 (56.6) 
Hypermetric saccadesj 82 (49.4) 
      UL=upper limb ; LL=lower limb 
      Missing values: 
a
n=2 ; 
b
n=2; 
c
n=1; 
d
n=4; 
e
n=4; 
f
n=2; 
g
n=1; 
h
n=1; 
i
n=5; 
j
n=4 
 
 
Figure 18: Weakness, spasticity & sensory loss for EFACTS patients as recorded in the 
INAS at baseline 
LL weakness is much commoner than UL. Spasticity is rare but commoner in the LLs. LL 
distal sensory loss is common 
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Figure 19: Symptoms reported by EFACTS patients at baseline as part of the INAS 
Dysphagia, dysarthria, problems with handwriting and muscular cramps are much 
commoner than diplopia and vertigo in FRDA 
 
Figure 20: Reflexes for EFACTS patients as recorded in the INAS at baseline 
Areflexia is common throughout in FRDA 
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Figure 21: Ophthalmological features of EFACTS patients as recorded in the INAS at 
baseline 
2.3.9 Spinocerebellar Ataxia Functional Index (SCAFI) 
SCAFI data were available at baseline for 155 patients from the EFACTS cohort, as 
described in the Method at 2.2.2. The individual features of the SCAFI can be found in 
the Appendix. All 155 (92.8%) completed the speech assessment (PATA test); 110 
patients (65.9%) completed the 9-hole peg test (9HPT) with both hands; however, just 
53 patients (31.7%) completed the 8-metre timed walk (8mTW). Lower values for the 
PATA test and higher values for the 8mTW and 9HPT represent greater disease 
involvement. 138 are recorded as being right-handed (82.6%); 14 are recorded as left-
handed (8.4%); handedness was not recorded in 12 cases when it was clear that the 
patient was unable to perform the 9HPT. Of the 12 patients for whom PATA test data 
are unavailable, only three were recorded in the speech component of the ADLs as 
being ‘mostly incomprehensible’ suggesting that the reason the test was not 
performed was not always because of anarthria. Other factors may have included 
fatigue, refusal on the part of the patient or lack of clinic time.  
It is known from the SDFS that 55.1% of the cohort is wheelchair-bound and so unable 
to perform the 8mTW. In addition, many patients whilst remaining mobile at home 
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with assistive devices, attend clinic in a wheelchair and do not bring potentially bulky 
mobility aids with them, and so may have been unable to complete this task on the 
day. At the baseline assessment, five patients used a wheeled walker, six patients used 
two sticks, eleven patients used one stick and 29 patients did not use a walking aid. No 
information was recorded for three patients.  
Similarly, lack of manual dexterity is a common reason for being unable to complete 
the 9HPT. This test has a cut-off value of 5 minutes above which patients are deemed 
unable to complete the task. It is not uncommon for patients to reach this limit. Taken 
together, these observations demonstrate one of the major failings of the SCAFI as a 
rating scale in FRDA, as a high proportion of patients are physically incapable of 
completing all parts of the test.  
The results of the raw data are summarized in Table 15 and shown graphically in Figure 
22. The 8mTW & 9HPT data are skewed toward lower values, particularly the 8mTW 
values. Only the PATA tests data are normally distributed. The distribution of results 
for the 9HPT for the dominant and non-dominant hand is similar, but the values for the 
non-dominant hand are slightly greater – typically by about 10s – as would be 
expected. 
Table 15: Raw data from SCAFI for EFACTS patients at baseline 
Task No. completing 
(%) 
Mean ± SD Range 
8mTW (s) 53 (31.7) 15.0 ± 20.8 4 – 135 
9HPT-D1 (s) 120 (71.9) 69.1 ± 47.4 19 – 253 
9HPT-ND2 (s) 110 (65.9) 69.6 ± 41.8 21 – 244 
9HPT-All3 (s) 115 (68.9) 69.3 ± 44.7 19 – 253 
PATA (/10s) 155 (92.8) 15.3 ± 4.9 1 - 33 
1
9HPT-D = 9-hole peg test for dominant hand 
2
9HPT-ND = 9-hole peg test for non-dominant hand 
3
9HPT-All = 9-hole peg test for both hands 
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Figure 22: Raw data from SCAFI for EFACTS patients at baseline 
(A) 8m timed walk; (B) 9-hole peg test time for dominant hand; (C) 9-hole peg test time 
for non-dominant hand; (D) PATA test 
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2.3.10 Structured Neurological Examination (SNE) 
Data from the SNE were available for 158 EFACTS patients participating although there 
were numerous instances of missing data in individual fields, hence the number of 
patients examined for each field is recorded. Missing data usually arose as a result of 
lack of time in clinic. The SNE is described in detail in the Method at 2.2.2 and the SNE 
proforma can be found in the Appendix. Ptosis was seen in 25 out of 151 patients 
(16.6%). One patient out of 146 had a relative afferent pupillary defect (0.7%). There 
were no documented cases of facial sensory loss. Five out of 153 patients (3.3%) had 
facial weakness. There was one out of 152 (0.7%) cases of masticatory muscle 
weakness recorded. Four out of 148 patients (2.7%) had weakness of palatal elevation. 
One out of 152 patients (0.7%) had sternocleidomastoid weakness. Three out of 152 
patients (2.0%) had trapezius weakness. There were seven out of 144 (4.9%) cases of 
tongue atrophy recorded. Out of 141 cases recorded, lingual tone was flaccid in four 
cases (2.8%), normal in 79 (56.0%), spastic in 47 (33.3%) and highly spastic in 11 (7.8%). 
The range of muscle power found at examination is given in Table 16 with each value 
the result of two measurements (ie one each side) for all patients (ie n measurements 
in total). The scale is described in the Method at 2.2.2 above with 0 representing no 
power and 7, full power. The mean values are depicted in Figure 23. 
Table 16: Muscle power from SNE for EFACTS patients 
 Mean SD Mode Range n 
Shoulder Abduction 6.46 1.15 7 0 - 7 316 
Shoulder Adduction 6.65 0.99 7 0 - 7 316 
Elbow Flexion 6.78 0.80 7 2 - 7 316 
Elbow Extension 6.78 0.88 7 1 - 7 316 
Wrist Flexion 6.56 1.17 7 0 - 7 316 
Wrist Extension 6.66 0.98 7 0 - 7 316 
Finger Flexion 6.55 1.08 7 0 - 7 312 
Finger Extension 6.13 1.54 7 0 - 7 314 
Index Finger Abduction 5.72 1.90 7 0 - 7 314 
Little Finger Abduction 5.84 1.88 7 0 - 7 314 
Thumb Abduction 5.82 1.91 7 0 - 7 314 
UL proximal 6.67 0.97 7 0 - 7 632 
UL distal 6.18 1.59 7 0 - 7 2200 
Hip Flexion 4.24 2.38 7 0 - 7 312 
Hip Extension 4.64 2.38 7 0 - 7 310 
Hip Abduction 4.50 2.76 7 0 - 7 308 
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Hip Adduction 4.54 2.73 7 0 - 7 308 
Knee Flexion 3.79 2.65 7 0 - 7 312 
Knee Extension 5.54 2.17 7 0 - 7 312 
Ankle Flexion 4.31 2.90 7 0 - 7 306 
Ankle Extension 4.16 2.86 7 0 - 7 310 
Ankle Inversion 3.78 3.07 7 0 - 7 302 
Ankle Eversion 3.62 3.10 7 0 - 7 302 
Toe Flexion 3.82 3.02 7 0 - 7 302 
Toe Extension 3.86 2.99 7 0 - 7 306 
LL proximal 4.54 2.57 7 0 - 7 1582 
LL distal 3.93 3.00 7 0 - 7 1828 
 
 
Figure 23: Mean muscle power values from SNE for (A) upper limb & (B) lower limb 
for EFACTS patients.  
LL weakness is more severe than UL. For an explanation of the scale, see text. 
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Values for deep tendon reflexes are recorded in Table 17 representing bilateral 
measurements for up to 157 patients at baseline. The results are illustrated in Figure 
24 showing percentages of the total number of patients examined. 
Table 17: Deep tendon reflexes from the SNE for EFACTS patients at baseline 
 Absent 
Present 
only with 
reinforce-
ment 
Present  but 
hyporeflexic 
Normal 
Hyper-
reflexic 
Hyper-
reflexic 
with 
clonus 
Biceps 282 (90.1) 2 (0.6) 11 (3.5) 12 (3.8) 6 (1.9) 0 (0) 
Supinator 280 (89.5) 0 (0) 9 (2.9)  15 (4.8) 9 (2.9) 0 (0) 
Triceps 140.5 (89.8) 2 (0.6) 12 (3.8) 12 (3.8) 6 (1.9) 0 (0) 
Patellar 132 (85.7) 0 (0) 7 (2.3) 17 (5.5) 20 (6.5) 0 (0) 
Ankle 139.5 (90.9) 2 (0.7) 6 (2.0) 13 (4.2) 7 (2.3) 0 (0) 
 
 Absent Present 
Finger jerks 286 (92.3) 24 (7.7) 
Hoffman reflex 297 (96.7) 10 (3.3) 
 
 Mute Flexor Extensor Withdrawal 
Plantar 72 (23.8) 21 (7.0) 188 (62.3) 21 (7.0) 
 
 
Figure 24: Distribution of deep tendon reflexes from SNE in EFACTS patients at 
baseline 
The overwhelming majority of reflexes are absent in FRDA, whilst the plantar reflexes 
are usually extensor 
Values for amyotrophy, muscle tone, sensory loss and skeletal foot abnormalities for 
the EFACTS patients as recorded in the SNE are shown in Table 18. The values 
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represent bilateral measurements for each patient using a series of semi-quantitative 
scales described in the Methods section at 2.2.2 above. The percentages represent the 
proportion of patients whose examination was recorded rather than of the whole 
cohort. As the SNE was time-consuming and not a core element of the EFACTS battery 
of assessments, this led to an incomplete data set. Sensation was assessed using a 
length-dependent scale described in the Methods section at 2.2.2 which is analyzed as 
a continuous variable with zero representing no sensory loss and each point 
representing sensory loss affecting a further joint. In the assessment of muscle tone, 
two patients were felt to have Gegenhalten rather than spasticity, defined as 
‘hypertonia characterized by involuntary variable resistance during passive 
movement…usually elicited by moving…rapidly from a contracted to a stretched 
position after instructing the patient not to resist’ (Kreutzer et al. 2011). Figure 25 
shows the proportion of patients with varying degrees of amyotrophy and spasticity. 
Figure 26 illustrates the extent of sensory loss covering the three modalities assessed. 
Figure 27 depicts the proportion of patients with various skeletal foot abnormalities 
seen in FRDA. 
Table 18: Values for muscle atrophy, muscle tone, sensory loss and skeletal foot 
abnormalities from the SNE for EFACTS patients 
  None Mild Moderate Severe 
Atrophy UL 189 (66.3) 63 (22.1) 31 (10.9) 2 (0.7) 
 LL 195 (73.6) 35 (13.2) 27 (10.2) 8 (3.0) 
 
  
Highly 
flaccid 
Flaccid Normal Spastic 
Highly 
spastic 
Other 
Tone UL 2 (0.7) 4 (1.5) 228 (83.2) 34 (12.4) 6 (2.2) 0 (0) 
 LL 6 (2.1) 3 (1.1) 206 (73.6) 45 (16.1) 18 (6.4) 2 (0.7)a 
 
   Mean SD Mode Range n 
Sensation UL Pin prick 1.13 1.8 0 0 – 7  284 
  JPS 0.86 1.46 0 0 – 6 276 
  Vibration 0.48 1.22 0 0 – 6 286 
 LL Pin prick 1.42 1.85 0 0 – 7 279 
  JPS 1.69 1.47 2 0 – 5 253 
  Vibration 2.33 1.94 0 0 – 6  288 
cont… 
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 Absent Mild Moderate Severe 
Pes cavus 145 (49.3) 33 (11.2) 62 (21.0) 54 (18.4) 
Talipes equinus 124 (44.3) 47 (16.8) 53 (18.9) 56 (20.0) 
Talipes varus 145 (63.0) 28 (12.2) 26 (11.3) 31 (13.5) 
  UL=upper limb; LL=lower limb; JPS=joint position sense 
   a
Gegenhalten 
 
Figure 25: (A) Muscle atrophy and (B) spasticity as recorded in the SNE for EFACTS 
patients at baseline 
Up to 40% of patients have some muscle atrophy, whilst up to 30% of patients have 
spasticity 
 
Figure 26: Extent of sensory loss as recorded in SNE for EFACTS patients at baseline. 
The degree of sensory loss was defined on a length-dependent scale with higher 
numbers representing more proximal spread of the sensory loss. For a more detailed 
explanation of scale, see the Method at 2.2.2 above. 
UL=upper limb; LL=lower limb; JPS=joint position sense 
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Figure 27: Skeletal foot abnormalities from SNE for EFACTS patients 
Talipes equnius is the coomonest foot abnormality in FRDA, followed by pes cavus and 
then talipes varus 
2.3.11 Disease Progression at Follow-Up Assessments 
The aim of the clinical strand of the EFACTS project was to recruit patients with 
genetically confirmed FRDA, and then perform clinical assessments at baseline and on 
a yearly basis to provide detailed natural history data regarding progression of the 
condition which would inform the planning of clinical trials and provide prognostic 
information for patients and clinicians. Figure 28 shows the passage of patients 
through the UK portion of the study. 167 genetically proven FRDA patients were 
recruited between 1 August 2011 and 1 August 2014 and underwent baseline (BL) 
assessment as described above. Of these, 125 were seen for follow-up assessment at 
year 1 ±3 months (FU1). Six patients were lost to follow-up : one died; two were 
known to have moved abroad; contact was lost with a further three despite repeated 
attempts to communicate with them. Seventeen were still awaiting assessment at the 
time of data collection for this thesis (all from phase 2, those patients recruited later in 
the study after the recruitment of the initial core phase 1 sample). Nineteen patients 
therefore missed the year 1 assessment, of which 16 were subsequently reassessed at 
year 2 and hence not lost to the study. In total 116 patients were seen at the year 2 
follow-up assessment (FU2). Twenty-seven were therefore still awaiting assessment at 
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the time of data collection for this thesis, all patients who had entered toward the end 
of phase 1 recruitment. 
 
Figure 28: Study profile of patients in UK contribution to EFACTS 
2.3.11.1 SARA  
Results are recorded for the SARA for 166 patients at BL, 122 at FU1 and 116 at FU2. 
Figure 29 shows the total SARA data for all patients passing through the study. 
Although this clearly shows that patients do not follow a simple pattern of uniformly 
deteriorating year after year, because of the large number of patients in the study and 
their variable outcome, this form of representation is not easy to interpret and so is 
not repeated for subsequent measures.  
The mean, SD and range of total SARA data are recorded in Table 19. Of note, 27 
patients were still awaiting FU2 assessment at the time of data collection for the 
thesis. In addition, the results of those patients seen at BL but not FU1 are recorded 
separately (‘BL patients without FU1 assessment’), and also those patients seen at BL 
who were subsequently seen at FU1 (‘BL patients with FU1 assessment’). The former 
group provide information about whether those individuals who were not seen at FU1 
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differed from the group who were followed-up. The latter group provide a directly 
comparable group of patients seen both at BL and FU1 which can be analyzed using a 
paired t-test. Analogous BL data are presented with respect to FU2, the maximal 
period of follow-up in this study.  
Of the 116 patients for whom both BL and FU2 data were available, 31 (26.7%) 
improved, 14 (12.1%) showed no change in total SARA and 71 (61.2%) deteriorated. 
Explanations of why patients should seem to improve in a progressive degenerative 
condition are explored extensively in subsequent pages and discussed further at the 
end of the Discussion of this Chapter at 2.4.6 below. Figure 31(A) shows the changes in 
the individual total SARA values for each patient ranked in order of change with 
positive values indicating deterioration. The BL total SARA for those individuals who 
improved was 27.0±8.0 (4-34), for those without change in total SARA 32.9±7.7 (12-
40), and those who deteriorated 19.7±9.8. These differences in BL total SARA are 
significant (1-way ANOVA, F=16.0, p<0.0005). When each group is compared 
separately, the differences are also significant (improved vs. no change, independent 
samples t-test, mean difference 5.9±2.6, 95% CI 0.7-11.0, t=2.3, p=0.027; no change vs. 
deteriorated, mean difference 13.2±2.4, 95% CI 8.3-18.1, t=5.6, p<0.0005; improved vs. 
deteriorated, mean difference 7.4±1.9, 95% CI 3.7-11.1, t=4.0, p<0.0005). These data 
suggest that individuals with milder disease tend to progress more than do those with 
more severe disease, as measured by the total SARA. It is possible, however, that this 
represents a ‘ceiling effect’ in the SARA, as those individuals with high BL total SARA 
scores have less scope within the scale to deteriorate as there is a maximal score. 
Indeed, it has already been observed on the analysis of the BL data in Section 2.3.7 
above, that many FRDA patients occupy the highest scores of many of the SARA 
subscores, particularly those reflecting LL function. 
Table 19: Total SARA for EFACTS patients at BL, FU1 and FU2 
 Mean SD Range n 
BL (all data) 22.5 10.0 1.5 – 40 166 
FU1 (all data) 24.4 9.7 2.5 – 40 122 
FU2 (all data) 24.6 9.5 2.5 – 40 116 
BL (patients with FU1 
assessment) 
23.5 10.0 1.5 - 40 122 
111 
 
BL (patients without FU1 
assessment) 
19.7 10.2 2.5 - 34 44 
BL (patients with FU2 
assessment) 
23.2 10.2 1.5 – 40 116 
BL (patients without FU2 
assessment) 
20.7 9.4 2.5 – 34 50 
 
Figure 30(A) shows the change in total SARA from BL to FU1 and FU2. However, as 
shown above, there are large numbers of missing data at the FU1 and FU2 visits. It is 
statistically problematical comparing data containing mixed paired and unpaired 
values, that is to say, the complete data sets including missing data. For those 
individuals for whom paired total SARA data were available, there were significant 
differences between BL and FU1 (paired t-test, mean difference 0.91±2.69, 95% CI 
0.43-1.40, t=3.76, p<0.0005) and between BL and FU2 (paired t-test, mean difference 
1.33±3.14, 95% CI 0.75-1.91, t=4.57, p<0.0005), with both deteriorating.  
There was a significant difference between the total SARA at BL for individuals who 
were subsequently seen at FU1 compared to those that were not (independent 
samples t-test, mean difference 3.7±1.7, 95% CI 0.3-7.2, t=2.1, p=0.033). Perhaps 
surprisingly, those who did not return for FU1 assessment had significantly lower BL 
total SARA, suggesting that the explanation of their failure to return for follow-up 
assessment was not because of increased disability. Indeed, it may be that these 
individuals who were less severely affected found it more difficult to return because 
they were more likely to be employed or lived further away. However, there was no 
significant difference in BL total SARA between those individuals seen at FU2 and those 
that were not (mean difference 2.52±1.69, 95% CI -0.82-5.86, t=1.48, p=0.139) 
suggesting that those patients who were not assessed at FU2 were not atypical of the 
group. This may be because at the point of data collection for the thesis, only six 
patients were truly lost to the project and the remaining 50 missing patients were still 
awaiting FU2 assessment rather than having formally missed their assessment in the 
context of the study. This is more likely to be a stochastic rather than systematically 
biased effect. For this reason, subsequent analysis will concentrate on the change from 
BL to FU2. This is obviously also the maximal period of follow-up in this study which 
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would therefore be expected to be associated with maximal change, as is seen for the 
total SARA.  
 
Figure 29: Total SARA values for individual EFACTS patients for BL, FU1 & FU2 (all 
data) 
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In order to try and minimize the ceiling effect of the SARA caused by the higher scores 
for the LL measures, the data were subdivided into three subcategories : upper limb 
(UL), lower limb (LL) and ‘other’. The UL SARA included the subscores for (i) finger 
chase test (ii) nose-finger test and (iii) fast alternating hand movements (maximum 
core 12). The LL SARA included the subscores for (i) gait (ii) stance and (iii) heel-shin 
test (maximum score 18). The ‘other’ SARA included the two remaining subscores for 
(i) sitting and (ii) speech (maximum score 10). Table 20 shows the results for these 
three subcategories at BL, FU1 and FU2. These are displayed graphically in Figure 30(B) 
& (D). Table 20 also shows the results of the paired samples t-test comparing UL, LL 
and ‘other’ SARA results between BL, FU1 and FU2 for those participants for whom 
paired data were available. This shows that the only significant differences were in fact 
for the LL and ‘other’ subcategories, all of which survived Bonferroni correction for 
multiple testing. These results suggest that although there is high occupancy of the 
higher values for the constituent LL subscores of the SARA (see Figure 16), progression 
as measured by the SARA still seems to be driven by an increase in the LL subscores (as 
well as speech and sitting). Figure 31(B),(C) & (D), which show the changes in SARA 
subcategory score for each individual patient, illustrate this point more clearly. For the 
UL subcategory, only 39 patients (33.6%) deteriorated. 24 (20.7%) remained 
unchanged and 53 (45.7%) actually improved. By contrast, for the LL subcategory, 48 
patients (41.4%) deteriorated, 56 (48.3%) remained unchanged and only 12 (10.3%) 
improved. For the ‘other’ subcategory, 42 (36.2%) deteriorated, 57 (49.1%) remained 
unchanged and 17 (14.7%) improved. Although numerically more patients improved 
than deteriorated on the UL subcategory, as Table 20 and Figure 30 show, the mean UL 
SARA increased (ie deteriorated) between BL and both FU1 and FU2. These differences 
were not, however, statistically different. As Figure 31(B) shows, the maximum 
improvement in the UL SARA was 4 points, whereas the maximum deterioration was 
10 points, and so although a smaller number deteriorated than improved, they 
deteriorated to a greater extent, making the mean change tend toward deterioration. 
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Table 20: SARA scores for BL, FU1 & FU2 visits divided into UL, LL & 'other' 
subcategories 
Subcategory Visit Mean SD n 
UL SARA BL (all data) 4.9 2.9 166 
 FU1 (all data) 5.3 2.9 122 
 FU2 (all data) 5.2 3.1 116 
 BL (patients with FU1 assessment) 5.1 3.0 122 
 BL (patients with FU2 assessment) 5.2 3.0 116 
LL SARA BL (all data) 13.5 5.5 166 
 FU1 (all data) 14.3 5.1 122 
 FU2 (all data) 14.7 4.8 116 
 BL (patients with FU1 assessment) 13.8 5.5 122 
 BL (patients with FU2 assessment) 13.6 5.5 116 
‘Other’ SARA BL (all data) 4.1 2.7 166 
 FU1 (all data) 4.8 2.5 122 
 FU2 (all data) 4.7 2.6 116 
 BL (patients with FU1 assessment) 4.2 2.7 122 
 BL (patients with FU2 assessment) 4.3 2.8 116 
 
Subcategory Visits 
Mean 
difference 
95% CI t p† 
UL SARA BL-FU1 0.28±1.79 -0.04-0.40 1.71 0.088 
 BL-FU2 0.04±1.95 -0.32-0.40 0.24 0.813 
LL SARA BL-FU1 0.52±1.86 0.19-0.85 3.09 0.002 
 BL-FU2 1.06±2.27 0.64-1.48 5.04 <0.0005 
‘Other’ SARA BL-FU1 0.52±1.31 0.28-0.75 4.33 <0.0005 
 BL-FU2 0.43±1.22 0.21-0.65 3.81 <0.0005 
          †Bonferroni correction reduces significant p value to 0.05/6=0.0083 
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Figure 30: Mean SARA values between BL, FU1 & FU2 
(A) Total SARA & (B) SARA subcategories for all available data (BL n=166, FU1 n=122, 
FU2 n=116). (C) Total SARA & (D) SARA subcategories for complete datasets for BL & 
FU2 only (n=116). Error bars=SD. 
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Figure 31: Change in (A) total SARA (B) UL SARA (C) LL SARA and (D) 'other' SARA. 
Each bar represents change in SARA from BL to FU2 for an individual patient (n=116), 
ranked by change from negative (on left) to positive (on right). Negative values 
represent improvement, positive values deterioration and zero, no change. 
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Figure 32 attempts to investigate whether there are any underlying factors which 
predict which patients will progress more rapidly. As can be seen, there was no 
correlation between rate of progression and GAA1 size, age at onset, age at 
examination, disease duration and BL total SARA. This observation has been made 
previously in a smaller sample (Marelli et al. 2011). In addition, no significant 
difference was seen in SARA disease progression between males (n=47) and females 
(n=69) (Mann-Whitney U-test, U=1509.5, p=0.528).    
 
Figure 32: Relationship between change in total SARA from BL to FU2 and (A) GAA 
size, (B) age at onset, (C) age at examination, (D) disease duration, and (E) BL total 
SARA 
The change in SARA is independent of these 5 measures 
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2.3.11.2 INAS 
INAS count data were available for 166 patients at BL, 124 at FU1 and 116 at FU2. 
These are shown in Table 21 and illustrated graphically in Figure 33. There were no 
significant differences between BL and FU1 (paired t-test, mean difference 0.17±1.44, 
95% CI -0.09-0.42, t=1.314, p=0.191) or between BL and FU2 (mean difference 
0.09±1.43, 95% CI -0.18-0.35, t=0.647, p=0.519). Between BL and FU2, 38 patients 
(32.8%) improved with regard to INAS count, 25 (30.2%) remained unchanged (30.2%) 
and 43 (37.0%) deteriorated. Thus, the INAS count failed to capture change in non-
ataxic signs and symptoms in the study population over a 2 year period. 
Table 21: INAS count values for EFACTS patients at BL, FU1 & FU2 
 Mean SD Range n 
BL (all data) 5.0 1.6 2 - 9 166 
FU1 (all data) 4.9 1.6 1 - 8 124 
FU2 (all data) 5.0 1.4 2 - 8 116 
BL (patients with FU1 
assessment) 
5.0 1.6 2 - 9 124 
BL (patients with FU2 
assessment) 
5.0 1.6 2 - 9 116 
 
 
Figure 33: Mean INAS count between BL, FU1 and FU2 
(A) for all available data (BL n=166, FU1 n=124, FU2 n=116) (B) for complete datasets 
for BL to FU2 only (n=116). Error bars=SD. 
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2.3.11.3 ADL 
Total ADL data were available for 162 patients at BL, 122 at FU1 and 113 at FU2. The 
data are shown in Table 22 and graphically in Figure 34. The total ADL detected change 
at both FU1 (paired t-test, mean difference 1.07±3.67, 95% CI 0.42-1.73, t=3.233, 
p=0.002) and FU2 (mean difference 2.04±3.22, 95% CI 1.45-2.64, t=6.756, p<0.0005). 
Between BL and FU2, 24 patients (21.2%) improved as measured by the total ADL, no 
change was recorded in 14 (12.4%) and 75 (66.4%) deteriorated.  
 
Table 22: Total ADL for EFACTS patients at BL, FU1 & FU2 
 Mean SD Range n 
BL (all data) 15.4 8.3 1 - 35 162 
FU1 (all data) 17.1 8.6 1 - 36 122 
FU2 (all data) 17.9 8.6 1 – 36 113 
BL (patients with FU1 
assessment) 
16.1 8.1 1 - 35 122 
BL (patients with FU2 
assessment) 
15.9  8.6 1-35 113 
 
 
Figure 34: Mean total ADL between BL, FU1 and FU2 
(A) for all available data (BL n=162, FU1 n=122, FU2 n=113) (B) for complete datasets 
for BL to FU2 only (n=113). Error bars=SD. 
 
2.3.11.4 SDFS 
SDFS data were available for 167 individuals at BL, 138 at FU1 and 129 at FU2. Table 23 
shows the mean, SD and ranges of these data. However, they are ordinal, heavily 
120 
 
skewed to the highest value and there are only seven possible responses (the seven 
disability stages of the SDFS). Table 23 therefore also shows the frequency and 
proportion of patients by SDFS stage. Figure 35 shows that the mean SDFS increases 
from BL to FU1 and FU2, and a greater proportion of patients pass into the higher 
disability stages. For the individuals for whom matched data were available, there was 
a significant increase in SDFS stage between BL and FU1 (Wilcoxon signed ranks test, 
Z=-2.874, p=0.004) and between BL and FU2 (Z=-4.673, p<0.0005). 
Table 23: SDFS for EFACTS patients for BL, FU1 & FU2 
 Mean SD Range n 
BL (all data) 5.0 1.3 1 - 7 167 
FU1 (all data) 5.2 1.2 1 - 7 138 
FU2 (all data) 5.3 1.0 2 - 7 129 
BL (patients with FU1 
assessment)* 
5.1 1.3 1 - 7 138 
BL (patients with FU2 
assessment)** 
5.0 1.4 1 - 7 129 
   
SDFS BL FU1 FU2 
BL with 
FU1* 
BL with 
FU2** 
Stage 1 1 (0.6) 1 (0.7) 0 (0) 1 (0.7) 1 (0.8) 
Stage 2 8 (4.8) 3 (2.2) 2 (1.6) 4 (2.9) 6 (4.7) 
Stage 3 25 (15.0) 15 (10.9) 11 (8.5) 20 (14.5) 19 (14.7) 
Stage 4 15 (9.0) 11 (8.0) 11 (8.5) 12 (8.7) 10 (7.8) 
Stage 5 23 (13.8) 24 (17.4) 24 (18.6) 20 (14.5) 17 (13.2) 
Stage 6 94 (56.3) 83 (60.1) 79 (61.2) 80 (58.0) 75 (58.1) 
Stage 7 1 (0.6) 1 (0.7) 2 (1.6) 1 (0.7) 1 (0.8) 
Total 167 138 129 138 129 
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Figure 35: SDFS for BL, FU1 & FU2 (A) & (C) for all available data (BL n=167, FU1 
n=138, FU2 n=129), (B) & (D) for complete datasets (n=129), (A) & (B) for mean 
values (error bars=SD), (C) & (D) proportion of patients with different SDFS stage 
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2.4 Discussion 
The data presented above represent the largest natural history study ever undertaken 
of Friedreich’s ataxia in the UK, and the cohort described forms the largest 
contributing centre to the largest natural history study ever published of FRDA (Reetz 
et al. 2015). Since the discovery of the FXN gene in 1996, there has been a paucity of 
large natural history studies in which the patients have a genetic as well as clinical 
diagnosis, with a single early study of 140 patients (Dürr et al. 1996) and most 
subsequent studies involving fewer than 60 patients (see Chapter 1). No study has 
assessed the clinical features of FRDA in such detail including a range of formal clinical 
assessment tools. Whilst there was an inevitable predilection of patients from the 
South-east of England, great effort was made to include patients from all over the 
British Isles including those from the Republic of Ireland. This therefore represents the 
largest and most detailed study of FRDA in the British Isles which will provide 
invaluable natural history data to be used in the planning and execution of 
interventional trials in FRDA, and essential information to be used in guiding the 
diagnostic process and counselling patients regarding prognosis. It has also permitted 
the compilation of a database of patients who are willing to participate in clinical trials 
which has already contributed to one of the first studies of an epigenetic therapeutic 
agent in FRDA. Significantly, preliminary evidence has shown increased levels of 
frataxin expression sufficient to warrant further study (Libri et al. 2014). More widely, 
the central clinical registry of EFACTS data allied to a biological sample repository will 
allow genetic, biomarker and other basic science projects to investigate underlying 
pathological processes. 
The very large size of the study has allowed it to encompass patients with a wide range 
of presentations from full mobility and minimal disability to complete dependence and 
confinement to bed. The latter necessitated a number of home visits to ensure these 
patients were included. Patients were seen with age at onset from 1 to 55, embracing 
the early, classical, late and very late onset phenotypes. Patients were also seen 
throughout the course of their disease from age 16 to 68 with disease duration of 
between 3 and 55 years. Patients with GAA expansions of between 100 and 1500 
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repeats were enrolled in the study providing a wide range of disease severities. Most 
patients recruited to the study already had a genetic diagnosis but two had to be 
excluded after inclusion as the genetic test failed to confirm the diagnosis: no 
alternative genetic diagnosis has since been found in either case. 
 The systematic prospective nature of the clinical assessment is a major advantage of 
this study ensuring comparability of the results from patient to patient. Furthermore, 
only two clinicians saw patients within this study and the vast majority of the 
assessments were undertaken by the author. Thus, there was minimal inter-rater 
variability between patients, and between baseline and subsequent assessments. The 
systematic central storage of data allowed very rigorous and independent 
management of data quality, and permits ‘data mining’ and downloading of easily 
statistically analyzable data. Whilst the centrally prescribed nature of the battery of 
assessments undertaken throughout all participating groups is a major advantage of 
the project, certain features were not captured well. Examples of visual and hearing 
impairment have already been discussed in the text. Certain other features were not 
assessed, such as imaging and cognition. The latter has been addressed as the patients 
currently undergo the Montreal Cognitive Assessment (MoCA). Furthermore, GAA size 
data (provided by the Université Libre de Bruxelles) were only available for 147 of the 
participants at the time of thesis production 
Whilst this thesis concentrated on analysis of the baseline data, progression data were 
available for more than 100 patients over a 2 year period. These data are vital in 
planning interventional trials and can only be obtained from large, well-funded, well-
structured studies. Retention rates were generally good and the patients have 
continued to attend after the point of data collection for this thesis, allowing the 
possibility of long-term progression data to be collected. The necessity to acquire the 
data for thesis production during an ongoing project meant that an arbitrary cut-off of 
1 August 2014 had to be made and the follow-up data are consequently incomplete: 
seventeen patients were awaiting their first follow-up assessment and twenty-seven 
their second when the data were downloaded for analysis. More seriously, nineteen 
patients missed their first follow-up assessment and so will skip directly to the second 
follow-up assessment.  
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Whilst on the one hand an advantage, the sheer size of the study and the profusion of 
data collected pose problems of which data to analyze and how to present them 
concisely and in a readily comprehensible fashion. Only the reader can decide if this 
endeavour has been successful.  
2.4.1 Clinical Features 
There has been no consistent gender predominance found previously, and the ratio of 
1:1.3 of males to females in the present study is broadly in keeping with previous 
studies. Although the UK is a multi-ethnic nation and patients were recruited who 
were born in 15 different countries across all six continents, it is significant that no 
patients of Afro-Caribbean origin were found. This is in keeping with previous studies 
which have found FRDA patients of European, North African, Middle Eastern and 
Indian origin but not from sub-Saharan Africa, Native America, China, Japan or South-
East Asia (Labuda et al. 2000). It is likely that whilst the origin of the GAA repeat 
sequence was somewhere between Old and New World Monkeys (González-Cabo et 
al. 1999), its pathological expansion did not take place until after the African diaspora. 
The demographics details reveal some of the social consequences of FRDA. Patients 
with FRDA typically manage high levels of education with more than 30% having a 
university degree and more than 50% having a post-school qualification. 
Approximately one third of the cohort are in employment. Just over 30% are in a 
relationship and just under 30% have children (see Table 3).  
The cohort contained 5% of compound heterozygotes which is comparable to previous 
studies. The commonest point mutation in this cohort is the p.Gly130Val missense 
mutation which is known to be common in Caucasian populations (Bidichandani et al. 
1997). The cohort also includes a patient bearing a macrodeletion which are extremely 
rare and have only recently been described (Zühlke et al. 2004). These cases will be 
described in greater detail in Chapter 3. For those individuals bearing two GAA 
expansions, the shorter of the two are distributed normally around a modal value of 
700 repeats and extending up to a maximum value of 1200. The longer of the two are 
distributed slightly more unevenly around a median value of 967 repeats and 
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extending up to 1500 repeats. These values are comparable with previous reports 
(Dürr et al. 1996).  
The study recruited patients with a wide variety of ages, disease durations and ages at 
onset, including patients with very late onset and long duration (see Figure 8 and 
Figure 9). A criticism of this cohort is that no children were included, an issue which is 
being addressed in the wider EFACTS cohort. The distribution of ages at onset is 
heavily skewed toward early onset. 148 of the patients (88.6%) had onset below the 
age of 25, in keeping with the Harding diagnostic criteria (Harding 1981). Only five 
patients (3.0%) had onset at or after age 40 putting them in the category of very late 
onset FRDA (see Figure 11). The first symptoms are almost always gait instability, falls, 
clumsiness or complications of poor manual dexterity, with gait instability forming by 
far the largest proportion. Scoliosis is the only non-neurological symptom which is 
found at presentation in a significant proportion of patients (9.6%). Presentation with 
diabetes or cardiomyopathy is very rare (see Figure 13).  
Progression in FRDA is slow but steady, predominantly affecting gait and lower limb 
function. Well over half of the cohort were wheelchair-bound by the time of 
assessment and less than 1% reported no effect on mobility (see Table 7). Nearly 80% 
used some aid to walking. Of those who are confined to a wheelchair, the median age 
was 19, with one patient requiring a wheelchair from the age of five. 26.4% of the 
cohort required a wheelchair before the age of 20, and 43.7% before the age of 30. 
The SNE reveals in far greater detail the pattern of impairment seen in FRDA. Upper 
limb power remains very well preserved, particularly proximally, with a large 
proportion of patients having full power. Significant lower limb weakness is much 
more common, both proximally and distally (see Figure 23). It has previously been 
noted that there is slowly progressive and symmetrical weakness mainly affecting the 
lower limbs, especially the muscles of the pelvic girdle. In a longitudinal study over 13 
years of 33 patients with FRDA, weakness of hip extension was by far the commonest 
first location of weakness, with pelvic girdle muscle power declining by 2.1% per year. 
Average lower limb power was approximately 70% of normal by the time a wheelchair 
was first used, and 56% when the patients were completely unable to walk. By 
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contrast, upper limb and truncal power were well preserved until late in the disease 
process with an overall strength of approximately 80% of normal (Beauchamp et al. 
1995). Similarly, in a cross-sectional study of 12 children with FRDA, lower limb 
weakness was significantly greater than upper limb weakness, and in the legs, proximal 
weakness was significantly greater than distal (Sival et al. 2011). Concordant with 
these clinical observations, neuropathological examination of the spinal cord shows 
that the dorsal root ganglia and dorsal columns are particularly affected. There is 
reduced calibre of the spinal cord at all levels but more pronounced in the thoracic 
region. There is loss of myelin and axons in the corticospinal tracts, dorsal columns and 
spinocerebellar tracts (Koeppen 2011). The pathology in the sensory pathways is 
dominated by dorsal root ganglial and spinal degeneration. Far less is known about the 
pathology of the motor pathways, but it seems likely that the greatest involvement is 
in the lower thoracic and lumbar spine giving rise to predominantly proximal as well as 
distal weakness in the lower limbs. 
The deep tendon reflexes are characteristically absent, with more than 85% of all 
reflexes studied, absent. Brisk reflexes are extremely rare. Extensor plantar responses 
are seen in over 60% of cases and flexor responses in less than 10% (see Table 17).  
Muscle atrophy is seen in around 30% of patients, particularly in the hands and feet, 
although this is sometimes difficult to discern because of poor growth in young-onset 
patients. This topic is explored in Section 2.4.3 below. Muscle tone is predominantly 
normal. Around 15-20% of patients show significant spasticity, more common in the 
lower limbs than the upper. In keeping with the frequent areflexia, sensory loss is 
common, extensive and debilitating. Posterior column modalities predominate, but pin 
prick sensation is also significantly affected, particularly in the ULs (see Table 18). 
Although 43% of the patients in the series have some degree of cardiomyopathy, 
patients with FRDA rarely have fulminant cardiac failure. Indeed, based on the 
reference values given in Table 10, 78.0% of patients had normal IVSd; only 2.2% had 
moderate or severe IVSd thickening. 79.1% of patients had normal LVPWd and only 
4.7% moderate or severe thickening. 86.2% had normal LVEF with only 5.7% having 
moderate or severe LV impairment. Repolarization changes (69.4%) and to a lesser 
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extent voltage criteria for LVH (40.0%) on ECG are, however, much more frequently 
observed. This is significant as these changes are evident from early in the disease 
process and are not typically seen in other early-onset ataxic disorders (in which 
cardiomyopathy is not a feature). It therefore acts as a diagnostic clue. Although only 
3.4% of the ECGs seen as part of the study showed any arrhythmia, 15.6% of the 
patients had a history of cardiac arrhythmia including both atrial fibrillation and 
supraventricular tachycardia. Ischaemic heart disease is very rare in FRDA (1.2%). 
However, to the uninitiated eye, the repolarization changes seen in FRDA, such as 
inferolateral T wave inversion, may resemble ischaemic changes. Compounding this, it 
has recently been reported that 46.9% of FRDA patients who were asymptomatic from 
a cardiac point of view, have cardiac troponin I levels above the 99th percentile of 
normal, and 16.3% have values typically seen during acute myocardial infarction 
(Friedman et al. 2013). Thus, in assessing a patient with FRDA, it is essential to 
understand the normal appearance of the ECG.  
In keeping with previous studies, the prevalence of diabetes mellitus in the cohort was 
low (8.9%). Previously reported rates of scoliosis have varied greatly, presumably 
depending on the degree of deformity counted as constituting significant scoliosis. 
Although 69.5% of the patients in the study showed some evidence of scoliosis, only 
30% of these had moderate to severe scoliosis.  
The study highlights certain features which have not previously attracted much 
attention. Ptosis was seen in 16.6% of the patients. Talipes equinus and varus 
abnormalities are as common as pes cavus and occur in around 50% of patients. Visual 
and hearing impairment are common. Probably a third of patients have hearing loss 
attributable to FRDA. These often coexist. Of the 24 patients thought to have visual 
loss attributable to FRDA, 14 also had hearing loss (58%). Unfortunately, these features 
were not well-captured by the assessment tools employed, and so warrant further 
more systematic investigation.  
Symptoms of urinary dysfunction such as urge, frequency, retention and incontinence 
are recorded as a formal urological problem in more than 20% of patients in this study 
(see  
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Table 8). These symptoms are common and troublesome, but potentially treatable. In 
an allied study on a subset of these patients employing more specific questionnaires, 
83% of patients reported lower urinary tract symptoms. In the same study, 64% also 
reported bowel symptoms and 83% sexual symptoms (Lad, Parkinson, et 
al.,manuscript in preparation). The present study recorded 14.4% as having symptoms 
of gastritis, acid reflux or hiatus hernia. This was far commoner than chronic 
constipation (6.6%) or diarrhoea (1.2%) and may relate in part to posture. These 
symptoms warrant greater clinical recognition because of their treatability and effect 
on quality of life.  
Patients with FRDA often describe cold, discoloured feet. In an exploratory study of 50 
consecutive patients toward the end of the project, 41 (82%) complained of 
persistently and unpleasantly cold feet. Twenty-five (50%) described colour changes, 
including 9 (18%) white, 8 (16%) red, 10 (20%) blue, 15 (30%) purple and 5 (10%) 
mottled. The underlying cause of these abnormalities is not clear. Resting blood 
pressure is frequently low in FRDA and syncope in response to phlebotomy is not 
uncommon. Of the 164 patients who had their blood pressure measured, 30 (18.3%) 
had systolic blood pressure below 100mmHg and 87 (53.0%) below 120mmHg, with 
the lowest pressure measured of 66mmHg. Of course, this is predominantly a young 
cohort which would not be expected to have a significant degree of hypertension. 
Autonomic dysfunction is not well studied in FRDA and there may well also be loss of 
postural vascular reflexes in response to immobility. However, anecdotally, this is a 
common and unpleasant problem, and one which is difficult to treat.   
Figure 36 summarizes the common clinical features of FRDA as recorded in the EFACTS 
Registry (scoliosis, visual impairment, pes cavus, cardiomyopathy, hearing impairment, 
dysuria, gastritic symptoms, diabetes), the INAS (dysarthria, dysphagia) and the SNE 
(talipes equinus, talipes varus). Figure 37 summarizes the common examination 
findings found in FRDA as recorded in the SDFS (wheelchair use), the INAS (areflexia, 
paresis, plantars, spasticity, amyotrophy, hyperreflexia) and the SNE (vibrational, 
proprioceptive and pin prick sensory loss). 
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Figure 36: Common clinical features of FRDA.  
Blue section indicates proportion likely to arise directly from FRDA. For explanation, 
see Section 2.3.5 above.  
 
 
Figure 37: Common examination findings in FRDA 
Thus, this study constitutes the largest ever natural history study of FRDA in the UK 
and adds considerable deep phenotyping data to our knowledge of this condition 
which may be used both in the clinical and research settings. Possible criticisms of the 
study include the lack of imaging data, although in fact, once the diagnosis is made, 
this rarely forms an important part of the assessment. Another criticism is the lack of 
cognitive assessment in the study. In fact, the original EFACTS battery of tests included 
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a single neuropsychological test, involving an assessment of phonemic verbal fluency 
(data not presented). There were problems in comparing the results between different 
European centres. It has been decided to use the Montreal Cognitive Assessment 
(MoCA) in future assessments although this also has problems as many participants 
cannot complete the visuoconstructive portions of the task which involve drawing a 
cube and a clockface, as well as the trailmaking test, because of poor manual dexterity 
rather than cognitive impairment. The study has no control group with which to 
compare. This feature is currently being addressed but data were not available at the 
time of data analysis.  
The data allow the investigation of a number of features, such as the nature of 
different phenotypes based on age at onset, the phenomenon of growth retardation in 
young-onset patients, correlations between clinical and genetic markers, and the 
validity of different rating scales. These will be discussed below. 
2.4.2 Clinical Characterization : Classical and Atypical Phenotypes 
The classical presentation of FRDA as defined by Harding (1984) involved symptom 
onset before the age of 25, progressive ataxia, absent lower limb reflexes and extensor 
plantar responses, amongst other features. The discovery of the causative mutation in 
1996 enabled the identification of atypical cases, notably those with late-onset, 
retained reflexes, pyramidal signs and a relative paucity of non-neurological features 
such as cardiomyopathy and diabetes. Little attention has been paid in the literature to 
those patients with early-onset disease (below the age of 5 years) who typically have a 
much more severe phenotype. We wished to investigate this matter further to see if 
these groups represented distinct nosological entities.  
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Table 24A: Comparison of GAA1 size, total ADL, total SARA, INAS count and SDFS for 
early-onset, classical and late-onset subtypes of FRDA in EFACTS 
Feature Early-onset 
(≤5 years)a 
Classical  
(6-24 years)b 
Late-onset  
(≥25 years)c 
ANOVA F 
value (p value) 
Age at onset 3.0±1.4 
(p<0.0005) 
12.5±4.5 
(p<0.0005) 
35.4±9.7 
(p<0.0005) 
230.1 
(p<0.0005)* 
Age at exam 25.5±7.4 
(p=0.008) 
33.5±12.6 
(p<0.0005) 
49.9±8.6 
(p<0.0005) 
23.9  
(p<0.0005)* 
Disease 
duration 
22.5±7.4 
(p=1.000) 
21.0±12.1 
(p=0.054) 
14.5±6.7 
(p=0.065) 
3.3  
(p=0.04) 
GAA1 759.7±197.6d,m 
(p=0.655) 
695.8±221.3e,n 
(p<0.0005) 
290.5±208.8f 
(p<0.0005) 
20.3  
(p<0.0005)* 
Total ADL 19.3±6.6d 
(p=0.152) 
15.7±8.5g 
(p=0.0005) 
8.4±4.4h 
(p<0.0005) 
9.8  
(p<0.0005)* 
Total SARA 26.9±7.9d 
(p=0.273) 
32.2±9.9i 
(p<0.0005) 
12.4±8.0h 
(p<0.0005) 
13.1  
(p<0.0005)* 
INAS count 5.2±1.6  5.1±1.7j  4.3±1.2k  2.6 (p=0.079) 
SDFS 5.5±1.0l 
(p=0.343) 
5.0±1.4e 
(p=0.05) 
3.9±1.4h 
(p=0.0005) 
7.4  
(p=0.0005)* 
Values are for mean ± SD in first 3 columns 
p values quoted in first 3 columns are for post-hoc analysis with Bonferroni corrections pre-adjusted in 
SPSS (ie significant at 0.05)  
Column 1 compares early-onset with classical. Column 2 compares classical with late-onset. Column 3 
compares late-onset with early-onset. 
a
n=23; 
b
n=125; 
c
n=19; unless otherwise specified below: 
d
n=22; 
e
n=114; 
f
n=17; 
g
n=122; 
h
n=18; 
i
n=120; 
j
n=124; 
k
n=19; 
l
n=21 
m
excludes 1 compound heterozygote with macrodeletion 
n
exlcudes 7 compound heterozygotes with point mutations 
*Significant at Bonferroni-adjusted p value of 0.006 (ie 0.05/8) 
 
 
Table 24B: Comparison of total ADL, total SARA, INAS count & SDFS for early-onset, 
classical and late-onset subtypes of FRDA in EFACTS corrected for disease duration 
Feature Early-onset 
(≤5 years)a 
Classical  
(6-24 years)b 
Late-onset  
(≥25 years)c 
MANCOVA F 
value (p value) 
Disease 
durationd 
22.5±7.4 21.0±12.1 14.5±6.7 - 
Total ADLe 18.4±1.3 
(p=0.18) 
15.7±0.6 
(p=0.012) 
11.0±1.5 
(p=0.001) 
6.9  
(p=0.001)* 
Total SARAe 25.9±1.7 
(p=0.298) 
22.9±0.7 
(p<0.0005) 
15.2±1.9 
(p<0.0005) 
9.9  
(p<0.0005)* 
INAS counte 5.1±0.3 
(p=1)  
5.1±0.1 
(p=0.488)  
4.6±0.3 
(p=0.727) 
1.0 
(p=0.363) 
SDFSe 5.4±0.2 
(p=0.42) 
5.0±0.1 
(p=0.022) 
4.2±0.3 
(p=0.005) 
75.4  
(p=0.005)* 
a
n=22; 
b
n=119; 
c
n=18 (cases for which all values available allowing MANCOVA) 
d
mean±SD 
e
mean±SEM; covariates are evaluated at disease duration=20.34 years 
p values quoted in 1
st
 3 columns are for post-hoc analysis with Bonferroni corrections pre-adjusted in 
SPSS (ie significant at 0.05)  
*Significant at Bonferroni-adjusted p value of 0.0125 
 
 
132 
 
 
Table 25: Comparison of examination findings from INAS and EFACTS assessment for 
early-onset, classical and late-onset subtypes of FRDA patients from EFACTS 
Feature Early-onset 
 (≤5 years) 
Classical  
(6-24 years) 
Late-onset  
(≥25 years) 
χ2 Valuec  
(p value) 
Corrected 
χ2 Valued 
(p value) 
Gender 9:14 56:69 7:1 0.852 
(p=0.653) 
- 
Amyotrophya 15/23 
(65.2) 
58/124 
(46.8) 
3/19 
(15.8) 
10.4 
(p=0.005) 
1.7 
(p=0.194) 
Paresisa 18/23 
(78.3) 
102/124 
(82.3) 
9/19 
(47.4) 
11.6 
(p=0.003)* 
0.1 
(p=0.807) 
Areflexiaa 23/23 
(100) 
123/124 
(99.2) 
10/19 
(52.6) 
64.8 
(p<0.0005)* 
8.0 
(p=0.005) 
Hyperreflexiaa 0/23 
(0) 
4/124 
(3.2) 
7/19 
(36.8) 
32.0 
(p<0.0005)* 
0.3 
(p=0.565) 
Sensory lossa 19/24 
(79.2) 
102/122 
(83.6) 
15/18 
(83.3) 
6.7 
(p=0.352) 
2.8 
(p=0.092) 
Spasticitya 12/23 
(52.2) 
56/124 
(45.2) 
12/19 
(15.0) 
2.3 
(p=0.316) 
0.2 
(p=0.681) 
Extensor 
plantarsa 
14/23 
(60.9) 
81/124 
(65.3) 
9/19 
(47.4) 
2.3 
(p=0.316) 
1.1 
(p=0.292) 
Dysarthriaa 20/22 
(90.9) 
108/122 
(88.5) 
16/18 
(88.9) 
0.1 
(p=0.948) 
3.1 
(p=0.077) 
Dysphagiaa 17/22 
(77.3) 
88/122 
(72.1) 
12/18 
(66.7) 
0.6 
(p=0.757) 
0.3 
(p=0.565) 
Wheelchair-
boundb 
15/21 
(71.4) 
66/114 
(57.9) 
2/18 
(11.1) 
16.6 
(p<0.0005)* 
0.6 
(p=0.447) 
Cardio-
myopathyb 
16/23 
(69.6) 
54/121 
(44.6) 
2/18 
(11.1) 
14.0 
(p=0.001)* 
7.6 
(p=0.006) 
Diabetes 
mellitusb 
3/21 
(14.3) 
10/114 
(8.8) 
0/18 
(0) 
2.6 
(p=0.274) 
0.5 
(p=0.489) 
Pes cavusb 18/23 
(78.3) 
74/124 
(59.7) 
4/19 
(21.1) 
14.6 
(p=0.001)* 
4.7 
(p=0.031) 
Scoliosisb 21/23 
(91.3) 
86/124 
(69.4) 
9/19 
(47.4) 
9.6 
(p=0.008) 
4.1 
(p=0.042) 
Values are for n/N (%) 
a
Categorical values (presence or absence) taken from INAS count calculation. A categorical value was 
calculated for dysarthria and dysphagia from the INAS data. Sensory loss refers to vibrational sensory 
loss at the external malleolus from the INAS 
b
Categorical values (presence or absence) taken from EFACTS Registry 
c
Uncorrected Pearson
 
χ
2
 test 
d
Wald χ
2
 test corrected for disease duration using ordinal logistic regression 
*Significant at Bonferroni-adjusted p value of 0.003 (ie 0.05/15) 
 
 
Table 24A shows the age at onset, age at examination, disease duration, GAA1 size, 
total ADL, total SARA, INAS count and SDFS for the 167 FRDA patients in the EFACTS 
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study for which data were available at the baseline assessment divided according to 
age at onset (early-onset ≤ 5 years, classical 6-24 years, late-onset ≥ 25 years). Column 
4 shows the ANOVA F-values and p-values. After Bonferroni adjustment for multiple 
testing the significance level is p<0.006. Table 24B shows total ADL, total SARA, INAS 
count and SDFS for these three groups corrected for disease duration as a confounding 
factor using a multivariate analysis of covariance (MANCOVA).  
In the uncorrected analysis (table 24A), the mean age at onset was significantly 
different between the three groups as this was the criterion on which the groups were 
selected. The mean age at examination was significantly different between the three 
groups but the difference in disease duration did not survive Bonferroni correction. 
The means of GAA1 size, total ADL, total SARA and SDFS were significantly different 
between the three groups and these parameters went on to individual pairwise post-
hoc testing for which p values pre-adjusted by SPSS are quoted (significant at p<0.05). 
The GAA sizes for the eight compound heterozygotes were excluded from all 
calculations involving GAA size, although these patients were included in the analysis 
of their clinical features. Figure 38 shows the mean ± SD for GAA1 size, total ADL, total 
SARA, INAS count and SDFS divided by subtype. Significant differences were found 
between classical and late-onset subtype, and between early- and late-onset subtype, 
but not between early-onset and classical subtype for GAA1 size, total ADL, total SARA 
and SDFS, with all values increasing with later onset of disease. 
 
Figure 38: Comparison of (A) GAA1 size, (B) total ADL, (C) total SARA, (D) INAS count 
and (E) SDFS for early-onset, classical and late-onset subtypes of FRDA from EFACTS.  
Error bars=SD. *Significant difference at p<0.05 after Bonferroni adjustment 
After correction for differences in disease duration between the three groups (Table 
24B), the results remain broadly similar with statistically significant differences in the 
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total ADL, total SARA and SDFS but not the INAS count, underlining its inferiority as an 
assessment tool in FRDA. Post-hoc analysis shows that all the significant differences 
after correction are between either (a) the early-onset and late-onset groups; or (b) 
the classical and late-onset groups. There were no statistically significant differences 
between the early-onset and classical groups, suggesting that these are part of a 
continuum rather than distinct nosological subtypes. 
Table 25 shows proportion of patients with various examination findings and 
associated features derived from the INAS data and EFACTS assessment for which data 
were available at baseline divided according to age at onset subtype. These are binary 
categorical data showing either presence or absence of the symptom or feature and do 
not express its severity. Column 4 shows the uncorrected Pearson χ2 and p-values. 
After Bonferroni adjustment for multiple testing the significance level is p<0.003. 
Column 5 shows the Wald χ2 and p-values corrected for disease duration as a 
confounder. 
There were no differences in gender between the three groups. There were significant 
differences between the three subtypes for muscle weakness, areflexia, hyperreflexia, 
cardiomyopathy, pes cavus and wheelchair-bound status. The late-onset group had 
significantly less muscle weakness and over 50% had retained reflexes. Hyperreflexia 
was only really seen in the late-onset group. A very small proportion of the late-onset 
group were wheelchair-bound or had cardiomyopathy (about 10% in each case). Pes 
cavus was similarly less prominent in the late-onset group. Differences in muscle 
wasting and scoliosis did not survive Bonferroni correction although in each case their 
prevalence decreased with later onset. There were no significant difference in 
dysarthria, dysphagia, vibrational sensory loss or the presence of extensor plantar 
reflexes between the three groups which were all very common throughout. 
Surprisingly, spasticity appeared to decrease with later onset although there was no 
significant difference between the groups. There was also no significant difference in 
diabetes although there were no cases amongst the late-onset group, and the early-
onset group had the highest prevalence, although at a low level (14%). Figure 39 and 
Figure 40 show these features graphically. After correction for disease duration, there 
were significant differences in areflexia (p=0.005), cardiomyopathy (p=0.006), pes 
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cavus (p=0.031) & scoliosis (p=0.042) but none of these survived Bonferroni correction 
for multiple tests (Bonferroni significance level 0.05/14=0.0036). 
 
Figure 39: Comparison of examination findings from INAS for early-onset, classical 
and late-onset subtypes of FRDA patients in EFACTS.  
*Differences significant at p=0.05 after Bonferroni correction 
 
 
Figure 40: Comparison of examination findings from EFACTS assessment for early-
onset, classical and late-onset subtypes of FRDA patients in EFACTS.  
*Differences significant at p=0.05 after Bonferroni correction 
Taken together, these data suggest that early-onset, classical and late-onset FRDA are 
not distinct nosological entities, and indeed the distinguishing feature chosen for 
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analysis was essentially arbitrary, although in the case of the late-onset subtype, on 
the basis of previously published diagnostic criteria (Harding 1984) and descriptions of 
atypical forms such as late-onset FRDA (LOFA) and FRDA with retained reflexes (FARR) 
(De Michele et al. 1994, Klockgether et al. 1996). Rather, FRDA forms a continuum in 
which there is a progressively more severe phenotype with earlier age at onset. This is 
particularly marked by increasing weakness, immobility and associated features of 
cardiomyopathy, pes cavus and areflexia. Muscle wasting, scoliosis and diabetes are 
probably also more prominent. There is greater justification for distinguishing LOFA 
from the other groups and this does appear to have some characteristic features of 
retained and in some cases brisk reflexes, together with an absence of diabetes and 
very low prevalence of cardiomyopathy, pes cavus and wheelchair confinement. 
Section 2.4.4  below explores the correlation between some of these features. 
2.4.3 Growth Retardation 
As noted by Harding (Harding 1984), patients with FRDA with onset of symptoms in 
childhood frequently do not develop muscle bulk and can appear to have growth 
retardation. The present study affords some scope to investigate this observation.  
World Health Organization (WHO) growth charts extend up to age 20 
(http://www.who.int/growthref/en/). The Royal College of Paediatrics and Child 
Health (RCPCH) uses the same data for their growth charts for children in the UK above 
the age of 4 (http://www.rcpch.ac.uk/growthcharts). There were 24 patients in the 
study between the ages of 16 and 20 (8 male, 16 female). Their heights and centile for 
age and sex are shown in Table 26 and plotted on the appropriate WHO growth chart 
in Figure 41. The mean height for the male participants corresponded to the 43.3th 
centile (range 30.9-65.4). The mean height for the female participants corresponded to 
the 27.0th centile, although one value was well below normal. Even excluding this 
value, the mean female height centile was 32.7. The mean height centile for all 
patients in the study aged 16-20 was 32.4.  
These data seem to add some credence to the idea of growth retardation amongst 
FRDA patients. If this were the case, one might expect a correlation between age at 
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onset and height as the earlier the age at onset, the greater the growth retardation. 
Figure 42 shows the height of the 102 patients of 40 or less at the time of baseline 
assessment plotted against age at onset. There is no correlation between the two 
parameters (Spearman’s rank correlation coefficient R=-0.113, R2=0.013, p=0.259).  
Only a small number of participants in the study were appropriate for the first 
calculation, and as Figure 41 shows, they appear on the portion of the graph which has 
plateaued, as the patients are adults. Indeed, not all growth charts extend to age 20. It 
would be interesting to repeat this calculation for children and in a larger sample size 
and with age-matched control data. 
Table 26: Height & centile for EFACTS patients aged 16-20  
(based on WHO growth chart) 
Sex Age Age at onset Height (cm) Centile 
M 16 2 175 54.2 
M 17 8 175 48.1 
M 18 6 170 30.9 
M 18 4.5 178 52.1 
M 18 1 183 65.4 
M 19 7 165 16.9 
M 19 14 177 48.9 
M 20 8 170 30.3 
F 16 3 153 18.7 
F 17 10 155 24.1 
F 17 12 164 51.4 
F 18 12 151 11.1 
F 18 11 167 60.1 
F 18 12 159 35.6 
F 19 10 165 54.0 
F 19 1 170 69.3 
F 19 7 128 -59.3 
F 19 4 152 14.2 
F 19 8 152 14.2 
F 19 12 148 1.9 
F 19 6 161 41.7 
F 19 10 160 38.7 
F 20 17 159 35.6 
F 20 10 154 20.3 
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Figure 41: Height of EFACTS patients aged 16-20 plotted on WHO growth charts. 
Male (left), female (right). 
 
 
Figure 42: Height of EFACTS patients of 40 or less plotted against age at onset 
2.4.4 Correlation with GAA Size and Clinical Rating Scales 
Previous studies have shown an inverse correlation between the size of the shorter 
GAA expansion in the frataxin gene and various markers of disease severity including 
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age at onset and time to wheelchair use (Dürr et al. 1996). GAA expansion size 
inversely correlates with frataxin protein level and mRNA expression in peripheral 
blood cells (Saccà et al. 2011). Only GAA expansion size was available at the time of 
data analysis. Figure 43 shows the negative correlation between the size of the shorter 
GAA expansion (GAA1) and age at symptom onset. This is greater than the correlation 
between the longer GAA expansion (GAA2) and age at onset. This may be because the 
GAA1 size is typically spread over a greater range of values than is GAA2 size, as shown 
in Figure 10 and discussed in the text at 2.3.3, particularly for shorter expansions. 
Almost all the GAA2 sizes are greater than 500 repeats which are associated with very 
low levels of frataxin production. Thus, there is likely to be less difference in frataxin 
levels between these larger expansions, and hence the GAA2 size exerts less influence 
over the clinical phenotype. 
Figure 44 shows the positive correlation between GAA1 size and various clinical 
assessment tools recorded in the study, of which the total SARA score shows the 
strongest correlation, although clearly with a wide spread of values. Figure 45 shows 
the positive correlation between age at onset and the same range of clinical 
assessment tools, again showing the strongest correlation with the total SARA score 
and overall a far stronger correlation than with GAA1 size. Figure 46 shows the positive 
correlation between disease duration and the four clinical assessment tools, this time 
showing the strongest correlation with the total ADL. This is the strongest correlation 
found. This also gives an impression of disease progression based on cross-sectional 
rather than longitudinal data. Values shown are for Pearson’s correlation. This is the 
first study to correlate GAA expansion size with these clinical rating scales. 
Taken together, these findings suggest that the SARA and the ADL are the best markers 
of clinical severity, and disease duration is the strongest predictor of disease 
progression. Thus, for every additional 100 GAA1 repeats, disease onset is predicted to 
be 2.1 years earlier, so that a GAA1 size of 100 predicts an age at onset of 25.7 years, 
and a GAA1 size of 1000 predicts an age at onset of 3.7 years. Many diagnostic labs use 
a GAA size of 100 as the lower limit of a pathological expansion. It is interesting that 
the Harding diagnostic criteria formulated before the FXN gene had been discovered, 
stipulated that disease onset should be below the age of 25 (Harding 1981) which 
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matches exactly with this result. Every additional 100 GAA1 repeats increase the SARA 
scale by 1.2 points on average, and the ADL by 0.7 points. Both early age at onset and 
disease duration predict clinical severity, so that every 10 years earlier that disease 
commences contributes 5.1 points on the SARA and 3.8 points on the ADL, and every 
additional 10 years of disease duration adds 5.4 points on the SARA and 4.8 points on 
the ADL.  
Samples have already been collected for assessment of frataxin mRNA and protein 
levels. At present the greatest correlation between a clinical and an underlying 
pathological marker is between age at onset and GAA1 size. However, this still only 
explains 33.1% of the variation [see Figure 43 (A)]. Alternative explanations may 
include epigenetic factors acting on the FXN gene. Downstream markers of gene 
function may therefore provide a more accurate prediction of clinical severity.  
 
Figure 43: Correlation between age at onset and (A) GAA1 size (B) GAA2 size for 
EFACTS patients 
141 
 
 
Figure 44: Correlation between GAA1 size and (A) total ADL (B) total SARA (C) INAS 
score (D) SDFS for EFACTS patients 
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Figure 45: Correlation between age at onset and (A) total ADL (B) total SARA (C) INAS 
score (D) SDFS for EFACTS patients 
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Figure 46: Correlation between disease duration and (A) total ADL (B) total SARA (C) 
INAS score (D) SDFS for EFACTS patients 
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2.4.5 Validity of Clinical Rating Scales  
One of the principal objectives of EFACTS was to validate a variety of clinical rating 
scales and systematically collect a mass of baseline and longitudinal data specifically 
related to FRDA in order that they might subsequently be used as part of appropriately 
planned and powered interventional trials. To that end, four scales were used, viz. the 
SARA, INAS, SCAFI and CCFS. The data relating to the CCFS are being analysed by a 
collaborator (Pr. Alexandra Dürr, Hôpital de la Pitié-Salpetrière, Paris) and are not 
presented in this thesis. In addition, the ADL questionnaire from the FARS and the 
SDFS were administered. These scales were supplemented by data collected as part of 
the EFACTS assessment and in the London centre by the SNE. None of the scales has 
previously been used in such a large and clinically well characterized sample as the 
EFACTS cohort. 
The ADL questionnaire was taken from the FARS (Subramony et al. 2005) and has 
previously been studied in FRDA (Lynch et al. 2006, Friedman et al. 2010, Bürk et al. 
2009). It is quick to administer and provides a rounded assessment of the burden of 
disease in FRDA including bladder function which this thesis has shown is a significant 
and probably undervalued feature of the condition. It takes into account practical 
functions such as washing, dressing and use of cutlery, which arguably are more 
meaningful for patients, if perhaps less objective than many examination findings. 
Each category is divided into a simple semi-quantitative 5-point scale, but each point is 
precisely defined preventing inter-rater variation : for example, the use of cutlery 
category uses such descriptive phrases as ‘mildly slowed and clumsy but no assistance 
required’, ‘can cut most dishes but slowed and clumsy, some assistance required’ and 
‘dishes have to be cut by caregiver, can eat slowly’ rather than less precise terms such 
as ‘mild’, ‘moderate’ and ‘severe’.  
It was initially envisaged that the questionnaire would be sent to patients and 
completed in advance of the clinical assessment. However, the graphic nature of some 
of the descriptions caused distress to some patients such as ‘helpless’, ‘completely 
depending on help’ and ‘incapable of walking even with support’ and so it was decided 
that the examiner would administer the questionnaire in clinic. This may have 
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engendered the additional benefit of improving inter-rater variability as only two 
clinicians saw patients as part of the project and the vast majority were seen by the 
author. However, it did represent a deviation from protocol. If the ADL questionnaire is 
to be issued to patients to complete themselves, it perhaps should contain more 
sympathetically worded responses. Figure 15 shows that, of the contributory 
categories, use of cutlery, dressing, washing and sitting show an even spread of values. 
Speech and swallowing are skewed toward the lower values but with a good spread of 
values up to the middle range. Only the walking and falls categories show the greatest 
proportion in the highest score, raising the possibility of a ceiling effect in these 
categories. Overall, when all the values are pooled, there is a very good spread of 
values across the five summed categories of the ADL. The total ADL score correlates 
with GAA1 size, age at onset and disease duration (see Section 2.4.4 above). 
The SARA was initially described for use in the SCAs (Schmitz-Hübsch et al. 2006) but 
has subsequently been studied in a variety of ataxias including FRDA (Weyer et al. 
2007, Bürk et al. 2009). It is quick and easy to administer, and assesses a broad range 
of functions known to be affected in FRDA including speech, gait, and measures of 
upper and lower limb ataxia. It employs a variety of examination techniques familiar to 
many clinicians, such as the ‘nose-finger test’, ‘heel-shin test’ and the test of fast 
alternating hand movements traditionally used to assess dysdiadocokinesis. The scores 
are precisely defined to reduce inter-rater variability : for example, in the ‘finger chase 
test’ the degree of dysmetria is ‘none’, ‘<5cm’, ‘<15cm’, ‘>15cm’ or unable to perform 
test. Whilst being precise and objective, the scale solely assess ataxia which is not the 
only cause of disability in FRDA, and only utilizes clinical examination findings. Thus, it 
may not be functionally meaningful for a patient with FRDA who is wheelchair-bound 
to be informed that the heel-shin test has progressed from three times in three cycles 
to four or more times in three cycles.  
Potentially more problematical for clinical trials is that it is heavily weighted toward 
lower limb function. Figure 16 shows that the vast majority of patients already occupy 
the highest score within the gait, stance, sitting and heel-shin test categories when 
first assessed at their baseline visit. This is consistent with the knowledge that more 
than half of the cohort were wheelchair-bound at this assessment. This introduces a 
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potential ceiling effect into the scale which might prompt researchers to exclude 
wheelchair-bound patients from clinical trials in order to improve sensitivity to change, 
with the possible effect that subsequent commissioning groups and prescribers might 
exclude these patients from treatment. The speech, finger chase, nose-finger test and 
fast alternating hand movement categories are much more evenly spread with modal 
values in the middle of each category. It is not possible to pool individual scores in the 
same way as for the ADL as each of the categories has a different number of scores. 
However, the total SARA score does still correlate with GAA1 size, age at onset and 
disease duration (see Section 2.4.4 above). 
The INAS was first described in SCA 1,2,3 & 6 in order to assess non-ataxic symptoms 
which may complicate these primarily ataxic disorders (Jacobi et al. 2013). It was found 
to have good reproducibility but unsatisfactory responsiveness. The authors concluded 
that it was a valid measure of extracerebellar involvement in these conditions but 
should not be used as a primary outcome measure. It has not hitherto been validated 
in FRDA. The INAS assesses 34 separate categories both of clinical signs elicited by the 
examiner and symptoms reported by the patient. Most are assessed on a semi-
quantitative scale of zero to three (none, mild, moderate, severe) without further 
precise definition leading to these assessment being open to some inter-rate variation. 
The only fully objective sign is the assessment of vibrational sensibility using the Rydel-
Seiffer graduated tuning fork, although four of the symptom categories are precisely 
defined (episodic vertigo, speech problems, handwriting problems, spontaneous 
cramps). The scale is necessarily more time-consuming to administer than the ADL and 
SARA and requires considerable experience of neurological assessment as it essentially 
involves a full neurological examination with the recognition of a variety of movement 
disorders and variations in muscle tone (eg spasticity versus rigidity versus dystonia). 
The assessment of eye movements is particularly rigorous.  
The INAS collects a large amount of useful examination information (see Table 14), the 
extracerebellar features of which are extracted using a slightly complicated technique 
to give the ‘INAS count’ covering 16 domains (see Table 13 and Figure 17). The INAS 
count domains highlight those features which are prominent in FRDA (areflexia, 
vibrational sensory loss, paresis, extensor plantar responses, muscle atrophy, urinary 
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dysfunction, brainstem oculomotor signs, and perhaps surprisingly, spasticity). 
However, it includes many domains which are rarely affected in FRDA (such as 
hyperreflexia and cognitive impairment) and domains which are practically never 
affected (such as myoclonus, chorea and parkinsonism). Nevertheless, the INAS score 
does correlate with GAA1 size, age at onset and disease duration, albeit with 
considerably lower correlation coefficients than for the ADL and SARA.  The absence of 
so many unaffected domains means than the maximum score obtained by any patient 
was 9 out of 16, meaning that the score contains a considerable floor effect in these 
domains. 
As stated, the INAS collects a large general amount of examination information which 
is not used in the calculation of the final INAS count. This information added 
considerably to the broad clinical description of FRDA given in Section 2.4.1 above and 
groups the signs so that they are easier to analyze and present than, for example, in 
the SNE. The INAS, for example, reveals the prominence of broken smooth pursuits, 
square wave jerks and saccadic dysmetria over other oculomotor abnormalities (see 
Figure 21). 
The SCAFI is the functional score taken from the FARS (Subramony et al. 2005) and has 
previously been studied in FRDA (Lynch et al. 2006, Bürk et al. 2009, Friedman et al. 
2010). The SCAFI assesses three functions : it assesses mobility by means of an 8-metre 
timed walk (8mTW), manual dexterity by means of a 9-hole peg test (9hPT) and speech  
by means of the ‘pa-ta test’. As more than half of the patients in the cohort were 
wheelchair-bound, this meant that more than half could not complete the task in its 
entirety. These patients are all assigned the same high score by default, leading to an 
immense ceiling effect in this scale. Indeed, only 31.7% of patients in the cohort 
completed the 8mTW as many, who are able to mobilize at home with a walking aid, 
had not brought this to clinic. If patients are assessed in their own homes, there is 
often not a suitable flat furniture-free 8-metre course over which to assess the patient. 
A considerable proportion (around 30%) also cannot complete the 9hPT because of 
severe lack of manual dexterity, and many find the four replications of the task tiring 
and distressing. The scale also requires specific equipment (the Rolyan plastic one-
piece 9hPT apparatus) which is not readily available in most clinics.  Figure 22 shows 
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that the raw data for the 8mTW and 9hPT for those patients who are able to 
undertake these tasks are heavily skewed toward lower values. Only the pa-ta test is 
normally distributed, able to be completed by a high proportion of patients and does 
not require special equipment.  
Thus, the ADL provides a reliable symptom-based assessment and the SARA a reliable 
examination-based assessment of the extent of disease in FRDA. The INAS provides a 
large amount of useful information but the INAS count is less relevant to FRDA. The 
majority of FRDA patients are unable to complete the SCAFI making it less reliable in 
FRDA. 
2.4.6 Disease Progression 
The EFACTS project enables the study of clinical rating scales both cross-sectionally as 
above, but also longitudinally which has only rarely been undertaken before (Fahey et 
al. 2007, Friedman et al. 2010, Marelli et al. 2011). This information is vital for planning 
therapeutic trials which in FRDA have been bedevilled by negative results even when 
large, prolonged, multi-centre designs have been employed. It is therefore important 
to know which scales are appropriate to the patient group, which are sensitive to 
change, how different subgroups of patients behave within those scales and what the 
magnitude of random variation and systematic progressive deterioration is according 
to these measures.  
Section 2.3.11 above shows how four of the rating scales varied over the 2-year period 
of the study (SARA, INAS, ADL and SDFS). Of these, the SARA was most exhaustively 
analyzed as the cross-sectional results were most promising for this measure. The UK 
wing of the EFACTS project which encompassed 167 genetically proven cases of FRDA, 
125 of whom were re-assessed after 1 year (FU1) and 116 after 2 years (FU2), was able 
to show statistically significant progression within the SARA both at the FU1 and FU2 
visits. However, the difference between the two means over that period was only 1.33 
points on the SARA scale, representing an increase from 23.2±10.2 to 24.6±9.5 and an 
annual rate of change of 0.7 SARA points (out of a possible maximum value of 40). 
Within this deterioration, there was enormous variation. Indeed, over the 2-year study 
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period 26.7% of the patients improved in terms of their total SARA score, 12.1% did 
not change and only 61.2% deteriorated.  
Within the SARA, progression was most marked within those subscores which assess 
lower limb function, despite the fact that these subscores are heavily skewed toward 
their higher values. It is therefore reasonable in clinical trials to recruit patients with 
less lower limb involvement such as those who remain mobile. It is less advisable to 
use measures which exclude or place less emphasis on lower limb involvement. 
Although there is some suggestion from the cross-sectional data that clinical 
progression plateaus when measured by the SARA (see Figure 46(B)), the longitudinal 
data show that progression is independent of disease severity. Figure 47 combines the 
cross-sectional and longitudinal data for the SARA giving an idea of overall disease 
progression and the considerable variation within this from individual patients. 
The INAS count was insufficiently sensitive in this study to detect change over the two 
year period of the study. Indeed, only 37% of patients showed deterioration in this 
measure. Figure 17 shows that six of the sixteen count parameters are barely 
populated for FRDA patients which may partly explain its inappropriateness as a 
measure of disease severity in FRDA. The method of calculation of the count also 
minimizes sensitivity to change. Although many of the parameters are assessed on a 4-
point semi-quantitative scale, these results are combined into simple binary scores of 
presence or absence for calculation of the final score. Although this has the undoubted 
benefit of simplifying the scale for statistical manipulation and presentation of results, 
it has the effect of reducing its sensitivity to change. This study therefore does not 
support the choice of the INAS count as an outcome measure to assess clinical change 
in FRDA.  
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Figure 47: Total SARA values at different disease durations shown (A) by individual 
patient, and (B) by visit 
The total ADL was able to detect progression over both one and two years of the study 
with a mean difference of 1.07 between BL and FU1, and 2.04 between BL and FU2 
(out of a possible maximum value of 36). As with the total SARA and unlike the INAS 
count, a far greater proportion of patients deteriorated (66.4%) than improved 
(21.1%). No evidence of ceiling effect was seen and in the cross-sectional data, there 
was a good spread of values within most of the subscores (see Figure 15).  
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Progression was also detected by the SDFS with patients moving from lower to higher 
disability stages throughout the study (see Figure 35(C)&(D)). This is most marked 
when considering stages 1-3 together (between no functional disability and limited 
walking but without aid), compared to stages 5-6 together (between walking with two 
sticks and confined to bed). Over the two years of the study, the proportion of patients 
in stages 1-3 drops from 20.4% at BL, to 13.8% at FU1 and 10.1% at FU2. By contrast, 
the proportion of patients in stages 5-7 increases from 70.7% at BL, to 78.3% at FU1 
and 81.4% at FU2. There is very little change overall in stage 4 (walking with one stick). 
Similarly, in the Wilcoxon signed ranks test, there are 16 positive and 2 negative rank 
changes between BL and FU1, and 28 positive and 1 negative rank changes between BL 
and FU2. The SDFS is therefore a good overall marker of disability which is sensitive to 
change over 1-2 years but provides very little scope for further analysis of the reasons 
for change. 
It is interesting to speculate as to why a significant proportion of patients with what is 
regarded as a relentlessly progressive condition, should in fact fail to progress within 
the clinical measures within this study. The majority of patients in the study were also 
seen as NHS patients within the Ataxia Centre of the NHNN and so are engaged with a 
tertiary centre of excellence in the management of ataxia, have their drug treatments 
optimized and are frequently referred for specialist physiotherapy, occupational 
therapy, speech and language therapy and other interventions. Many of the remaining 
patients were also seen at specialist centres around the country. Several patients were 
engaged in therapeutic drug trials during the study, including those of idebenone, 
nicotinamide and pioglitazone. Many patients were taking co-enzyme Q10 or other 
dietary supplements and several started these agents during the period of the study. 
The study was purely observational with the express objective of establishing a registry 
from which patients could be recruited into therapeutic trials, and so participation in 
such trials and use of medicinal agents was entirely consistent with the ethos of the 
study. An alternative approach is to exclude these patients from calculations or subject 
the data to stratification or multivariate analysis, all of which risk diminishing the 
power of the study. 
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Patients were quite often seen by chance in the aftermath of a recent fall, fracture, 
infection, period of unwellness or hospital stay, giving a confoundingly suppressed 
baseline assessment after which they would recover either with or without active 
rehabilitation, and appear to have improved clinically at subsequent assessments. Such 
temporary effects are difficult to capture and quantify in natural history studies. The 
intention of recruiting such a large sample with assessments over such a long period is 
to attenuate these natural variations, but the present study would seem to indicate 
that these effects are considerable when compared to the exceptionally slow 
underlying progression of the disorder. Of course, the data presented in this thesis 
represent a fraction of a wider European study which has recruited more than 600 
patients and will assess patients over at least three years and informally beyond, which 
should help to minimize these effects. 
The majority of disease-modifying treatments for neurodegenerative disorders are 
aimed at minimizing or stabilizing cellular and hence clinical deterioration. Therefore, 
with the exception of actively regenerative interventions such as gene or stem cell 
therapy, future therapeutic trials will continue to be tested for their ability to show a 
reduction in an already exceptionally slow decline against considerable background 
variation. This may be more than any of the rating scales investigated in this project is 
capable of. One possible solution to this problem is to develop one or more 
biomarkers which reliably track disease activity in the long run but which react more 
rapidly in the short term. The wider EFACTS project may provide useful evidence in this 
regard as the blood and urine samples derived from this study will be subjected to 
proteomic analysis. Frataxin protein and mRNA levels will also be quantified. These are 
perhaps the most biologically plausible markers of disease activity in FRDA but have 
hitherto not formed part of the routine evaluation of FRDA patients in therapeutic 
trials. Early studies of the anti-oxidant idebenone used markers of oxidative stress such 
as plasma dihydroxybenzoic acid levels after salicylate administration and urinary 8-
hydroxy-2’-deoxyguanosine levels (Schulz et al. 2000), or markers of oxidative 
phosphorylation such as phosphocreatine recovery after exercise measured by 31-
phosphorus magnetic resonance spectroscopy (Schöls et al. 2001). A recent study of 
the histone deacetylase inhibitor, nicotinamide, using patients included in this study, 
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showed significant increases in protein and mRNA levels of frataxin, although no 
clinical changes were detected in this exploratory study because of its necessarily short 
duration and small size (Libri et al. 2014). However, this holds hope for future studies 
which is essential if large amounts of money and resources are not to be expended, 
and patients not put to the inconvenience and expense of attending studies which run 
the risk of falsely rejecting effective treatments because of the non-responsiveness of 
clinical rating scales. 
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Chapter 3 :  Friedreich’s Ataxia Point Mutations & 
Deletions 
 
3.1 Introduction 
This chapter describes the clinical presentation of patients with compound 
heterozygous FXN point mutations and deletions both recruited as part of and outside 
the EFACTS project, with particular attention on the only deletion found as part of the 
UK wing of the EFACTS project. It also describes a project to determine the frequency 
of FXN deletions amongst patients referred to the Neurogenetics service at the NHNN 
with suspected FRDA.  
3.1.1 FXN Compound Heterozygotes with Point Mutations 
Whilst most patients with FRDA are homozygous for pathological GAA expansions in 
the FXN gene, approximately 4% show compound homozygosity for a point mutation 
in the FXN gene combined with a pathological GAA expansion (Campuzano et al. 1996). 
More than forty pathogenic point mutations have been described spanning all five 
exons of the principal gene transcript (collated by the Human Gene Mutation Database 
(HGMD), University of Cardiff, http://www.hgmd.cf.ac.uk/ac/index.php). These have 
included missense mutations caused by base pair substitutions and an in-frame 
insertion-deletion. There are also null mutations caused by base pair substitutions in 
the start codon resulting in incorrect translational initiation, as well as nonsense 
insertions, deletions and indels causing frame-shift variants resulting in premature 
termination. Intronic variants have also been described at all four splice-sites. Their 
location relative to the FXN gene exons and frataxin protein secondary structural 
elements is illustrated in Figure 49 (Forrest et al. 1998, Cossée et al. 1999, Pook et al. 
2000, De Castro et al. 2000, Gellera et al. 2007, Galea et al. 2015, Heidari et al. 2013). 
No homozygous FXN point mutations have yet been described. 
Frataxin is a nuclear-encoded protein which is translated in the cytoplasm as a 23.1kDa 
210 amino acid species sometimes called human frataxin precursor. The amino-
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terminal residues are likely to act as a mitochondrial-targeting sequence and are 
cleaved proteolytically in the mitochondria by the mitochondrial processing peptidase 
(MPP). Several cleavage sites have been demonstrated under different experimental 
conditions including those after residues 55 and 77. However, it is likely that 
processing occurs in vivo in humans via a two-step process. This involves cleavage of 
the mitochondrial signal peptide (residues 1-42) to produce a 18.8kDa 168 amino acid 
intermediate protein. Subsequent cleavage of the intermediate N-terminal tail 
(residues 42-81) produces the functional, mature 14.2kDa 130 amino acid protein 
(Branda et al. 1999, Cavadini et al. 2000, Condò et al. 2007, Schmucker et al. 2008). 
The mature protein localizes to the inner mitochondrial membrane. Expression is 
ubiquitous but highest in the heart and spinal cord, intermediate in the cerebellum, 
liver, skeletal muscle and pancreas, and low in other organs including the cerebral 
cortex (Campuzano et al. 1996). Reduced frataxin expression affects mitochondria-rich 
cells such as cardiomyocytes, sensory neurones of the dorsal root ganglia (DRG), 
pancreatic islet β-cells and cells of the cerebellar dentate nuclei and spinocerebellar 
tracts.  
Frataxin plays a role in iron-sulphur cluster (ISC) assembly, haem biosynthesis and 
intracellular iron homoeostasis. These functions are undertaken by interaction with 
cellular proteins. Frataxin interacts with the cysteine desulphurase enzyme IscS which 
catalyzes the conversion of cysteine to alanine producing a highly reactive sulphide 
species which interacts with ionic iron to form the ISC. Frataxin also interacts with the 
scaffold protein IscU on which the ISC assembles (Prischi et al. 2010, Pandolfo & 
Pastore 2009). Furthermore, an extramitochondrial form of mature frataxin has been 
found to interact with the bifunctional ISC-dependent cytosolic aconitase/iron 
regulatory protein-1 (IRP1) (Condò et al. 2010). There is evidence that frataxin has a 
role in reducing oxidative stress. One of the principal fucntions of ISCs is to participate 
in reversible redox reactions because of the variable valency of ironic iron (Fe2+/Fe3+). 
Complexes I, II and II of the mitochondrial electron transport chain, as well as the 
tricarboxylic acid cycle enzyme aconitase, all contain iron-sulphur clusters which 
exploit this property (Lill 2009, Johnson et al. 2005). Frataxin also interacts with 
ferrocheletase, a mitochondrial protein able to mediate insertion of iron into the 
159 
 
porphyrin precursor as part of haem biosynthesis (Lesuisse et al. 2003). The 
significance of this in FRDA is not fully understood as failure of haem synthesis is not 
recognized as a major feature of the condition. 
The mature frataxin protein consists of a large, twisted β-sheet composed of at least 
six anti-parallel β-strands (β1-6), flanked by two α-helices (α1 & α2). The β-sheet occurs 
between residues 122 & 181. The amino-terminal α1 helix occurs between residues 95 
& 113, and the second α2-helix between residues 182 & 194, with a carboxy-terminal 
tail formed by residues 194 onwards. The two α-helices lie roughly parallel to each 
other with the carboxy-terminal tail filling the groove between them (see Figure 48). 
One surface of the β-sheet is therefore exposed and the other in close apposition with 
the α-helices and carboxy-terminal tail (Musco et al. 2000, Dhe-Paganon et al. 2000). 
The α-helices contain a large proportion of anionic residues and may be involved in 
binding to iron. By contrast, the β-sheet is largely composed of uncharged residues and 
may be involved in protein-protein interactions (Santos et al. 2010, Adinolfi et al. 
2002). 
 
Figure 48: Ribbon representation of human frataxin 
α-helices shown in turquoise, β-strands in gold and C-terminal tail in red.  
Figure from Galea et al. 2015 
Figure 49 shows all the point mutations hitherto described in the FXN gene. It can be 
seen that all the missense mutations result in changes within the mature frataxin 
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protein and none causes alterations of the cleaved amino-terminal elements. The vast 
majority therefore occur in the terminal three exons. By contrast, most nonsense 
mutations occur within the first three exons including many in those portions of the 
gene encoding the cleaved amino-terminal elements. This is presumably because 
changes in the amino acid sequence of those portions of the protein which will 
ultimately be cleaved, do not affect the function of the final protein and so may be 
relatively tolerated. On the other hand, mutations which cause truncation of the 
protein both within the cleaved mitochondrial-targeting sequence and the final 
mitochondrially expressed molecule, will be deleterious; truncation of the terminal 
portion of the mitochondrial protein seems not be so harmful.  
 
Figure 49: Location of point mutations relative to exons of the FXN gene and 
secondary structure of the frataxin protein 
Genetic data from Human Gene Mutation Database 
(http://www.hgmd.cf.ac.uk/ac/index.php), Gellera et al. (2007), Galea et al. (2015) and original 
papers. RefSeq NM_000144.4, NP_000135. 
Protein structural data from UniProtKB (www.uniprot.org). ID: Q16595. PDB: 3T3L 
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Campuzano and colleagues described the first three FXN point mutations together 
with the initial identification of the FXN GAA triplet repeat expansion (Campuzano et 
al. 1996). These included missense (p.I154F), nonsense (p.L106X) and splice-site 
(g.IVS3-2A>G) mutations. Bidichandani et al. (1997) described the fourth, and to this 
date, commonest mutation (p.G130V) which they found resulted in an atypically mild 
clinical phenotype with very slow progression, no dysarthria and little or no 
incoordination. Cossée and co-workers then described the first of a number of 
mutations in the start codon (c.3G>T, p.M1I) that cause improper translational 
initiation (Cossée et al. 1997a). At that point, Forrest and colleagues compared a small 
series of five FXN compound heterozygotes including three further novel mutations 
(p.R165C, p.L182F & g.IVS4+2T>G) with those already described in the literature 
(Forrest et al. 1998). They concluded that splice-site, nonsense and initiation codon 
mutations which cause absence of functional frataxin were associated with a severe 
phenotype, but that missense mutations, even in highly evolutionarily conserved 
residues, cause a mix of mild and severe phenotypes. 
Cossée et al. (1999) compared the clinical features of 25 compound heterozygotes 
from 19 families, with 196 patients homozygous for the GAA repeat expansion. 
Patients with truncating mutations, or missense mutations in sequences encoding the 
carboxy-terminal half of the frataxin protein, had a similar phenotype to those with a 
homozygous GAA expansion. However, patients with a missense mutation in 
sequences encoding the amino-terminal half of the frataxin protein (D122Y and 
G130V) had a milder clinical phenotype with slow disease progression, early-onset 
spastic gait, retained upper and lower limb reflexes, no dysarthria and little or no 
ataxia. Compound heterozygotes also showed increased prevalence of optic disc 
pallor, an observation which has not subsequently been replicated. 
Galea and collaborators (2015) have published the largest series to date of FXN 
compound heterozygotes including cases from the present thesis (Galea et al. 2015). 
They studied the effect of FXN point mutation on (i) the tertiary structure of the 
frataxin protein by molecular modelling based on the known crystal structure of the 
protein; (ii) frataxin stability using a series of in silico structure-based protein stability 
prediction programs; and (iii) protein function, iron binding and protein-protein 
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interactions referring to previously published experimental data. They found that 
residues buried within the interior of the protein form a tightly packed hydrophobic 
core which helps to stabilize the protein structure. Mutations affecting residues within 
the hydrophobic core had the greatest impact on protein stability by generating steric 
clashes in the case of substitution by larger residues; cavities in the case of substitution 
by smaller residues; and unfavourable interactions in the case of substitutions of 
hydrophobic residues for charged ones. Null mutations caused the most severe 
phenotype but the clinical effect of particular missense mutations depended on factors 
acting at each individual site including effects on the tertiary structure of the protein, 
its ability to interact with other species and hence the overall functionality of the 
molecule. 
The majority of FXN point mutations described have been private mutations; cases 
have been reported from Asia, Australia, the South Pacific, USA and throughout Europe 
(Gellera et al. 2007). However, certain mutations have been reported recurrently. 
These include the following missense mutations: p.G130V (Bidichandani et al. 1997, 
Forrest et al. 1998, Cossée et al. 1999), p.I154F (Campuzano et al. 1996, Filla et al. 
1996, Cossée et al. 1999, Gellera et al. 2007), p.R165C (Forrest et al. 1998, McCormack 
et al. 2000) and p.W173G (Cossée et al. 1999, Gellera et al. 2007). It may be that some 
of these cases share a common founder, and that, for example in the case of p.G130V 
described above, a milder clinical phenotype with later onset allows the generation of 
progeny and the consequent propagation of this mutation in the population. Certain 
mutational hot-spots have also been identified. For example, five different nucleotide 
changes in the start codon (c.1A>C, c.2T>C, c.2delT, c.3G>T & c.3G>A) result in four 
different amino acid changes in the first residue (p.M1L, p.M1T, p.M1S & p.M1I) all 
causing incorrect translational initiation (Cossée et al. 1999, Zühlke et al. 1998, Potter 
et al. 2000, Zhu et al. 2002). At nucleotide 317, three different sequence changes 
(c.317T>G, c.317delT & c.317T>C) cause either nonsense mutations because of the 
direct generation of a stop codon (p.L106X) or a pathogenic missense mutation 
(p.L106S) (Campuzano et al. 1996, Bartolo et al. 1998, Pook et al. 2000).  
DeCastro et al. (2000) looked for pathological GAA expansions in the FXN gene 
amongst 241 patients with early-onset spinocerebellar ataxia. They found 175 patients 
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with a GAA expansion including seven (4%) with just one expansion. Of these, four 
were compound heterozygous for a point mutation including three nonsense 
mutations (p.W155X, p.E100fsX & p.R39fsX) and a splice-site variant (g.IVS3-2A>G). All 
were of Spanish or Cuban origin. The authors noted that three of the patients (those 
with p.W155X, p.R39fsX & g.IVS3-2A>G) clinically had classical FRDA with early onset 
between the ages of 3 & 4, whereas the last (p.E100fsX) had late-onset disease and 
was still ambulant after 12 years. The first three all had GAA expansion sizes of 
between 800 and 900 repeats, whereas the milder atypical case had a much smaller 
expansion of 250 repeats. They concluded that the size of the single pathological GAA 
expansion in a compound heterozygote continues to determine disease severity 
particularly in those who share nonsense mutations.  
Gellera and colleagues also compared age at onset with GAA expansion size amongst 
13 compound heterozygotes bearing FXN point mutations and found a statistically 
significant inverse correlation which was even stronger when only the nonsense 
mutations were considered. Furthermore, there was also a statistically significant 
inverse correlation between GAA expansion size and frataxin expression as measured 
by Western blot analysis of lymphoblastoid cell lines derived from these patients, 
although only after two outliers were excluded from analysis (Gellera et al. 2007). In 
the same restricted sample, age at onset positively correlated with frataxin levels. 
Taken together, these results suggest that even in the presence of a point mutation, 
GAA expansion size remains one of the principal determinants of frataxin production 
which in turn determines clinical severity. This is particularly marked in the case of 
nonsense mutations in which the allele bearing the GAA expansion is presumably 
solely responsible for frataxin production.  
Thus, a large range of point mutations in the FXN gene has been described. Null 
mutations which are usually clustered in the first three exons of the gene, have the 
most severe clinical effects. Missense mutations usually occur in the terminal three 
exons and are rarely found in those parts of the gene which encode the peptide 
sequences which are cleaved before mitochondrial expression. Missense mutations 
have variable effects depending upon their effect on the tertiary structure of the 
protein, its ability to interact with other molecules and overall function. The size of the 
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GAA expansion on the other allele remains an important determinant on clinical 
severity, particularly in the presence of null mutations. 
3.1.2 FXN Compound Heterozygotes with Large Deletions 
The development of methods for measuring gene dosage such as multiplex ligation-
dependent probe amplification (MLPA) has enabled the identification of compound 
heterozygotes with large FXN deletions (Deutsch et al. 2010). Eleven such cases have 
thus far been described some of which have atypical features. Zühlke and colleagues 
described a 2776 base pair deletion including exon 5a of the FXN gene using a 
quantitative duplex PCR assay with exon-specific oligonucleotide probes analogous to 
MLPA, followed by sequencing of the 5a exon (g.120032_122808del). The individual 
concerned had typical features of FRDA and progression to wheelchair use over 6 years 
(Zühlke et al. 2004). Deutsch and co-workers described an individual with a deletion in 
exons 2-3 which had typical features except rapid progression to wheelchair use in 4 
years and no dysarthria (Deutsch et al. 2010). The same group mention en passant a 
second unpublished case of an 11-year old boy with a compound heterozygous 
deletion of exon 5 and classical disease phenotype although a severe presentation. His 
younger brother also developed gait disturbance and loss of deep tendon reflexes 
(Brigatti et al. 2012). Van den Ouweland and others described a large de novo deletion 
of between 1,603kbp and 2,477kbp including complete deletion of the FXN gene and 
possibly contiguous genes. The exact extent of the deletion could not be determined 
because of poor probe coverage. The patient had an abnormal presentation with 
chorea and intention tremor but slow progression over nearly 30 years (van den 
Ouweland et al. 2012).  
The largest series to date was published by Anheim and colleagues in a large 
collaboration of specialist centres in France (Anheim et al. 2012). They described six 
cases from five families clustered in two sites in Brittany and the South of France. Four 
cases involved deletions of exons 4 & 5, one involved only exon 4, and one exons 2 & 
3. The familial case involved a great-aunt and great-niece who shared the same exon 
4/5 deletion but had inherited GAA expansions from unrelated relatives resulting a 
form of pseudo-dominant inheritance. Anheim’s cases typically had young onset 
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(range 3-12) with severe neurological phenotype, usually presenting with 
unsteadiness. Half also had diabetes, 80% scoliosis and 83% cardiomyopathy including 
one case of severe angina at 9 years old.   
The only systematic study of exonic FXN deletions has occurred in the Norwegian 
population (Wedding et al. 2015). This study contacted all 22 public hospitals in 
Norway which have a paediatric or neurology unit, the three laboratories that 
undertake FXN gene testing, patient support organizations and the national centre for 
rare diagnoses. The hospitals’ electronic coding records were searched by diagnostic 
category and the project was presented at the national neurological meeting. Twenty-
seven patients had genetically confirmed FRDA with homozygous GAA expansions. A 
further four had clinical ataxia and one GAA expansion. Of these, one was 
heterozygous for a FXN point mutation and a further one had a large deletion. Of the 
remaining two, one had an OPA1 mutation and the last currently has no genetic 
diagnosis. The FXN deletion spanned 2776 base pairs around exon 5a and was identical 
to that described by Zühlke et al. (2004). Clinically, the patient had typical presentation 
with onset at age 7 with unsteadiness and progression to use of a wheelchair. There 
was cardiac involvement and scoliosis but no diabetes. 
No homozygous exonic FXN deletions have yet been reported. Furthermore, no 
examples of FXN multiplication are known. 
3.1.2.1 Clinical Case: Patient D 
During the assessment of the patients for the EFACTS project, it became apparent that 
there was a discrepancy between the genetic diagnosis of one of the study patients 
recorded in EFACTS, and that reported by the patient himself. Genetic testing for the 
study patients was undertaken by the Université Libre de Bruxelles as described in 
Section 2.2.4 of Chapter 2 above. Patient D was reported as having two homozygous 
GAA expansions of 785 repeats (and hence no normal-sized GAA sequence). The 
patient reported that he was a compound heterozygote for a GAA expansion and a 
deletion and had paperwork supporting this. He had previously been assessed by the 
Clinical Genetics Service of the Royal Devon and Exeter Hospital who were able to 
supply further information. 
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They had also initially thought that he had homozygous pathological GAA expansions 
but testing of his mother, who also had neurological symptoms, revealed no evidence 
of an expanded allele by long-range PCR, triplet-primed PCR or Southern blotting. He 
had therefore not inherited a pathological GAA expansion from her. It was unlikely that 
he had a FXN gene point mutation as these are always accompanied by a normal-sized 
GAA sequence on the same allele and an expanded sequence on the other allele, 
making the patient a compound heterozygote. They hypothesized that she might carry 
a pathological deletion encompassing the GAA repeat sequence. They analyzed three 
microsatellite markers neighbouring the FXN gene, viz D9S1787, D9S1879 and 
D9S1862. D9S1787 (also known as AFMA142YD1) is 154.5kbp centromeric to the start 
of the FXN gene. D9S1879 (also known as AFMA070WH1) is 187.7kbp centromeric to 
the start of the FXN gene. Both of these markers lie within the phosphatidylinositol-4-
phosphate-5-kinase type 1β (PIP5K1B) gene. D9S1862 (also known as AFMC013YH5) 
lies 505.9kbp centromeric to the start of the FXN gene between the transmembrane 
protein 252 (TMEM252) and phosphoglucomutase-5 (PGM5) genes. Figure 50 shows 
the location of the markers and their relation to the FXN gene. Both mother and son 
were heterozygous for these markers excluding a deletion encompassing genes 
upstream of but some distance from the FXN gene. 
 
PGM5: Phosphoglucomutase-5 
TMEM252: Transmembrane protein 252 
PIP5K1B: Phosphatidylinositol-4-phosphate-5-kinase type 1β 
PRKACG: Protein kinase cAMP-dependent catalytic γ 
Figure 50: Location of microsatellite markers relative to FXN gene 
They then developed a quantitative fluorescence PCR assay following a method 
previously used to detect exonic deletions in cases of Becker and Duchenne muscular 
dystrophy (Yau et al. 1996). They used the primers GAA-104F (5'-GGC TTA AAC TTC CCA 
CAC GTG TT-3') and GAA-629R (5'-AGG ACC ATC ATG GCC ACA CTT-3') which flank the 
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GAA sequence and have previously been used to determine GAA repeat length (Filla et 
al. 1996) but are different from those used in the laboratories at NHNN and the 
Université Libre de Bruxelles (Campuzano et al. 1996). The exact binding sites of these 
primers are shown in Figure 59. Primers were also used against a reference sequence 
in exon 9 of the glucokinase gene GCK on chromosome 7p15.3-15.1, mutations in 
which cause maturity-onset diabetes of the young type 2 (MODY2). Control samples 
were used from individuals with homozygous normal-sized GAA sequences. Dosage 
quotients (DQ) were calculated by comparing the FXN/GCK peak area ratios of the 
patient and his mother with those of controls. These were consistent with 
heterozygous deletions in both. Exact characterization of the breakpoints was not 
undertaken (Thomson et al. 2003)(Martina Owens, personal communication).  
This case is interesting as it involves a FXN gene deletion. Very few cases have been 
reported and the clinical phenotype is not fully characterized. Although they are 
assumed to be rare, no systematic studies of their prevalence have been undertaken. 
The finding on long-range PCR of a single band corresponding to a pathological GAA 
expansion and no normal-sized band, is interpreted by most diagnostic laboratories as 
implying that the patient has two equal-sized GAA expansions. This case shows that 
the absence of a normal-sized band does not necessarily imply that the patient has 
two pathological expansions which potentially is important in the context of genetic 
counselling and has implications in understanding underlying pathological mechanisms 
in FRDA. Fifteen of the 147 patients in the UK wing of EFACTS (10.2%) for whom GAA 
sizing was available, were reported by the laboratory of the Université Libre de 
Bruxelles as having equally sized pathological GAA expansions. The above observation 
is therefore relevant to all these patients. 
3.2 FXN Compound Heterozygotes with Point Mutations 
3.2.1 Method 
The database of the Neurogenetics Department of the NHNN and the EFACTS Registry 
were searched for known cases of compound heterozygotes with point mutations 
(NHNN search undertaken by Dr Mary Sweeney & Dr Robyn Labrum). Clinical data 
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were obtained from the patients’ notes and the EFACTS Registry as described in 
Chapter 2. Testing for repeat expansions was undertaken in the Neurogenetics 
laboratory of the NHNN as described in 3.3.1 below, and in the laboratory of the 
Université Libre de Bruxelles as described in Chapter 2. Sequencing for point mutations 
was undertaken in the Merseyside and Cheshire Regional Molecular Genetics 
Laboratory, Liverpool Women’s Hospital, Liverpool, UK and the laboratory of the 
Université Libre de Bruxelles. Both laboratories use the same previously published 
technique (Pandolfo 2006) using the following primers: 
Exon 1:  5’-AGC ACC CAG CGC TGG AGG-3’   (forward) 
5’-CCG CGG CTG TTC CCG G-3’   (reverse) 
Exon 2:  5’-AGT AAC GTA CTT CTT AAC TTT GGC-3’   (forward) 
5’-AGA GGA AGA TAC CTA TCA CGT G-3’   (reverse) 
Exon 3:  5’-AAA ATG GAA GCA TTT GGT AAT CA-3’   (forward) 
5’-AGT GAA CTA AAA TTC TTA GAG GG-3’   (reverse) 
Exon 4:  5’-AAG CAA TGA TGA CAA AGT GCT AAC-3’   (forward) 
5’-TGG TCC ACA ATG TCA CAT TTC GG-3’   (reverse) 
Exon 5a:  5’-CTG AAG GGC TGT GCT GTG GA-3’   (forward) 
5’-TGT CCT TAC AAA CGG GGC T-3’   (reverse) 
This technique screens for mutations in exons 1-5a and so covers the entire coding 
region of the most commonly expressed FXN transcript. It does not exclude pathogenic 
mutations in the promoter region, the alternative exon 5b, the untranslated exon 6 or 
the 3’-untranslated region, and does not exclude cryptic splice site mutations or 
somatic mosaicism. 
3.2.2 Results 
Thirteen examples of compound heterozygotes with point mutations were found, 
including three pairs of siblings. Of the thirteen, seven were included in EFACTS 
including two of the pairs of siblings. The genetic and basic demographic data relating 
to all these patients are detailed in Table 27. The location of the mutations is shown in 
Figure 51. Unfortunately, very little clinical information was available for patients 11 to 
13 which are therefore not included in the ensuing discussion or analysis. 
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Table 27: Basic demographic & genetic details of FXN compound heterozygotes 
P
at
ie
n
t 
n
o
. 
M
u
ta
ti
o
n
 
P
ro
te
in
 c
h
an
ge
 
Ex
o
n
  
M
u
ta
ti
o
n
 t
yp
e
 
Ef
fe
ct
 
P
ro
te
in
 t
ru
n
ca
ti
n
g 
G
A
A
1
 s
iz
e 
G
A
A
2
 s
iz
e 
G
en
d
er
 
Fa
m
ily
 h
is
to
ry
 
A
ge
 a
t 
ex
am
 
A
ge
 a
t 
o
n
se
t 
D
is
ea
se
 d
u
ra
ti
o
n
 
A
ge
 a
t 
w
h
ee
lc
h
ai
r-
b
o
u
n
d
 
In
 E
FA
C
TS
 
1 c.389G>T p.Gly130Val 4 S MS NT 67 1100 F 
Sibling of 
2 
48 13 35 N/A Yes 
2 c.389G>T p.Gly130Val 4 S MS NT NK NK M 
Sibling of 
1 
50 10 40 N/A Yes 
3 c.389G>T p.Gly130Val 4 S MS NT 30 612 M No 41 15 26 N/A Yes 
4 c.389G>T p.Gly130Val 4 S MS NT 45 745 M 
Sibling of 
5 
50 13 37 30 Yes 
5 c.389G>T p.Gly130Val 4 S MS NT NK NK F 
Sibling of 
4 
46 15 31 30 No 
6 c.389G>T p.Gly130Val 4 S MS NT 10 867 M No 27 15 12 N/A Yes 
7 c.389G>T p.Gly130Val 4 S MS NT NK NK F 
Sibling of 
11 
28 13 15 N/A No 
8 c.389G>T p.Gly130Val 4 S MS NT NK NK F 
Sibling of 
10 
22 19 3 N/A No 
9 
c.493_494 
CG>GA 
p.Arg165Asp 5a S MS NT 6 867 M 
Yes 
(cousin) 
23 12 11 N/A Yes 
10 c.2T>C p.Met1Thr 1 S II T NK NK F No 21 16 5 N/A Yes 
11a c.389G>T p.Gly130Val 4 S MS NT NK NK F NK NK NK NK NK No 
12b c.2T>C p.Met1Thr 1 S II T NK NK F NK NK NK NK NK No 
13c 
c.357_378 
dup22 
p.Phe127fsX 3 D NS T NK NK M NK NK NK NK NK No 
Very minimal clinical information available for cases 11 to 13 (see below). Consequently not included in subsequent 
tables 
a
Ataxia 
b
Progressive ataxia & cardiomyopathy 
c
Progressive ataxia, absent ankle reflexes, MRI brain & spine normal 
S=base substitution; D=deletion; MS=missense; NS=nonsense; II=incorrect initiation;  
T=truncating; NT=non-truncating; NK=not known; N/A=not applicable 
RefSeq: NM_000144.4, NP_000135 
 
Figure 51: Location of FXN mutations described in this study 
Nonsense mutations (red), missense mutations (blue), novel mutations (*)  
Residue numbers (above box), exon numbers (within box). RefSeq NM_000144.4, 
NP_000135 
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3.2.2.1 Genetic Studies 
Nine examples were found of the previously documented c.389G>T mutation which 
causes a pathogenic missense mutation with substitution of valine for glycine at 
residue 130 in exon 4 (Bidichandani et al. 1997, Forrest et al. 1998, Cossée et al. 1999). 
There were two examples of the previously reported c.2T>C mutation involving a 
change in the start codon in exon 1 from ATG to ACG causing an amino acid change 
from methionine to threonine and consequently incorrect translational initiation 
(Cossée et al. 1999).  
Two novel mutations were found. The first involved a duplication of a 22bp sequence 
(TTTGGGGTACCTCTTGACTTCT) starting at nucleotide 357 at the end of exon 3. This 
causes a frameshift mutation starting at residue 127 and resulting in a premature stop 
codon after 12 codons because of the previously out-of-frame TGA codon within the 
duplicated sequence (in bold above). Such a nonsense mutation is considered 
obligately pathogenic. No duplication mutations have previously been reported in 
FRDA, and no mutations have previously been reported at this location. Unfortunately, 
the only clinical information available for the patient was that she had progressive 
ataxia with absent ankle reflexes and normal MR imaging of the brain and spine. She 
was a five year old child when tested and had symptoms which had progressed over at 
least one year. 
The second novel mutation involved a dinucleotide substitution (or short indel) at 
positions 493 & 494. This causes a missense mutation with substitution of aspartic acid 
for arginine. These two positions form a mutational hot-spot with two different single-
nucleotide mutations already described, causing different amino acid substitutions at 
the same residue, viz. c.493C>T/p.Arg165Cys (Forrest et al. 1998, McCormack et al. 
2000) and c.494G>C/p.Arg165Pro (De Michele et al. 2000, Ygland et al. 2014). The 
present case forms a third. The previous description of different nucleotide variants 
causing an amino acid substitution at this residue in the context of a clinical diagnosis 
of FRDA supports the pathogenicity of the present mutation although is not specific for 
this amino acid change.  
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In silico tests of pathogenicity also provide supportive evidence. No variant was found 
for either position 493 or 494 in the database of the 1000 Genomes Project, the Exome 
Sequencing Project (ESP) or the Database of Single Nucleotide Polymorphisms (dbSNP), 
indicating the rarity of variants at these positions in the general population and 
supporting the pathogenicity of the present mutation. The Genome Evolutionary Rate 
Profiling (GERP) score was 5.07, the Phylogenetic Analysis with Space/Time models 
Conservation Program (PhastCons) score was 1 and the Phylogenetic p-values (PhyloP) 
score was 5.515. These values each indicate conservation over evolutionary time at 
this position which supports the pathogenicity of the variant. The Grantham score is 65 
which is only a moderately conservative change. The Sorting Intolerant From Tolerant 
(SIFT) algorithm predicted that the change would be damaging with a score of zero. 
The Polymorphisms Phenotyping version 2 (PolyPhen2) program predicted that the 
variant was probably damaging with a score of 0.995. The prediction of the Mutation 
Tasting program which incorporates multiple pathogenicity prediction techniques is 
that the mutation is disease-causing with a probability of 0.9999. The multiple 
sequence alignments generated by the program are shown in Table 28 demonstrating 
evolutionary conservation at these sites over multiple species. Thus, these measures 
provide good evidence that the mutation is pathogenic. For a more detailed 
description of these in silico techniques, see Chapter 5. 
Table 28: Multiple sequence alignments for human FXN c.493_494CG>GA 
Species Match Gene aa Alignment 
  
Human wt        37364 G T G G A C C T A A G C G T T A T G A C T G G A  
Human mutated   not conserved      37364 g t g g a c c t a a g g a t t a t g a c t g g a 
 
P troglodytes   no homologue        
                        
M mulatta   all identical   ENSMMUG00000000357  39574 g t g g a c c c a a g c g t t a t g a c t g g a 
 
F catus   all identical   ENSFCAG00000008813  33434 g t g g g c c g a a g c g c t a c g a c t g g a 
 
M musculus   all identical   ENSMUSG00000059363  20563 g c g g c c c c a a g c g c t a t g a c t g g a 
 
G gallus   all identical   ENSGALG00000015108  8585 g t g g g c c c a a g c g c t a t g a c t g g a 
 
 
3.2.2.2 Clinical Features 
The clinical features of the ten compound heterozygotes for which adequate clinical 
information is available are given in Table 29 and Table 30. Table 31 summarizes the 
clinical findings and records the results of the clinical ratings scales (SDFS, total ADL, 
total SARA, INAS count & SCAFI). The clinical information is derived from the EFACTS 
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assessment in the case of patients 1, 2, 3, 4, 6, 9 & 10, and from the medical notes and 
clinic letters in the case of patients 5, 7 & 8. Consequently, the clinical rating scales 
were only undertaken in patients from the former group. In keeping with the main 
EFACTS cohort, only four out of the seven patients for whom SCAFI testing was 
undertaken were able to complete the 8-metre timed walked. All patients were able to 
complete the 9-hole peg test and the PATA test. 
The mean±SD age at onset of the ten patients was 14.1±2.3 (range 10-19). The 
mean±SD age at examination was 35.6±12.4 (range 21-50) and disease duration 
21.5±13.9 (range 3-40). There was no statistical difference in these parameters 
between the compound heterozygotes and the homozygous patients (see Table 32). 
There were also no statistically significant differences in the SDFS, total ADL and INAS 
count. The total SARA was significantly lower in the compound heterozygotes 
compared to the homozygous patients (13.7±5.6 vs 22.9±10.0, Mann-Whitney U-test, 
Z=-2.349, p=0.019) suggesting that they have less severe ataxia even for the same age 
and disease duration. However, this difference did not survive Bonferroni correction. 
Various meaningful clinical features for which data were available in a form with which 
statistical comparison could be made between the compound heterozygotes and the 
homozygous patients are given in a binary form (presence/absence) in Table 31. The 
results of the statistical comparison of these two groups are given in Table 33. Patient 
2 was excluded from the comparison of spasticity as he had such marked cogwheeling 
rigidity associated with a diagnosis of Parkinson’s disease which made the independent 
assessment of spasticity impossible. He was included in other comparisons although 
the Parkinson’s disease may have affected other parameters such as weakness, 
dysarthria and dysphagia, albeit to a less clearly definable extent. He had symptoms of 
gait instability from age 10 but was not diagnosed with FRDA until age 35. He was 
diagnosed with Parkinson’s disease at age 42. He carries the p.Gly130Val mutation for 
which coexistent parkinsonism has not previously been described. Indeed, no other 
patient in the EFACTS cohort has a diagnosis of Parkinson’s disease or clinical features 
of parkinsonism. Furthermore, his sister who has the same point mutation and similar 
age at onset, does not have evidence of Parkinson’s disease. His diagnosis of 
Parkinson’s disease is therefore presumably incidental. 
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From the clinical parameters summarized in Table 31, six showed statistically 
significant differences between the compound heterozygotes and the homozygous 
patients of which four survived Bonferroni correction. These were hyperreflexia (60.0% 
vs 4.4%, Fisher’s exact test, p<0.0005), square wave jerks (10.0% vs 68.4%, p<0.0005), 
dysarthria (30.0% vs 90.9%, p<0.0005) and dysphagia (20.0% vs 74.0%, p=0.001). The 
presence of broken pursuits eye movements (40.0% vs 80.4%, p=0.008) and 
wheelchair-bound status (20.0% vs 58.2%, p=0.023) did not survive Bonferroni 
correction. Thus, it appears that compound heterozygotes have more brisk deep 
tendon reflexes, a lower frequency of square wave jerks and suffer less dysarthria and 
dysphagia than homozygotes. They may also have a lower frequency of broken 
pursuits and less frequently be confined to a wheelchair. 
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Table 29: Clinical features of compound heterozygous FRDA patients with point mutations (part 1) 
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1 
Instability & 
abnormal gait 
Severe ataxic 
gait 
Rare 
UL: Slight  
LL: Moderate 
UL/LL: NAD Mild 
UL: NAD 
LL: Mild 
UL: NAD  
LL: NAD 
UL: NAD  
LL: Mild 
UL: NAD 
LL: Mild 
UL/LL: Absent Up Mild No 
2 Gait instability NK None Mild 
UL/LL: 
Cogwheeling 
rigidity 
Severe 
UL: NAD  
LL: Severe 
UL/LL: Mod 
UL: Mod  
LL: Severe 
NK 
UL: Absent  
LL: Brisk 
Up No No 
3 
Turned foot in; 
progressive 
stiffness 
Severe spastic 
gait 
None None 
UL: NAD  
LL: Severe 
Severe 
UL: NAD 
LL: Severe 
UL/LL: NAD UL/LL: NAD 
UL: NAS 
LL: Mod 
UL: Normal or 
reduced.  
KJ: Brisk; AJ: Absent 
Up No No 
4 
Walked on toes, 
then feet 
turned in 
Unable to walk Yes None LL: Severe Severe 
UL: NAD 
LL: Severe 
UL/LL: 
severe 
UL: Mod  
LL: Severe 
UL/LL: 
Mod 
UL/LL: Absent Down Mild No 
5 Abnormal gait Unable to walk None None LL: Severe NK 
UL: NAD.  
LL: Severe 
UL/LL: Mod 
UL: NAD  
LL: Severe 
UL: NAD 
LL: 
severe 
UL: Brisk  
LL: Absent 
Up No Mild 
6 Spinal scoliosis 
Severe ataxic 
gait 
Rare 
UL: NAD  
LL: Moderate 
UL/LL: NAD Severe 
UL: NAD 
LL: Mild 
UL: NAD  
LL: Severe 
UL: NAD  
LL: Mod 
UL: 
Severe 
LL: Mod 
UL : Normal or 
reduced; TJ: Brisk.  
KJ: Brisk; AJ: Reduced 
Up No No 
7 
Difficulty 
running 
Spastic gait with 
bilateral foot 
drop 
NK UL: NAD UL: Slight catch  NK 
UL: NAD  
LL: Mild 
NK  
UL: NAD  
LL: Severe 
UL: NAD 
LL: Mild 
UL: Brisk  
KJ: Brisk AJ: Absent 
Up No No 
8 
Clumsiness on 
playing sport 
Spastic gait with 
scissoring 
Rare  
UL: NAD  
LL: Mild 
UL: NAD  
LL: Mild 
 NK UL/LL: NAD NK  UL/LL: NAD 
UL/LL: 
Mild 
UL: NAD  
KJ: Brisk AJ: Absent 
Up No No 
9 Abnormal gait 
Severe spastic-
ataxic gait 
None 
Only visible 
on gait 
UL: NAD  
LL: Severe 
Severe 
UL: NAD 
LL: Mild 
UL/LL: NAD 
UL: NAD  
LL: Mod 
UL: NAD 
LL: Mild 
UL : Absent; SJ: Brisk 
KJ: Brisk; AJ: NAD 
Absent Mild No 
10 
Clumsiness & 
falls 
Severe ataxic 
gait with hyper-
extended knees 
Freque
nt 
Only visible 
on gait 
UL/LL: NAD Severe 
UL: NAD  
LL: Mild   
UL: NAD  
LL: Mild 
UL/LL: NAD 
UL: NAD 
LL: Mod 
UL/LL: Absent Up No Mild 
NAD=No abnormality detected 
UL=Upper limb; LL=Lower limb; BJ=Biceps jerk; TJ=Triceps jerk; SJ=Supinator jerk; KJ=Knee jerk; AJ=Ankle jerk 
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Table 30: Clinical features of compounds heterozygous FRDA patients with point mutations (part 2) 
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1 No 
Hyper-
metropia 
only 
Yes No Mild Yes Mild Bilateral PC/EV No Yes
d 
IVSd 7mm. 
LVPWd 7mm. 
EF 60% (age 42) 
SR.  
No RA. 
No LVF 
Normal Normal NK NK 
2 No 
Hyper-
metropia 
only 
Yes Yes No No No Pes planus No No NK NK Mild 
urgency 
Normal NK NK 
3 No 
Astigmatism 
only No No No No Mild 
Bilateral 
PC/EV No No 
IVSd 8mm. 
LVPWd 9mm. 
EF 63% (age 41) 
NK 
Mild 
urgency Normal NK 
Medial right parietal 
cavernoma. No other 
intracranial 
abnormalities 
4 Yes 
Poor acuity 
since 
strabismus 
operation 
No No No Yes No Bilateral 
PC/EV 
No No 
IVSd 10mm. 
LVPWd 9mm.  
EF 69% (age 48) 
SR.  
No RA. 
No LVF. 
Frequent 
urge & 
incont-
inence 
Normal 
Absent SAPs with 
mild motor 
changes  
NK 
5 No Normal No No No No None Talipes equinus No No 
IVSd 9mm. 
LVPWd 9mm.  
EF 60% (age 46) 
Normal Normal Normal Sensory axonal neuropathy 
Brain normal. Spinal 
cord slender in thoracic 
region. 
6 No Myopia only No No No No Yesc No No No NK Normal 
Mild 
urgency Normal NK NK 
7 No Poorb Mild No No No Slight 
Claw toes & 
moderate 
PC 
No No NK Normal Normal Normal 
Mild length-
dependent 
sensorimotor 
neuropathy 
Brain normal. Cord thin 
throughout. 
8 No Normal No No No Mild No 
Slight 
talipes 
equinus 
No No NK NK Normal Normal NK NK 
9 No Normal Yes Yes Yes No No No No Yes NK 
SR.  
No RA.  
LVF 
Normal Normal NK NK 
10 Yesa Normal No No No No Mild 
Mild PC & 
talipes 
equinus 
T1DM 
since 
19 
No NK NK Normal Normal NK NK 
aDeaf since 3 years old (cause unknown) 
bPoor acuity right eye secondary to ocular toxoplasmosis. No progressive visual problem 
cRequired corrective surgery aged 18 
dAlso rheumatic fever 
PC=Pes cavus; EV=Equinovarus; ECG=Electrocardiogram; SR=Sinus rhythm; RA=Repolarization abnormalities; LVF=Left ventricular failure 
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Table 31: Summary of clinical features and clinical rating scales for compound heterozygous FRDA patients with point mutations 
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SC
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-9
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SC
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TA
 
1 + R* - + + + + - - + + - - 5 7 12 5 10.5 23 26 23.5 
2 + + + + + + + + - - - - - 5 13 19.5 9 N/A 25 25 23 
3 + + - - + - - - - - - - - 5 8 16 7 38.5 22.5 22.5 30 
4 + + - + - + - - - - + - + 6 19 22 6 N/A 36.5 32.5 34 
5 + + + + + + - - - - - + + 6 NK NK NK NK NK NK NK 
6 + - + - + + - - - - - - - 5 6 11 4 N/A 24 24 36 
7 + + + + + + + - - - - - - 4 NK NK NK NK NK NK NK 
8 - + + + + - - - - - - - - 3 NK NK NK NK NK NK NK 
9 + + + + - + + - - + + - - 3 4 8 4 13.5 21.5 22 21 
10 + - - + + - - - + + - + - 4 7 7.5 4 12 26.5 23.5 22.5 
*R=severe cogwheeling rigidity due to comorbid Parkinson’s disease. Sample excluded from analysis of spasticity  
ADL=Activities of daily living 
SARA=Scale for the assessment and rating of ataxia 
INAS=Inventory of non-ataxic symptoms 
SCAFI=Spinocerebellar ataxia functional index 
8mTW=9-metre timed walk 
9HPT-D=9-hole peg test (dominant hand) 
9HPT-ND=9-hole peg test (non-dominant hand) 
NK=not known;  N/A=not applicable 
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Table 32: Demographic details and clinical rating scales for compound 
heterozygotes and homozygous patients 
 Compound Heterozygotes Homozygous GAA+/+ 
Mann-Whitney 
U-test 
 Mean SD Range n Mean SD Range n Z p† 
AAO 14.1 2.5 10-19 10 13.8 9.8 1-55 159 -1.157 0.247 
AAE 35.6 12.4 21-50 10 34.2 13.2 16-68 159 -0.543 0.587 
DD 21.5 13.9 3-40 10 20.3 11.1 3-55 159 -0.163 0.870 
SDFS 4.6 1.1 3-6 10 5.0 1.4 1-7 158 -1.655 0.098 
Total ADL 9.5 5.5 4-19 6 15.6 8.3 1-35 154 -1.847 0.065 
Total SARA 13.7 5.6 7.5-22 7 22.9 10.0 1.5-40 157 -2.349 0.019 
INAS count 5.6 1.9 4-9 7 5.0 1.6 2-9 158 -0.519 0.604 
AAO=Age at onset; AAE=age at examination; DD=disease duration; SD=standard deviation 
SDFS=Spinocerebellar degeneration functional score 
ADL=Activities of daily living 
SARA=Scale for the assessment and rating of ataxia 
INAS=Inventory of non-ataxic symptoms 
SD=Standard deviation 
†Bonferroni correction reduces significant p value to 0.05/7=0.0071 
Table 33: Clinical features in compound heterozygotes and homozygous patients 
Feature Score 
Compound 
Heterozygotes 
Homozygous GAA+/+ 
Fisher’s 
Exact 
  n % N n % N p† 
Paresis 
INAS 
counta 
9 90.0 10 122 77.2 158 0.693 
Spasticity 
INAS 
counta 
7 77.7 9 76 48.1 158 0.099 
Hyper-
reflexia 
INAS 
counta 
6 60.0 10 7 4.4 158 <0.0005 
Areflexia 
INAS 
counta 
8 80.0 10 149 94.3 158 0.130 
Extensor 
plantars 
INAS 
counta 
8 80.0 10 98 62.0 158 0.327 
Vibrational 
sensory loss 
INAS 
counta 
7 70.0 10 138 87.3 158 0.141 
Broken 
pursuits 
INAS 
scoreb 
4 40.0 10 127 80.4 158 0.008 
Square 
wave jerks 
INAS 
scoreb 
1 10.0 10 108 68.4 158 <0.0005 
Diabetes 
EFACTS 
Registryc 
1 10.0 10 13 8.2 158 0.592 
Cardio-
myopathy 
EFACTS 
Registryc 
3 30.0 10 69 45.4 152 0.514 
Dysarthria 
 
ADLd 3 30.0 10 140 90.9 154 <0.0005 
Dysphagia 
 
ADLd 2 20.0 10 114 74.0 154 0.001 
Wheelchair-
bound 
SDFSe 2 30.0 10 92 58.2 158 0.023 
cont… 
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INAS=Inventory of non-ataxic symptoms 
SARA=Scale for the assessment and rating of ataxia 
EFACTS=European Friedreich’s ataxia Consortium for Translational Studies 
ADL=Activities of daily living 
a
Binary values taken from the calculation for the INAS count 
b
Taken directly from the INAS score 
c
From EFACTS Registry (various & cardio sections) 
d
Binary value derived from score of ≥1 on dysarthria & dysphagia questions of ADL 
e
Binary value derived from score of ≥6 on SDFS 
†Bonferroni correction reduces significant p value to 0.05/13=0.0038 
 
At the time of thesis production, the results of GAA expansion sizing were only 
available for 5 patients (those from phase 1 of the EFACTS cohort) of which four had 
the p.Gly130Val mutation and one the novel p.Arg165Asp mutation. Although there 
are too few data to make a meaningful analysis, there does still appear to be a 
trend to toward increased disease severity with the increased size of the larger of 
the two GAA expansions (‘GAA2’) as measured by earlier age at onset and greater 
total SARA (see Figure 52). This is likely to be significant as most of the point 
mutations were the same, eliminating this as a variable. In the case of compound 
heterozygotes the larger of the two expansions is used in this analysis, as the 
smaller (on the allele with the point mutation) is below the pathological limit of 
expansion. Interestingly, two of the patients (patients 1 & 4 with GAA1 sizes of 67 & 
45 respectively) fall within the ‘intermediate’ zone (35-89 GAA repeats) between 
normal and pathologically expanded as used in the Neurogenetics laboratory of the 
NHNN. There may therefore be some small additional frataxin deficiency 
contributed by these alleles. 
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Figure 52: Correlation of GAA2 size with (A) age at onset and (B) total SARA in 
compound heterozygous FRDA patients 
For each patient, the mutation (G130V in blue, R165D in red), GAA1 and GAA2 
values are given 
 
3.3 FXN Compound Heterozygotes with Large Deletions 
3.3.1 Method 
The database of the Neurogenetics Department of the NHNN was searched for 
requests for and positive results of FXN gene testing between 2003 and 2013. 
Positive results included patients with two GAA expansions, those with one GAA 
expansion and those with point mutations (search undertaken by Dr Mary Sweeney 
& Dr Robyn Labrum, Department of Neurogenetics, NHNN). Testing for GAA 
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expansions was undertaken in the Neurogenetics Laboratory of the NHNN using 
previously described techniques (Campuzano et al. 1996, Potdar & Raghu 2013, 
Warner et al. 1996). This involves triplet-primed PCR followed by fragment size 
analysis by capillary electrophoresis (ABI-3730 fragment analyser, Applied 
Biosystems), as well as long-range PCR using the GAA-F and GAA-R primers 
described by Campuzano and colleagues (GAA-F: 6-FAM-5’-GGG ATT GGT TGC CAG 
TGC TTA AAA GTT AG-3’; GAA-R: 5’-GAT CTA AGG ACC ATC ATG GCC ACA CTT 
GCC-3’) . Expanded sequences were defined as having ≥90 GAA repeats. Sequencing 
for point mutations was undertaken in the Merseyside and Cheshire Regional 
Molecular Genetics Laboratory, Liverpool Women’s Hospital, Liverpool, UK using 
previously published techniques (Pandolfo 2006) as described in 3.2.1 above. 
Those individuals with an appropriate clinical history and either two GAA 
expansions, or one GAA expansion plus a pathogenic mutation were deemed to 
have FRDA either because of a homozygous or compound heterozygous mutation 
respectively. Clinical details were sought for all patients reported as having one 
GAA expansion. Stored DNA was requested for all patients having one GAA 
expansion and clinical symptoms (as the search revealed asymptomatic individuals 
with one GAA expansion, that is to say asymptomatic carriers). DNA is extracted in 
the accredited Neurogenetics laboratory of the NHNN using standard procedures 
and stored indefinitely at -70°C. The internal policy of the Department is only to 
subject individuals to mutational analysis if a single GAA expansion has already 
been found, and so the search revealed no individuals with homozygous FXN point 
mutations.  
Large deletions were detected using the multiplex ligation-dependent probe 
amplification (MLPA) technique which has been used previously to detect exonic 
FXN deletions (Deutsch et al. 2010, Anheim et al. 2012, van den Ouweland et al. 
2012). The General Protocol issued by the manufacturer was followed (MRC-
Holland, Amsterdam, Netherlands; version MDP-v002, 23.1.2012). The 
commercially available SALSA MLPA P136-B2 Recessive Ataxias Probemix was used 
(MRC-Holland, Amsterdam, Netherlands; lot 0511). This contains probes against the 
five coding exons in the FXN gene (see Table 34). There is no probe for the non-
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coding exon 6. The probemix also contains probes against the nine exons of the 
APTX gene and the 26 exons of the SETX gene. Thus, this probemix will incidentally 
detect exonic deletions in these genes. Mutations in APTX cause ataxia with 
oculomotor apraxia type 1, and those in SETX cause ataxia with oculomotor apraxia 
type 2.  
The probemix also contains nine reference probes in exons of unrelated genes on 
different chromosomes, which provide quality control data. The reference probes 
bind to the following sites: KDR (4q12, exon 14), IL4 (5q31.1, exon 1), GHRHR 
(7p14.3, exon 2), KCNQ3 (8q24.22, exon 2), CHEK1 (11q24.2, exon 8), AMN 
(14q32.32, exon 3), SPG11 (15q21.1, exon 11), COPS3 (17p11.2, exon 12) and 
SMARCB1 (22q11.23, exon 7). Patients are presumed to have no deletions in these 
exons, or point mutations or SNPs at the site of probe binding. If any of these are 
present, this becomes apparent at the data analysis stage.  
The probemix also contains internal quality control fragments (the ‘QDX2 control 
fragment set’) (see Table 35). This includes a 92nt control probe which behaves 
similarly to other MLPA probes and is used by the software for comparison to other 
control fragments. There are four ‘Q-fragments’ which are oligonucleotides 
containing both PCR primer sequences in a single molecule and are therefore not 
dependent on target DNA to be amplified during the PCR. They are present in 
extremely low concentrations so that if sufficient target DNA is used, they are out-
competed by the amplicons of the MLPA probes. If the height of these peaks is 
greater than one third that of the 92nt control probe, this indicates that insufficient 
DNA was used or the ligation reaction failed. There are two ‘D-fragments’ which 
detect sequences within CpG islands which are known to be difficult to denature. If 
the height of these peaks is less than 40% that of the 92nt control probe, this 
indicates that DNA denaturation was incomplete resulting in unreliable results for 
probes detecting sequences in or within 5kb of CpG islands. These are typically near 
mRNA transcription start locations and so most commonly affect exon 1 probes. 
There are also probes detecting sequences within the Q and Y chromosomes 
allowing identification of the gender of the sample and hence gross identification of 
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incorrect sample use. The complete list of probes by fragment size including control 
fragments is given in Table 36 from the MRC-Holland Product Description. 
Table 34: Probes in MHC-Holland SALSA MLPA P316-B2 Recessive Ataxias 
probemix 
FXN 
Exon 
SALSA 
MLPA 
Probe 
Length 
(nt) 
Ligation 
Site
a
 
Start-End
a
 Distance 
to next 
Probe 
Left (5') Probe- 
Right (3’) Probe 
1 10891-
L11561 
234 43nt 
before 
exon 1 
70840233-
70840293 
10.9 kb 5’:CAGCAAGACAGCAGCTCCCAAGT 
3’: TCCTCCTGTTTAGAATTTTAGAAGCGGCGGGCCACCAG 
2 10893-
L11563 
208 463-464 70851166-
70851235 
6.7 kb 5’:CAGAGTGTCTATTTGATGAATTTGAGGAAATCT 
3’: GGAACTTTGGGCCACCCAGGGTAAGATAAAACACCTT 
3 10894-
L13901 
258 517-518 70857878-
70857950 
11.9 kb 5’:CTCTCTAGATGAGACCACCTATGAAAGACTAGCA 
3’: GAGGAAACGCTGGACTCTTTAGCAGAGTTTTTTGAAGACCT 
4 14129-
L15733 
472 24nt 
after 
exon 4 
70869764-
70869842 
8.3 kb 5’:CCATCCAGGTATGTAGGTATGTTCAGAAGTCA 
3’: ACATATGTAATTCTTAAAGACTTCCGAAATGTGACATTGTGGACCAT 
5 10895-
L11565 
154 1448-
1449
b 
70878073-
70878130 
- 5’:TGGCCTGCACTGGGTTGTCCA 
3’: GGGAGACCTAGTGCTGTTTCTCCCACATATTCACATA 
Table adapted from MHC-Holland Product Descriptions v8 (7.3.12) & v11 (10.12.15) 
aNM_001161706.1  bNM_0001444.4 
Table 35: QDX2 control fragments in MHC-Holland SALSA MLPA P316-B2 
Recessive Ataxias probemix 
Length (nt) Name Gene 
Chromosomal 
Location 
64 64nt Q-fragment - - 
70 70nt Q-fragment - - 
76 76nt Q-fragment - - 
82 82nt Q-fragment - - 
88 88nt D-fragment CARM1 19p13.2 
92 92nt control fragment IL1B 2q13 
96 96nt D-fragment JPH3 16q24.2 
100 100nt X-fragment AMOT Xq23 
105 105nt Y-fragment UTY Yq11.221 
Table adapted from MHC-Holland Product Description v8 (7.3.12) 
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Table 36: Complete list of probes by fragment size in MHC-Holland SALSA MLPA 
P316-B2 Recessive Ataxias probemix 
 
Table from MHC-Holland Product Description v8 (7.3.12). Note, fragment 472 was subsequently corrected to FXN exon 4 in 
later versions. 
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DNA quality and concentration were determined using a NanoDrop ND-1000 
spectrophotometer (Thermo Scientific, Wilmington, DE, USA). At least 150μg of 
genomic DNA was used per sample. For each patient, 5μl DNA solution in tris-EDTA 
buffer (TE) was denatured at 98°C for 5 minutes and cooled to 25°C on a 
thermocycler (Applied Biosystems Gene Amp PCR System 9700, Thermo Fisher 
Scientific, Waltham, MA, USA). A hybridization mastermix was prepared containing 
1.5μl MLPA buffer and 1.5μl of probemix for each reaction. 3μl of the mastermix 
was added to each denatured DNA sample. The samples were hybridized by 
incubating for 1 minute at 95°C, then 16-20 hours at 60°C of the thermocycler. On 
day 2, a ligase mastermix was prepared containing 25μl distilled water, 3μl ligase 
buffer A, 3μl ligase buffer B and 1μl ligase 65 enzyme for each sample. The 
thermocycler temperature was lowered to 54°C. 32μl of ligase mastermix was 
added to each hybridized sample. The samples were ligated by incubating at 54°C 
for 15 minutes, and the enzyme inactivated by heating to 98°C for 5 minutes before 
cooling to 20°C. 
The ‘one-tube PCR’ protocol was followed. A polymerase mastermix was prepared 
containing 7.5μl distilled water, 2μl carboxyfluoroscein-labelled (6-FAM) SALSA PCR 
primer and 0.5μl SALSA polymerase for each sample. 10μl of polymerase mastermix 
was added to each sample and the PCR program followed (35 cycles of 95°C for 30s, 
60°C for 30s and 72°C for 60s). The samples were then held at 72°C for a further 20 
minutes and then cooled to 15°C. The overall thermocycler program is given in 
Table 37. 
On day 3, fragment analysis by capillary electrophoresis was undertaken using an 
Applied Biosystems ABI-3730 fragment analyzer (Thermo Fisher Scientific). 0.2μl 
GeneScan 500 LIZ dye size standard (Applied Biosystems) and 9μl Hi-Di formamide 
(Applied Biosystems) were added to 1μl of each PCR product. The samples were 
heated to 80°C for 2 minutes on the thermocycler, then cooled rapidly on ice for 3 
minutes before transferring to the fragment analyzer. The data were analyzed using 
Coffalyser software (MRC-Holland) and GeneMarker v2.2.0 (Soft Genetics, PA, USA) 
which generates an EDQ for each probe. 
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Table 37: Thermocycler program for MLPA reaction 
 
3.3.2 Results 
1768 genetic tests for FRDA were undertaken at the NHNN between 2003 and 
2013. 196 cases (11.1%) showed homozygous GAA expansions in the FXN gene. 
Forty carried a single GAA expansion. Of these, eleven were found to have 
pathological point mutations on sequencing, making the total diagnosed cases of 
FRDA 207 (11.7% of tests requested). Thus 5.3% of the diagnosed cases of FRDA 
processed by the NHNN Neurogenetics laboratory were compound heterozygotes. 
Of the remaining 29 cases bearing a single pathological expansion, it was found on 
inspection of the clinical records that nine were asymptomatic carriers and had 
been referred either for predictive clinical testing and partner testing to inform 
reproductive decisions. Twenty cases were therefore suitable for the MLPA study. 
No DNA was available for 2 cases leaving 18 cases from NHNN to be subjected to 
MPLA analysis.  
Figure 58 in the Discussion below shows the flow of these 18 NHNN patients 
through the MLPA study and the pathway by which patients were identified from 
the NHNN Neurogenetics database as having a single pathological GAA expansion 
and symptoms compatible with FRDA. Analysis of these patients’ results therefore 
provides evidence as to whether exonic deletions are common in patients who 
present with ataxia and have a single GAA expansion and no associated point 
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mutation, and so whether testing for exonic deletions is indicated in such patients. 
The implications of this for a diagnostic neurogenetics laboratory are explored in 
the Discussion.  
In addition to the above 18 patients from the NHNN database, a number of other 
patients from the EFACTS project were also studied. Table 38 shows all the patients 
in the study with the EDQ results for each FXN exon. Samples 1 to 18 are the 18 
NHNN patients described above. Samples 19 and 22 are duplicate runs of the the 
proband patient D described in 3.1.2.1 above and 3.3.2.1 below. Sample 20 is a 
negative control used by the NHNN laboratory who is known clinically not to have 
FRDA and who does not have pathological GAA expansions. The individual in fact 
has dopa-responsive dystonia with a mutation in the GTP cyclohydrolase 1 gene on 
chromosome 14q22.1-q22.2. This sample was set as the control sample for the 
study which the software uses to calculate the EDQ for the disease exons. Sample 
21 is a ‘no DNA’ control containing TE buffer in place of a DNA sample to test for 
contamination of any of the reaction constituents by extraneous DNA. Samples 23 
to 26 are EFACTS patients who were reported by the laboratory of the Université 
Libre de Bruxelles as having identically sized GAA expansions (1200 repeats for 
sample 23, 1167 for sample 24, 1000 for sample 25, 834 for sample 26). Their test 
result is therefore subject to the same potential misattribution as that of patient D 
as the finding of a single band on triplet-primed PCR does not exclude the 
possibility of the patient having a single pathological GAA expansion as well as an 
exonic deletion. 
The MLPA reaction failed for samples 2 and 4. These have subsequently been 
repeated by Mr Alex Browne (PhD student) with the same result. The TE control 
also failed showing that there was no DNA contamination of the reagents. An EDQ 
result of 1±0.25 indicates no evidence of exon deletion or duplication. A result of 
0.5±0.25 indicates heterozygous deletion at that exon, whilst a result of 0±0.25 
indicates a homozygous deletion. A result of 1.5±0.25 indicates heterozygous 
duplication and 2±0.25 homozygous duplication. Theoretically, the higher gene 
multiplications such as triplications could further modify this result although these 
have not hitherto been described in FRDA. The EDQs for the five FXN exons in the 
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16 GAA +/- cases for which MLPA results were available, were all within 1±0.25 
indicating no evidence of exon deletion or duplication at each of the probe sites. 
The mean±SD EDQ for these samples was 1.004±0.046 (range 0.886-1.133). The 
EDQs for all the remaining samples inlcuding the two samples from patient D and 
the four EFACTS samples, were also all within the range 1±0.25. All the cases 
together (including controls) had a mean±SD EDQ of 1.004±0.043 (range 0.886-
1.151). The results are shown in Table 38. Figure 53 as an example shows the signal 
intensity peaks for each of the probes for sample 22 (patient D) in blue and the GAA 
-/- control (sample 20) in red, with the five FXN exon probes individually labelled. 
The ratio of the blue to red peaks generates the EDQ; it can be seen that they are 
all of similar height, hence the ratios are all aproximate to unity. Figure 54 shows 
the peak ratios (EDQs) for the same sample with the disease probes in green and 
reference probes in blue. The five FXN gene probes are again highlighted. All values 
are within the upper and lower limits of normal, indicating no evidence for 
deletions or duplications of any exon of the FXN gene. As an incidental finding, no 
evidence was also found in any of the samples of APTX or SETX deletions or 
duplications (data not presented). 
Table 38: FXN exon dosage quotients (EDQ) for patients in MLPA study 
Sam-
ple 
Pre-test 
status 
EDQ Exon 1 EDQ Exon 2 EDQ Exon 3 EDQ Exon 4 EDQ Exon 5 
1 GAA +/- 1.033 0.925 1.065 1.080 0.887 
2 GAA +/- - - - - - 
3 GAA +/- 1.050 1.032 1.014 1.040 1.007 
4 GAA +/- - - - - - 
5 GAA +/- 1.126 0.971 1.061 1.065 0.886 
6 GAA +/- 1.040 0.994 0.981 1.010 0.988 
7 GAA +/- 1.069 1.016 1.049 1.133 0.942 
8 GAA +/- 1.091 1.024 1.005 1.011 0.988 
9 GAA +/- 1.041 0.913 0.982 0.956 0.909 
10 GAA +/- 1.024 0.996 1.009 0.982 0.972 
11 GAA +/- 0.992 1.004 0.989 0.965 0.968 
12 GAA +/- 1.036 1.023 0.981 0.943 0.993 
13 GAA +/- 1.056 1.017 1.020 0.965 0.988 
14 GAA +/- 1.017 1.028 0.990 1.025 0.996 
15 GAA +/- 1.013 1.035 0.991 1.031 0.993 
16 GAA +/- 1.028 1.010 0.970 1.003 0.982 
17 GAA +/- 1.009 0.989 0.976 0.930 0.983 
18 GAA +/- 1.021 1.048 1.012 0.946 1.008 
19 Patient D 1.055 1.023 0.999 0.981 0.988 
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20 GAA -/- 1.000 1.000 1.000 1.000 1.000 
21 TE 
control 
- - - - - 
22 Patient D 1.071 1.030 1.000 0.993 0.988 
23 GAA +/+ 1.030 0.983 0.962 0.985 0.975 
24 GAA +/+ 1.151 0.980 1.015 0.944 0.959 
25 GAA +/+ 1.012 1.009 1.014 0.981 0.979 
26 GAA +/+ 1.061 1.004 1.031 0.960 0.962 
Mean
±SD 
All GAA 
+/- 
1.040±0.033 1.002±0.038 1.006±0.030 1.005±0.056 0.968±0.040 
Range 0.992-1.126 0.913-1.048 0.970-1.065 0.930-1.133 0.886-1.008 
Mean
±SD All values 
1.044±0.038 1.002±0.033 1.005±0.027 0.997±0.049 0.971±0.034 
Range 0.992-1.151 0.913-1.048 0.962-1.065 0.930-1.133 0.886-1.008 
GAA +/- one GAA expansion (ie symptomatic carrier) 
GAA -/- no GAA expansions (ie negative control) 
GAA +/+ two GAA expansions (ie known FRDA patient reported as having two identically sized 
expansions) 
TE=Tris-EDTA buffer (ie no DNA control) 
SD=standard deviation 
 
 
Figure 53: Peak height comparison chart for sample 22 (patient D) 
Chart generated by GeneMarker software. Blue peaks=patient samples; red 
peaks=control samples. 64-82 peaks=Q-fragments; 88-105 peaks=D,X,Y & 92bt 
control fragments; 128-481 peaks=FXN, SETX, APTX & 9 control genes including FXN 
peaks at 154, 208, 234, 258 & 472. 
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Figure 54: Peak ratios (EDQ) for sample 22 (patient D) 
Chart generated by GeneMarker software. Peak ratio (EDQ) for disease (green) and 
reference (blue) probes. The five FXN gene probes are highlighted (154, 208, 234, 
258 & 472nt). The remainder are for SETX and APTX. All values are within the upper 
and lower limits of normal, indicating no evidence for deletions or duplications of 
any FXN exon. 
3.3.2.1 Case History: Patient D 
The proband (patient D) was a right-handed Caucasian male who was 30 years old 
at the baseline assessment. His first symptoms were of gait instability at one-and-a-
half years of age. He walked late at 18 months and was always very tired as a child 
and had to be carried. He first noticed significant falls at age 9 and started using an 
aid to walking intermittently at age 16, and then permanently at age 18. He started 
using a wheelchair at age 23 and by the baseline assessment was unable to stand or 
walk. FRDA was diagnosed at age 20. He does not have diabetes but was diagnosed 
with cardiomyopathy at age 26. ECG at age 33 showed sinus rhythm with voltage 
evidence of left ventricular hypertrophy. Echocardiogram at the same time showed 
IVSd of 13mm, LVPWd of 11mm and left ventricular ejection fraction of 46%. He has 
moderate spinal scoliosis which has never required surgical correction. He has 
moderate bilateral pes cavus and mared bilateral talipes varus. Both feet were 
operated on at age 26. He has some hearing impairment but does not use a hearing 
aid. Other medical problems include myopia, gastro-oesophageal reflux disease and 
psoriasis. 
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Total SARA was 33/40 (gait 8, stance 6, sitting 4, speech 3, finger chase 2, nose-
finger 3, alternating hand movements 3, heel-shin 4). The gait, stane, sitting and 
heel-shin subscores represent the maximal for these fields. The SDFS was 6. Total 
ADL was 25/36 (speech 3, swallowing 2, use of cutlery 2, dressing 3, washing 3, falls 
4, walking 4, sitting 4, bladder function 0). The walking, falls and sitting subscores 
are therefore at their maximal values. On the SCAFI, he was unable to undertake 
the 8mTW. He managed the 9HPT using his dominant hand in 232 and 202s, but 
was unable to complete the task using his non-dominant hand. His PATA score was 
14 and 13 words in 10s. The INAS count was 5/16 gaining points for areflexia, 
extensor plantar reflexes, spasticity, paresis and vibrational sensory loss.  
Neurological examination showed no facial weakness or sensory loss. There was no 
lingual atrophy but moderate lingual spasticity resulting in marked dysarthria. There 
was no ptosis or ophthalmoparesis. There were saccadic intrusions into pursuit eye 
movements with bilateral horizontal gaze-evoked nystagmus and hypometric 
saccades but no square wave jerks. There was mild (4+/5) proximal UL weakness 
with mild UL spasticity but no atrophy. There was distal UL pin prick and 
proprioceptive sensory loss but no vibrational sensory loss. There was areflexia 
throughout the upper and lower limbs. In the LLs, there was severe weakness (0/5) 
throughout with no spasticity or atrophy. There was marked distal pin prick, 
proprioceptive and vibrational sensory loss. The plantar reflexes were plantar 
bilaterally. There was no evidence of myoclonus, chorea, dystonia or parkinsonism. 
The total SARA at BL, FU1 and FU2 was 33, 31 and 34 respectively. The total ADL 
was 25, 28 and 26 respectively. The INAS count was 5, 5 and 4 respectively. The 
SDFS remained 6 throughout. The only complete part of the SCAFI was the PATA 
test. The mean scores were 13.5, 12.5 and 16 respectively. 
Long-range PCR in the NHNN Neurogenetic laboratory confirmed the findings of the 
Exeter laboratory (see                      Figure 55). Patient D is in lane 20 showing a 
single expanded band sized at between 514 and 3181 GAA repeats. Lanes 22 and 23 
show two unaffected individuals with no GAA expansions. Lanes 24 and 25 show 
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two heterozygous carriers with one GAA expanded and one non-expanded allele, 
Lane 26 shows a known FRDA patient with two GAA expansions. 
 
Lane 20=Patient D. Lane 21=‘no DNA control’. Lanes 22/23=Negative (GAA-/-) controls.  
               Lanes 24/25=Carriers (GAA+/-). Lane 26=Positive control (GAA+/+).  
          1kB size ladder (Promega, Madison, WI, USA) with equivalent GAA sizes.  
                    Gel courtesy of Dr Robyn Labrum & Dr Ese Mudanohwo. 
                     Figure 55: Long-range FXN PCR for patient D 
There is a strong family history of neurological problems. The patient has a brother 
and a sister neither of whom has balance, coordination or gait problems, but his 
brother has a complex cranial tic involving blepharospasm and versive head 
movements. Neither was examined as part of the study. His mother was examined 
as part of the study. She was born to a normal birth without consanguinuity. She 
walked at 14 months but always had problems with riding a bicycle and playing 
sports, and had difficulty walking in the dark without assistance. She continued to 
have balance problems as an adult and was extremely sensitive to alcohol which 
caused unsteadiness and slurred speech.  At around age 30-40, she started to 
notice sensory loss and tingling in the hands on waking, and problems with manual 
dexterity. Previous neurophysiological investigations were said to have shown a 
predominantly sensory axonal neuropathy. She has hearing difficulty in conditions 
of background noise. 
On examination, the only sensory loss was decreased pin prick sensation on the 
lateral borders of the feet and shins. The reflexes were all present and normal. The 
plantar reflexes were mute. Cranial nerve examination including the eye 
movements was normal. The total SARA was 9 (gait 2, stance 3, sitting 1, speech 0, 
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finger chase 1, nose-finger 0, alternating hand movements 1, heel-shin 1) although 
it was felt that many aspects of the examination were dominated by distractible 
functional overlay. A routine panel of blood tests showed no cause of neuropathy. 
Electromyography and nerve conduction studies in this institution showed no 
evidence of a generalized neuropathy but there was evidence of median 
neuropathies at the wrist, consistent with bilateral carpal tunnel syndrome. Upper 
and lower limb sensory evoked potentials were within normal limits. MR imaging 
showed normal intracranial appearances with no regional or generalized volume 
loss. There were mild degenerative changes in the cervical and lumbar spine with 
moderate intervertebral foraminal narrowing on the left at C3/4. The vertebral 
canal was capacious and the spinal cord of normal calibre and signal intensity 
throughout. A next generation sequencing panel of genes for inherited 
neuropathies (Charcot-Marie-Tooth syndromes type 1 & 2) showed only two rare 
variants in the genes TRPV4 and MARS which were not predicted to be pathological. 
The sister of the patient’s mother also had problems with balance although had had 
a horse-riding accident in her 30s. Both of her daughters also had problems with 
balance. The father of the patient’s mother also had problems riding a bicycle and 
his brother walked with a stick and had speech problems from early in life. None of 
these individuals was examined as part of the study.  
3.4 Discussion 
This Chapter provides a comprehensive clinical and genetic assessment of two rarer 
causes of FRDA, namely compound heterozygotes involving either point mutations 
or large deletions.  
3.4.1 FXN Compound Heterozygotes with Point Mutations 
Compound heterozygous FRDA patients with four different FXN point mutations 
were identified as part of this study. The mechanism of damage for the 
c.2T>C/p.Met1Thr and c.357_378dup22/p.Phe127fsX mutations is clear, given that 
they either induce incorrect translational initiation or introduce premature 
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termination. The second mutation has not previously been published and 
represents the first case described of a duplication in the FXN gene.  
 
Figure 56: Tertiary structure of human frataxin showing selected mutated 
residues 
Green spheres show IscU-binding residues including Arg165 (R165). Blue sphere 
shows ferrochelatase-binding residue. Gold spheres show non-binding residues 
including Gly130 (G130). Coils are α-helices. Arrows are the β-strands.  
Figure from Galea et al. (2015) 
 
The Arg165 residue lies within the β5 strand of the β-sheet which binds the iron-
sulphur cluster scaffold protein, IscU (see Figure 56). The p.Arg165Asp mutation 
involves a change from an arginine residue whose side chain is long and cationic 
under physiological conditions (-CH2CH2CH2NHCHNHNH3
+) to an aspartate residue 
whose side chain is short and anionic (-CH2COO
-). This change is predicted to have 
little effect on protein stability but to affect interactions with IscU and so disrupt ISC 
biosynthesis (Galea et al. 2015). Studies of the interaction of the bacterial 
orthologue of frataxin, CyaY, with IscU and IscS suggest that a ternary complex is 
formed, with IscU interacting with a series of conserved arginine residues on the β-
sheet (Prischi et al. 2010). This mutation has not been described previously but 
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previous descriptions of mutations involving different nucleotide changes resulting 
in different amino acid changes at the Arg165 residue make this a mutational hot-
spot. 
The Gly130 residue lies within a tight turn formed by residues Gly128, Ser129 and 
Gly130 between strands β1 and β2 of the β-sheet (Correia et al. 2008) (See Figure 
56). Introduction of the larger valine residue introduces local strain at that point. 
The backbone carbonyl oxygen atom of the Gly130 residue also forms a hydrogen 
bond with the backbone amide hydrogen atom of the Lys147 residue in the 
neighbouring β3 strand which helps preserve the integrity of the β-sheet (see Figure 
57). Previous thermodynamic studies confirm that the p.Gly130Val variant has 
lower stability than wild-type protein which may relate to these effects (Correia et 
al. 2008). Modelling predicts that substitution of valine for glycine at residue 130 
results in the loss of this hydrogen bond. This may be because of a steric clash 
between the larger aliphatic valine side chain [-CH(CH3)2] and that of lysine 
[-CH2CH2CH2CH2NH3
+]. The lysine side chain amino group forms a strong 
electrostatic interaction with the side chain carboxyl moiety [-CH2CH2COO
-] of the 
Glu96 residue within the α1 helix (see Figure 57). This may prevent the Lys147 
residue from adopting a different conformation to accommodate the large aliphatic 
side chain of the p.Gly130Val variant (Galea et al. 2015). Taken together, these 
changes are likely to decrease frataxin stability in vivo and disrupt the binding of the 
β-sheet with the iron-sulphur cluster scaffold protein, IscU, and thus disturb ISC 
biogenesis. The Gly130Val mutation was one of the first FXN point mutations to be 
described. The results of this thesis suggest that it may be the commonest in the 
UK. There is evidence from haplotype analysis that affected individuals from as far 
afield as the USA, France and Australia may share a common founder (Delatycki et 
al. 1999). This could be tested in the UK cases. 
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Figure 57: Effect of Gly130Val mutation on frataxin tertiary structure 
Left panel shows wild-type protein structure with hydrogen bond between the 
Gly130 (G130) residue and the Lys147 (K147) residue and the electrostatic 
interaction with residue Glu96 (E96). Right panel shows the disruption of the 
hydrogen bond by the introduction of valine at residue 130 (G130V).  
Figure from Galea et al. (2015) 
 
The clinical results of the patients studied within this thesis suggest that the 
existence of hyperreflexia, and lower frequency of square wave jerks, dysarthria, 
dysphagia and possibly broken pursuit eye movements and wheelchair-bound 
status are associated with the compound heterozygous state. Of the clinical rating 
scales, only the SARA came close to detecting a difference between the two groups 
suggesting a lesser degree of ataxia. This further confirms the greater utility of the 
SARA as a clinical rating scale in FRDA compared to other scales. There appears to 
be a residual effect of the size of the one expanded GAA repeat sequence on 
disease severity. These findings are consistent with previous reports that 
compound heterozygotes have an atypical milder phenotype with retained or brisk 
reflexes, absence of dysarthria and lower severity of ataxia (Cossée et al. 1999) with 
a residual effect of GAA2 size (De Castro et al. 2000, Gellera et al. 2007). Thus there 
is a suggestion that disease progression is slower. This thesis does not find, 
however, that age at onset was later amongst the compound heterozygotes. This 
may be because of the small number of cases studied and the high proportion of 
the mild p.Gly130Val missense mutation. 
With this in mind, the cases described above which had adequate clinical 
information were pooled in a worldwide study incorporating cases from major 
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research centres in the USA, Australia and Europe which is due for publication in 
2016 (Galea et al. 2015). This found 111 compound heterozygotes making it by far 
the largest study of FRDA compound heterozygotes yet published. The study found 
that patients with null mutations had significantly earlier onset of symptoms than 
homozygotes and compound heterozygotes with missense mutations, but there 
was no significant difference between homozygotes and those with missense 
mutations. Homozygotes were more likely to have cardiomyopathy than both null 
and missense mutants. Individuals with null mutations were 4.5 times more likely to 
have diabetes than homozygotes but there was no difference between 
homozygotes and missense mutants.  
One intriguing question which neither this thesis nor the study of Galea resolves is 
why there has never been a case of a homozygous point mutant described. 
Homozygous null mutations would presumably be devastating if not lethal in utero. 
However, given the relatively mild clinical nature and relatively common incidence 
of the p.Gly130Val mutation, one might expect homozygous individuals to exist, 
particularly in regions in which consanguinuity is common. None has yet been 
described. In the UK, only symptomatic individuals with at least one pathological 
GAA expansion are tested for point mutations, which potentially makes the absence 
of discovery of homozygous point mutants a self-fulfilling prophecy. It may be that 
the alteration in function of the protein caused by the point mutations is sufficient 
to make homozygous point mutants inviable, in a way that simple deficiency of the 
otherwise normally functioning protein in individuals with homozygous pathological 
GAA expansions does not. Further work is warranted on this subject. 
3.4.2 FXN Compound Heterozygotes with Large Deletions 
3.4.2.1 Frequency of Large Deletions amongst FRDA Patients 
The principal objective of the MLPA study was to assess the frequency of exonic 
FXN deletions in a large cohort of patients referred to a tertiary neurogenetics 
service with a clinical history compatible with FRDA. This is important as, in this 
situation, most neurogenetics laboratories currently look for the presence or 
absence of pathological GAA expansions by triplet-primed and long-range PCR. If 
197 
 
two expansions are found, a genetic diagnosis of FRDA is made. If one GAA 
expansion is found in a symptomatic individual, the DNA is subjected to sequence 
analysis for point mutations. This process therefore only allows the diagnosis of 
FRDA caused by homozygous GAA expansions, or compound heterozygous GAA 
expansions and point mutations. We wished to test the hypothesis that 
symptomatic individuals with one GAA expansion and no point mutation might also 
have an exonic deletion.  
To that end, details of all the referrals to the specialist Neurogenetics laboratory at 
the NHNN for genetic testing for FRDA over a 10 year period were obtained. Figure 
58 shows the results of genetic testing on these samples both in the NHNN 
laboratory and as part of this project. No exonic deletions were detected as part of 
the MLPA study, either from the NHNN or EFACTS patients. It is therefore 
reasonable to assume that the proportion of FRDA patients with an exonic deletion 
is exceedingly low, so low that none was detected amongst 10 years’ referrals to a 
major tertiary referral centre for neurogenetics with a particular interest in the 
hereditary ataxias. It may be that none of these mutations is present in the UK 
population. None has so far been described. Of the eleven patients previously 
described in the medical literature, two were from the USA and nine from Western 
Europe (Germany, Netherlands, France and Norway). It therefore seems reasonable 
that this test is not routinely offered in the UK, although it might still be considered 
on a case-by-case basis if there is a very strong clinical suspicion of FRDA and a 
single pathological GAA expansion or point mutation is found.  
Previously described cases with exonic FXN deletions have been identified because 
of the strong clinical suspicion of FRDA but inconclusive genetic results (van den 
Ouweland et al. 2012, Zühlke et al. 2004). The case described by Zühlke and co-
workers was identified from a screen of fourteen patients, six of whom had a single 
pathological GAA expansion and all clinical features of ataxia. The two cases 
identified by Deutsch, Brigatti and others were derived from a screen of at least six 
patients but presumably taken from an extensive cohort, as the main research 
group involved (Children’s Hospital of Philadelphia) is one of the principal centres of 
FRDA research in North America and the coordinating centre of a large multi-centre 
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longitudinal study of FRDA (the Collaborative Clinical Research Network in 
Friedreich’s Ataxia) (Deutsch et al. 2010, Brigatti et al. 2012). The six patients 
described by Anheim and colleagues were identified by screening thirteen patients 
taken from an estimated 600 patients seen over twelve years, although the search 
does not appear to be systematic (Anheim et al. 2012). The most recently published 
study of FRDA in Norway aims systematically to identify every diagnosed case of 
FRDA in that country which is presumably possible because of the small population 
and limited number of centres involved. From a population of 5.1 million, 27 cases 
of FRDA with two GAA expansions were found, as well as one compound 
heterozygote with a point mutation and one with an exonic deletion (Wedding et 
al. 2015). The present thesis therefore includes the largest study to date which has 
systematically screened a large consecutive cohort of patients for exonic FXN 
deletions.  
 
Figure 58: Flow diagram of patients in MLPA study 
GAA +/+ two GAA expansions; GAA +/- one GAA expansion; GAA -/- no GAA 
expansions. MLPA=multiplex ligand-dependent probe amplification 
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This study also provides some interesting incidental epidemiological information. 
207 positive diagnoses of FRDA were made over 10 years out of a total of 1768 
referrals, giving a diagnostic rate of 11.7%. Eleven of those diagnoses were from 
compound heterozygous point mutations, making the proportion 5.3%. No 
systematic studies have been undertaken to determine the prevalence of FXN point 
mutations in the general population but Campuzano and colleagues found eleven 
patients out of 258 patients from two different cohorts to have point mutations (all 
compound heterozygotes), making a rate of 4.3%. They therefore reported GAA 
expansions as being present in approximately 98% of chromosomes studied (and 
not 98% of patients as is commonly reported in many academic papers) 
(Campuzano et al. 1996). Cossée and colleagues found 25 patients compound 
heterozygous for a point mutation out of 719 patients with a genetic diagnosis of 
FRDA, making a rate of 3.5% (Cossée et al. 1999). De Castro and colleagues found 
four patients with a point mutation out of 179 with a genetic diagnosis of FRDA, 
giving a rate of 2.2% (De Castro et al. 2000). 
Twenty-nine GAA expansion carriers were found. Twenty were symptomatic and 
nine asymptomatic, making a carrier rate of between 1.1 and 1.6% or 
approximately 1/88 to 1/61. No systematic studies have been undertaken assessing 
the frequency of FRDA carrier status in the UK but Harding & Zilka estimated the 
rate in Great Britain at approximately 1/110 (Harding & Zilkha 1981). Other studies 
in Western Europe have estimated the carrier rate at 1/191 in the Torino region of 
North-western Italy (Leone et al. 1990), 1/85 in France (Cossée et al. 1997b), 
between 1/60 and 1/90 in Germany (Epplen et al. 1997) and 1/196 in Norway 
(Wedding et al. 2015). Filla and co-workers estimated the prevalence of FRDA in the 
Molise region of Southern Italy to be between 1/20,000 and 1/250,000 (Filla et al. 
1992). Assuming the population is in Hardy-Weinberg equilibrium and there is no 
consanguinuity (both of which may not be true), these correspond to carrier rates 
of between 1/77 and 1/177. A further study in Cantabria, Spain found a prevalence 
rate of 1/21,277 which corresponds with a carrier rate of 1/73 (Polo et al. 1991). Of 
note, all of the studies published before 1996 rely on clinical rather than genetic 
diagnoses which introduces a further level of uncertainty. Whilst the present 
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sample may not be wholly representative of the UK population and no attempt was 
made for this to be a comprehensive epidemiological study, the results provide 
further information on this subject and are broadly in line with previous analogous 
studies.  
3.4.2.2 Patient D 
The rationale for studying patient D is given in the Introduction at 3.1.2.1. The 
method for the MLPA technique used to analyze patient D is given in Section 3.3.1 
and the results in Section 3.3.2. Patient D’s history is given in Section 3.3.2.1. The 
case of patient D is interesting as the most likely explanation of his genetic 
abnormality is a large deletion, and so he might represent the twelfth case so far 
described and the first in the UK. Unfortunately, this study does not determine the 
exact site of the genetic abnormality. There is no deletion of exons 1 and 2 detected 
by the MLPA technique. It is known that both the long-range PCR using two 
different sets of primers produced the same result of a single expanded band on 
the PCR gel. Triplet-primed PCR is uninformative as this cannot discern a single 
heterozygous expansion from two homozygous expansions. It is further known that 
long-range PCR using the primers described in Filla et al. (1996) in the patient’s 
mother showed no expanded band. Figure 59 shows the locations of these primers 
and the MLPA probes relative to exons 1 and 2 and the GAA repeat sequence. The 
GAA repeat sequence is located 1.3kbp from the start of intron 1 which itself is 
10.4kbp in length. The Filla and Campuzano primers bind within 150-200bp on 
either side of the GAA repeat sequence. The exon 1 probe binds in the first half of 
exon 1, 390bp from the exon 1-intron 1 splice site. The exon 2 probe binds in the 
second half of the much smaller exon 2, 45bp from the intron 1-exon 2 boundary 
and in fact overlaps the exon 2-intron 2 boundary.  
Thus, a number of possibilities might have given rise to patient D’s result. 
Genetically, he could have a small deletion encompassing either or both of the 
primer sets flanking the GAA repeat sequence. Indeed, any small sequence change 
preventing the binding of these primers could give rise to this result (akin to a SNP 
under a conventional primer), although it would have to be under the GAA-R/GAA-
629R pair as the GAA-F/GAA-104F pair do not overlap. However, the patient does 
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have symptoms and so presumably exon 1 or 2, or both, is also involved. 
Alternatively, either or both of their splice sites could be involved. A large deletion 
seems the most likely explanation. This could extend from one of the primer sites 
toward exon 1 and encompass part of the 390bp of exon 1 downstream of its probe 
binding site, or toward exon 2 and include part of the 45bp of exon 2 upstream of 
its binding site, or indeed both. Further analysis of the deletion breakpoints is 
required. 
Patient D has a severe clinical phenotype with very early symptom onset at age 1½ 
progressing to wheelchair dependency, cardiomyopathy, scoliosis and pes cavus. He 
does not however have diabetes. This is in keeping with previous observations that 
truncating mutations or those in the amino terminal half of the protein produce a 
more severe phenotype. Patient D has a GAA expansion of 785 repeats which would 
be expected to cause significant frataxin deficiency. A deletion of one or both of the 
first two exons would most likely result in no usable frataxin. Further work remains 
to determine the exact nature and extent of the mutation and other downstream 
effects such as frataxin protein and mRNA levels. Further clinical and genetic 
assessment is also warranted of other affected family members, the significance of 
which remains unclear. 
Four additional cases were included in the MLPA study as a limited exploratory 
investigation of whether the EFACTS cohort contained other examples of patients 
reported as having equally sized expanded GAA sequences, but who in reality might 
have a single GAA expansion and a deletion encompassing the GAA repeat 
sequence or its associated primer binding sites. None of these cases showed exonic 
deletions. There are a further eleven such cases in the UK wing of the EFACTS 
cohort reported as having equal-sized GAA expansions who could be tested, and 
presumably many more in the whole European sample. However, the current study 
does not provide any additional examples of this phenomenon. 
Nevertheless, the example of patient D is potentially significant as, if this 
phenomenon is more widespread than currently appreciated, although it is unlikely 
to lead to a clinical misdiagnosis in an affected individual, the genetic diagnosis 
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would be inaccurate. If disease-modifying medications become available which 
specifically interact with the GAA expansion or its related features such as 
epigenetic modifications, these may not be effective if the patient’s disease is not 
associated with this pathological mechanism. It is also important in the 
interpretation of genetic tests of relatives being undertaken to provide 
reproductive advice. An asymptomatic carrier of this deletion might be falsely 
reassured that she could not pass on the genetic abnormality if her routine genetic 
test with a single normal-sized band were interpreted as providing evidence of two 
normal-sized alleles. This misinterpretation is potentially more common than that 
of expanded alleles, as most patients with unexpanded alleles only have a single 
small band on long-range PCR because the range of normal repeat sizes is much 
narrower than that of expanded repeat sequences.  
The unusual nature of patient D’s mutation was discovered effectively by accident 
as his mother was also tested as she had neurological symptoms. The parents of 
affected individuals are rarely tested as part of the diagnostic process for a variety 
of reasons. It adds expense and complexity to the diagnostic process. They may 
simply not be present, available or indeed alive. There are ethical considerations in 
the routine testing of parents - particularly fathers - because of the possibility of 
inadvertently revealing non-parentality. Indeed, in the case of patient D, if the 
absence of a pathological GAA expansion had been found in the father, it might 
initially have been attributed to non-paternity although this could quickly have 
been disproved by further testing. Thus, testing for a an exonic deletion is 
warranted if testing of the parent of a patient with genetically proven FRDA, fails to 
reveal carrier status, particularly if the patient appears to have two equal-sized GAA 
expansions on long-range PCR. However, the conventional MLPA technique may 
not pick up all large FXN gene deletions and consideration should be given to 
undertaking alternative techniques to assess the exact breakpoints of a deletion. 
The currently commercially available MLPA probes may require revision, 
particularly for the larger exons 1 and 5b to provide more comprehensive coverage. 
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Figure 59: Locations of primer and MLPA probe binding sites for FXN exons 1-2  
Exons are shaded in grey. Exon 1 & 2 probes relate to MHC-Holland SALSA MLPA P316-B2 Recessive 
Ataxias probemix. Primers GAA-104F & GAA-629R relate to Filla, et al. 1996. Primers GAA-F & GAA-R 
relate to Campuzano, et al. 1996. Note, the GAA-629R and GAA-R binding sites overlap. Genetic data 
from www.genome.ucsc.edu. Homo sapiens FXN transcript variant 1. Chr 9:69,035,259-69,074,213. 
RefSeq NM_000144.4 Genome GRCh38/hg38. 
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Chapter 4 :  Autosomal Recessive Spastic Ataxia of 
Charlevoix-Saguenay (ARSACS) 
 
4.1 Introduction 
The core features of ARSACS are a slowly progressive cerebellar ataxia, spasticity and 
an axonal-demyelinating peripheral neuropathy, causing incoordination, dysarthria, 
cerebellar eye signs, limb weakness, muscle cramps, distal amyotrophy, sensory loss, 
pyramidal signs and skeletal foot abnormalities. Less commonly, hearing and visual 
loss, dysphagia, urinary symptoms, epilepsy and cognitive deficits have been reported. 
The condition was first described in, and considered to be confined at relatively high 
frequency to the descendants of founder populations of, the Charlevoix and Saguenay-
Lac Saint Jean regions of North-eastern Québec (Bouchard et al. 1978). However, the 
discovery of the causative SACS gene has permitted its identification throughout the 
world and has extended the diversity of mutations known, and the spectrum of clinical 
features described (Gomez 2004). ARSACS is now recognized as one of the important 
causes of autosomal recessive ataxia.  
4.2 History 
Québec was one of the first regions of North America to be colonized by Europeans 
and the majority of French Canadians living in Québec Province today are thought to 
descend from these original founders. As a result, a number of rare neurogenetic 
disorders show increased prevalence or local variants in this region, including 
Friedreich’s ataxia (FRDA), and other hereditary ataxias, spastic parapareses and 
neuropathies (Dupré et al. 2006; Bouchard et al. 2007). Québec City was founded in 
1608 under the rule of the French crown and between 1665 and 1725, around forty 
families migrated from there to the isolated mountainous region of Charlevoix on the 
north shore of the Saint Lawrence River, with little population exchange with the 
original colony. Between 1838 and 1855, further families moved from Charlevoix to 
the more distant Saguenay and Lac Saint Jean regions to the north which had until 
then been protected for the fur trade (Bouchard et al. 1978; see Figure 60).  
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Figure 60: Maps showing (A) location of Charlevoix and Saguenay regions of Québec 
province, Canada and (B) migration of French Canadian populations  
(adapted from Bouchard et al. 1978) 
The clinical syndrome of ARSACS was first described in 1978 in these populations 
(Bouchard et al. 1978), and this community of more than 300 affected individuals 
remains the most numerous and most extensively studied to this date. It is estimated 
that the carrier frequency of SACS mutations is 1/22 in Charlevoix and Saguenay-Lac 
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Saint Jean. The clinical phenotype of the original cases was remarkably homogeneous, 
probably because more than 92% of carrier chromosomes in these regions have the 
same mutation (c.8844delT). Although it was initially considered that the condition 
may have originated in a founder couple living in Québec City around 1650 (Bouchard 
et al. 1978), subsequent analysis has found at least 13 other pathogenic mutations in 
this community (Thiffault et al. 2013). 
The causative gene was first described in 2000 (Engert et al. 2000) enabling the 
subsequent identification of cases in Europe, North Africa, Turkey, Japan, Brazil, Israel 
and other provinces of Canada (Bouhlal et al. 2011; Pedroso et al. 2011; Blumkin et al. 
2015; Guernsey et al. 2010) with considerable phenotypic heterogeneity, so that now 
none of the canonical signs of spasticity, ataxia, or origin in Charlevoix-Saguenay is an 
obligate feature of the condition (Synofzik et al. 2013). Alternative names such as 
‘sacsin-related autosomal recessive ataxia’ or ‘sacsinopathy’ (Takiyama 2007; El Euch-
Fayache et al. 2003) have therefore been proposed although not widely accepted. 
However, because of the historical and numerical primacy of the Québecois cases, the 
world literature is dominated by these initial descriptions and few other large case 
series have been undertaken with none in the UK. It is therefore vital to characterize 
this condition clinically and genetically in a large series from the UK which can inform 
clinical practice and genetic testing in this country and more widely. 
4.3 Genetics and Sacsin Protein Function 
The causative gene on chromosome 13q12.12 is named SACS and was originally 
thought to contain a single giant exon (Engert et al. 2000; see Figure 61). A further 8 
exons and a tenth non-coding exon have subsequently been identified upstream of 
this, forming a 13,737bp open reading frame (Ouyang et al. 2006). Nearly 200 different 
pathogenic mutations have now been described (Thiffault et al. 2013; Baets et al. 
2010; Brais & Dicaire 2015), largely missense, nonsense, frameshift and splice-site 
mutations spread over exons 1, 2, 4, 6, 7, 8 and 9, but still primarily in the giant exon 
10 (Thiffault et al. 2013; Brais & Dicaire 2015). Large deletions have also been 
described causing atypical features such as late onset or prominent hearing loss. These 
have included an intragenic deletion of exons 3-5 (Baets et al. 2010), deletions of the 
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whole gene (Breckpot et al. 2008; Pilliod et al. 2015) and deletion of SACS and the 
contiguous genes (Piluso et al. 2011; Terracciano et al. 2009; Pyle et al. 2013) including 
SGCG causing concomitant limb girdle muscular dystrophy type 2c (McMillan et al. 
2009). 
The gene encodes a massive 4,579 amino acid 520kDa protein called sacsin (see Figure 
61) which is most highly expressed in cerebellar Purkinje cells; thalamic, midbrain, 
precerebellar and brainstem nuclei; and large pyramidal forebrain neurones. At a 
subcellular level, it has been shown to localize to the cystoplasm with a mitochondrial 
component in SH-SY5Y neuroblastoma cells (Parfitt et al. 2009) and to colocalize with 
mitochondria in the soma, dendrites and axons of cultured hippocampal neurons, COS-
7 and HeLa cells (Girard et al. 2012).  
 
The true function of the protein is unknown but it has been shown to contain : 
 a ubiquitin-like (UBL) domain that can interact with the proteasome;  
 three sacsin repeat regions (SSRs) which possess ATPase activity; 
 a xeroderma pigmentosum complementation group C binding (XPCB) domain which 
has been implicated in ubiquitin ligase Ube3A interactions;  
 a J-domain (DnaJ motif) associated with chaperone activity and the regulation of 
the Hsp70 heat shock system; and 
 a higher eukaryote and prokaryote nucleotide binding (HEPN) domain that mediates 
dimerization and nucleotide binding (Girard et al. 2012; Kozlov et al. 2011; Prodi et 
al. 2013; Romano et al. 2013).  
 
 
Figure 61: (A) Primary structure of SACS gene showing the 10 exons. (B) Domain 
organization of sacsin protein.  
UBL, ubiquitin-like domain; SSR, sacsin repeat region; XPCB, xeroderma pigmentosum complementation 
group C binding domain; DnaJ, J-domain; HEPN, higher eukaryote and prokaryote nucleotide binding 
domain 
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Because of the presence of the ubiquitin-like domain and DnaJ motif, it was postulated 
that sacsin might participate in the cellular ubiquitin-proteosome and heat shock 
protein chaperone systems which are crucial in preventing the aggregation of mutant 
proteins which have been implicated in the aetiology of several neurodegenerative 
diseases including polyglutamine disorders (Ciechanover & Brundin 2003 ; Dantuma et 
al. 2014) A siRNA-mediated sacsin knockdown model enhanced the toxicity of mutant 
polyglutamine-expanded ataxin-1 supporting this idea (Parfitt et al. 2009). 
More recently, cultured immortalized fibroblasts from patients homozygous for the 
Québecois c.8844delT SACS mutation showed balloon-like or bulbed mitochondria 
suggestive of a mitochondrial hyperfusion seen with enhanced mitochondrial fusion or 
impaired fission. Coimmunoprecipitation showed an interaction between the N-
terminal portion of sacsin and Drp1, a protein involved in mitochondrial fission, 
suggesting that sacsin might be involved in this process. A siRNA-mediated sacsin 
knockdown model showed a more interconnected mitochondrial network. In the same 
model, physiological studies of the mitochondrial membrane potential (ΔΨm) which is 
generated by oxidative phosphorylation and thus an indicator of mitochondrial 
function, showed decreased fluorescence with the ΔΨm-sensitive dye 
tetramethylrhodamine (TMRM), indicating impaired mitochondrial function. 
Furthermore, recovery of fluorescence by the ΔΨm-sensitive marker MitoTracker after 
treatment with carbonyl cyanide m-chlorophenyl hydrazone (CCCP) which disrupts 
oxidative metabolism, was significantly slower in the sacsin knockdown cells. 
Cerebellar slice cultures from SACS-/- knockout mice also showed impaired ΔΨm using 
the immunofluorescent dye JC-1 when compared with controls. Cultured hippocampal 
neurons from the siRNA knockdown model showed mitochondria clustered in the 
soma and proximal dendrites compared to a more widespread distribution in control 
cells, as well as fewer, thicker dendrites. Thus, sacsin may be involved in mitochondrial 
fission and transport, preservation of mitochondrial membrane potential and dendritic 
morphology (Girard et al. 2012). 
Further work on the SACS-/- knockout mouse model has shown abnormally increased 
staining for heavy-chain neurofilament (NFH) in the cell bodies and dendrites of 
thalamic neurons, cerebellar Purkinje cells and neurons of the deep cerebellar nuclei 
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and superior olive. This appears to be specific to the non-phosphorylated form of NFH. 
These changes have also been seen in samples of brain tissue from human ARSACS 
patients. Studies of spinal motor neuron axons from the SACS-/- knockout mice showed 
decreased mitochondrial motility and markedly increased mitochondrial length. The 
NFH accumulation and decreased mitochondrial motility were noted before the 
mitochondrial elongation. SACS-/- knockout mice show abnormal gait with progressive 
motor, cerebellar and peripheral nerve dysfunction, accompanied by early onset 
progressive loss of cerebellar Purkinje cells followed by spinal motor neuron loss and 
peripheral neuropathy, indicating that the model is an accurate reproduction of the 
human disease. These findings further support the notion that sacsin is intimately 
involved with mitochondrial function and may play a role in the neuronal cytoskeletal 
network (Larivière et al. 2015).  
Studies of primary culture of skin fibroblasts from European patients with ARSACS has 
recently shown altered mitochondrial morphology with an increase in bulbed 
mitochondria; decreased global mitochondrial mass measured by MitoTracker; 
decreased mitochondrial DNA (mtDNA) measured by quantitative PCR; and impaired 
ΔΨm measured by TMRM. This team felt that mitochondrial network anomalies were 
so striking that they should be used as a biomarker in determining the pathogenicity of 
newly proposed SACS gene mutations (Pilliod et al. 2015). Thus, there is increasing 
evidence that sacsin plays an important role in mitochondrial function and this may be 
a key feature of the underlying neurodegenerative process in common with several 
other neurodegenerative diseases (Burté et al. 2014). 
4.4 Histopathology  
Nerve and muscle biopsies are commonly performed in suspected cases of ARSACS 
during the often long diagnostic process, but neither provides pathognomonic 
information. Nerve biopsies most consistently show a marked decrement in large 
myelinated fibres. More variably, axonal degeneration with condensation of the 
axoplasm, increased collagen pockets and accumulation of mitochondria and vesicular 
bodies is seen, sometimes with regenerative axonal sprouting. Thinning of the myelin 
sheaths with rare onion bulbs may also be observed (Peyronnard et al. 1979; El Euch-
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Fayache et al. 2003; Takiyama 2006). Taken together, these findings suggest an axonal 
neuropathy associated with some demyelinating features. Muscle biopsies show 
variation in fibre size with mildly atrophic and hypertrophic fibres, moderate type 
grouping and variable loss of type I or type II fibres. There are minimal signs of chronic 
or active denervation (Peyronnard et al. 1979; Takiyama 2006; Bouchard 1991). Overall 
these findings are typical of neurogenic atrophy. 
The results of only two post-mortem examinations of patients with ARSACS have been 
published (Bouchard et al. 1998). The first in a young patient who died in a road traffic 
accident, showed a grossly atrophied superior cerebellar vermis especially in the 
anterior structures (central lobule and culmen). No changes were seen in the dentate 
nucleus and inferior olives. The molecular and granular cell layers were thinned with 
practically absent Purkinje cells. The pyramids, lateral and anterior corticospinal tracts 
and posterior spinocerebellar tracts all showed significant loss of myelin staining, 
particularly the lateral corticospinal tracts. The corticospinal changes were more 
marked in the upper cord, whereas the spinocerebellar changes were more marked 
caudally. The second, in an older patient, showed similar findings although to a more 
pronounced degree. Swollen thalamic and cerebellar cortical neurones were seen, 
suggestive of a storage disorder. Most of these cells showed dense, lipofuscin-like 
granules within lysosomes, although testing of an extensive panel of lysosomal 
enzymes was normal. Interestingly, lipofuscin deposits have also been seen in the skin 
biopsy of a patient with ARSACS performed to exclude Lafora body disease (Stevens et 
al. 2013). Peripheral nerve and muscle biopsies have not shown lipofuscin deposits. 
The significance of this finding therefore remains unclear. 
4.5 Clinical Features 
Much of the clinical knowledge of ARSACS is based on the relatively homogeneous 
Québecois cases. However, subsequently identified cases from elsewhere have 
demonstrated a genetic and clinical variability which continues to extend the 
phenotypic description of this condition. The original Québecois cases were published 
as a series of largely descriptive papers (Bouchard et al. 1978; Bouchard 1991) and only 
216 
 
a handful of systematic case series encompassing more than five patients have been 
published. These are summarized in Table 34. 
In the Québecois cases, unsteadiness was noted from commencement of walking (12-
18 months old) which was rarely delayed (Bouchard et al. 1998; Bouchard 1991). 80% 
initially presented because of walking difficulties and a tendency to fall. At first 
presentation, approximately 60% were found to have limb ataxia, 80% showed some 
pyramidal involvement and 50% had both pyramidal and cerebellar involvement. 
There was no clinical evidence of neuropathy at presentation in the form of pes cavus 
or intrinsic hand muscle wasting (Duquette et al. 2013). There is some evidence that 
age at onset may be a little later in non-Québecois cases, particularly in Japanese and 
Tunisian cases (Takiyama 2007). In a series of 17 Belgian patients, 29% had onset at or 
after age 20 with one as late as 40 (Baets et al. 2010). There is no male-female 
preponderance.  
Thus, limb and gait ataxia are early signs followed by spasticity, which is more 
prominent in the lower limbs. Spasticity and ataxia affect speech, which is often 
slightly slurred in childhood and can become explosive in adulthood. Dysphagia is 
usually mild or absent (Bouchard 1991; Prodi et al. 2013). Plantar reactions are 
frequently upgoing from childhood. Eye movements show horizontal bidirectional 
nystagmus, saccadic alterations of smooth ocular pursuit and saccadic dysmetria 
(Bouchard 1991). Supranuclear gaze palsy has been described in one case (Stevens et 
al. 2013). In the Québecois cases, by the age of 10 more than 90% showed both 
pyramidal and cerebellar involvement (Duquette et al. 2013). Muscle cramps may be a 
troublesome feature. Progression of symptoms is slow. In the Québecois cases, only 
4% used a wheelchair before the age of 18 (Duquette et al. 2013). Mean age to being 
wheelchair-bound was around 40 (range 17-58) and to death around 50 (range 21-72) 
(Bouchard 1991). 
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Table 34: Frequencies of clinical features in published case series 
 Bouchard et al. 
1978 
El Euch-
Fayache et al. 
2003 
Takiyama 2006 Vermeer et al. 
2008 
Baets et al. 
2010 
Prodi et al.  
2012 
Synofzik et al. 
2013 
Pilliod et al. 
2015 
Origin Canada Tunisia Japan Netherlands, 
Turkey, UK  
Belgium, 
Morocco, 
Serbia, Hungary 
Italy Germany, 
Turkey, Greece, 
Macedonia 
France, Turkey, 
Maghreb, 
Portugal, Italy, 
Australia, 
Poland 
Genetic diagnosis No Yes Yes Yes Yes Yes Yes Yes 
No. of patients 42 18 8 23 17 14 13 47 
No. of families 24 4 5 16 11 13 9 39 
Male:female 1 : 0.7 1 : 0.4 1 : 1 1 : 0.9 - 1 : 1.3 1 : 1.2 1 : 1.6 
Age at onset (years)
a 
No patients 
ever walked 
normally 
4.5±3.3  
(1-14) 
5.5±1.6  
(3-8) 
3.5±3.1 
(1-12) 
13.1±11.1  
(1-40) 
3.6±2.6  
(1-32) 
7.6±8.7  
(1-28) 
5.1±7.4  
(0-30) 
Age at examination 
(years)
a 
30.5±11.2  
(9-52) 
32.6±11.5  
(16-55) 
35.3±6.1  
(26-44) 
40.3±10.9 
(26-58) 
34.7±11.1  
(12-52) 
32.2±9.4  
(18-46) 
28.7±13.5  
(6-50) 
29.7±12.9  
(8-53) 
Disease duration 
(years)
a 
Lifelong 28.1±9.8  
(11-45) 
29.5±6.3  
(22-39) 
36.2±9.9  
(25-56) 
22.0±6.6  
(11-35) 
26.6±10.3  
(12-44) 
23.0±9.4  
(4-39) 
24.9±12.1  
(7-52) 
Age at wheelchair 
use (years)
a 
- 30.0±0.8  
(29-31) 
36.8  
(30-43) 
- - - - - 
Wheelchair-bound 
(%) 
- 22 - 68 65 - - 22 
Typical initial 
symptoms 
Never walked 
properly 
Cerebellar 
syndrome 
involving gait & 
movement 
Gait 
disturbance & 
falls 
Slowly 
progressive 
cerebellar 
ataxia 
Multiple 
symptoms 
Gait instability 
& falls 
Gait 
disturbance 
Unsteadiness 
Progression of 
symptoms 
Progressive 
with periods of 
stability 
Spasticity later Progresses in 
late teens/early 
20s 
Subsequent LL 
spasticity, then 
neuropathy 
- Spasticity 
developed later 
- - 
Mobility - 22% wheelchair 
use 
- 32% aids;  
68% wheelchair 
use 
18% unaided; 
18% aids;  
65% wheelchair 
use 
64% 
autonomous; 
36% with aids 
- 46% unaided; 
32% aids;  
22% wheelchair 
use 
218 
 
Spastic gait (%) - - - 100 - 79 - - 
UL spasticity (%) - - - 24 - - 
- 
12 
LL spasticity (%) - - (75)
c 
100 59 100 (67)
c
 65 
Dystonia (%) - - - 13 - - - 4 
Ataxic gait (%) 100 - - - - 79 - - 
UL ataxia (%) - - 
- 
100 
- 
- 83 
- 
LL ataxia (%) - - (100)
c 
100 (88)
c 
- 75 (100)
c 
Dysarthria (%) 100 78 100 - 59 - 50 - 
Dysphagia (%) 36 - - 30 - 7 - 6 
Nystagmus (%) 100 100 100 - 65 - 67 83 
UL reflexes (%)
b 
- - (H:75)
c 
N:59 A:35 H: 6 (H:59)
c 
H:36 - N:28 A:35 H:37 
Patellar reflexes (%)
b 
- N:0 A:0 H:100 - N:32 A:26 H:42 - - - N:9 A:23 H:68 
Ankle reflexes (%)
b 
N:7 N:0 A:100 H:0 - N:0 A:95 H:5 - N:0 A:57 H:43 - N:9 A:61 H:30 
Extensor plantar 
responses (%) 
100 - 100 - 82 100 58 78 
Sensory loss (%) 100 100 - - 53 - - 68 
UL weakness (%) - - - - 41 - - 33 
LL weakness (%) - - - - 82 - - 67 
UL amyotrophy (%) 21 67 (88)
c 
- - 100 - 19 
LL amyotrophy (%) - 67 - - - 100 - 35 
Scoliosis (%) 0 11 - - - 36 - 9 
Foot abnormalities 
(%)
d 
86 44 75 - 35 - - 57 
Hand abnormalities 
(%)
e 
‘sometimes 
seen’ 
- 63 - - - - - 
Mitral valve 
prolapse (%) 
57 - - 0 6 - - - 
Other cardiac 
involvement (%) 
0 0 - 8
f 
- - - - 
Urinary problems 
(%) 
64 >65% - 48 - 21 77 23 
Hearing loss (%) - - - - - 14 0 13 
Cognitive 
impairment (%) 
See note
g 
- 75 7
h 
12 14 - 9 
Epilepsy (%) 
 
5
i 
- - 4 6 0
j 
- 9 
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Rating scales
k,l 
- ICARS: 
33.6±15.8 (4-
60) 
- SARA:  
22.2±5.1 (14-
31.5) 
- - SARA:  
12.4±8.7 (1-25) 
- 
EMG/NCS  100% showed  
severe to 
moderate 
axonal 
neuropathy 
with 
demyelinating 
features 
100% showed 
moderate to 
severe sensory 
motor axonal 
neuropathy 
with 
demyelinating 
features 
100% sensory 
axonal 
neuropathy; 
54% secondary 
demyelinating 
features 
91% abnormal 
with 
predominantly 
mixed axonal-
demyelinating 
100% showed  
severe sensory 
motor axonal 
neuropathy 
with 
demyelinating 
features 
89% abnormal 
with marked 
axonal-
demyelinating 
sensory motor 
neuropathy 
56% 
demyelinating; 
25% axonal; 
11% mixed;  
8% other 
polyneuropathy 
Imaging 
Cerebellar atrophy 
(%) 
- - 100 65 47 100 89 90 
Pontine 
hypodensities (%) 
- - -
m 
- - 100 100 38 
Spinal cord atrophy 
(%) 
- - 38 - 6 89 NR 20 
Fundoscopy 
Retinal hypertrophy  
(%) 
100 11 63 100 13 0 17 19 
aExpressed as mean±SD (range) 
bN=normal, A=absent or hyporeflexic, H=hyperreflexic 
cSite not specified (UL vs LL) 
dPes cavus, pes planus, claw toes, hammer toes, varus or equinus deformities 
eClaw hands, swan-neck deformities 
fRight bundle branch block on ECG in 1 case 
g21 patients underwent psychometric evaluation showing deficits in non-verbal scales, particularly scales of object assembly & digit symbols 
hOne patient had meningitis with epilepsy & another strokes which may independently explain cognitive decline 
iSubsequently described in Bouchard et al. 1991 in which 5 out of 104 patients had epilepsy 
jFive patients had non-specific EEG abnormalities ‘mainly epileptiform activity’ 
kICARS=International cerebellar ataxia rating scale (0-100 with higher number representing greater involvement) 
lSARA=Scale for the assessment and rating of ataxia (0-40 with higher number representing greater involvement) 
mIn a subsequent overlapping series, 100% of patients showed pontine hypodensities (Shimizaki et al. 2013) 
- Not known or not recorded 
UL=upper limb ; LL=lower limb 
EMG=Electromyogram ; NCS=Nerve conduction studies 
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From childhood, deep tendon reflexes are frequently increased, but by adulthood, 
may diminish or become absent due to progressive neuropathy. Ankle jerks are 
commonly absent whilst knee jerks may be hyperreflexic but patients may have a 
very mixed and asymmetric picture. Sensory deficits usually appear later and 
progressively into adulthood, involving vibrational sense more than proprioception 
and cutaneous sensation. Distal amyotrophy also appears progressively later in the 
condition (Bouchard 1991). The combination of early spasticity and progressive 
neuropathy commonly causes skeletal abnormalities of the foot including pes 
cavus, talipes equinus or varus, and hammer or clawed toes. Unlike FRDA, spinal 
scoliosis is not a prominent feature (Bouchard 1991) but has been described in 
Tunisian (El Euch-Fayache et al. 2003) and Italian (Prodi et al. 2013) series. Straight 
dorsal spine has been described in a Spanish series (Gazulla et al. 2012). In the 
hands, swan-neck deformity of the fingers and claw hands has been described 
(Bouchard et al. 1978; Takiyama 2006) with dystonia sometimes causing abnormal 
posturing of the hands and neck (Vermeer et al. 2008). 
Cognition is generally preserved particularly on tests of verbal function, but 
visuospatial handling may be diminished and deteriorate with time (Bouchard et al. 
1998). Cognitive impairment may be a more prominent feature amongst non-
Québecois patients, with intellectual impairment and dementia described in 
patients from Japan, Italy and Turkey (Takiyama 2006). Although cerebellar eye 
signs may cause visual disruption, optic nerve and retinal function are not generally 
affected with normal acuity, fields and colour vision, despite the presence of 
thickened retinal nerve fibres (see Chapter 8) (Bouchard 1991). Hearing loss is not 
generally found but may be more prominent amongst cases involving SACS gene 
deletions (Breckpot et al. 2008; Prodi et al. 2013; Terracciano et al. 2009). 
Bladder and bowel symptoms are not well-studied in ARSACS although urinary urge 
incontinence has been most commonly described (Bouchard et al. 1978; Synofzik et 
al. 2013; Bouchard 1991; Prodi et al. 2013; Vermeer et al. 2008). Faecal 
incontinence and constipation may also be a problem in patients with long disease 
duration (Bouchard 1991). Co-existent epilepsy has been described in a minority of 
cases and it remains unclear whether this is a definite association (Stevens et al. 
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2013; Vermeer et al. 2008). It appears more common in the Québecois cases, 
occurring in more than 15% in one series (Duquette et al. 2013). Frequent abnormal 
electroencephalographic features have also been described (see 4.7 below).   
Currently no clinical diagnostic criteria exist for ARSACS. The descriptive clinical 
features published by Bouchard, et al (1991, 1998) have come closest to this, 
although may be more representative of the Québecois cases (see Table 35).  
Table 35: Clinical Features of ARSACS (modified from Bouchard et al. 1991 & 1998) 
 
 
4.6 Imaging  
The predominant radiological manifestations of ARSACS on MRI and CT are marked 
atrophy of the superior cerebellar vermis with consequent enlargement of the 
supravermian cisterns and cisterna magna (see Figure 62) (Baets et al. 2010; 
Takiyama 2006; Prodi et al. 2013; Gazulla et al. 2012). Posterior fossa arachnoid 
cysts are also sometimes reported (Synofzik et al. 2013). While such prominent 
cerebellar atrophy is uncommon in FRDA, these findings are also seen in other 
causes of spinocerebellar ataxia (SCA). More specific appear to be the paramedian, 
bilaterally symmetrical, parallel, linear hypointensities in the pons on T2 and T2-
Onset 
Unsteadiness at gait initiation 
Progressive Signs 
Mostly spastic ataxia of the four limbs 
Slurred and dysrythmic speech 
Discrete to severe distal amyotrophy 
Absent ankle jerks after 25 years of age 
Early Non-Progressive Signs 
Increased deep tendon reflexes 
Bilateral abnormal plantar response 
Marked saccadic alteration of ocular pursuit 
At funduscopy: prominent retinal nerve fibres radiating from the 
disc and embedding retinal vessels 
Positive Diagnostic Tests 
CT or MRI: atrophy of the superior vermis; progressive atrophy of 
the cerebellar hemispheres and of the cervical spinal cord 
NCS: axonal neuropathy with absent sensory action potentials and 
low motor conduction velocities 
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FLAIR MRI sequences (Gazulla et al. 2012; Martin et al. 2007) which some have 
called ‘pontine tigroid hypointensities’ (Terracciano et al. 2010). Associated with 
these may be bilateral T2-FLAIR hyperintensities of the lateral pons at the level of 
the middle cerebellar peduncles (MCPs) (Synofzik et al. 2013). The hypo- and hyper-
intensities may extend into the MCPs (Shimazaki et al. 2013). The pons generally 
may be bulky (Prodi et al. 2013) and the MCPs thickened (Synofzik et al. 2013; Prodi 
et al. 2013; Gazulla et al. 2012). The pontine striations have not been reported in 
other causes of ataxia or spastic paraparesis, making them useful in distinguishing 
ARSACS from these conditions when present. Diffusion tensor imaging (DTI) has 
shed some light on the underlying nature of these changes and the cause of 
symptoms in ARSACS, with hyperplastic pontocerebellar fibres at the same level as 
thin and abnormally placed pyramidal tracts, suggesting that the former may be 
compressing the latter (Prodi et al. 2013; Gazulla et al. 2012). 
Atrophy of the superior cerebellar peduncles (SCPs), medulla, cervical and thoracic 
cords has also been observed (Bouchard 1991; Prodi et al. 2013), although again 
not consistently, particularly in non-Québecois cases (Shimazaki et al. 2007). More 
widespread cerebral atrophy, particularly bilaterally in the parietal lobes (Synofzik 
et al. 2013), may be seen later in the course of the condition but is not as 
prominent as the cerebellar or cervical atrophy (Baets et al. 2010; Bouchard et al. 
1998). Thinning of the corpus callosum and a rim of T2 hyperintensity around the 
thalami have also variably been reported (Synofzik et al. 2013; Prodi et al. 2013). No 
white matter abnormalities have been seen in either brain or spine (Takiyama 2006; 
Bouchard 1991) except in one atypical case in which the explanation was felt to be 
concomitant multiple sclerosis (Terracciano et al. 2010). Single photon emission 
computed tomography (SPECT) has shown decreased blood flow in the superior 
cerebellar vermis (Shimazaki et al. 2007). 
Thus, the salient imaging features of ARSACS are prominent early superior vermian 
cerebellar atrophy, thinning of the predominantly cervical spinal cord and pontine 
linear hypointensities. 
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Figure 62: Radiological features of ARSACS 
A) Sagittal T1 MRI showing superior vermian atrophy and corpus callosal thinning ; 
B) Sagittal T1 MRI showing superior vermian atrophy ; C) Sagittal T1 MRI showing 
generalized cerebral volume loss, most preponderant in the parietal lobe ; D) Axial 
T1 MRI showing pontine hypointensities ; E) Axial T2 MRI showing pontine 
hypointensities ; F) Sagittal T2 MRI showing thinning of the cervical spinal cord 
 
4.7 Neurophysiological studies 
Nerve conduction studies show increased distal motor latency and decreased 
conduction velocities which are more pronounced in the lower limbs than the 
upper limbs. Typical median nerve conduction velocities are 29-44ms-1 and 
peroneal nerve 17-35ms-1. This appears to distinguish ARSACS from FRDA in which 
motor conduction velocities are usually preserved. Motor conduction slowing 
appears early in life with progressive degeneration which may make compound 
motor action potentials impossible to detect at the feet by middle age. Sensory 
nerve conduction is usually of low amplitude or unrecordable, especially in the 
lower limbs (Peyronnard et al. 1979; El Euch-Fayache et al. 2003; Bouchard 1991; 
Gazulla et al. 2012). Electromyography shows fibrillations, occasional fasciculations, 
increased polyphasic action potentials and decreased or absent recruitment, 
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indicating chronic denervation of distal muscles early in the disease process 
(Bouchard 1991; Gazulla et al. 2012). Sympathetic skin responses are normal. 
Somatosensory evoked potentials show a dispersed and delayed cortical response 
indicating slowed central sensory conduction. Brainstem and visual evoked 
potentials show increased latencies even in the absence of auditory or visual 
symptoms (Bouchard 1991; Gazulla et al. 2012). Electroretinography is normal 
(Prodi et al. 2013; Desserre et al. 2011). Transcranial magnetic stimulation also 
shows marked delay in the central pathways (Bouchard 1991). Thus, 
neurophysiological studies suggest an early demyelinating sensorimotor 
neuropathy with progressive axonal degeneration, and involvement of the central 
sensory and motor pathways.  
Electronystagmography (ENG) most commonly shows horizontal gaze-evoked 
nystagmus and impairment of smooth ocular pursuit. There is also impairment of 
optokinetic nystagmus and defective fixation suppression of caloric nystagmus. 
Saccades are dysmetric but saccadic velocities are normal (Bouchard 1991). 
Electroencephalography (EEG) reveals abnormalities in 40-60% of patients although 
frank epilepsy is much less commonly reported (Bouchard 1991; Prodi et al. 2013). 
These abnormalities may be non-specific findings indicating involvement of cortical 
and subcortical structures similar to those reported in FRDA. 
4.8 Differential Diagnosis 
FRDA is the commonest cause of autosomal recessive cerebellar ataxia and the 
chief condition in the differential diagnosis of ARSACS. Retained or brisk reflexes 
and spasticity are rarely features of FRDA except in atypical late-onset cases known 
as Friedreich’s ataxia with retained reflexes (FARR) (Parkinson et al. 2013). 
Cerebellar atrophy is more pronounced in ARSACS. A striking feature which 
distinguishes ARSACS from FRDA and other mitochondrial disorders, is the absence 
of extraneurological features such as diabetes, cardiomyopathy and scoliosis. The 
electrocardiogram in ARSACS is typically normal, as compared to the frequent 
existence of repolarization abnormalities in FRDA. Although mitral valve prolapse 
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was described in the original cases of ARSACS (Bouchard et al. 1978), this finding 
has not been replicated in subsequent studies of families outside Québec. 
Ataxia with oculomotor apraxia (AOA) may be distinguished from ARSACS because 
of the presence of oculomotor apraxia, dystonia, chorea and the absence of 
pyramidal features. AOA type 1 is associated with low levels of serum albumin and 
elevated levels of low density lipoproteins (LDLs), whilst AOA type 2 shows elevated 
levels of α-fetoprotein (AFP). Ataxia telangiectasia has many features in common 
with AOA together with cutaneous and scleral telangiectasiae, diabetes, 
immunodeficiency and sensitivity to radiation causing tumours (Desserre et al. 
2011).  
Late-onset Alexander’s disease may have onset in adolescence and have a 
presentation similar to ARSACS. Cerebellar atrophy is less prominent and there may 
be periventricular white matter changes on MRI which are not seen in ARSACS. 
Cerebrotendinous xanthomatosis has onset in infancy but is often associated with 
diarrhoea, cataracts and tendon xanthomata, and is identifiable because of 
elevated serum cholestanol and urinary bile alcohols. Of the hereditary spastic 
parapareses (HSPs), HSP7 may be one of the most common to be complicated by 
ataxia, although onset is generally in adulthood. HSP 11, 15, 20, 21 and 27 may also 
present with ataxia, although often show distinguishing features (de Bot et al 2012; 
Salinas et al. 2008). In the spinocerebellar ataxias (SCAs), cerebellar ataxia generally 
predominates and inheritance is autosomal dominant. Amongst these, SCA1 and 
SCA3 (Machado-Joseph disease) are the most common which can present with a 
spastic paraparesis, however in both of these conditions, age at onset is in 
adulthood.  
If neuropathy dominates the clinical picture over spasticity and ataxia, Charcot-
Marie-Tooth (CMT) disease may be considered (Synofzik et al. 2013). A number of 
other rare causes of ataxia or spastic paraparesis may need to be considered 
including spastic ataxia types 1 to 5 (SPAX1-5), abetalipoproteinaemia, ataxia with 
vitamin E deficiency (AVED), ataxia with coenzyme Q10 deficiency, Niemann-Pick 
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disease type C, Refsum’s disease and autosomal recessive cerebellar ataxia type 2 
(ARCA2), for which genetic or metabolic tests are available (Anheim et al 2012).  
Once acquired causes of spastic ataxia have been excluded, the combination of age 
at onset, suspected mode of inheritance, associated clinical, neuroimaging, 
neurophysiological and other features should guide genetic testing. In the future, 
next generation (Németh et al. 2013) and whole exome sequencing will allow 
parallel testing of multiple suspected genes, although it will remain vital to interpret 
the results in terms of pre-existing suspicions from careful clinical phenotyping. 
The triad of early-onset ataxia, spasticity and axonal-demyelinating neuropathy, 
together with sporadic or autosomal recessive inheritance, prominent superior 
cerebellar, cervical atrophy and pontine linear hypointensities on MRI and no 
extraneurological features, should provoke the suspicion of ARSACS. These clinical 
features will be explored in a large cohort of patients seen at NHNN in Chapter 5. 
The presence of thickened retinal nerve fibres on OCT may be a sensitive marker of 
ARSACS. This feature will be explored in Chapter 6.  
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Chapter 5 :  Natural History of Autosomal Recessive 
Spastic Ataxia of Charlevoix-Saguenay (ARSACS) 
 
5.1 Introduction 
Chapters 5 and 6 of this thesis are formed from data as part of a natural history study 
of ARSACS in the UK analogous to EFACTS, and a study of the sensitivity and specificity 
of ocular coherence tomography (OCT) in the diagnosis of ARSACS. Chapter 6 also 
includes a description of an Illumina TruSeq Custom Amplicon panel designed to detect 
mutations in a range of genes causing spastic ataxia. 
5.2 Method 
5.2.1 Ethics, Recruitment & Funding 
The project was approved by the London Brent Research Ethics Committee (reference 
12/LO/1291) and subsequently amended. Patients with ARSACS were identified from 
the records of the NHNN and contacted initially using a standard letter enclosing the 
Participant Information Sheet (PIS). Telephone contact was subsequently made if 
necessary. Advertisements were placed in The Ataxian, the newsletter of Ataxia UK, 
and in the electronic newsletter of the Association of British Neurologists (ABN). 
Through the latter method, patients were identified via neurologists in Newcastle and 
Southampton. One patient was referred directly from a collaborator in Switzerland. 
Funding for travel expenses was provided by Ataxia UK. 
5.2.2 Neurological Assessment 
Patients were invited to attend a research clinic at the NHNN. Those who were unable 
or unwilling to attend were offered a home visit. In one case a patient was seen in the 
local District General Hospital. Each patient provided signed informed consent after 
having received the PIS. The clinical assessment lasted approximately 2 hours. Each 
patient provided basic demographic details including country of birth, ethnic origin, 
level of educational achievement, occupational history, marital and family status. A 
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structured history of the disease was elicited including age and nature of first 
symptoms, date of clinical and genetic diagnosis, and significant disability milestones 
such as age of first falls, and intermittent or permanent use of aids to mobility or 
wheelchair. Age at onset was taken as the date at which the patient first experienced 
symptoms adjudged by the examiner to be consistent with ARSACS. Details of 
associated symptoms were recorded such as visual impairment, hearing loss, scoliosis 
and skeletal hand and foot abnormalities. A detailed family history was recorded 
including the relation, age, age at onset and age at death of family members diagnosed 
with or suspected of having ARSACS and other causes of ataxia. A detailed structured 
past medical history was recorded. A detailed history was recorded of present and past 
use of medications, vitamins, supplements, alcohol, smoking and recreational drugs.  
Functional disability was assessed using the 9-field Activities of Daily Living (ADL) 
section of the Friedreich’s Ataxia Rating Scale (FARS) and the Spinocerebellar 
Degeneration Functional Score (SDFS), as described in Chapter 2. The SDFS has been 
used extensively the Spastic ataxia research network SPATAX 
(https://spatax.wordpress.com/the-network-2/) in the assessment of patients with 
spastic ataxia (Pilliod et al. 2015). A detailed structured neurological examination was 
performed and recorded including assessments of muscle atrophy, tone, power, deep 
tendon reflexes, pin-prick, joint position and vibrational sensation. Ataxic signs were 
specifically assessed using the Scale for the Assessment and Rating of Ataxia (SARA) 
and the Spinocerebellar Ataxia Functional Index (SCAFI), as described in Chapter 2. 
Where available, a detailed review was made of the patients’ paper and electronic 
medical records. The results of previous neurophysiological and radiological 
investigations were collated where available, but were not collected prospectively as 
part of this study. 
5.2.3 Genetic Studies 
Genomic DNA from peripheral blood lymphocytes was extracted using standard 
procedures in the Department of Neurogenetics, NHNN. Subsequent SACS gene 
analysis was performed by the diagnostic service in the Department of Human 
Genetics, Radboud University, Nijmegen Medical Centre, Nijmegen, Netherlands, using 
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previously described methods (Vermeer et al. 2008). In a small number of cases, the 
diagnosis was made using the Illumina TruSeq Custom Amplicon technique (Illumina, 
San Diego, CA USA) described more fully in chapter 6. These cases were confirmed in a 
commercial laboratory (Centogene, Rostock, Germany, http://www.centogene.com/). 
The gene variants are annotated according to reference sequences NM_014363.4 
(cDNA) and NP_055178.3 (protein). 
In silico techniques were used to predict the pathogenicity of the novel missense 
variants identified. These are divided into four principal categories: (1) presence in 
variant databases; (2) DNA sequence conservation data; (3) prediction of 
physicochemical properties of amino acid change; and (4) predictions of protein 
stability. Exact sources (websites, etc) of these techniques are given in the footnotes to 
Table 39. 
The presence of a variant at significant frequency in databases of unaffected 
individuals provides evidence of non-pathogenicity. Hence, one would expect a 
proposed pathogenic variant for a rare condition to be absent or appear in extremely 
low frequency in such databases. This frequency is conventionally recorded as the 
frequency of the least common allele, called the minor allele frequency (MAF). Three 
commonly used databases were searched for the presence or absence of the missense 
variants found in the study. The 1000 Genomes Project used the genomes of 1,092 
individuals from 14 populations from Europe, East Asia, Sub-Saharan Africa and the 
Americas, analyzed through a combination of low-coverage whole-genome sequence 
data, targeted deep exome sequence data and dense single nucleotide polymorphism 
(SNP) genotype data, to identify 38 million SNPs, 1.4 million bi-allelic indels and 14,000 
large deletions (The-1000-Genomes-Consortium 2012). The National Heart, Lung and 
Blood Institute Grand Opportunity Exome Sequencing Project (NHLBI GO ESP) 
sequenced the exomes of 15,336 genes from 6,515 individuals of European American 
or African American origin, resulting in a dataset of 1.1 million autosomal protein-
coding variants (Fu et al. 2013). The National Center for Biotechnology Information 
(NCBI) Database of Single Nucleotide Polymorphisms (dbSNP) is a web-based central 
public repository of genetic variation data covering a wide variety of organisms 
submitted by registered individuals and organizations (Sherry et al. 1999). The variants 
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include SNPs, deletion/insertion polymorphisms (DIPs), short tandem repeats (STRs) 
and multiple nucleotide polymorphisms (MNPs). However, because there is no 
assumption about the minimum allele frequency, the data are known to contain both 
pathogenic and non-pathogenic variants (Wallis et al. 2013). 
Pathogenic variants are often found at sites which show evolutionary conservation in 
homologous genes across many species as these sites are considered to encode 
structurally or functionally active regions of the encoded protein. Correspondingly, 
evolutionary variation will be tolerated at sites which encode less important regions of 
the protein, and these are less likely to be sites of pathogenic variation. Various 
algorithms have been developed to compare multiple sequences of homologous genes 
in alignment (multiple sequence alignments, MSA), and generate a score to predict the 
likely pathogenicity or tolerance of the variant in question. The scores vary in the 
number and selection of MSAs used, the extent to which flanking DNA sequences are 
included, the use of different statistical models of evolution, and the degree to which 
they invoke the phylogenetic relationships between the species in question. Some use 
pre-defined annotations to train the model in detecting variation in particular regions 
of the genome, whilst others act in an undirected manner. A variety of statistical 
methods are used to generate the final scores (Pollard et al. 2010).  
Genome Evolutionary Rate Profiling (GERP) measures the degree of evolutionary 
conservation or constraint by comparing the number of substitutions expected at a 
particular site under neutral evolution with those observed in reality over 29 
mammalian species. This results in a ‘rejected substitutions’ score (Cooper et al. 2005). 
Positive scores represent fewer substitutions than would be expected and hence 
evolutionary constraint. Therefore, the greater the positive score, the greater the 
likelihood of pathogenicity. Negative scores suggest that a site is probably naturally 
varying under neutral evolution but cannot be used to deduce accelerated evolution 
for statistical reasons. The maximum genome-wide score of about 5.8 applies to sites 
that are perfectly conserved across all sequenced mammals (Cooper & Shendure 
2011), although values greater than this are possible depending on the statistical 
parameters employed.  
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The Phylogenetic P-Values (PhyloP) program similarly compares the variation in single 
nucleotide sites across different species using MSAs (Siepel et al. 2006). The score 
generated represents the -log10 of the p-value from a null hypothesis test of neutral 
evolution using a statistical technique called the hidden Markov model. Unlike GERP, 
PhyloP can measure both acceleration (faster evolution than expected under neutral 
drift) as well as conservation. Positive values represent conservation, and negative, 
acceleration. As with GERP, the greater the positive score, the greater the likelihood of 
pathogenicity.  
PhyloP measures conservation at the single nucleotide level, ignoring the effects of 
flanking nucleotides. By contrast the Phylogenetic Analysis with Space/Time Models 
Conservations (PhastCons) program uses the same methodology based on a two-state 
phylogenetic hidden Markov model to estimate the probability that each nucleotide 
belongs to a more widely conserved element (Siepel et al. 2005). The resulting score 
represents a probability between 0 and 1, the closer the value to 1, the more likely the 
nucleotide is conserved, and hence if the site of a variant, the more likely to be 
pathogenic. 
The third group of techniques used to assess the predicted pathogenicity of a variant 
involve assessments of the degree of physicochemical change between the amino 
acids in the wild type and mutant proteins. The Grantham score uses differences in 
three properties (composition, polarity and molecular volume) between each of 20 
amino acids weighted so that the result correlates with the relative frequency of 
substitution in commonly found proteins (Grantham 1974, McLachlan 1972). 
Composition is defined as the ratio of the atomic weight of the non-carbon elements 
of the side chain to that of the carbon atoms in the side chain. The resulting score 
varies between 5 and 215 with the larger value representing greater change and 
therefore greater likelihood of pathogenicity. The smallest change is between leucine 
and iso-leucine, and the greatest between tryptophan and cysteine. Grantham scores 
are designated as conservative (0-50), moderately conservative (51-100), moderately 
radical (101- 150) or radical (≥151) according to the classification proposed by Li (Li et 
al. 1984). 
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Sorting Intolerant From Tolerant (SIFT) is a homology-based program which takes into 
account both DNA conservation data and chemical differences in the predicted amino 
acid change (Ng & Henikoff 2001, Ng & Henikoff 2002, Ng & Henikoff 2003). SIFT 
searches for similar DNA sequences, chooses closely related sequences that may have 
similar function, and obtains MSAs for these sequences. SIFT considers the extent of 
conservation and the nature of the amino acid change, so that if all sequences contain 
the same amino acid at a particular position, the program will consider any variance 
from this as deleterious, whereas for example, if multiple different hydrophobic amino 
acids are found, only variances including non-hydrophobic amino acids would be 
considered deleterious. The program calculates normalized probabilities for all 
possible substitutions and predicts those less than 0.05 to be damaging, and those 
greater, to be tolerated. 
The final category of pathogenicity predicting software employed uses DNA sequence 
data as well as predictions about the physical and chemical properties of the final 
protein produced. The Polymorphisms Phenotyping version 2 (PolyPhen2) program 
first selects a set of homologous sequences using a clustering algorithm and then 
constructs and refines the MSA using algorithms which predict features of the tertiary 
structure of the protein (eg coiled coils, transmembrane helices and low-complexity 
regions). The program then uses eight sequence-based methods (such as changes in 
the residue side chain volume and whether the variant happened amongst CpG 
repeats) and three structure-based methods (change in accessible surface area of 
amino acid residue, change in hydrophobic propensity and the crystallographic B-
factor) to predict the functional significance of an amino acid change (Adzhubei et al. 
2010). Two datasets were used to train the program. For Mendelian disorders which 
usually involve a significant change in protein function compared to other forms of 
human variation, use of the HumVar dataset (Capriotti et al. 2006) which treats some 
mildly deleterious variants as non-damaging, was found to be most appropriate. The 
program calculates a probability between 0 and 1 that the variant is damaging, and 
reports the prediction as benign (>20% false positive rate, FPR), possibly damaging (10-
20% FPR) or probably damaging (<10% FPR). 
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Because it is recognized that there are inconsistencies between different pathogenicity 
prediction tools and no one technique should be relied upon, a multifactorial program, 
Mutation Taster (Schwarz et al. 2014), was also used which integrates many of the 
above and other methods into a final prediction. The program contains variant data 
from the 1000 Genomes Project, ClinVar, dbSNP, HGMD Public and HapMap, and tests 
for regulatory features, splice site variants, evolutionary conservation, and alterations 
in protein length and other features. A variety of models are used to integrate the 
above tests according to the nature of the amino acid alteration, with the ‘simple_aae’ 
model used for the missense variants found in this study which is appropriate for 
single amino acid substitutions. A trained Bayes classifier is used to assign a prediction 
of pathogenicity using disease-causing mutations known from OMIM, HGMD and the 
literature. The program reports a prediction of ‘polymorphism’ (ie harmless) or 
‘disease causing’ together with a probability in the range 0 to 1. If the variant is already 
known to be harmless or pathogenic, the term ‘automatic’ is appended. The program 
also evaluates a number of allied tests (eg Grantham score) not directly used in the 
prediction, but which can be quoted as further supportive evidence. 
5.3 Results 
5.3.1 Demographics 
Twenty-six patients were assessed between November 2012 and June 2014. Fifteen 
were seen at NHNN, one at Ipswich Hospital and ten as part of home visits.  The basic 
demographic details of the patients including gender, ethnicity, country of birth, 
marital status, offspring, education and employment are summarized in Table 36, and 
the locations of the UK patients in Figure 63. Basic demographic details of each patient 
individually are given in Table 37. The range of ages at which the patients were 
examined as part of the study is shown in Figure 64 with ages from 21 to 69 years. It 
should be noted that the ethics permission of the project did not permit recruitment of 
patients below the age of 16 and so these necessarily do not appear in this project. The 
duration of disease at examination is shown in Figure 65 with a range from 8 to 56 
years. This is also influenced by the age at which patients could be recruited. 
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Table 36: Basic demographic details of patients in ARSACS natural history study 
  Number (%) 
Gender Male : Female 15 : 11   (57.7 : 42.3) 
Age (years) Mean ± SD 43.4 ± 13.7 
 Median 46 
 Range 21 - 69 
Disease duration Mean ± SD 28.5 ± 12.9 
(years) Median 28.5 
 Range 8 – 56 
Ethnicity White Caucasian 26 (100) 
Country of birth UK 25 (96.2) 
 Switzerland 1 (3.8) 
Marital status Single 13 (50) 
 Married/in relationship 8 (30.8) 
 Divorced/separated/widowed 5 (19.2) 
Offspring Children 13 (50) 
 No children 13 (50) 
Education (ISCED) 1 : Primary school 0 
 2 : ‘O’ level/GCSE 14 (53.8) 
 3 : ‘A’ level 1 (3.8) 
 4 : BTEC/NVQ/HND 9 (34.6) 
 5 : BSc/MSc 1 (3.8) 
 6 : PhD 0 
 Not known 1 (3.8) 
Employment Not in employment 20 (76.9) 
 In employment 5 (19.2) 
      Full time 2 (7.7) 
      Part time 3 (11.5) 
 Not known 1 (3.8) 
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Figure 63: Geographical location of UK patients in ARSACS natural history study 
Red dots represent the location of individual patients 
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Figure 64: Age at examination of patients in ARSACS natural history study 
 
Figure 65: Disease duration at time of examination of patients in 
ARSACS natural history study 
5.3.2 Family Groups 
The patients came from 16 families (A-P). Five families (F, J, L, M & P) contained pairs 
of siblings; one family included 5 siblings (D); one family included a distant cousin as 
well as two siblings (P). Ten families contained only a single affected individual (A, B, C, 
E, G, H, I, K, N & O). The genealogical tables of the 16 families are given in Figure 66. 
Black boxes indicate patients affected with ARSACS (not each of which is in the study). 
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The meaning of other boxes is described in the text below. Patient numbers, family 
codes and genetic tree identifiers are summarized in Table 37. 
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Figure 66: Genealogical tables of families in the ARSACS natural history study.  
Explanations of the coloured boxes are given in the text. 
The clinical features of several of the patients in the study have previously been 
described to a greater or lesser extent. In particular, patient 1 (Nethisinghe et al. 2011) 
and patient 9 (Stevens et al. 2013) have been described in publications from this 
institution. Patients 18-19 (Pyle et al. 2013), 20-21 (Pyle et al. 2012) and 18-22 (Yu-
Wai-Man et al. 2014) were described by Professor Patrick Chinnery’s team at the 
University of Newcastle, and patient 23 was described by Dr Simon Hammans’ team at 
the University of Southampton (Terracciano et al. 2010). 
In family D, patient V-3 (grey box), the grandchild of affected patient III-3, was said to 
have an unexplained, progressive neurological condition from early life which may 
have involved ataxia. Few clinical details were available although he and his mother 
(patient IV-3) supplied a DNA sample with consent (see Section 5.3.3). In family G, only 
patient III-2 was seen as part of the study. He disclosed that he had a first cousin 
(patient III-3) with a very similar early-onset progressive neurological condition causing 
unsteadiness on walking but also mental retardation. The whole family came from the 
same small Swiss village but were originally of Calabrian origin. He is presumed to have 
the same condition clinically, although no DNA was available for genetic confirmation.  
Two siblings were seen from family M but the family also included a number of other 
neurological and genetic conditions. The affected siblings’ paternal grandmother 
246 
 
(patient I-2, blue circle) was diagnosed with muscular dystrophy. Their paternal first 
cousin (patient III-4, green circle) had cystic fibrosis. A further three cousins (patients 
III-1, III-2 & III-3, red boxes) were diagnosed with Huntington’s disease, although this 
was known to be inherited from an unrelated uncle (patient II-1) and from patient 
II-1’s father (not included in table). In family N, patient II-2 was recruited into the 
study. His sister (patient II-3) had died but had progressive difficulty in walking with her 
feet turned in and slurred speech. The onset was said to be before her 30s and 
possibly in childhood. She was diagnosed clinically with ARSACS by her neurologist. She 
died in her 60s. Her son (patient III-5, grey box) also has walking problems with the 
feet turned in and slurred speech with onset in childhood. He had not been diagnosed 
genetically. 
Family O has already been published as an example of pseudo-dominant inheritance of 
ARSACS (Terracciano et al. 2010). Patient III-2 was recruited into the study. He had 
delayed motor milestones and a broad-based unsteady gait and slurred speech by the 
age of 3. He subsequently developed a spastic gait, bilateral pes cavus, limb ataxia, 
nystagmus, brisk patellar reflexes and absent ankle jerks. His mother (patient II-3) who 
had already died, had normal early milestones but was noted to be clumsy at school. 
She suffered further motor deterioration in her teens and was subsequently found to 
have cerebellar dysarthria, jerky pursuit eye movements, brisk arm and knee reflexes, 
absent ankle jerks and bilateral Babinski’s sign. She was reassessed in her 30s following 
an episode of diplopia and relapsing weakness. Visual, auditory, and somatosensory 
evoked potentials showed delayed responses, and CSF examination showed oligoclonal 
bands. MRI brain showed periventricular white matter abnormalities as well as mild 
cerebellar, brainstem, and cervical cord atrophy. Genetic analysis showed she was 
heterozygous for a novel nonsense mutation c.13237C>T (p.Gln4413X) and a 1.5Mb 
deletion of chromosome 13q12.12 removing 6 genes (SCGC, SACS, TNFRSF19, MIPEP, 
SPATA13 & C1QTNF9).  It was concluded that she had multiple sclerosis in addition to 
ARSACS. Her son (patient III-2) had a progressive, non-relapsing condition and MRI 
brain showed pontine tigroid hypointensities and a severely atrophied upper 
cerebellar vermis but no white matter hyperintensities suggestive of demyelinating 
disease. Genetically, he had inherited the macrodeletion from his mother and not the 
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c.13237C>T mutation, but had also inherited a novel nonsense mutation c.2224C>T 
(p.Arg742X) from his father confirming pseudo-dominant inheritance. 
Family P included two siblings who were homozygous for a novel missense variant 
c.623G>T, and a second cousin once removed who was heterozygous for the c.623G>T 
variant and a second novel missense variant c.4723C>T (see Figure 66). The cousins 
were in fact linked genetically via the maternal line of each in two ways, since in 
generation II, two brothers had married two sisters. It is therefore presumed that each 
affected individual inherited the c.623G>T variant from one of four common ancestors 
in generation I (individuals I-1, I-2, I-3 or I-4), and the mothers of each affected 
individual (individuals III-2 and IV-6) are presumed to be carriers of this variant. If this 
is the case, patient IV-2’s father (individual III-1) must have been a carrier of the 
c.4723C>T variant. Furthermore, the father of the two affected siblings (individual IV-
7) must also be a carrier of the c.623G>T variant. There was no known consanguinuity 
on this side of the family, but his father (individual III-6) was known to have come from 
the same small Cornish village, and known to be illegitimate and not to have known 
who his father was. His wife (individual III-7) was said to have been of German 
ancestry. A search of the UK General Register Office Index of Births, Deaths and 
Marriages revealed that no birth certificate was available for individual III-6 in his 
known name at death. His marriage certificate omitted his father’s name and 
occupation but confirmed that his wife and wife’s father had characteristically 
Germanic names with the occupation of his wife’s father recorded as ‘Burgomaster’. 
The family name of individual III-6 is characteristically Cornish. It is therefore presumed 
that the union of individuals IV-6 and IV-7 was consanguineous and that individual III-6 
in some way descended from the same common ancestor of individuals IV-2 and IV-6 
who all carried the c.623G>T private variant. 
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Table 37: Patient numbers, genetic tree identifiers, mutations and basic demographic 
data of ARSACS patients in natural history study 
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1 A III-4 c1144G>T c11352_11353dupAA M 33 0 33 
2 B III-1 c7255_7259delGAGAA c9956_9957delAA M 23 5 18 
3 C II-2 c5820_5821delAC c7162_7163delAC F 33 1 32 
4 D III-9 c8339T>G;c12416T>C c11675C>G F 60 48 12 
5 D III-3 c8339T>G;c12416T>C c11675C>G F 62 51 11 
6 D III-5 c8339T>G;c12416T>C c11675C>G F 61 43 18 
7 D III-13 c8339T>G;c12416T>C c11675C>G M 47 35 12 
8 D III-7 c8339T>G;c12416T>C c11675C>G M 60 46 14 
9 E III-1 c5151dupA c5948C>T; 6392delT M 40 2 38 
10 F III-1 c9404T>C c11265_11266delAT M 45 10 35 
11 F III-2 c9404T>C c11265_11266delAT F 39 13 26 
12 G  III-2 c6078delT c6078delT M 21 2 19 
13 H  III-2 c4226_4229delATGA c9404T>C F 50 32 18 
14 I III-3 c3149C>A c4744G>T F 32 5 27 
15 J II-1 c9404T>C c12028C>T F 46 3 43 
16 J II-2 c9404T>C c12028C>T M 51 5 46 
17 K III-1 c9956_9957delAA c10115dupC M 31 1 30 
18 L II-2 c13048G>T 0.7Mb del 13q12.12 M 47 13 34 
19 L II-1 c13048G>T 0.7Mb del 13q12.13 M 50 1 49 
20 M III-6 c3965_3966delGT c2076delC M 46 19 27 
21 M III-7 c3965_3966delGT c2076delC F 49 3 46 
22 N II-2 c6781C>A c1580G>C M 69 34 35 
23 O III-2 c2224C>T 1.5Mb del 13q12.12 M 24 1 23 
24 P IV-2 c623G>T c4723C>T F 57 1 56 
25 P V-10 c623G>T c623G>T F 31 1 30 
26 P V-12 c623G>T c623G>T M 22 14 8 
 
5.3.3 Genetic Studies 
The 26 patients harboured 30 different variants which are predicted to be pathogenic. 
The genetic variant for each patient is shown in Table 37. The nature of each of the 
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genetic variants is shown in Table 38 including the predicted amino acid change, 
predicted consequence to the protein, mutation type and exon site. The LOVD SACS 
variant ID is given for those variants which have previously been described and 
registered in the SACSIN database of the Leiden Open Variation Database (LOVD) 
(https://grenada.lumc.nl/LOVD2/mendelian_genes/home.php?select_db=SACS). This 
site aims to record all pathogenic variants published in the SACS gene. Patient 9 
harbours 3 variants predicted to be pathogenic (c.5151dupA, c.5948C>T and 
c.6392delT). It was known from a previous study that this patient’s unaffected mother 
carried the c.5948C>T and c.6392delT variants, whilst his unaffected father carried the 
c.5151dupA variant, showing that c.5948C>T and c.6392delT cosegregate (Stevens et 
al. 2013). Of note, the c.6392delT variant is a nonsense mutation resulting in 
frameshift and a premature stop codon after 15 codons, and is therefore obligately 
pathogenic. The five affected siblings in family D (patients 4,5,6,7 & 8) also harbour 3 
variants predicted to be pathogenic (c.8339T>G, c.11675C>G and c.12416T>C). Studies 
on unaffected first degree relatives of these individuals for the OCT study in Chapter 6 
show that c.8339T>G and c.12416T>C cosegregate. Patient V-3 who had an 
unspecified, early-onset, progressive neurological condition, was not found to have 
inherited any pathogenic variants. His mother was found to carry the c.11675C>G 
variant but not the c.8339T>G and c.12416T>C variants. His neurological condition 
therefore remains unexplained. 
The variants seen in this study included two macrodeletions, ten microdeletions, 
fifteen nucleotide substitutions and three duplications. These gave rise to twenty-one 
nonsense changes including the direct insertion of a stop codon in six cases, and 
frameshift changes leading to the premature insertion of a stop codon in a further 
thirteen cases. There were nine missense changes involving substitution of a different 
amino acid.  
Four of the variants occur in exon 8; all the remainder are in the giant exon 10 where 
most other published mutations have been found. Sixteen of the variants have 
previously been published as causing ARSACS. The remainder do not appear as known 
variants in the LOVD SACSIN database, or the University of California Santa Cruz (UCSC) 
Genome Browser (http://genome.ucsc.edu/cgi-bin/hgTracks?db=hg19&position= 
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chr13%3A23902915-24007891&hgsid=446324527_b6GeP7MXW8byWKW8v 
ECMoV2TmRhR), or in the Online Mendelian Inheritance in Man (OMIM) database 
(http://www.omim.org/entry/604490) or in the Human Gene Mutation Database 
(http://www.hgmd.cf.ac.uk/ac/index.php). Five variants are described in the PhD 
thesis of Dr Sacha Vermeer of the University of Radboud, Nijmegen, Netherlands 
(Vermeer 2012) which have not been published in peer-reviewed journals. These 
include four nonsense mutations and one missense variant (c.9404T>C). Nine further 
variants have never previously been described. These include four nonsense mutations 
and five missense variants (c.623G>T, c.3149C>A, c.4723C>T, c.8339T>G and 
c.12416T>C). Of note, Baets et al have described a symptomatic missense mutation in 
the neighbouring nucleotide to the c.4723C>T variant which results in a different 
amino acid sequence change in the same codon (c.4724G>C/p.Arg1575Pro), 
supporting the notion that the novel mutation is pathogenic (Baets et al. 2010). 
The nonsense mutations are considered obligately pathogenic because they involve 
the premature insertion of a stop codon. Taking the fourteen variants from the 
Vermeer thesis and the novel variants together, in two cases these occurred by direct 
substitution of an amino acid residue for a stop codon and in six cases by a frameshift 
mutation (five deletions and one duplication) which resulted in premature insertion of 
a stop codon between four and fifty-seven codons later in the DNA sequence. The 
remaining six (missense) variants involved substitution of one amino acid for another.  
Various in silico techniques were employed in order to predict pathogenicity in the six 
novel missense variants, described in 5.2.3. The results are summarised in Table 39. All 
the variants were absent from the 1000 Genomes and dbSNP databases except 
c.8339T>G which was present with minor allele frequencies (MAF) of 0.0009 and 
0.0008 respectively. Both this variant and the c.9404T>C variant were present in the 
ESP database with MAFs of 0.0035 and 0.00008 respectively. The GERP scores for all 
the variants were positive, indicating conservation, with four of the values greater than 
5, indicating very strong conservation. The lowest was for the c.623G>T variant with a 
value of 1.27. The lowest PhastCons score was 0.964, with four of the values 1.000, 
indicating very strong conservation. All the PhyloP scores were positive, indicating 
conservation, five of which were greater than 4, and two of which were greater than 6, 
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indicating very strong conservation. The lowest value was for the c.4723C>T variant 
with a value of 1.072. Multiple sequence alignments for homologous genes from 
vertebrate species are shown in Table 40.  
All the Grantham scores were greater than 100 corresponding with a moderately 
radical change in amino acid properties; the value for the c.8339T>G variant in which a 
phenylalanine residue is changed to a cysteine residue, was 205 representing a radical 
change in amino acid properties. Four of the SIFT scores were less than 0.05 resulting 
in a prediction of pathogenicity. The c.8339T>G variant had a SIFT score just above this 
threshold resulting in a prediction of non-pathogenicity. The c.12416T>C variant had a 
SIFT value of 0.38 placing it clearly in the tolerated category. Four of the variants were 
predicted by the PolyPhen2 program to be probably damaging with scores of 0.941 or 
more. The c.3149C>A variant had a PolyPhen2 score of 0.184 which the program 
predicts to be benign. The Mutation Tasting program which integrates a panoply of 
different tests representing the above categories, predicts all the variants to be 
disease-causing, with all the probabilities greater than 0.9366; three of the variants 
had probabilities of 0.9999 indicating extreme confidence in the prediction. 
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Table 38: SACS gene variants seen in ARSACS patients in natural history study 
Varianta Predicted amino 
acid changeb 
Mutation type Predicted 
consequence 
Exon Patient(s) Reference LOVD ID 
0.7Mb del 13q12.12 - Macrodeletion - - 18,19 (Pyle et al. 2013) SACS00048 
1.5Mb del 13q12.12 - Macrodeletion - - 23 (Terracciano et al. 2010) SACS00048 
c.1144G>T p.Glu401X Nonsense 
substitution 
Premature stop 
codon 
8 1 (Vermeer 2012, 
Nethisinghe et al. 2011) 
- 
c.1580C>G p.Ser527X Nonsense 
substitution 
Premature stop 
codon 
8 22 (Yu-Wai-Man et al. 
2014) 
SACS00188 
c.2076delC p.Thr692Thr fs*22 Nonsense 
deletion 
Premature stop 
codon 
8 20,21 (Pyle et al. 2012, Yu-
Wai-Man et al. 2014) 
SACS00184 
c.2224C>T P.Arg742X Nonsense 
substitution 
Premature stop 
codon 
10 23 (Terracciano et al. 2010) SACS00061 
c.3965_3966delGT p.Gly1322Val fs*23 Nonsense 
deletion 
Premature stop 
codon 
10 20,21 (Pyle et al. 2012, Yu-
Wai-Man et al. 2014) 
SACS00185 
c.4744G>T p.Asp1582Asn Missense 
substitution 
Amino acid 
substitution 
10 14 (Thiffault et al. 2013) SACS00089 
c.5151dupA p.Ser1718Ile fs*20 Nonsense 
insertion 
Premature stop 
codon 
10 9 (Stevens et al. 2013) SACS00127 
c.5948C>T c p.Ser1983Phe Missense 
subsitution 
Amino acid 
substitution 
10 9 (Stevens et al. 2013) SACS00129 
c.6392delT c p.Phe2131Ser fs*15 Nonsense 
deletion 
Premature stop 
codon 
10 9 (Stevens et al. 2013) SACS00128 
c.6781C>A p.Leu2261Ile Missense 
substitution 
Amino acid 
substitution 
10 22 (Yu-Wai-Man et al. 
2014) 
SACS00189 
c.7255_7259delGAGAA p.Glu2419Phe fs*10 Nonsense 
deletion 
Premature stop 
codon 
10 2 (Prodi et al. 2013) SACS00135 
c.11265_11266delAT p.Ile3755Met fs*9 Nonsense 
deletion 
Premature stop 
codon 
10 10,11 (Baets et al. 2010) SACS00074 
c.11352_11353dupAA p.Arg3785Lys fs*16 Nonsense 
insertion 
Premature stop 
codon 
10 1 (Vermeer 2012, 
Nethisinghe et al. 2011) 
- 
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c.13048G>T p.Glu4350X Nonsense 
substitution 
Premature stop 
codon 
10 18,19 (Pyle et al. 2013, Yu-
Wai-Man et al. 2014) 
SACS00120 
c.5820_5821delAC p.Thr1941Leu fs*10 Nonsense 
deletion 
Premature stop 
codon 
10 3 (Vermeer 2012) - 
c.7162_7163delAC p.Thr2388Arg fs*11 Nonsense 
deletion 
Premature stop 
codon 
10 3 (Vermeer 2012) - 
c.9404T>C p.Leu3153Ser Missense 
substitution 
Amino acid 
substitution 
10 10,11,13,15
,16 
(Vermeer 2012) - 
c.9956_9957delAA p.Lys3319Ser fs*57 Nonsense 
deletion 
Premature stop 
codon 
10 2,17 (Vermeer 2012) - 
c.11675C>G p.Ser3892X Nonsense 
substitution 
Premature stop 
codon 
10 4,5,6,7,8 (Vermeer 2012) - 
c.623G>T p.Ser208Ile Missense 
substitution 
Amino acid 
substitution 
8 24,25,26 Novel - 
c.3149C>A p.Ala1050Asp Missense 
substitution 
Amino acid 
substitution 
10 14 Novel - 
c.4226_4229delATGA p.Asn1409Thr fs*19 Nonsense 
deletion 
Premature stop 
codon 
10 13 Novel - 
c.4723C>T p.Arg1575Trp Missense 
substitution 
Amino acid 
substitution 
10 24 Novel - 
c.6078delT p.Ala2026Ala fs*8 Nonsense 
deletion 
Premature stop 
codon 
10 12 Novel - 
c.8339T>G d p.Phe2780Cys Missense 
substitution 
Amino acid 
substitution 
10 4,5,6,7,8 Novel - 
c.10115dupC p.Ser3372Ser fs*4 Nonsense 
duplication 
Premature stop 
codon 
10 17 Novel - 
c.12028C>T p.Gln4010X Nonsense 
substitution 
Premature stop 
codon 
10 15,16 Novel - 
c.12416T>C d p.Leu4139Ser Missense 
substitution 
Amino acid 
substitution 
10 4,5,6,7,8 Novel - 
a NM_014363.4      b NP_055178.3       c These variants cosegregate in family E          d These variants cosegregate in family D 
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Table 39: In silico pathogenicity predictions for SACS gene missense variants in ARSACS natural history study 
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 l 
c.623G>T p.Ser208Ile 13:23932576 No No No 1.27 1.000 6.311 142 Moder
ately 
radical 
0.00 Damaging 0.998 Probably 
damaging 
Disease 
causing 
0.9999 
c.3149C>A p.Ala1050Asp 13:23914866 No No No 5.96 1.000 6.315 126 Moder
ately 
radical 
0.01 Damaging 0.184 Benign Disease 
causing 
0.9999 
c.4723C>T p.Arg1575Trp 13:23913292 No No No 4.44 1.000 1.072 101 Moder
ately 
radical 
0.01 Damaging 0.946 Probably 
damaging 
Disease 
causing 
0.9973 
c.8339T>G 
 
p.Phe2780Cys 13:23909676 0.0009 
(2)
m 
0.0035 
(46)
m 
0.0008
m 
5.32 1.000 4.684 205 Radical 0.07 Tolerated 0.947 Probably 
damaging 
Disease 
causing 
0.9999 
c.9404T>C p.Leu3153Ser 13:23908611 No 0.00008 
(1)
m 
No 5.75 0.964 4.793 145 Moder
ately 
radical 
0.00 Damaging 0.997 Probably 
damaging 
Disease 
causing 
0.9366 
c.12416T>C 
 
p.Leu4139Ser 13:23905599 No No No 5.30 0.998 4.946 145 Moder
ately 
radical 
0.38 Tolerated 0.941 Probably 
damaging 
Disease 
causing 
0.9986 
a
 UCSC Genome Browser, https://genome-euro.ucsc.edu/cgi-bin/hgGateway?redirect=manual&source=genome.ucsc.edu 
b
 1000 Genomes Project (phase 1, version 3), https://secure.ngrl.org.uk/1kg_querytool/   (accessed via the National Genetics Reference Laboratory (NGRL), Manchester, 
UK, http://www.ngrl.org.uk/Manchester/page/1000-genomes-dataset).  
c
 Exome Sequencing Project (ESP), National Heart, Lung and Blood Institute (NHLBI) Seattle, USA, http://evs.gs.washington.edu/EVS/             
d
 Database of Single Nucleotide polymorphisms (dbSNP), National Center for Biotechnology Information (NCBI), http://www.ncbi.nlm.nih.gov/projects/SNP/      
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e
 Genome Evolutionary Rate Profiling (GERP), http://mendel.stanford.edu/SidowLab/downloads/gerp/index.html  (calculated using UCSC Genome Browser, 
http://genome.ucsc.edu/cgi-bin/hgTracks?db=hg19&position=chr13%3A23902915-24007891&hgsid=447609615_9t6hmVTUgKfvup5vkmGmQx4vcqqP) 
f
 Phylogenetic Analysis with Space/Time models Conservation Program (PhastCons) (calculated using Mutation Taster,  http://www.mutationtaster.org/ which uses values 
precomputed by the UCSC Genome Browser
a
 comparing MSAs from a phylogeny of 46 vertebrate species) 
g
 Phylogenetic p-values (PhyloP) (calculated using Mutation Taster,  http://www.mutationtaster.org/ which uses values precomputed by the UCSC Genome Browser
a
 
comparing MSAs from a phylogeny of 46 vertebrate species) 
h
 Granthan R. (1974) Amino Acid Difference Formula to Help Explain Protein Evolution. Science.  185, 862-864. 
i
 Li W.H., Wu C.I., and Luo C.C. (1984) Non-randomness of Point Mutation as Reflected in Nucleotide Substitutions in Pseudogenes and its Evolutionary Implications. J. Mol. 
Evol. 21, 58–71. 
j
 Sorting Intolerant From Tolerant (SIFT) algorithm, accessed via http://sift.jcvi.org/ 
k
 Polymorphisms Phenotyping version 2 (PolyPhen2), accessed via http://genetics.bwh.harvard.edu/pph2/ 
l
 Mutation Taster 2, accessed via http://www.mutationtaster.org/ using simple_aae model for substitution of a single amino acid 
m
 These values are quoted as minor allele frequency MAF (absolute count) 
 
 
1000 Genomes Project: The 1000 Genomes Project Consortium (2012) An integrated Map of Genetic Variation from 1,092 Human Genomes. Nat. 491, 56-65. 
ESP: Fu W., O’Connor T.D., Jun G., Kang H.M., Abecasis G., Leal S.M., et al. (2013) Analysis of 6,515 Exomes Reveals the Recent Origin of Most Human Protein-Coding 
Variants. Nat. 493, 216-220. 
dbSNP: Sherry S.T. Ward M., and Sirotkin K. (1999) dbSNP—Database for Single Nucleotide Polymorphisms and Other Classes of Minor Genetic Variation. Genome Res. 9, 
677-679. 
GERP:  Cooper G.M., Stone E.A., Asimenos G., NISC Comparative Sequencing Program, Green E.D., Batzoglou S., Sidow A. (2005) Distribution and Intensity of Constraint in 
Mammalian Genomic  Sequence. Genome Res. 15, 901-913.     
PhastCons:  Siepel A., Bejerano G., Pedersen J.S., Hinrichs A.S., Hou M., Rosenbloom K., Clawson H., et al. (2005) Evolutionarily conserved elements in vertebrate, insect, 
worm, and yeast genomes. Genome Res. 15, 1034-1050. 
PhyloP: Siepel A., Pollard K.S. & Haussler D. (2006) New Methods for Detecting Lineage-Specific Selection. In: Research in Computational Molecular Biology. 3909, 190-205. 
Grantham Score: Granthan R. (1974) Amino Acid Difference Formula to Help Explain Protein Evolution. Science.  185, 862-864. 
SIFT: Ng P.C., and Henikoff S. (2003) SIFT - Predicting Amino Acid Changes that Affect Protein Function. Nuc. Ac. Res. 31(13), 3812-3814. 
PolyPhen2: Adzhubei I.A., Schmidt S., Peshkin L., Ramensky V.E., Gerasimova A., Bork P., Kondrashov A.S., Sunyaev S.R. (2010) A Method and Server for Predicting 
Damaging Missense Mutations. Nat. Methods 7(4), 248-249.      
Mutation Taster: Schwarz J.M., Cooper D.N., Schuelke M., Seelow  D. (2014) MutationTaster2: mutation prediction for the deep-sequencing age. Nat. Methods.11(4), 361-
362. 
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Table 40: Multiple sequence alignments generated by the Mutation Taster program 
Species: Homo sapiens – Human; Pan troglodytes – Common chimpanzee; Macaca mulatta –  Rhesus macaque; 
Felis catus – Domestic cat; Mus musculus – House mouse; Gallus gallus – Chicken; Takifugu rubripes – Japanese pufferfish; 
Danio rerio - Zebrafish 
 
c.623G>T 
Species Match Gene aa Alignment 
Human wt   77714 T T G T A T C T T T A G T G G T G A C C A A A T 
Human mutated not conserved  77714 t t g t a t c t t t a t t g g t g a c c a a a 
 
P troglodytes all identical ENSPTRG00000005703 21156 t t g t a t c t t t a g t g g t g a c c a a a 
 
M mulatta all identical ENSMMUG00000001292 23295 t t g t a t c t t t a g t g g t g a c c a g a 
 
F catus all identical ENSFCAG00000012121 14091 c t g t a t c t t t a g t g g t g a c c a g a 
 
M musculus all identical ENSMUSG00000048279 54660 t t g t a t c t t t a g t g g t g a c c a g a 
 
G gallus all identical ENSGALG00000017120 14530 t a g t a t t t t c a g t g g t g a c c a a a 
 
T rubripes no alignment ENSTRUG00000000662 
                         
 
 
c.3149C>A 
Species Match Gene aa Alignment 
Human wt   92976 G A T G G T A T C A G C T G G T G A A C T C T T 
Human mutated not conserved  92976 g a t g g t a t c a g a t g g t g a a c t c t 
 
P troglodytes all identical ENSPTRG00000005703 36391 g a t g g t a t c a g c t g g t g a a c t c t 
 
M mulatta all identical ENSMMUG00000001292 38818 g a t g g t a t c a g c t g g c g a a c t c t 
 
F catus all identical ENSFCAG00000012121 25231 g a t g g t g t c a g c c g g c g a a c t c t 
 
M musculus all identical ENSMUSG00000048279 67205  g t g g t a g c a g c t g g t g a t c t c t 
 
G gallus no alignment ENSGALG00000017120 
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c.4723C>T 
Species Match Gene aa Alignment 
Human wt   94550 T C A T T A T G A G T C G G G A A T T C A T G A 
Human mutated not conserved  94550 t c a t t a t g a g t t g g g a a t t c a t g 
 
P troglodytes all identical ENSPTRG00000005703 37965 t c a t t a t g a g t c g g g a a t t c a t g 
 
M mulatta all identical ENSMMUG00000001292 40392 t c a t t a t g a g t c g g g a a t t c a t g 
 
F catus all identical ENSFCAG00000012121 28061 t c a t t a t g a g t c g a g a a t t c a t g 
 
M musculus not conserved ENSMUSG00000048279 68779 t c a t t a t g a g c a g a g a a t t t a t g 
 
G gallus all identical ENSGALG00000017120 24338   a t t t t g a g c c g g g a a t t c a t g 
 
T rubripes not conserved ENSTRUG00000000662 10641 t c a t a a t g a g c a g a g a g t t c a t g 
 
D rerio no alignment ENSDARG00000091042 
                         
 
 
c.8339T>G 
Species Match Gene aa Alignment 
Human wt   98166 A A G G A A A C A A T T T C A T G C A T C T G T 
Human mutated not conserved  98166 a a g g a a a c a a t g t c a t g c a t c t g 
 
P troglodytes all identical ENSPTRG00000005703 41581 a a g g a a a c a a t t t c a t g c a t c t g 
 
M mulatta all identical ENSMMUG00000001292 44008 a a g g a a a c a g t t t c a t g c a t c t g 
 
F catus all identical ENSFCAG00000012121 31702      a a c a g t t t c a c g c a t c t g 
 
M musculus all identical ENSMUSG00000048279 72395 a a g g a a g c a a t t c c a c g c c t c t g 
 
G gallus all identical ENSGALG00000017120 27960        c a a t t c c a t g c a t c t g 
 
T rubripes no alignment ENSTRUG00000000662 n/a 
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c.9404T>C 
Species Match Gene aa Alignment 
Human wt   99231 T T T A A A A C T T T T A G T T G A T T A T T G 
Human mutated not conserved  99231 t t t a a a a c t t t c a g t t g a t t a t t 
 
P troglodytes all identical ENSPTRG00000005703 42646 t t t a a a a c t t t t a g t t g a t t a t t 
 
M mulatta all identical ENSMMUG00000001292 45463 t t t a a a a c t t t t a g t t g a t t a t t 
 
F catus no alignment ENSFCAG00000012121 n/a  
                       
M musculus all identical ENSMUSG00000048279 73460 t t t a a a a c t t t t a g t t g a t t a c t 
 
G gallus all identical ENSGALG00000017120 29025 c c t c a a a c t t c t g g t t g a c t a t t 
 
T rubripes no alignment ENSTRUG00000000662 
                         
 
 
c.12416T>C 
Species Match Gene aa Alignment 
Human wt   102243 A C T T G A C A G T T T A G G A G T G A A A T A 
Human mutated not conserved  102243 a c t t g a c a g t t c a g g a g t g a a a t 
 
P troglodytes all identical ENSPTRG00000005703 45658 a c t t g a c a g t t t a g g a g t g a a a t 
 
M mulatta all identical ENSMMUG00000001292 48475 a c t t g a c a g t t t g g g a g t g a a a t 
 
F catus no alignment ENSFCAG00000012121 n/a  
                       
M musculus all identical ENSMUSG00000048279 76472 g c t t g a c a g t t t a g g g g t g a a a t 
 
G gallus all identical ENSGALG00000017120 32037 g c t t g a c a g t t t a g g g g t a a a g t 
 
T rubripes all identical ENSTRUG00000000662 18331 g t t g g a c a a c c t c g g g g t t a a a t 
 
D rerio all identical ENSDARG00000091042 
                         
 
259 
 
5.3.4 Onset & Progression 
The mean age at onset amongst the 26 patients in this natural history study was 15.0 
years with a range from 0 to 51 years. Twenty-three patients (88.5%) used an aid to 
walking at least intermittently, from a mean age of 33.2 years. Twenty-two patients 
(84.6%) used an aid to walking permanently, from a mean age of 39.8 years. Only five 
patients in the study (19.2%) were permanently wheelchair-bound, which occurred at 
a mean age of 43.4 years. Further details of these significant milestones in disease 
progression are given in Table 41. 
Table 41: Significant milestones in ARSACS disease progression   
  Age (years) 
Age at onset  Mean ± SD 15.0 ± 17.4 
(n=26) Median 5.0 
 Range 0 – 51 
Age at intermittent support for walking Mean ± SD 33.2 ± 16.3 
(n=23) Median 28.0 
 Range 1 – 61 
Age at permanent support for walking Mean ± SD 39.8 ± 12.0 
(n=22) Median 39.0 
 Range 20 – 61 
Age at wheelchair-bound Mean ± SD 43.4 ± 16.8 
(n=5) Median 43.0 
 Range 20 - 67 
 
The range of ages at onset is depicted in Figure 67 showing a clear tendency to onset in 
the first 5 years of life as had been seen in the original Québecois cases, but with onset 
up to 51 years of age, which was not described in those original cases but has been 
seen in cases from other parts of the world. Figure 68 shows the symptoms at onset of 
patients in the study which are dominated by gait instability and falls. 
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Figure 67: Age at onset of patients in ARSACS natural history study 
 
Figure 68: Symptoms at onset in ARSACS patients 
The level of disability at examination was classified according to the Spinocerebellar 
Degeneration Functional Scale (SDFS) as described in Chapter 2 which is based on 
mobility. The absolute values and descriptions of stages are given in Table 42, and the 
proportions depicted in Figure 69. Twenty-four of the 26 patients (92.3%) complained 
of falls. The mean age at onset of falls was 16.6 ± 19.3 years (median 5 yrs; range 1-60).  
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Table 42: Spinocerebellar Degeneration Functional Score for ARSACS patients 
SDFS Number (%) 
1: No functional handicap but signs at examination 0 (0) 
2: Mild, able to run, walking unlimited 2 (7.7) 
3: Moderate, unable to run, limited walking without aid 4 (15.4) 
4: Severe, walking with one stick 6 (23.1) 
5: Walking with two sticks 9 (34.6) 
6: Unable to walk, requiring wheelchair 5 (19.2) 
7: Confined to bed 0 (0) 
 
 
Figure 69: Spinocerebellar Degeneration Functional Score for ARSACS patients 
5.3.5 Associated Clinical Features 
Nineteen patients (73.1%) complained of visual problems. This included 14 patients 
(53.8%) which myopia, hypermetropia or astigmatism corrected by spectacles and 
three (11.5%) with astigmatism. Patient 12 had visual loss attributable to keratoconus. 
Patient 20 had diplopia corrected by prism spectacles, although no ophthalmoparesis 
was found on formal examination. Patient 22 had prolonged loss of vision in earlier life 
as a result of involvement in a gas explosion but had subsequently regained vision. 
Only two patients (7.7%) complained of oscillopsia directly attributable to ARSACS. 
Eight patients (30.8%) complained of hearing problems. Two used a hearing aid, in 
both cases with minimal benefit. Three patients (11.5%) complained of hearing 
problems in noisy environments. 
Five patients (19.2%) complained of headaches or migraines. One patient (3.8%) had 
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undergone ulnar nerve transposition. Significantly, five patients (19.2%) reported a 
diagnosis of epilepsy. In one case (patient 25) this was described as ‘petit mal’ epilepsy 
in a patient who was found to have a brain cyst on imaging. In one case the epilepsy 
was described as myoclonic epilepsy (patient 9). Two cases (patients 6 & 8) were 
siblings in family D who shared the same SACS gene mutations. 
Twenty-four of the patients (92.3%) had skeletal foot abnormalities. This included 23 
(88.5%) with pes cavus, 9 (34.6%) with talipes equinus, 1 (3.8%) with pes planus, 9 
(34.6%) with claw toes, and 2 (7.7%) with hammer toes. One patient (3.8%) had spinal 
scoliosis. 
Urological problems such as urinary frequency, incontinence or retention were 
relatively common affecting 7 patients (26.9%). Five of these were using 
antimuscarinic medications (tolterodine, trospium chloride, solifenacin & oxybutynin). 
One was prescribed prophylactic antibiotics (nitrofurantoin). Bowel problems such as 
chronic constipation were much less common than urological problems, affecting just 
one patient.  
Table 43 details the general medical features seen in the 26 patients with ARSACS. 
Both patients with diabetes mellitus had type 2 disease. Three patients (patients 5, 9 & 
10) had hypertension: all three were aged over 40. Three patients (patients 2, 6 & 10) 
had hypercholesterolaemia: one of these patients was aged 23, but the others were 
aged 45 and 61. One patient (patient 10) had all three conditions suggesting an 
underlying metabolic syndrome. Four patients complained of depression (patients 1, 
13, 20 & 23): their ages varied from 24 to 50 but all had disease duration of at least 18 
years and two had had essentially lifelong disease. Three patients (patients 11, 14 & 
17) had no concomitant medical problems: all were aged in their 30s when seen (mean 
34.0, range 31-39). 
Patients were taking a wide variety of medications. These included spasticity-related 
medications in four cases, namely baclofen (patient 4), tizanidine (patient 10), quinine 
sulphate (patient 16) and gabapentin (patient 21). Two patients took co-enzyme Q10 
supplements (patients 20 & 21). 
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Table 43: General medical features seen in ARSACS patients 
System Diagnosis Number (%) 
Metabolic Diabetes mellitus 2 (7.7) 
 Hypothyroidism 2 (7.7) 
 Hypercholesterolaemia 3 (11.5) 
 Androgen insensitivity 1 (3.8) 
Cardiovascular Hypertension 3 (11.5) 
 Supraventricular tachycardia 1 (3.8) 
 Viral pericarditis 1 (3.8) 
Respiratory Asthma 3 (11.5) 
 Obstructive sleep apnoea 2 (7.7) 
Gastrointestinal Gastritis/acid reflux 2 (7.7) 
 Chronic constipation 1 (3.8) 
 Coeliac disease 1 (3.8) 
 Abdominal hernia 1 (3.8) 
 Appendicectomy 1 (3.8) 
Urological Urinary frequency/incontinence/retention 7 (26.9) 
 Nephrolithiasis 2 (7.7) 
Gynaecological Uterine fibroids 1 (3.8) 
 Hysterectomy (menorrhagia) 1 (3.8) 
Ophthalmological Myopia/hypermetropia/astigmatism 14 (53.8) 
 Amblyopia 3 (11.5) 
 Keratoconus 1 (3.8) 
 Loss of vision after explosion 1 (3.8) 
 Blepharitis 1 (3.8) 
Otorhinolaryngological Tonsillectomy/adenoidectomy 2 (7.7) 
Rheumatological Osteoarthritis 2 (7.7) 
 Osteoporosis 2 (7.7) 
Orthopaedic Ingrowing toenail 1 (3.8) 
 Meniscectomy 1 (3.8) 
Dermatological Psoriasis 1 (3.8) 
 Malignant naevus 1 (3.8) 
Psychiatric Depression 4 (15.4) 
Neurological Headaches/migraine 5 (19.2) 
 Epilepsy 5 (19.2) 
 Brain cyst 1 (3.8) 
 Ulnar nerve transposition 1 (3.8) 
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5.3.6 Activities of Daily Living (ADL) 
All 26 patients in the study completed the ADL questionnaire from the Friedreich’s 
Ataxia Rating Scale (FARS). Table 44 shows these results by subscores of the ADL 
questionnaire. Higher scores represent greater disability. These are depicted 
graphically in Figure 70. The mean ADL was 15.9±7.7 out of possible total score of 36. 
The walking and falls subscores were most affected, and the sitting, swallowing and 
use of cutlery subscores, least. 
Table 44: Subscores of the ADL section of the FRDA Rating Scale for ARSACS patients 
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0 5 12 9 4 7 4 0 12 11 64 
1 10 7 13 15 10 7 3 11 6 82 
2 10 6 4 4 8 3 2 2 3 42 
3 1 1 0 2 1 7 16 1 5 34 
4 0 0 0 1 0 5 5 0 1 12 
Mean 1.3 0.8 0.8 1.3 1.1 2.1 2.9 0.7 1.2 15.9 
SD 0.8 0.9 0.7 1.0 0.9 1.4 0.9 0.8 1.3 7.7 
Mode 1,2 0 1 1 1 1,3 3 0 0 1 
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Figure 70: Subscores of the Activities of Daily Living section of the FRDA Rating Scale 
for ARSACS patients 
5.3.7 Scale for the Assessment and Rating of Ataxia (SARA) 
The SARA was completed on all 26 ARSACS patients in the natural history study. The 
results of the subscores are shown in Table 45 and illustrated graphically in Figure 71. 
The mean SARA score was 16.0±7.7 out of a possible total of 40 points. Higher scores 
represent more prominent ataxia. The gait and stance subscores were most affected, 
with the speech, finger chase, nose-finger and fast alternating hand movements 
subscores, least affected.  
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Table 45: Subscores of the SARA for ARSACS patients 
Score Gait Stance Sitting Speech 
Finger 
Chase 
Nose-
Finger 
Test 
Fast 
Alternating 
Hand 
Movements 
Heel-
Shin Test 
0 0 0 12 12 4 3 5 5 
0.5 - - - - 4 4 5 2 
1 2 2 6 9 18 15 13 7 
1.5 - - - - 0 2 0 1 
2 3 6 1 3 0 2 0 2 
2.5 - - - - 0 0 0 0 
3 2 1 3 2 0 0 3 1 
3.5 - - - - 0 0 0 0 
4 2 3 4 0 0 0 0 8 
5 3 4 - 0 - - - - 
6 6 0 - 0 - - - - 
7 2 - - - - - - - 
8 6 - - - - - - - 
Mean 5.2 4.2 1.3 0.8 0.8 0.9 0.9 1.9 
SD 2.3 1.9 1.5 0.9 0.4 0.5 0.9 1.6 
Mode 6,8 2 0 0 1 1 1 4 
 
 
Figure 71: Subscores of the SARA for ARSACS patients 
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5.3.8 Inventory of Non-Ataxic Symptoms (INAS) 
The INAS was assessed for all 26 ARSACS patients in the study. The mean INAS count 
was 5.7 ± 1.9. Higher scores represent greater disease involvement. The number of 
patients having each of the INAS count values is shown in Table 46 and shown 
graphically in Figure 72. 
 
Figure 72: INAS count values for ARSACS patients 
The commonest non-ataxic symptom is spasticity, followed by sensory loss, Babinski’s 
sign, weakness and areflexia. Fasciculations, myoclonus, rigidity, dyskinesia, dystonia 
and resting tremor were not seen, and cognitive dysfunction and brainstem 
oculomotor signs were only seen in a very low proportion of patients. Table 47 records 
the base data of non-ataxic signs and symptoms found in the ARSACS patients in the 
study. Weakness, spasticity & sensory loss are depicted in Figure 73; symptoms 
reported by patients (diplopia, dysphagia, episodic vertigo, speech problems, problems 
with handwriting and muscle cramps) are depicted in Figure 74; the pattern of reflexes 
found at examination as part of the INAS are depicted in Figure 75; ophthalmological 
features are depicted in Figure 76. 
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Table 46: INAS count values for ARSACS patients 
 No. of 
patients (%) 
Hyperreflexia 12 (46.2) 
Areflexia 19 (73.1) 
Extensor plantar 22 (84.6) 
Spasticity 23 (88.5) 
Paresis 20 (76.9) 
Muscle atrophy 11 (42.3) 
Fasciculations 0 (0) 
Myoclonus 0 (0) 
Rigidity 0 (0) 
Chorea/dyskinesia 0 (0) 
Dystonia 0 (0) 
Resting tremor 0 (0) 
Sensory symptoms 22 (84.6) 
Urinary dysfunction 13 (50.0) 
Cognitive dysfunction 3 (11.5) 
Brainstem oculomotor signs 4 (15.4) 
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Table 47: Non-ataxic features from the INAS for ARSACS patients [Number (%)] 
  None Mild Moderate Severe 
Weakness UL proximal 24 (92.3) 0 (0) 2 (7.7) 0 (0) 
 UL distal 14 (53.8) 9 (34.6) 1 (3.8) 2 (7.7) 
 LL proximal 10 (38.5) 8 (30.8) 3 (11.5) 3 (11.5) 
 LL distal 7 (26.9) 9 (34.6) 5 (19.2) 5 (19.2) 
Spasticity UL 10 (38.5) 15 (57.7) 0 (0) 1 (3.8) 
 LL 6 (23.1) 7 (26.9) 8 (30.8) 5 (19.2) 
Impaired vibration LL distal 5 (19.2) 1 (7.7) 5 (19.2) 15 (53.6) 
 
 None Mild Moderate Severe 
Diplopia 19 (73.1) 5 (19.2) 1 (3.8) 1 (3.8) 
Dysphagia 12 (46.2) 9 (34.6) 3 (11.5) 2 (7.7) 
Episodic vertigo 16 (61.5) 3 (11.5) 2 (7.7) 5 (19.2) 
Speech problems 8 (30.8) 13 (50.0) 4 (15.4) 1 (3.8) 
Handwriting problems 2 (7.7) 9 (34.6) 11 (42.3) 4 (15.4) 
Muscle cramps 3 (11.5) 6 (23.1) 5 (19.2) 12 (46.2) 
 
 Normal Hyperreflexic Areflexic 
Biceps reflex 14 (53.8) 1 (3.8) 11 (42.3) 
Patellar reflex 7 (26.9) 12 (46.2) 7 (26.9) 
Achilles reflex 8 (30.8) 0 (0) 18 (69.2) 
 None Unilateral Bilateral 
Extensor Plantar 4 (15.4) 3 (11.5) 19 (73.1) 
 
 Number (%) 
Broken smooth pursuits 26 (100) 
Square wave jerks on fixation 2 (7.7) 
Downbeat nystagmus on fixation 1 (3.8) 
Gaze-evoked nystagmus on horizontal testing 25 (96.2) 
Gaze-evoked nystagmus on vertical testing 8 (30.8) 
Ophthalmoparesis on horizontal gaze 1 (3.8) 
Ophthalmoparesis on vertical gaze 1 (3.8) 
Slowing of saccades 2 (7.7) 
Hypometric saccades 2 (7.7) 
Hypermetric saccades 7 (26.9) 
      UL=upper limb ; LL=lower limb 
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Figure 73: Weakness, spasticity & sensory loss for ARSACS patients as recorded in the 
INAS 
 
Figure 74: Symptoms reported by ARSACS patients as part of the INAS 
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Figure 75: Reflexes for ARSACS patients as recorded in the INAS 
 
 
Figure 76: Ophthalmological features of ARSACS patients as recorded in the INAS 
GEN=gaze-evoked nystagmus 
5.3.9  Spinocerebellar Ataxia Functional Index (SCAFI) 
Twenty-five of the 26 ARSACS patients in the natural history study completed the 
SCAFI although, in common with the EFACTS patients, not all could complete all parts 
of the rating scale. Eleven patients were able to complete the 8 metre timed walk and 
10 were unable to do so. The timed walk was not completed in four cases who were 
seen on home visits where there was not a flat indoor 8 metre course over which to 
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time the patient. Therefore, in a clinical setting in which this component of the test 
could be undertaken, only 52% of the patients could complete it, illustrating a major 
deficiency in this test. Twenty-three of the 25 patients (92%) were able to undertake 
the 9-hole peg test. All patients were right hand dominant. All patients could perform 
the PATA test. The raw data are shown in Table 48 and the calculated Z scores in Table 
49. The raw data for all values (before averaging) are shown in Table 48. For the raw 
data, lower values for the PATA test and higher values for the 8mTW and 9HPT 
represent greater disease involvement. 
Table 48: Raw data from SCAFI for ARSACS patients 
Task No. completing 
(%) 
Mean ± SD Range 
8mTW1 (s) 11 (52.4) 11.7 ± 3.9 6 - 20 
9HPT-D2 (s) 23 (92.0) 43.5 ± 11.7 25 – 69 
9HPT-ND3 (s) 23 (92.0) 55.3 ± 32.5 26 – 184 
9HPT-All4 (s) 23 (92.0) 49.6 ± 25.0 25 – 184 
PATA (/10s) 25 (100) 17.9 ± 5.29 11 - 33 
1
missing values n=4 
2
9HPT-D = 9-hole peg test for dominant hand 
3
9HPT-ND = 9-hole peg test for non-dominant hand 
4
9HPT-All = 9-hole peg test for both hands 
 
Table 49: Calculated Z scores from SCAFI for ARSACS patients 
 Z-8mTW Z-9HPT Z-PATA SCAFI 
Mean -1.43 -0.26 0.00 -0.03 
SD 1.69 1.23 0.96 0.63 
Min -2.99 -3.05 -1.30 -1.35 
Max 1.88 1.88 2.11 1.12 
n 21 25 25 21 
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Figure 77: Raw data from SCAFI for ARSACS patients: (A) 8m timed walk; (B) 9-hole 
peg test for dominant hand; (C) 9-hole peg test for non-dominant hand; (D) PATA 
test 
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5.3.10 Structured Neurological Examination (SNE) 
All 26 ARSACS patients had the SNE recorded. No patients had ptosis or pupillary 
abnormalities including a relative afferent pupillary defect (RAPD). Only one patient 
(patient 9) had any form of ophthalmoparesis; this involved a vertical supranuclear 
gaze palsy as previously published (Stevens et al. 2013). Eight patients (30.8%) wore 
spectacles. There were no cases of facial weakness or sensory loss, and no examples of 
masticatory, palatal, sternocleinomastoid or trapezius weakness. One patient reported 
hearing loss. One patient had tongue atrophy. Six patients (23.1%) showed tongue 
spasticity and the remainder had normal lingual tone. No patients displayed evidence 
of parkinsonism. 
The range of muscle power found at examination is given in Table 50, with each value 
summating 52 power measurements (bilateral for the 26 ARSACS patients). It should 
be noted that the values recorded are on a 7 point scale related to the MRC rating 
scale as described in Chapter 2. In short, the values up to 3 correspond directly with 
those of the MRC scale, whilst 4 in the Table below corresponds to 4-/5 in the MRC 
scale, 5 to 4/5, 6 to 4+/5 and 7 to 5/5. Thus, the mean value of 6.96 for shoulder 
abduction represents near full power in all patients (in fact, 25 patients had power of 
5/5 and one patient 4+/5 bilaterally). The mean values are depicted in Figure 78.  
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Table 50: Muscle power from SNE in ARSACS patients 
 Mean SD Mode Range 
Shoulder Abduction 6.96 0.19 7 6-7 
Shoulder Adduction 6.96 0.19 7 6-7 
Elbow Flexion 6.98 0.14 7 6-7 
Elbow Extension 6.98 0.14 7 6-7 
Wrist Flexion 6.96 0.19 7 6-7 
Wrist Extension 6.92 0.39 7 5-7 
Finger Flexion 6.90 0.36 7 5-7 
Finger Extension 6.81 0.60 7 4-7 
Index Finger Abduction 6.15 1.33 7 3-7 
Little Finger Abduction 5.92 1.56 7 2-7 
Thumb Abduction 6.23 1.55 7 1-7 
UL proximal 6.97 0.17 7 6-7 
UL distal 6.56 1.09 7 1-7 
Hip Flexion 5.17 2.19 7 0-7 
Hip Extension 5.85 2.12 7 0-7 
Hip Abduction 6.15 2.05 7 0-7 
Hip Adduction 6.15 2.05 7 0-7 
Knee Flexion 5.25 2.46 7 0-7 
Knee Extension 6.17 1.62 7 1-7 
Ankle Flexion 5.12 2.54 7 0-7 
Ankle Extension 5.15 2.44 7 0-7 
Ankle Inversion 5.00 2.58 7 0-7 
Ankle Eversion 4.83 2.63 7 0-7 
Toe Flexion 4.28 2.58 7 0-7 
Toe Extension 4.44 2.73 7 0-7 
LL proximal 5.79 2.12 7 0-7 
LL distal 4.81 2.58 7 0-7 
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Figure 78: Mean muscle power values from SNE for (A) upper & (B) lower limbs in 
ARSACS patients.  
For an explanation of the scale, see text. 
Values for deep tendon reflexes are given in Table 51 which represent bilateral 
measurements from the 26 patients in the study. The results are recorded on a 6-point 
scale from absent (0) to ‘hyperreflexic with clonus’ (5) for the biceps, supinator, 
triceps, patellar and ankle reflexes. Finger jerks and Hoffman’s reflex are recorded as 
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present or absent. The plantar reflexes are recorded as mute, flexor, extensor or 
withdrawal (unassessable). The results are further depicted in Figure 79. 
Table 51: Deep tendon reflexes from the SNE for ARSACS patients 
 Absent 
Present 
only with 
reinforce-
ment 
Present  but 
hyporeflexic 
Normal 
Hyper-
reflexic 
Hyperreflexic 
with clonus 
Biceps 24 (46.2) 0 (0) 0 (0) 28 (53.8) 0 (0) 0 (0) 
Supinator 21 (40.4) 0 (0) 1 (1.9) 30 (57.3) 0 (0) 0 (0) 
Triceps 16 (30.8) 0 (0) 3 (5.8) 29 (55.8) 4 (7.7) 0 (0) 
Patellar 8 (15.4) 0 (0) 6 (11.5) 19 (36.5) 18 (34.6) 1 (1.9) 
Ankle 30 (57.7) 4 (7.7) 4 (7.7) 14 (26.9) 0 (0) 0 (0) 
 
 Absent Present 
Finger jerks 50 (96.2) 2 (3.8) 
Hoffman reflex 50 (96.2) 2 (3.8) 
 
 Mute Flexor Extensor Withdrawal 
Plantar 6 (11.5) 3 (5.8) 40 (76.9) 3 (5.8) 
 
 
Figure 79: Distribution of deep tendon reflexes from SNE in ARSACS patients 
Table 52 gives values for muscle atrophy, muscle tone, sensory loss and skeletal foot 
abnormalities derived from the SNE for the 26 patients in the ARSACS natural history 
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study. All values are semi-quantitative and averaged over 52 measurements (bilateral 
for each value). Muscle atrophy & skeletal foot abnormalities were assessed using a 4-
point scale (none, mild, moderate, severe). Muscle tone was evaluated using a 6-point 
scale from highly flaccid to highly spastic with a further category for other causes of 
altered tone such as rigidity or Gegenhalten; no patients fell into this category. 
Sensation was assessed for the three modalities pin prick, proprioception and 
vibration, using a length-dependent scale described in detail in Chapter 2. This has 
been analyzed as a continuous variable with zero representing no sensory loss and 
each point representing a further joint more distal affected. Figure 80 depicts the 
results for muscle atrophy and spasticity. Figure 81 shows the results for the various 
modalities of sensation. Figure 82 shows the results for the various types of skeletal 
foot abnormality seen in ARSACS. 
Table 52: Values for muscle atrophy, muscle tone, sensory loss and skeletal foot 
abnormalities from the SNE for ARSACS patients 
  None Mild Moderate Severe 
Atrophy UL 38 (73.1) 12 (23.1) 2 (3.8) 0 (0) 
 LL 41 (78.8) 7 (13.5) 4 (7.7) 0 (0) 
 
  
Highly 
flaccid 
Flaccid Normal Spastic 
Highly 
spastic 
Other 
Tone UL 0 (0) 2 (3.8) 26 (50) 24 (46.2) 0 (0) 0 (0) 
 LL 0 (0) 0 (0) 16 (30.8) 12 (23.1) 24 (46.2) 0 (0) 
 
   Mean SD Mode Range 
Sensation UL Pin prick 1.02 1.62 0 0-6 
  JPS 0 0 0 0 
  Vibration 0.15 0.64 0 0-3 
 LL Pin prick 1.4 1.56 0 0-5 
  JPS 0.92 1.13 0 0-3 
  Vibration 1.77 1.37 2 0-4 
 
 Absent Mild Moderate Severe 
Pes cavus 7 (13.5) 7 (13.5) 18 (34.6) 20 (38.5) 
Pes planus 50 (96.2) 0 (0) 2 (3.8) 0 (0) 
Hammer/claw toes 32 (61.5) 0 (0) 14 (26.9) 6 (11.5) 
Talipes equinus 34 (65.4) 6 (11.5) 7 (13.5) 5 (9.6) 
Talipes varus 36 (69.2) 6 (11.5) 5 (9.6) 5 (9.6) 
UL=upper limb; LL=lower limb; JPS=joint position sense 
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Figure 80: (A) Muscle atrophy and (B) spasticity as recorded in the SNE for ARSCACS 
patients 
 
 
Figure 81: Extent of sensory loss as recorded in SNE for ARSACS patients.  
For an explanation of the scale, see text.  
UL=upper limb; LL=lower limb; JPS=joint position sense 
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Figure 82: Skeletal foot abnormalities from SNE for ARSACS patients 
Table 53 brings together all the clinical features and rating scales of the 26 patients in 
the study. 
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Table 53: Summary of all clinical findings for 26 ARSACS patients in natural history study 
Clinical features are recorded on a semi-quantitative scale (0 absent; (+) equivocal; + mild; ++ moderate; +++ severe; ++++ very severe) based on the research rating scores 
given at the foot of the table. Reflexes are recorded as: 0 absent; (+) present only with reinforcement; + hyporeflexic; ++ normal; +++ hyperreflexic; ++++ hyperreflexic with 
clonus. Binary features eg extensor plantar reflexes are recorded as: 0 absent; + present. 
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5.3.11 Neurophysiology 
Many of the patients in the study had had nerve conduction studies as part of their 
diagnostic work-up. The results of 13 of these, all undertaken in the Department of 
Neurophysiology of the National Hospital for Neurology & Neurosurgery, were 
available. These were not collected prospectively as part of the study, and so in several 
instances had taken place several years before the patients were seen in the study, 
indeed often before they had a diagnosis. They were not collected in a systematic 
fashion or under identical conditions or following a set protocol, and were undertaken 
by a variety of operators. In several instances comparable results were not available. 
Table 54 summarizes some of the principal findings which broadly allow comparison 
between patients. Examples are shown of upper and lower limb motor and sensory 
nerve findings with compound action potentials and conduction velocities. The overall 
impression of the neurophysiologist at the time is quoted. 
All patients had measurable compound motor action potentials (CMAP) in the median 
nerve at the wrist with a mean CMAP of 7.3±2.5mV (range 1.8-12.2mV; lower normal 
limit 4.1mV) and a mean motor conduction velocity (MCV) of 37.8±14.2m/s (range 19-
58m/s; lower normal limit 49m/s). Sensory action potentials (SAP) were absent in the 
median nerve at the wrist in seven (58.3%) of the twelve patients in whom it was 
measured. In the remaining five patients, the mean SAP was 4.0±2.5μV (range 1-8μV; 
lower normal limit 10μV) with a mean sensory conduction velocity (SCV) of 
43.8±5.5m/s (range 38-51m/s). Seven CMAP results were available for the common 
peroneal nerve at the ankle giving a mean CMAP of 0.4±0.5mV (range 0.1-1.4mV; 
lower normal limit 1.3mV). In one case the CMAP is recorded as unobtainable at the 
ankle. In the remaining 4 cases, the CMAP was measured at the fibular neck with mean 
CMAPs of 2.3±0.7mV (range 1.5-3.1mV; lower normal limit 1.7mV). This may have 
happened because the CMAPs were unobtainable at the ankle. The mean MCV for all 
11 measurable cases in the common peroneal nerve was 33.9±7.6m/s (range 27-
53m/s; lower normal limit 38m/s). SAPs were only measurable in three (25%) of the 
twelve patients in whom they were assessed. In these cases, the mean SAP was 
4.0±1.0μV (range 3-5μV; lower normal limit 4μV) with a mean SCV of 35.3±6.8m/s 
(range 30-43m/s). Normal limits are quoted from (Buschbacher & Prahlow 2006).  
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In addition, patient 18 was previously noted to show evidence of chronic partial 
denervation with absent sensory and motor responses consistent with a generalized 
axonal neuropathy (Pyle et al. 2013). Patient 20 was described as having a large-fibre 
sensorimotor axonal-demyelinating neuropathy and patient 21 a mixed demyelinating 
axonal neuropathy (Pyle et al. 2012). Patient 23 was recorded as having a 
demyelinating sensorimotor neuropathy (Terracciano et al. 2010). The formal results 
of these investigations were not available for analysis within the current study. 
Thus, in all cases there was evidence of a mixed sensory and motor neuropathy. MCVs 
were reduced in both upper and lower limbs in nearly all cases. CMAPs were less 
affected and were generally well preserved in the upper limbs. SAPs were typically 
absent or markedly reduced in both upper and - to a greater extent - lower limbs, with 
reduced conduction velocities where measurable. Overall, the neurophysiologist felt 
the diagnosis was consistent with a demyelinating picture in 8 (61.5%) cases, with an 
axonal picture in 2 (15.4%) cases and a mixed picture in 3 (23.1%) cases.  
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Table 54: Neurophysiological findings for ARSACS patients 
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5.3.12 Neuropathology 
Five patients underwent quadriceps muscle biopsy (patients 6, 9, 11, 13 & 17) and 
three sural nerve biopsy (patients 9, 11 & 13). This was usually during the diagnostic 
process and often long before inclusion in the current study. The results were collated 
from the previous notes and not collected prospectively as part of this study. The 
results are shown in Table 55. The muscle biopsies were generally uninformative as to 
the diagnosis but did not show evidence of mitochondrial cytopathy except in the case 
of patient 13. Most consistently they showed an excess of type I muscle fibres 
suggestive of denervation and reinervation. The nerve biopsies generally showed loss 
of large myelinated axons and little evidence of demyelination. 
Patient 9 also underwent skin biopsy looking for Lafora body disease. This showed 
globular, discrete periodic acid-Schiff-positive inclusions within the apocrine glands 
resembling Lafora bodies but Lugol’s iodine reaction was negative and ultrastructurally 
they contained filamentous aggregates, features not typical of Lafora bodies. There 
was prominent lipofuscin present in basal myoepithelial cells. This observation has 
previously been reported (Stevens et al. 2013) who raised the question of whether 
ARSACS might represent a lysosomal storage disorder or a condition of abnormal 
protein aggregation. 
In addition, a muscle biopsy on patient 18 has previously been reported as 
demonstrating angular fibres, small group atrophy, fibre type grouping and type II fibre 
predominance consistent with neurogenic changes (Pyle et al. 2013). Patient 21 
showed type I fibre clustering (Pyle et al. 2012). The formal results of these 
investigations were not available for the current study. 
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Table 55: Muscle & nerve biopsy results for ARSACS patients in study 
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 Muscle biopsy result 
6 43 - Not done 54 
Occasional polygonal atrophic fibres. Small number of 
nuclear bag fibres. No increase in connective tissue or 
internal nuclei. No regeneration, necrosis or 
inflammation. No ragged red or cytochrome oxidase 
negative fibres. Lipid and glycogen content normal. Acid 
phosphatase, phosphorylase and adenylate deaminase 
activities normal. Type I fibre predominance. 
9 2 30 
Some myelinated axons are atrophic but there 
is no evidence of degeneration, regeneration, 
demyelination or onion bulb formation. Many 
myelinated and unmyelinated axons contain 
more electron dense bodies than is normal, 
and contain varying amounts of neurofilament 
fibrils. There are fewer large myelinated axons 
than normal. 
 
29 
No significant atrophy or increase in connective tissue. No 
regeneration, necrosis or inflammation seen. No ragged 
red or cytochrome oxidase negative fibre. Lipid content 
slightly increased. Glycogen normal. Acid phosphatase, 
phosphorylase & adenylate deaminase activities normal. 
Fibre typing shows disturbance of the normal pattern 
with only scanty type IIa fibres present. The presence of a 
slight increase in lipid content raises the possibility of a 
metabolic myopathy. No evidence of mitochondrial 
myopathy. 
11 13 32 
Reduced density of large myelinated fibres 
and large axons. Significant endoneurial 
oedema. Negative for amyloid. A mild 
neuropathy particularly affecting large 
myelinated axons with a small demyelinating 
component. The lack of inflammatory cell 
activity and the homogenous nature of the 
pathology favours a genetic cause rather than 
an acquired neuropathy. 
32 
No increase in connective tissue or internal nuclei. No 
regeneration, necrosis or inflammation. No ragged red or 
cytochrome oxidase negative fibres. Slight increase in 
lipid content. Glycogen content normal. Acid phosphatase 
adenylate deaminase & phosphorylase activities normal 
Excess of type I fibres. Degree of type IIb fibre atrophy. 
No evidence of denervation. 
 
13 32 NK 
Moderately severe axonal neuropathy with 
selective loss of large fibres & some 
regeneration. No evidence of demyelination. 
NK 
Small numbers of cytochrome oxidase negative fibres 
suggestive of mitochondrial myopathy. Some denervation 
and reinervation. EM studies showed collections of 
mitochondria with free glycogen but no para-crystalline 
inclusions. Respiratory enzyme studies consistent with a 
degree of heteroplasmy and indicated reduced complex 4 
activity. 
17 1 - Not done 25 
Scattered & clustered polygonal atrophic fibres. No 
increase in connective tissue or internal nuclei. No 
regeneration, necrosis or inflammation. No ragged red or 
cytochrome oxidase negative fibres.  Fibres have normal 
internal architecture.  Lipid & glycogen content normal. 
Acid phosphatase and adenylate deaminase activities are 
normal. Fibre typing reveals small groups of all 3 fibre 
types.  The atrophic fibres are predominantly type 2b 
fibres and likely to represent a degree of previous 
denervation with reinervation. No features of 
mitochondrial disease. 
 
 
5.3.13 Neuroimaging 
Sixteen patients underwent MR imaging of the neuraxis as part of their diagnostic 
work-up and subsequent clinical monitoring. All 16 had imaging of the brain and a 
further 12, imaging of the spinal cord. The results were obtained by reviewing the 
neuroradiological reports of previous imaging which was not collected prospectively as 
part of this study. The results are summarized in Table 56. Thirteen patients (81.3%) 
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were noted to have cerebellar volume loss, which was predominantly in the superior 
vermis, but to a lesser extent in the cerebellar hemispheres or cerebellar peduncles. 
Eight patients (66.7%) showed thinning of the spinal cord. Four patients (25%) were 
recorded as having pontine hypodensities. Corpus callosal thinning was observed in 
three cases (18.8%) and generalized cerebral volume loss in a further three. More focal 
parietal volume loss was seen in 2 cases (12.5%). 
In addition, MR imaging on patient 18 was previously reported as showing marked 
cerebellar vermian atrophy and reduced spinal cord diameter (Pyle et al. 2013). The 
MRI of patient 20 showed cerebellar atrophy and that of patient 21, generalized 
atrophy most prominently affecting the cerebellum (Pyle et al. 2012). Patient 23 was 
reported to have a severely atrophied upper cerebellar vermis as well as pontine 
tigroid hypointensities (Terracciano et al. 2010). 
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Table 56: Neuroimaging features of ARSACS patients in natural history study 
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1 1 24 + - - 
Superior vermis - 
2 5 19 ++ +(T) - 
Superior vermis, 
hemispheres & superior 
peduncles 
- 
3 1 25 - +(T) + 
n/a Signal change ventrolateral 
thalami 
4 48 59 + - + 
Superior vermis Posterior corpus callosal 
volume loss 
5 51 58 - ND - 
n/a - 
6 43 61 - ND - 
n/a - 
7 35 53 + ND - 
Superior vermis & 
hemispheres 
Mild generalized cerebral 
atrophy 
8 46 57 + - - 
Superior cerebellum - 
9 2 37 ++ +(D) + 
Superior vermis & 
peduncles 
Mild generalized cerebral 
atrophy, especially in parietal 
region. Corpus callosal 
thinning 
10 10 43 + (+)(D) - 
Hemispheres Incidental cisterna magna 
11 13 31 (+) ND - 
NR - 
13 32 48 + +(C) + 
Hemispheres Mature right cerebellar 
infarct. Left mesial temporal 
sclerosis. Parietal volume 
loss. 
14 5 32 ++ +(C) - 
NR - 
15 23 45 + ++(C) - 
 Generalized cerebral atrophy. 
Abnormal signal posterior 
internal capsule. 
17 1 29 + +(C) - 
Vermis Corpus callosal thinning 
25 1 22 (+) - - 
Vermis - 
NR=not recorded; n/a=not applicable 
C=Cervical; T=thoracic; D=diffuse 
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5.4 Discussion 
The analysis described herein represents the largest single centre prospective 
natural history case series of ARSACS patients described outside Charlevoix & 
Saguenay, and the first large systematic clinical and genetic study of ARSACS in the 
UK. It describes the clinical features of patients bearing nine completely novel 
pathogenic SACS gene mutations, as well as those of a further five mutations which 
have previously only been briefly described from a genetic point of view (Vermeer 
2012). It applies a series of research-based rating scales which have not hitherto 
been evaluated in ARSACS patients and whose knowledge is vital in the planning of 
future drug trials. Since the data herein were collected alongside and using an 
analogous protocol to a large systematic prospective natural history study of FRDA, 
it enables direct comparison with the commonest and closest genetic condition in 
the differential diagnosis of ARSACS. 
The 26 patients in the study bear 30 pathogenic mutations which are 
predominantly point mutations (deletions, duplications and substitutions causing 
largely premature termination of the protein either directly or by frameshift effect) 
but include two large deletions of 0.7 & 1.5Mb, both of which have previously been 
published (Terracciano et al. 2010, Pyle et al. 2013). Sixteen of the mutations have 
previously been described. These do not include either of the common mutations 
thought to represent founder mutations in the Québecois population (c.8844delT & 
c.7504C>T), and only one of the rarer mutations subsequently identified amongst 
this population (c.4744G>T) (Thiffault et al. 2013, Engert et al. 2000). This is 
significant as the Québecois cases were the first to be described and remain the 
most numerous single population studied; their clinical features therefore 
dominate the world literature. When cases were identified outside Québec, they 
were often described as atypical (Baets et al. 2010), most prominently having 
significantly later onset. It may be that these features represent part of the normal 
clinical spectrum of ARSACS in the genetically more heterogeneous worldwide 
population.  
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In keeping with previous studies which describe a large number of private 
mutations, the current study has identified nine completely novel mutations and a 
further five hitherto not described in the peer-reviewed literature. These consist of 
eight nonsense mutations which are considered obligately pathogenic, and six 
missense mutations for which in silico analysis implies pathogenicity. Although 
several of the mutations described are shared by multiple family members as would 
be expected, only two mutations are found in individuals not known to be related: 
the nonsense mutation c.9956_9957delAA is seen in patients 2 & 17, whilst the 
missense mutation c.9404T>C appears to be more common in the UK as it is 
present in five individuals from three families (patients 10,11,13,15 & 16 from 
families F, H & J). The current study is important as, for the first time, it provides an 
overview of the clinical and genetic spectrum of ARSACS in the UK. However, the 
current evidence suggests that as further cases are identified, they may well have 
further unique mutations and therefore potentially different clinical features. 
There has been no consistent gender preponderance reported previously in 
ARSACS, with the male:female ratio varying in previous published cohorts from 
1:0.4 (El Euch-Fayache et al. 2003) to 1:1.6 (Pilliod et al. 2015); the ratio in the 
present study of 1:0.7 is therefore not inconsistent with these. All the participants 
in this study were Caucasian in origin. This is in keeping with previous studies, as 
although cases from Japan and the Maghreb have been reported, no Afro-
Caribbean or South Asian cases have been identified.  
In common with previous studies, nearly half the patients had disease onset before 
the age of 5. However, the mean age at onset (15.0±17.4), age at examination 
(43.4±13.7) and disease duration (28.5±12.9) of patients in the study are greater 
than in most other published cohorts. This may be because there are no children in 
the study, but is also partly driven by a single family (family D) containing five 
affected members with unusually late onset of between 35 and 51; the latter is one 
of the latest onset cases yet described. It seems likely this is a genetic effect. This 
family all share two missense mutations in cis (c.8339T>G & c.12416T>C) which are 
predicted to be pathogenic, and a nonsense mutation (c.11675C>G) whose effect is 
to truncate the protein toward its carboxyl-terminus (at amino acid 3892 out of 
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4579). These may therefore represent less severe mutations. Genotype-phenotype 
correlations are difficult in a small cohort containing a large number of mutations 
where each patient has at least two contributory pathogenic mutations. The 
siblings within families F & J also seem to have similar ages at onset, but there is 
marked variation within families L, M & P. 
In common with FRDA, the predominant symptoms at onset were gait problems 
and falls, although unlike FRDA, the majority of patients maintained the ability to 
mobilize by the time they were seen as part of the study. The ADL assessment 
shows that walking remains the most affected function studied causing frequent 
falls. Speech, swallowing and activities involving fine manual dexterity such as 
dressing, washing and use of cutlery, are comparatively less affected. The SARA 
results mirror this functional finding with gait and stance most affected, and lower 
limb measures of ataxia more severely affected. The INAS shows that both distal 
and proximal lower limb weakness are common in ARSACS. There is often mild 
distal upper limb weakness but rarely significant proximal weakness. Spasticity is 
common and more severe in the lower limbs than the upper with the majority of 
patients having both upper and lower limb spasticity. Muscle cramps are common 
and rated as severe in nearly are half of all patients. There is commonly a mixed 
pattern of reflexes reflecting the neuropathy and pyramidal features seen in this 
condition. This is most prominently displayed by the patellar reflex for which half of 
the patients are hyperreflexic, a quarter areflexic and a quarter normal. For the 
biceps and ankle jerks, patients are far less commonly hyperreflexic and far more 
frequently areflexic. Extensor plantar reflexes are seen in more than 80% of cases. 
Regarding the eye movements, broken smooth pursuits and horizontal gaze-evoked 
nystagmus are the most common feature which are almost universally found. 
The SNE provides a much more detailed view of the examination findings, 
particularly those not studied in the SARA and INAS. This confirms preservation of 
muscle power in the upper limbs especially proximally where there is very rarely 
weakness. Lower limb power is more severely affected, particularly distally. The 
reflexes are recorded in a slightly different way in the SNE from the INAS but the 
results are broadly comparable. The supinator and triceps reflexes which are not 
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evaluated as part of the INAS, show similar findings to the biceps reflexes : they are 
rarely brisk, normal in just over half of cases and absent in 30-40% of cases. Finger 
jerks and Hoffman’s reflexes are present in only a very small fraction of cases. 
Muscle atrophy is present in approximately a quarter of cases, and then usually 
very mild. Sensory loss is common and more prominent in the lower limbs. Lower 
limb vibrational sense is the most severely affected, with over half of patients 
recorded as severely affected at the ankle by the INAS, and most extensively 
impaired by the SNE. Pin prick and proprioceptive sensory loss is also common in 
the lower limbs. In the upper limbs, distal pin prick loss was seen much more 
commonly that vibrational loss; proprioceptive loss was not observed in the upper 
limbs. Light touch and temperature sensation were not assessed as part of this 
study. A range of skeletal foot abnormalities were seen : pes cavus is almost always 
found, with hammer or claw toes or talipes equinovarus seen in 30-40% of cases. 
Nerve conduction studies consistently showed evidence of a mixed sensory and 
motor neuropathy with reduced conduction velocities and to a lesser extent action 
potentials, affecting the lower more than the upper limbs. These findings were 
most consistent with a demyelinating neuropathy with an axonal component. 
However, the few cases which had nerve biopsies generally showed loss of large 
myelinated axons and little evidence of demyelination. Muscle biopsy typically 
shows an excess of type I muscle fibres suggestive of denervation and reinervation 
and is rarely informative, although usually excludes a mitochondrial cytopathy 
which may be under consideration during the diagnostic work-up. 
The most common features on neuroimaging are superior vermian cerebellar 
atrophy and spinal cord thinning, most commonly in the cervical region. Pontine 
tigroid hypodensities, which are probably a more specific feature of ARSACS, were 
only seen in 25% of this cohort. However, the imaging results were not collected 
prospectively and the pons may not have been specifically scrutinized for these 
changes. The sensitivity and specificity of this feature warrants further investigation 
with a prospectively planned study and a protocol designed specifically to study this 
feature. 
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Epilepsy was seen in 5% of the Québecois patients but has only variably been 
reported in subsequent cohorts. It was seen at similar levels in two predominantly 
European studies (Vermeer et al. 2008, Baets et al. 2010) and up to 9% in a similar, 
more recent but larger study (Pilliod et al. 2015). In the present study, epilepsy was 
reported in 19% of cases, making this the highest prevalence reported to date in 
any natural history series. Of note, one patient (patient 13), was has mesial 
temporal sclerosis on MR imaging which may independently explain her diagnosis 
of epilepsy. Whether epilepsy is causally linked with ARSACS is still unclear, but it 
may well have been overlooked in previous studies and should be more 
systematically studied in the future. The higher prevalence in the present study may 
represent particular genetic features of the UK cases. Interestingly, 19% of patients 
also complained of headaches.  
Urological complications such as urinary frequency, incontinence and retention 
were commonly seen, affecting over a quarter of cases. These features are 
frequently overlooked and are often treatable. Approximately 15% of patients 
complained of depression. Other general medical conditions including asthma, 
hypertension, hypercholesterolaemia and common eye conditions were present at 
greater than 10% frequency, likely reflecting there prevalence in the general 
population. Mitral valve prolapse was reported in 57% of the original cohort of 
ARSACS patients (Bouchard et al. 1978) but was not observed in subsequent case 
series. The current series has also not found evidence of valvular cardiac problems.  
Thus, this study confirms previous descriptions of ARSACS as causing early onset 
gait disturbance and falls, followed by spasticity, ataxia and distal sensory loss 
which predominantly affect the lower limbs. Muscle atrophy is less common. The 
deep tendon reflexes show a mixed pattern with areflexia commoner than 
hyperreflexia, but the two frequently coexisting in the same patient. The plantar 
reflexes are typically extensor. Skeletal foot abnormalities are very common with 
pes cavus most frequently present. A predominantly demyelinating sensorimotor 
neuropathy is found on neurophysiological testing. Taken together, these findings 
confirm the coexistence of cerebellar, pyramidal and neuropathic features which 
have been more systematically evaluated than previously. This study also confirms 
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the common existence of late-onset forms of ARSACS which were not seen amongst 
the originally described populations in Charlevoix and Saguenay. However, it does 
raise the suspicion of an association with epilepsy which was described in the 
original population. This may have been underestimated in subsequent studies and 
merits further investigation.  
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Chapter 6 :  Ocular Coherence Tomography in 
Diagnosing Autosomal Recessive Spastic Ataxia of 
Charlevoix-Saguenay 
 
6.1 Introduction   
Within the earliest clinical descriptions of ARSACS, Bouchard observed ‘striking and 
markedly increased visibility of the retinal nerve fibers, mainly in the papillomacular 
bundle area’ akin to the changes seen in the early stages of Leber’s hereditary optic 
neuropathy (LHON) (Bouchard et al. 1978). The fundoscopic changes appear as 
prominent streaks emanating in all directions from the optic disc, most striking in the 
papillomacular bundle and nasal to the disc where such striations are rarely visible in 
healthy people. The retinal vessels, which normally lie on the surface of the nerve fibre 
layer, may be buried within this thickened layer obscuring their normally crisp margins 
(see Figure 83 A & B). These retinal striations are often described in the literature as 
composed of myelinated (Bouchard 1991) or hypermyelinated (Takiyama 2006, Prodi 
et al. 2013) retinal fibres, although their exact nature remains unknown as no 
histopathological studies of the eyes in ARSACS have yet been published.  
However, these retinal changes are not consistently observed on fundoscopy, 
particularly in non-Québecois cases of ARSACS, such as those from Japan, Turkey, 
Tunisia, Italy, the Netherlands and Spain (Takiyama 2006, Gücüyener et al. 2001, 
Mrissa et al. 2000, Grieco et al. 2004, Garcia-Martin et al. 2013, Vermeer et al. 2008), 
supporting the idea of increasing phenotypic variability associated with the increasing 
genetic diversity of cases identified outside Québec. A more sensitive method of 
detecting them appears to be ocular coherence tomography (OCT). In ARSACS, OCT 
shows thickening of the retinal nerve fibre layer (RNFL) in all sectors around the disc, 
with average peripapillary thicknesses of between 119 and 220m (Vingolo et al. 2011, 
Pablo et al. 2011, Desserre et al. 2011, Garcia-Martin et al. 2013, Stevens et al. 2013, 
Nethisinghe et al. 2011, Gazulla et al. 2012). In the macula, RNFL thickening extends 
over the fovea and can obscure the foveal pit (see Figure 83Figure C) (Nethisinghe et 
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al. 2011). Only one series has reported absence of RNFL thickening on OCT, in a single 
case with RNFL thicknesses of 86 and 111m (Yu-Wai-Man et al. 2014). It has also been 
reported that unaffected heterozygous carriers of two different SACS mutations in a 
single family showed partial RNFL thickening on OCT of up to 119m thickness 
(Nethisinghe et al. 2011). 
 
Figure 83: Retinal appearance in ARSACS (A) in colour; (B) red-free image; (C) OCT 
The optic disc is normal but there is visible thickening of the RNFL in all quadrants; in 
some places this has obscured the normally sharp edges of the retinal vessels 
(asterisks). OCT scan along green line in image (B) shows thickening of both ganglion 
cell and nerve fibre layers extending across the fovea (arrowed).  
Image courtesy of Dr Fion Bremner, NHNN. 
 
OCT provides micron-scale, cross-sectional images (tomographs) of biological tissue to 
a depth of a few millimetres acquired by non-invasive means without direct contact 
(see Figure 84). The resulting images of the retina are of such quality that they have 
been described as ‘optical biopsies’ comparable to non-invasive histological sections 
(Anderson et al. 2011). The technique is analogous to B-mode ultrasound or radar but 
uses a focused beam of light, typically 800-1400nm in the near infra-red region. This is 
split with half scanned across the tissue in question and half directed to a moving 
reference mirror. The two reflected beams are recombined in a Michelson-type 
interferometer which detects interference between the two light signals and so time-
of-flight delay caused by reflection from different histological layers. As the light beam 
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is scanned across the tissue, multiple individual A-scans showing the interference 
pattern are obtained, which are combined to form a B-scan showing a 2-dimensional 
cross-sectional image of the tissue. This is usually displayed as either a grey-scale or 
false-colour image (Costa et al. 2006, Anderson et al. 2011, Jindahra et al. 2010).  
 
Figure 84: OCT images of the human retina and corresponding histopathological 
layers 
(A) Haematoxylin & eosin stain of human retina; (B) schematic representation of 
human retina; (C) colourized cross section of human retina by SD-OCT taken 
from (D). Image from (Galetta et al. 2015) 
ILM=inner nuclear layer; RNFL=retinal nerve fibre layer; GCL=ganglion cell layer; IPL=inner 
plexiform layer; INL=inner nuclear layer; OPL=outer plexiform layer; ONL=outer nuclear layer; 
OLM=outer limiting membrane; PL=photoreceptor layer; RPE=retinal pigment epithelium; 
BM=Bruch membrane; CC=choriocapillaris layer.   
 
Two OCT methodologies are available. The first to be developed was time-domain OCT 
(TD-OCT). This uses a linear or circular scan, often positioned around the optic nerve 
head (peripapillary view) or macula (perifoveal view), to produce a single 2-
dimensional image. Acquisition times can be up to several seconds which can 
introduce artefact due to eye movements, and the scan is usually positioned manually 
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by the examiner, potentially leading to variation between patients. More recently, 
spectral-domain OCT (SD-OCT) has been introduced in which the reference mirror is 
kept stationary, and the reflected light is analyzed according to variation in wavelength 
rather than time. Acquisition times are much shorter and spatial resolution much 
greater. The larger amount of data obtained is analyzed by Fourier transform allowing 
the production of 3-dimensional images known as OCT fundus images. The decreased 
acquisition time reduces movement artefact and scanning of the whole fundus allows 
automated fixation improving variation between patients and allowing comparable 
sequential measurements in the same patient (Jindahra et al. 2010, Anderson et al. 
2011, van Velthoven et al. 2007). 
OCT has been used extensively in studying retinal disease and glaucoma, including the 
effects of drugs on the retina. Thinning of the RNFL has been demonstrated after optic 
neuritis, neuromyelitis optica and non-arteritic anterior ischaemic optic neuropathy 
(NAION). In the neurological sphere, OCT has been mostly extensively studied in 
multiple sclerosis with correlations found between RNFL thinning and various 
measures of disease progression. RNFL thinning has also been described in Alzheimer’s 
disease and Parkinson’s disease although with less consistent correlations with clinical 
parameters or other markers of neurodegeneration (Jindahra et al. 2010). Amongst the 
ataxic conditions, peripapillary RNFL thinning has been demonstrated in 
spinocerebellar ataxia (SCA) types 2, 3 and 7, and perifoveal thinning in SCA1, 3, 6 and 
the cerebellar subtype of multiple system atrophy (MSA-C) (Pula et al. 2011, Manrique 
et al. 2009). In Friedreich’s ataxia (FRDA), peripapillary RNFL thicknesses have been 
shown to be reduced with correlations to markers of clinical severity and the 
underlying genetic process (Fortuna et al. 2009, Noval et al. 2012, Seyer et al. 2013). 
Thus, thinning of the peripapillary RNFL appears to be a common feature of 
neurodegenerative disease, whether or not visual loss is a major feature. 
By contrast, thickening of the RNFL is rarely seen in the context of chronic progressive 
neurodegenerative disease. Most commonly it is seen as a result of acute optic disc 
oedema associated with the acute phases of inflammatory optic neuropathy, NAION, 
retinal vein occlusion or other causes of papilloedema (Karam & Hedges 2005, Savini et 
al. 2006). This commonly changes over time. For example, in the acute phase of LHON, 
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the RNFL is acutely significantly thickened but later in the atrophic phase of this 
condition (more than 6 months after onset), the RNFL becomes significantly thinned 
(Barboni et al. 2005). OCT studies in patients with retinitis pigmentosa have shown 
RNFL thickening in the absence of optic disc swelling  (Hood et al. 2009); however in 
these cases there is gross disruption to the outer retinal layers making interpretation 
of these RNFL measurements unclear.  RNFL thickening is therefore not normally seen 
in the context of chronic progressive neurodegenerative disease. ARSACS may be an 
exception to this rule.  
It is therefore not clear whether RNFL thickening as detected by OCT is present in all 
cases of ARSACS, nor is it known whether similar OCT changes may be seen in patients 
with other non-ARSACS causes of ataxia or asymptomatic carriers of SACS mutations.  
The purpose of the present study is to measure RNFL thickness in patients with 
ARSACS and compare these measurements to those in a large cohort of patients 
referred to a tertiary hospital specialist ataxia clinic with other types of ataxia, as well 
as first degree relatives of known patients with ARSACS. Nearly 200 different 
mutations have now been described in the SACS gene. The large size of the gene and 
diversity of mutations means that diagnostic testing usually requires sequencing of the 
entire gene which is expensive, time-consuming and is not available in many centres. 
There is therefore a pressing need for a reliable surrogate test for ARSACS. Assessment 
of RNFL thickness by OCT may provide such a test. 
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Table 57: Demographic & OCT results by disease group 
Disease Number of 
participants 
Number of 
eyes 
examined 
Age [mean ± 
SD (range)] 
M:F ratio OCT-S 
[mean ± SD 
(range)] 
OCT-N [mean 
± SD (range)] 
OCT-I [mean 
± SD (range)] 
OCT-T [mean 
± SD (range)] 
OCT-Av [mean 
± SD (range)] 
ARSACS 17 34 42.8 ± 13.4 
(21-61) 
9:8 172.6 ± 19.2 
(145.0-200.0) 
126.4 ± 18.3 
(95.5-152.5) 
185.3 ± 21.1 
(146.5-225.5) 
115.7 ± 21.6 
(78.5-153.5) 
150.0 ± 16.0 
(119.3-174.8) 
ARSACS carriers 13 26 47.2 ± 16.9 
(25-70) 
5:8 115.8 ± 11.2 
(94.5-128.5) 
78.1 ± 16.4 
(54.5-96.5) 
120.0 ± 13.4 
(92.0-145.5) 
61.3 ± 9.1 
(50.5-81.5) 
93.8 ± 7.5 
(82.0-105.5) 
FRDA 59 113 31.7 ± 11.7 
(15-61) 
32:27 
 
88.5 ± 25.2 
(34.0-150.5) 
59.4 ± 20.2 
(29.5-140.5) 
91.5 ± 21.5 
(39.0-134.5) 
59.5 ± 11.9 
(30.0-84.5) 
74.7 ± 15.1 
(35.1-104.2) 
SCAs 53 96 55.6 ± 14.1 
(24-81) 
30:23 103.3 ± 20.4 
(40.5-136.5) 
63.1 ± 17.3 
(22.0-114.0) 
106.0 ± 20.1 
(45.0-139.0) 
63.4 ± 18.2 
(34.0-130.0) 
83.9 ± 13.0 
(40.2-103.5) 
 SCA1 5 9 42.2 ± 8.5  
(30-54) 
3:2 105.5 ± 22.7 
(76.0-132.5) 
68.5 ±18.7 
(41.0-83.5) 
100.9 ± 26.3 
(57.0-120.0) 
57.6 ± 11.4 
(40.0-68.0) 
83.1 ± 18.5 
(57.3-101.0) 
 SCA2 10 18 48.9 ± 11.9 
(28-65)   
3:7 95.0 ± 25.2      
(40.5-122.5) 
60.6 ± 13.7      
(40.0-79.0) 
104.0 ± 24.8 
(45.0-135.0) 
56.1 ± 12.2    
(36.0-77.0) 
78.8 ± 16.8 
(40.2-98.0) 
 SCA3 9 13 52.7 ± 10.4 
(35-70) 
5:4 95.2 ± 18.6    
(73.0-136.0) 
52.8 ± 19.5      
(22.0-81.5) 
98.9 ± 15.5 
(77.0-121.0) 
77.4 ± 31.6  
(41.0-130.0) 
81.0 ± 7.8  
(67.2-94.0) 
 SCA6 20 39 64.5 ± 11.3 
(43-81) 
12:8 108.7 ± 18.1     
(74.0-136.5) 
67.5 ± 17.9      
(31.0-114.0) 
113.0 ± 16.4  
(71.5-139.0) 
65.0 ± 13.7  
(50.5-103.5) 
88.5 ± 10.7  
(65.6-103.5) 
 SCA7 6 12 45.8 ± 16.3 
(24-64) 
5:1 102.4 ± 20.4    
(68.4-128.5) 
63.4 ± 18.2      
(40.0-81.0) 
94.1 ± 19.4 
(62.5-113.0) 
53.4 ± 9.9  
(34.0-60.5) 
78.3 ± 14.6 
(51.3-90.8) 
 SCA14 2 3 71.0 
(67-75) 
1:1 110.0  
(106.0-114.0) 
61.5 
(56.0-67.0) 
129.8 
(124.0-136.0) 
68.3 
(60.0-77.0) 
92.0 
(90.1-94.0) 
 SCA28 1 2 65 1:0 131 69 99 60 89.4 
Other genetic 
ataxias 
17 32 52.1 ± 16.4 
(25-77) 
7:10 107.6 ± 20.1 
(74.5-143.5) 
64.7 ± 22.0 
(34.0-108.0) 
114.3 ± 21.7 
(59.0-144.5) 
64.1 ± 16.1 
(46.0-106.5) 
87.7 ± 14.1 
(56.3-106.3) 
 AOA2 6 12 44.2 ± 17.1 
(25-73) 
3:3 115.3 ± 22.9 
(85.5-143.5) 
68.5 ± 21.7 
(43.5-100.5) 
123.5 ± 12.9 
(110.5-144.5) 
81.2 ± 14.8 
(67.5-106.5) 
97.0 ±8.9 
(85.4-106.3) 
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 HSP7 4 8 61.0 ± 13.6 
(47-77) 
3:1 116.6 ± 14.6 
(103.5-129.5) 
72.3 ± 18.2 
(52.0-94.5) 
119.8 ± 4.9 
(114.0-124.5) 
53.4 ± 7.5 
(46.0-63.0) 
90.4 ± 8.1 
(85.1-102.3) 
 EA1 2 4 51.5 
 (35-68) 
0:2 103.5  
(90.5-116.5) 
88.0 
(68-108) 
119.5 
(100.5-138.5) 
55.0 
(53-57) 
91.6 
(79.0-104.2) 
 EA2 1 2 44 0:1 99.0 53.0 139.0 58.0 88.5 
 FXTAS 1 2 72 1:0 74.5 43.5 100.5 46.0 66.4 
 FGF 1 2 60 0:1 111.0 51.0 78.0 56.0 73.7 
 SLS 1 1 33 0:1 76.0 34.0 59.0 56.0 56.3 
 ACoQ10D 1 1 64 0:1 105.0 43.0 109.0 65.0 80.0 
iCA 45 83 50.3 ± 15.2 
(21-82) 
16:29 112.2 ± 20.7 
(52.0-144.5) 
72.4 ± 17.3 
(39.0-115.0) 
117.5 ± 22.2 
(61.0-159.5) 
62.9 ± 14.4 
(30.0-93.5) 
91.5 ± 13.4 
(45.5-124.0) 
All non-ARSACS 
(excluding carriers) 
174 325 45.8 ± 17.2 
(15-82) 
85:89 101.0 ± 24.0 
(34.0-150.5) 
64.4 ± 19.3 
(22.0-140.5) 
104.9 ± 23.6 
(39-159.5) 
62.0 ± 15.1 
(30.0-130.0) 
83.1 ± 15.4 
(35.1-124.0) 
ARSACS=Autosomal recessive spastic ataxia of Charlevoix-Saguenay; FRDA=Friedreich’s ataxia; SCA=Spinocerebellar ataxia; AOA=Ataxia with oculomotor apraxia 
HSP=Hereditary spastic paraparesis; EA=Episodic ataxia; FXTAS=Fragile X tremor ataxia syndrome; FGF=Ataxia with fibroblast growth factor mutation  
SLS=Sjögren-Larsson syndrome; ACoQ10D=Ataxia with co-enzyme Q10 deficiency (ADCK3 mutation)  
iCA=idiopathic cerebellar ataxia 
S=superior ; N=nasal ; I=inferior ; T=temporal ; Av=average over all quadrants 
SD=standard deviation 
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6.2 Subjects and Methods 
6.2.1 Study Population & Ethical Approval 
Patients were recruited from the Ataxia Centre of the National Hospital for Neurology 
and Neurosurgery (NHNN), which receives referrals for specialist opinions from across 
the UK and internationally. The majority of patients live in London and the South-East 
of England. All patients gave informed consent, and the study was given approval by 
the London Brent Research Ethics Committee (reference 12/LO/1291). In total, 204 
individuals were assessed: 17 cases had ARSACS, 13 were SACS mutation carriers and 
174 cases had other types of ataxia, including 59 cases of FRDA, 53 with various SCAs 
and 17 with other genetically diagnosed ataxias. The 17 ARSACS cases were all drawn 
from the group of 26 patients described in Chapter 5. All are of UK descent except one 
who came from Switzerland from a family of Calabrian origin (patient 12 in Table 59). 
Note, the patient numbering system in this Chapter and Chapter 5 are not the same. 
Seventeen patients had various other genetically determined ataxias [ataxia with 
oculomotor apraxia type 2 (AOA2), hereditary spastic paraparesis type 7 (HSP7), 
episodic ataxia types 1 & 2 (EA1/2), fragile X tremor ataxia syndrome (FXTAS), ataxia 
with fibroblast growth factor mutation (FGF), Sjögren-Larsson syndrome (SLS) and 
ataxia with co-enzyme Q10 deficiency (ACoQ10D)]. The patient with ACoQ10D had a 
pathogenic mutation in the aarF domain-containing kinase 3 gene (ADCK3). In 45 
cases, the cause of ataxia was considered idiopathic, the patients previously having 
been assessed routinely in the NHNN Ataxia Centre and undergone clinically 
appropriate genetic, metabolic and other diagnostic tests. The demographic details 
and diagnoses of the study patients are given in Table 57.   
6.2.2 Genetic Studies & Spastic Ataxia Custom Amplicon Panel 
ARSACS cases were diagnosed by extracting genomic DNA from peripheral blood 
lymphocytes using standard procedures; subsequent analysis was performed by the 
diagnostic service in the Department of Human Genetics, Radboud University, 
Nijmegen Medical Centre, Nijmegen, Netherlands, using previously described methods 
(Vermeer et al. 2008). The ‘non-ARSACS’ cases were diagnosed using standard 
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diagnostic techniques in the Department of Neurogenetics, NHNN. The idiopathic 
cases were investigated using the same standard diagnostic techniques and were 
confirmed not to have SACS mutations using an Illumina TruSeq Custom Amplicon 
panel (Illumina, San Diego, CA USA) designed specifically for this study to detect 
mutations in genes causing spastic ataxia (de Bot et al. 2012). The genes on the panel 
are given in Table 58. Library preparation was undertaken using the manufacturer’s 
protocol (part 15027983, revision C, August 2013) using MiSeq reagent kit version 3 
with amplicons designed to cover SACS gene exons with 99% coverage. Subsequent 
amplification used the polymerase chain reaction (PCR) according to the 
manufacturer’s protocol (Applied Biosystems Gene Amp PCR System 9700, Thermo 
Fisher Scientific, Waltham, MA USA) and massively parallel sequencing used the MiSeq 
sequencer (Illumina, San Diego, CA USA). Analysis was undertaken using the company’s 
in-house software. The SACS mutation carriers were confirmed using the same 
technique. SACS gene variants are annotated according to reference sequence 
NM_014363.4. 
Table 58: Genes on Illumina TruSeq Custom Amplicon spastic ataxia panel 
Condition Gene Protein Location 
ARSACS (SPAX6) SACS Sacsin 13q12.12 
Hereditary spastic paraplegia, type 7 (HSP7) SPG7 Paraplegin 16q24.3   
Hereditary spastic paraplegia, type 11 
(HSP11) 
SPG11 Spastacsin 15q21.1 
Adult-onset Alexander disease GFAP Glial fibrillary acidic protein 17q21.31 
Cerebrotendinous xanthomatosis (CTX) CYP27A1 Cytochrome P450, subfamily 
XXVIIA, polypeptide 1 
2q35 
 
Fatty acid dehydrogenase deficiency (with 
brain iron accumulation) 
FA2H Fatty acid 2 dehydroxylase 16q23.1 
 
Spastic ataxia with leukoencephalopathy 
(SPAX3) 
MARS2 Methionyl tRNA synthetase 2 2q33.1 
Autosomal recessive spastic ataxia, type 4 
(SPAX4) 
MTPAP Mitochondrial poly(A) polymerase 10p11.23 
Autosomal recessive spastic ataxia, type 5 
(SPAX5) 
AFG3L2 ATPase family gene 3-like 2 18p11.21 
Adrenomyeloneuropathy ABCD1 ATP-binding cassette, subfamily D, 
member 1 
Xq28 
 
Ataxia with co-enzyme Q10 deficiency 
(ACoQ10D) 
ADCK3 aarF domain-containing kinase 3 1q42.13 
308 
 
6.2.3 Optical Coherence Tomography  
After dilating the pupils with 1% tropicamide eyedrops, the patient was seated at a 
time-domain OCT device (Stratus, Carl Zeiss Meditec, Dublin, CA) and asked to fixate 
on the device’s internal target using the test eye whilst the fellow eye was occluded.  
Polarization was machine-optimised then the RNFL thickness was measured in a circle 
around the optic disc using the ‘Fast RNFL Thickness’ acquisition protocol (see Figure 
85). OCT data were analyzed using the proprietary software (Stratus version 4.07) 
which provides automated estimates of RNFL thickness in each quadrant around the 
disc (superior, nasal, inferior and temporal) and an average measurement of RNFL 
thickness around the entire circumference of the optic disc.  The analysis software also 
provides a measure of scan quality referred to as ‘signal strength’ on an arbitrary scale 
0-10; we took the decision to accept recordings only if the signal strength was at least 
5, the scan circle was well-centred on the optic disc and there was no eye movement 
or blink artefact. In each patient OCT scans were repeated three times per eye, and the 
results for both eyes averaged. In a small number of cases, imaging of both eyes was 
not possible for technical reasons such as inability to fixate or poor image quality. 
6.2.4 Ophthalmological Examination  
Patients had their best corrected visual acuity (Snellen) and colour vision (Ishihara 
pseudo-isochromatic plates) tested in both eyes, and then underwent a full ophthalmic 
examination by an experienced ophthalmologist (Dr Fion Bremner, NHNN). 
Fundoscopy was specifically performed to determine whether or not there was any 
clinically apparent abnormal thickening of the RNFL. 
6.2.5 Neurological Examination 
Each participant with ARSACS underwent full neurological examination as described in 
Chapter 5. The assessment included examination of tone, power, reflexes, sensation, 
coordination, eye movements and skeletal foot abnormalities. A thorough history was 
recorded and past medical notes and previous investigations reviewed. Age at onset 
was taken as the age of first symptoms compatible with the subsequent diagnosis of 
ARSACS as judged by the patient or in the medical notes. 
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Figure 85: Typical TD-OCT scan for ARSACS patient showing RNFL thickness above 
95% centile in all retinal quadrants 
TEMP=temporal quadrant; SUP=superior quadrant; NAS=nasal quadrant;  INF=inferior quadrant  
OD=right eye; OS=left eye 
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Table 59: Neurological, ophthalmological and OCT findings in ARSACS patients 
     Neurological Features Ophthalmological Features Refraction RNFL Thickness (μm) 
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1 
c1144G>T; 
c11352_11353dup 
1 30 29 + + (+) (+) 
N/-
/++ 
E/E + + + N - RT D 3 100 NR NR 200 151.5 195.5 152 174.8 
2 
c7255_7259del; 
c9956_9957delAA 
5 23 18 + + - - N - + - + N - RT A 3 100 NR NR 156 120 182.5 120.5 144.9 
3 
c5820_5821del; 
c7162_7163del 
1 33 32 ++ ++ ++ + N E/E + + + N - RT A 4 92 3 3 194.5 111.5 179 153.5 159.4 
4 
c8339T>G; 
c11675C>G; 
c12416T>C 
48 60 12 ++ + ++ + N E/F + - - N - RT A 1 100 -0.25 0 161 152.5 190.5 84.5 147.1 
5 
c8339T>G; 
c11675C>G; 
c12416T>C 
51 62 11 + + ++ - N/- E/E + - - N - RT A 3 100 NR NR 152.5 119.5 181.5 100.5 138.5 
6 
c8339T>G; 
c11675C>G; 
c12416T>C 
43 61 18 + ++ + + N/++ E/E + + + N - N A 2 100 0 0 150 103 146.5 78.5 119.3 
7 
c8339T>G; 
c11675C>G; 
c12416T>C 
35 47 12 + + + - N/++ E/E + - + N CB N A 2 100 0 0 145 133 164.5 94 134.1 
8 
c8339T>G; 
c11675C>G; 
c12416T>C 
46 60 14 + (+) + + N/- E/E + - + N CB N A 4 65 NR NR 148 114 157 93 128.1 
9 
c5151dupA; 
c5948C>T; 
c6392delT 
2 40 38 + + ++ 
++
+ 
- E/E + - + N - N A 4 100 -8.5 -10.25 175.5 103.5 157 120 139.4 
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10 
c9404T>C; 
c11265_11266delAT 
10 45 35 + ++ ++ 
++
+ 
- - + + + N LA RT A 4 100 2.25 2.25 188 148 225.5 121 170.7 
11 
c9404T>C; 
c11265_11266delAT 
13 39 26 (+) + ++ + N/++ E/F + + + N LA N N 4 100 NR NR 180 147.5 195 114 158.9 
12 
c6078del 
homozygous 
2 21 19 + ++ - - ++ E/E + + + N M RT K 7 100 -0.5 -1.75 190 136.5 215 143.5 171.1 
13 
c4226_4229del; 
c9404T>C 
32 50 18 + + ++ + N/- - + + + N - RT A 
N
R 
NR 2 2 155 126.5 180 121 145.6 
14 
c3149C>A; 
c4744G>T 
5 32 27 + (+) - - 
N/-
/++ 
E/- + ++ + N - RT A 2 100 0 0 171.5 113.5 182.5 114 145.3 
15 
c9404T>C ; 
c12028C>T 
3 46 43 (+) - 
++
+ 
+ N/- F/F + + + N - RT A 4 100 0 0 195 127.5 210.5 129 165.6 
16 
c9404T>C ; 
c12028C>T 
5 51 46 + (+) ++ + - E/E + + + N - RT A 2 100 -0.75 -0.5 177 95.5 196 108.5 144.4 
17 
c9956_9957del ; 
c10115dup 
1 31 30 (+) ++ (+) + N/- E/E + (+) + N - RT A 4 100 0 0 196 144.5 191.5 119.5 163.0 
Reference sequence NM_014363.4 
Reflexes: N=normal ; - = absent ; ++ = increased 
Plantar reflexes: E=extensor ; F=flexor ; - = mute 
Other neurological features:  - = absent ; (+) equivocally present ; + = present ; ++ strongly present ; +++ very strongly present 
Foot abnormalities: PC=pes cavus ; TEV=talipes equinovarus ; TE=talipes equinus ; HT=hammer toes ; CT=claw toes 
Ocular history: CB=colour blind ; LA=left eye amblyopia ; M=myopia ; - = No past ocular history 
Fundal appearance : RT=retinal thickening 
Other ophthalmic features : D=diplopia ; A=asymptomatic ; K=keratoconus ; N=symptomatic nystagmus 
Snellen acuity: 1=6/4 ; 2=6/5 ; 3=6/6 ; 4=6/9 ; 5=6/12 ; 6=6/18 ; 7=6/24 
RE=right eye; LE=left eye 
NR=not recorded 
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6.3 Results 
The 17 patients with ARSACS came from 11 families and showed 20 different 
pathogenic mutations (see Table 59). The patients were between the ages of 21 and 62 
when assessed. Disease onset varied between 1 and 46 years, and disease duration 
between 11 and 46 years. In contrast to previous descriptions of the Québecois cohort 
of ARSACS patients (Bouchard et al. 1998), members of one family (patients 4-8) had 
disease onset in middle life (range 35-51 years). All from this family share three 
pathogenic mutations, none of which is found in the Québecois population (Thiffault et 
al. 2013). Two mutations (c.8339T>G and c.12416T>C) are known from studies of 
related carriers to cosegregate. All patients in the study had ataxia and all but one had 
spasticity (94.1%). Fourteen (82.4%) showed clinical evidence of sensory loss. Twelve 
(70.6%) had limb weakness. Deep tendon reflexes were absent in ten patients (58.8%) 
and hyperreflexic in six (35.3%), sometimes with mixed absent and increased reflexes 
in the same patient. Thirteen had extensor plantar reflexes (76.5%). Eleven patients 
had dysarthria (64.7%) and fifteen had skeletal foot abnormalities (88.2%). All patients 
displayed nystagmus. 
The results of the ophthalmological assessment of patients with ARSACS are given in 
Table 59. In general, patients had no complaints about their eyes or vision.  In a few 
cases there was a history of previous ophthalmic problems (two patients with 
amblyopia, two with congenital colour blindness and one with myopia). No patients 
had visual symptoms ascribable to retinal disease, with 14/17 (82.4%) patients visually 
asymptomatic, one patient with diplopia, one with symptomatic nystagmus and one 
with focussing problems caused by keratoconus.  All patients except the patient with 
keratoconus had Snellen acuity of 6/9 or better, and only one patient was unable to 
identify correctly the Ishihara pseudo-isochromatic plates.  In all cases the pupillary 
reaction to light was clinically normal.  Apart from the one case with keratoconus, no 
other ARSACS patient was found to have any abnormality in the anterior segment of 
the eye on slit lamp biomicroscopy. 
Fundoscopy revealed abnormal thickening of the RNFL in 13/17 patients (76.5%). None 
of these cases had any associated swelling or elevation of the optic nerve head, nor 
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were there any abnormalities seen in the overlying vitreous, retinal vessels, outer 
retina, retinal pigment epithelium or choroid.  In four of the 17 cases of ARSACS 
(23.5%), fundoscopy was normal with no clinically apparent thickening of the RNFL.  
There was no clear correlation between genotype and retinal phenotype; indeed in 
patients 4-8, individuals sharing the same mutations had different fundoscopic 
appearances. 
OCT measurements of the RNFL thickness in these ARSACS patients are shown in Table 
59 (for each patient, figures shown are the mean of measurements from both eyes 
unless it was only possible to obtain a scan from one eye). The average RNFL thickness 
measurements (estimated from the entire 3600 of the scanned circle around each disc) 
ranged from 119.3μm to 174.8μm, and in all cases lay above the 95% upper limit 
defined in the normative database provided by the manufacturer.  OCT measurements 
of RNFL thickness were significantly lower in the four cases where fundoscopy was 
clinically normal (mean±SD of 130.2±8.6) than in the remaining 13 cases where it was 
visibly thickened (mean±SD of 156.1±12.3; p=0.001).  Further analysis of OCT 
measurements by quadrant (superior, nasal, inferior and temporal) showed similar 
degrees of abnormal thickening of the RNFL in all meridians.  Among the whole cohort 
of 17 patients with ARSACS there was a significant decline in RNFL thickness with age 
(linear regression coefficient R=0.624, p=0.007) and a negative correlation with age at 
onset (linear regression coefficient R=0.629, p=0.007) but a non-significant positive 
correlation with disease duration (linear regression coefficient R=0.368, p=0.146; see 
Figure 86).  
 
Figure 86: Correlation between average RNFL thickness for ARSACS patients and age 
at disease onset (left), age at examination (middle) and disease duration (right) 
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Thirteen asymptomatic individuals carrying heterozygous SACS gene mutations who 
were all relatives of the patients studied had RNFL thickness measured by OCT. The 
mean±SD average RNFL thickness was 93.8±7.5 (range 82-105.5). 
One hundred and twenty-nine patients with genetically confirmed ataxias other than 
ARSACS were seen (FRDA n=59, SCA n=53, others n=17). Many but not all of these 
patients had RNFL thickness measurements below the 95% lower limit of normal 
compared to the machine’s age-matched bank of normative data. None of these 
patients had average RNFL measurements ≥ 106μm whereas all the ARSACS patients 
had RNFL measurements ≥ 119μm, providing an absolute differentiation between 
cases of ARSACS and other genetically proven ataxias. However, it is important to 
calculate average peripapillary RNFL thickness, as individual sectoral values have 
greater and overlapping ranges (lowest ARSACS 78.5m temporal quadrant; highest 
FRDA 150.5m nasal quadrant). 
Fundoscopy was performed in 112 patients with other types of hereditary ataxia (data 
not shown). As expected, a number of typical abnormalities were seen including optic 
atrophy (in FRDA) and pigmented maculopathy (in SCA7), but none of these patients 
showed thickened RNFL similar to that seen in ARSACS. Visual acuity was measured in 
88 patients (FRDA n=43, SCA n=34, others n=11). There were no significant differences. 
Performance on Ishihara pseudo-isochromatic plates was assessed in 78 patients 
(FRDA n=35, SCA n=34, others n=9). There were no significant differences between 
groups and with ARSACS patients and carriers, although unlike ARSACS patients and 
carriers, there were patients in all 3 genetic groups who could not identify more than 
half of the plates. 
Forty-five patients with were assessed, for whom no clear genetic or metabolic cause 
of ataxia including ARSACS had been identified (ie idiopathic ataxia), and none was a 
carrier of a SACS gene mutation. All patients except two had average RNFL thickness 
below 110m with the lowest value of 45.5m. Twenty-two patients also had both 
Snellen visual acuity and Ishihara colour plates assessed. There were no significant 
differences in visual acuity or colour vision between the idiopathic and any other 
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group, although again, unlike the patients with ARSACS and SACS gene mutation 
carriers, the idiopathic group included individuals with extremely poor vision.  
Average OCT measurements of the RNFL thickness for ARSACS and all other groups 
studied are shown in Table 57 and displayed as box-and-whisker plots in Figure 87. The 
RNFL thickness of the ARSACS group was significantly different from all other groups 
(Mann-Whitney U test, p<0.0005 for all 5 tests). 
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Figure 87: Box-and-whisker plots of average OCT measurements of RNFL thickness 
Boxes show median and interquartile range; whiskers show 5th and 95th percentiles; 
points show values outside 9th and 95th percentiles. 
6.4 Discussion 
This is the largest cohort of patients with ARSACS and other genetic ataxias to undergo 
systematic evaluation by OCT and comprehensive visual assessment. The results of this 
study show that OCT can be used to differentiate ARSACS from other genetically 
diagnosed causes of progressive ataxia as well as idiopathic ataxias and can therefore 
be used as a reliable screening tool for deciding whether to order the genetic test in 
order to make a definitive genetic diagnosis. This is an important finding as, due to the 
large size of the SACS gene and number of mutations causing ARSACS, genetic testing 
316 
 
for ARSACS is expensive, and not available in many neurological or ophthalmological 
centres. An average RNFL thickness of 119m on TD-OCT should be used as a cut-off to 
distinguish ARSACS from other causes of ataxia.  
Table 60: Table of frequencies for RNFL thickening in ARSACS 
  ARSACS genetic 
test positive 
ARSACS genetic 
test negative 
 
RNFL thickness 
≥119μm by TD-OCT 
17 
(true positive) 
1 
(false positive) 
18 
RNFL thickness 
<119μm by TD-OCT 
0 
(false negative) 
173 
(true negative) 
173 
 17 174  
Amongst patients with symptomatic ataxia, this gives a sensitivity of 100%, a specificity 
of 99.4% (area under ROC curve 1.000, p<0.001), a positive predictive value of 94.4%, a 
negative predictive value of 100%, a false positive rate of 0.6% and a false negative 
rate of 0%. Thus, RNFL thickness is an excellent test for distinguishing cases of ARSACS 
from non-ARSACS cases amongst a population of patients with symptomatic ataxia.  
Patients should first be thoroughly assessed to exclude acute causes of RNFL 
thickening such as LHON and optic neuritis. Fundoscopy should always be performed 
to exclude papilloedema and retinitis pigmentosa as non-genetic causes of thickened 
RNFL. Typically, ARSACS patients also do not have accompanying visual symptoms, 
other than those associated with cerebellar eye signs such as nystagmus. Thus, their 
presence should alert the clinician to an alternative diagnosis or an additional 
unrelated cause of ocular pathology. Similarly, patients diagnosed with ARSACS 
undergoing assessment in the neurology or ophthalmology clinics can be reassured 
that visual loss is rare in ARSACS and unrelated to RNFL thickening.  
However, caution should be exercised when assessing unaffected individuals, 
particularly those related to ARSACS patients, as it has previously been shown that two 
asymptomatic heterozygous carriers of a c.1144G>T mutation have partial thickening 
of the RNFL on OCT, with average values of 115.5m. The present study found no 
more cases amongst a further 13 known SACS gene mutation carriers, suggesting that 
this is not a common finding in this group. 
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Of the patients with average RNFL thickness close to or above the proposed cut-off of 
119m, the first was a 22-year old woman with a four year history of progressive 
imbalance, dysarthria, dysphagia and diplopia. Imaging showed significant cerebellar 
atrophy and a thoracic syrinx from T9 to T11 but no brainstem or supratentorial 
atrophy. There was ataxia of all four limbs and brisk reflexes, but normal tone, power 
and sensation throughout, and she was able to walk unaided. There was no pes cavus. 
Eye movements showed jerky pursuits, saccadic dysmetria and gaze-evoked horizontal 
nystagmus. Genetic tests were negative for SCA 1,2,3,6,7,12, FRDA, AOA1, AOA2, 
ataxia telangiectasia, ARSACS and HSP7. There was no family history. She had average 
RNFL thickness of 118.6m.  
The second was a 21-year old man who was born following a prolonged delivery. He 
had delayed development of walking and was diagnosed with cerebellar ataxia at the 
age of 18 months. By the age of 10, he required a wheelchair, and he developed 
progressive dysarthria and dysphagia. There were some learning difficulties.  He 
subsequently developed progressive spasticity and spasms. There was weakness and 
wasting of all four limbs and bilateral facial weakness. Tone was increased throughout 
with intermittent extensor spasms. Deep tendon reflexes were brisk in the upper limbs 
but absent at the ankles. There was lumbar scoliosis and pectus excavatum but no pes 
cavus. Eye movements showed jerky pursuits but no nystagmus or saccadic dysmetria. 
Pupillary reactions, visual fields, visual acuity and colour vision were normal. 
Neurophysiological studies showed a severe length-dependent axonal sensorimotor 
polyneuropathy with patchy demyelinating features. Imaging of the brain and 
cerebellum was normal. Genetic testing was negative for SCA 1,2,3,6,7, FRDA, BSCL2, 
connexion-32, HSP7, mitochondrial point mutations and ARSACS. There was no family 
history. Fundoscopy was visually normal. The average RNFL thickness by TD-OCT was 
124.0m. In both cases, there was no other ocular explanation for the RNFL 
thickening. SD-OCT confirmed global RNFL thickening but with normal foveal contour. 
The foveal contour is commonly obliterated in ARSACS (see Figure 83C) and so this 
may represent a means of distinguishing borderline cases.  
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It should be noted that the Illumina TruSeq Custom Amplicon technique has >99% 
coverage of the SACS gene but does not cover a short sequence of exon 10. The 
amplicons flank the exons by 25nt and so should detect splice-site variants, which have 
previously been described in ARSACS (Vermeer et al. 2008). It would not necessarily 
detect mutations in the 5’- and 3’-untranslated regions or within introns, and would 
not detect large deletions of which several have been described (Breckpot et al. 2008, 
Baets et al. 2010, Pyle et al. 2013, Terracciano et al. 2009, Piluso et al. 2011, Pilliod et 
al. 2015). The presence of two macrodeletions in the present study suggests that this 
may be a relatively common cause of ARSACS (and certainly more common than large 
deletions in FRDA). Taken together, these may therefore be alternative explanations of 
the two anomalous cases which could be investigated genetically. Alternative methods 
for detecting SACS gene dysfunction might include looking at downstream effects such 
as mRNA or sacsin protein levels. 
The underlying nature of the retinal changes seen in ARSACS remains obscure. Visibly, 
they comprise radial white or yellow streaks emanating from the optic disc, most 
commonly in the interpapillomacular region, often following the retinal vessels and 
even obscuring them (see Figure , A & B). Although these changes were initially 
descriptively termed ‘retinal striation’ due to ‘increased visibility of the retinal nerve 
fibers’ (Bouchard et al. 1978), they subsequently took on the pseudo-pathological 
description of ‘myelinated retinal fibers’ (Bouchard 1991) or ‘retinal hypermyelination’ 
(Takiyama 2006, Gücüyener et al. 2001, Ogawa et al. 2004, Prodi et al. 2013). However, 
there is no published pathological or other evidence to support these appellations. 
Myelin is not normally present in the human retina. Myelination of optic nerve axons 
occurs by migration of oligodendrocyte progenitors along long axons, starting at the 
lateral geniculate body and ceasing at the lamina cribrosa of the optic nerve head 
where they are prevented from penetrating the retina probably by a dense 
aggregation of astrocytic processes (Hunter et al. 1997, Fitzgibbon & Nestorovski 
1997). The intraretinal course of the retinal ganglion axons is therefore not usually 
myelinated.  
However, myelinated axons are observed in the human retina in approximately 1% of 
cases (Straatsma et al. 1981), giving rise to the syndrome of (persistent) myelinated 
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retinal nerve fibres (SMRNF) which can also be associated with structural or 
developmental abnormalities of the retina, eye, brain or skull, or neoplastic disorders 
(see Figure 88). They usually cause a visual field defect, myopia or amblyopia 
(Tarabishy et al. 2007). As in the present series, these clinical features are not typically 
seen in ARSACS. When the eyes of patients with ARSACS are directly compared with 
those of patients with known myelinated retinal nerve fibres, a number of differences 
are apparent. In SMRNF, RNFL thickening is only seen where myelinated nerve fibres 
are visible, whereas in ARSACS RNFL thickening is more widespread, includes the 
macula causing filling of the foveolar depression and is present even in subjects 
without visible RNFL thickening. In SMRNF, the myelinated nerve fibres cause posterior 
shadowing on OCT obscuring the deeper layers because of hyperreflectivity which is 
not seen in ARSACS. These findings suggest the material deposited in the retina is 
different in the two cases (Vingolo et al. 2011, Desserre et al. 2011). Furthermore, 
nerve conduction studies are usually consistent with an axonal neuropathy with 
demyelinating features (Peyronnard et al. 1979, Prodi et al. 2013, Gazulla et al. 2012, 
Takiyama 2006). This was seen in the patients in the present series. Thus, depletion of 
myelin rather than overproduction seems to be the common pathological feature of 
ARSACS. 
  
Figure 88: Myelinated retinal nerve fibres 
Image from (Bruce et al. 2007) 
Different groups have therefore proposed the alternative terms ‘pseudomyelination’ 
(Vingolo et al. 2011) or ‘RNFL hypertrophy’ (Garcia-Martin et al. 2013, Pablo et al. 
2011) to describe the retinal appearance in ARSACS. The simpler and more descriptive 
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term ‘thickened retinal nerve fibre layer’ may be more appropriate (Nethisinghe et al. 
2011). A greater understanding of these changes may help elucidate the underlying 
pathophysiological processes in this condition. 
In summary, the genetic test for ARSACS is expensive, technically difficult and not 
widely available. In contrast, OCT is cheap, fast and widely available. This study shows 
that OCT is a sensitive and specific tool for identifying characteristic retinal changes in 
patients with ARSACS and can be used to distinguish ARSACS from other genetically 
diagnosed and idiopathic forms of ataxia. Its routine use in the assessment of 
suspected cases of ARSACS even in the absence of fundoscopic changes is advisable. 
The underlying pathophysiology of these changes remains obscure but there is 
increasing evidence that the thickness is not related to excess myelin.
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Afterword 
 
This thesis synthesizes clinical and genetic studies in two rare and devastating 
autosomal recessive ataxic syndromes. 167 patients with FRDA were recruited as part 
of the UK wing of the European Friedreich’s Ataxia Consortium for Translational 
Studies (EFACTS) making this the largest natural history study of FRDA ever undertaken 
in the UK. The wider European study has now recruited more than 650 patients with 
the UK wing recruiting the largest cohort. The baseline clinical data from this project 
have recently been published (Reetz et al. 2015) including all the cases described in 
this thesis. This forms the largest clinical study of FRDA in the world literature.  
The baseline clinical and demographic data for the 167 FRDA patients recruited and 
studied as part of the UK wing of EFACTS are described in detail in the Results section 
2.3 of Chapter 2 of this thesis. Follow-up data for 125 patients after one year and 116 
after two years were obtained, and data on disease progression as defined by the 
SARA, INAS, ADL and SDFS are described in detail in the Results section 2.3.11. The 
validity of these rating scales is discussed in section 2.4.5 and their ability to capture 
disease progression discussed in section 2.4.6. In essence, the ADL provides a reliable 
symptom-based assessment of disease involvement in FRDA, and the SARA, a reliable 
examination-based assessment. The raw INAS data provide a large amounts of useful 
supportive information which are statistically anaylzable but the INAS count is far less 
relevant in FRDA because of its dependence on non-ataxic features (which are less 
prominent in FRDA and therefore probably not the predominant determinants of 
disability). A large proportion of patients are unable to undertake all parts of the SCAFI 
which therefore introduces a significant ceiling effect and makes it less reliable in 
FRDA. In particular, more than half of the patients in the study were unable to 
complete the 8mTW because of wheelchair dependence. The SDFS provides a good 
overall marker of disability but provides little scope for further analysis as it is a simple 
7-point score. The SARA, ADL and SDFS were all sufficiently sensitive to capture disease 
progression at 2 years but the INAS count failed to detect any statistically significant 
change over this period.  Overall therefore, this thesis finds that the SARA is the best 
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rating scale for the assessment of objective examination-based disease involvement 
and change in FRDA, whilst the ADL provides the best assessment if subjective disease 
involvement. 
Previous pharmacological trials in FRDA have concentrated on two pathological 
mechanisms, namely directly increasing frataxin expression and ameliorating the 
downstream effects of frataxin depletion, particularly by decreasing oxidative stress 
and improving mitochondrial function (Wilson 2012, Perlman 2012, Strawser et al. 
2014). Agents aimed at increasing frataxin production have included erythropoietin, 
pioglitazone, resveratrol and interferon-γ. One group administered a protein formed 
by fusing the transduction domain of the transactivator of transcription (TAT) protein 
with the frataxin molecule (TAT-frataxin) producing encouraging results in cell culture 
and mouse models of FRDA (Vyas et al. 2012). More recently, strategies aimed at 
decreasing pathological heterochromatin formation using histone deacetylase 
inhibitors have been used to increase frataxin production (Sandi et al. 2014). In the 
future, further techniques may include gene therapy, stem cell therapy and RNA-based 
treatments. 
Strategies aimed at improving mitochondrial dysfunction have included oral iron-
chelating agents such as deferiprone which prevent mitochondrial iron accumulation 
and decrease oxidative stress (Wilson 2012, Perlman 2012, Strawser et al. 2014). A 
number of other anti-oxidant agents have been employed including vincerinone and 
oxigon, but by far the greatest number of human trials has been conducting on co-
enzyme Q10 and its synthetic analogue, idebenone. These have been comprehensively 
reviewed by the author (Parkinson et al. 2013). Although initial results were 
encouraging, these have not been replicated in large, multicentre, longitudinal trials. 
Further techniques at ameliorating the consequences of increased oxidative stress in 
FRDA include the use of deuterated polyunsaturated fatty acids which helps prevent 
free-radical-mediated damage to membranes (Cotticelli et al. 2013). 
This thesis provides some evidence as to which rating scales might be useful in future 
trials. This is based on data from the 116 patients who were seen both at baseline and 
the second follow-up visit. An increase (deterioration) of 1.33±3.14 (mean±SD) was 
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seen in the SARA over this 2 year period, representing normal disease progression. For 
a therapeutic agent to reduce disease progression by 50% (or 0.67 SARA points) would 
require a sample size of at least 240 patients, based on a power of 80% (ie an 80% 
probability of rejecting the null hypothesis) and a significance level of 5% (using 
Altman’s nomogram with standardized difference of 2δ/σd
2=0.67 for the paired t-test, 
where δ is the smallest mean difference and δd the standard deviation) (Petrie & Sabin 
2005, Altman 1982). Similarly, an increase (deterioration) of 2.04±3.22 was seen in the 
ADL over the 2 years of the study. To detect a 50% reduction in progression (or 1.02 
ADL points) would require at least 75 patients. An increase (deterioration) of 0.29±0.63 
was seen in the SDFS over 2 years. To detect a 50% reduction in progression would 
require at least 140 patients. No statistically significant change in the INAS count was 
detected over the 2 years of the study and so it is not possible to comment on the 
sample size required to detect a 50% reduction in progression according to this rating 
scale. These large sample sizes are required because of the large standard deviation 
when compared to the mean change in each case. Larger sample sizes would be 
required to detect more modest and perhaps more realistic reductions in disease 
progression, indicating, as discussed in 2.4.6 above, that these rating scales may not be 
appropriate to detect change in such a slowly progressive condition in which there is 
considerable background variation. 
Seven patients in the EFACTS part of the study were compound heterozygotes bearing 
one pathological GAA expansion and one pathogenic point mutation. In addition, six 
further patients were identified from the records of the NHNN, making a total of 
thirteen compound heterozygotes. These cases are discussed in Chapter 3. The clinical 
features of these patients were studied and compared to those of the patients with 
two GAA expansions, showing that increased frequency of hyperreflexia, and lower 
frequency of square wave jerks, dysarthria, dysphagia and possibly broken pursuit eye 
movements and wheelchair-bound status are associated with the compound 
heterozygous state as compared to those with two pathological GAA expansions. Of 
the clinical rating scales only the SARA came close to detecting a difference between 
the two groups suggesting a lesser degree of ataxia.  
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Eleven patients had previously described FXN mutations (c.389G>T/p.Gly130Val [n=9] 
and c.2T>C/p.Met1Thr [n=2]). Two novel mutations were identified.  The 
c.357_378dup22/p.Phe127fsX mutation introduces a premature termination codon in 
exon 3 of the FXN gene by a frameshift mechanism, and represents the first 
duplication mutation described in FRDA. The c.493_494CG>GA/p.Arg165Asp mutation 
causes a novel missense change at a known mutational hot-spot in exon 5a which in 
silico techniques predict to be pathogenic. 
The clinical and genetic features of a final case (patient ‘D’) are discussed in which the 
most likely explanation of the patient’s genetic abnormality is that of a compound 
heterozygote with a pathological GAA expansion and a large deletion. This case would 
constitute the twelfth case described in the world literature and the first in the UK. The 
discovery of this case has important implications for genetic testing as currently 
employed laboratory techniques may not distinguish certain compound heterozygous 
macrodeletions from homozygotes carrying two equally sized GAA expansions.  
The prevalence of compound heterozygous exonic deletions amongst a sample of 1768 
cases referred to the NHNN over a ten year period with a possible diagnosis of FRDA, 
was studied using the multiplex ligation-dependent probe amplification (MLPA) 
technique. The sample included forty cases with one pathological GAA expansion of 
which 11 also carried a pathogenic point mutation. Of the remaining 29 cases, nine 
were subsequently found to be asymptomatic leaving twenty symptomatic cases. DNA 
was available for 18 cases. The MLPA study was successful in 16 cases in none of which 
was an exonic deletion discovered. This result indicates that exonic deletions are not a 
common cause of FRDA, and this test should not routinely be offered for individuals 
with ataxia and a single pathological GAA expansion unless there is a very strong 
clinical suspicion of FRDA. Patient ‘D’ discussed above also did not show an exonic 
deletion using this technique which has implications for the sensitivity of the test and 
the composition of the probemix which is currently commercially available. As part of 
this study, the rate of compound heterozygotes in the sample was 5.3%, and that of 
carriers 1.1 to 1.6%. 
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Twenty-six patients with ARSACS were recruited into a natural history study of that 
condition. This represents the largest single centre prospective natural history case 
series of this very rare disease described outside Québec, and the first large systematic 
clinical and genetic study of ARSACS in the UK. The only larger study was recently 
published combining cases from twelve French centres with 47 patients from eight 
different countries (Pilliod et al. 2015). In the present study, nine novel mutations 
were identified which included four nonsense mutations 
(c.4226_4229delATGA/p.Asn1409Thr fsX, c.6078delT/p.Ala2026Ala fsX, 
c.10115dupC/p.Ser3372Ser fsX and c.12028C>T/p.Gln4010X) and five missense 
mutations (c.623G>T/p.Ser208Ile, c.3149C>A/p.Ala1050Asp, c.4723C>T/p.Arg1575Trp, 
c.8339T>G/p.Phe2780Cys and c.12416T>C/p.Leu4139Ser). These cases are discussed in 
Chapter 4 including a detailed discussion of the in silico predictions of pathogenicity for 
the missense mutations.  
The parallel natural history studies of FRDA and ARSACS in which the participants 
underwent substantially the same clinical assessment afford the possibility of 
comparing these two similar conditions. Table 61 shows the comparison of clinical 
rating scales between the two condition, as well as ages of significant events. There 
was no difference in age at onset, but the ARSACS patients were significantly older 
when seen as part of the study and so had significantly longer disease duration. A 
smaller proportion of the ARSACS patients were wheelchair-bound (15.4%) compared 
to the FRDA patients (51.5%) and the age at becoming wheelchair-bound was 
significantly later for ARSACS. The FRDA patients had significantly greater total SARA 
sores indicating a greater burden of ataxia despite shorter disease duration. Figure 89 
compares the mean vales for the individual subscores of the SARA. It can be seen that 
all subscores are greater in FRDA than ARSACS, but the subscores for speech, sitting 
and upper limb ataxia are approximately twice as great for FRDA as ARSACS. The INAS 
count was greater in the ARSACS than the FRDA patients. Figure 90 shows the 
individual components of the INAS count and it can be seen that the difference is 
largely driven by the greater incidence of hyperreflexia, extensor plantar reactions and 
spasticity in the ARSACS patients. The SDFS was slightly greater in the FRDA patients 
but neither the differences in INAS count nor SDFS survived Bonferroni correction. 
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Figure 91 shows the individual measurements of eye movement abnormalities within 
the INAS. This shows that nystagmus is more common in ARSACS, whilst square wave 
jerks, saccadic dysmetria and slowing of saccades are more common in FRDA. Broken 
smooth pursuits are very common in both conditions. Figure 92 shows a summary of 
muscle power measurements derived from the SNE as described in Chapters 2 and 5 
(based on the MRC rating scale of muscle power). This shows that weakness is usually 
greater in FRDA than ARSACS, the lower limbs are affected more than the upper and 
the distal muscles, more than the proximal.  
Figure 93 shows sensory loss derived from the SNE. This shows that there are 
comparable levels of pin prick loss between the two conditions, but that vibration 
sense and proprioception are much more affected in FRDA than ARSACS. In particular, 
there is very little upper limb vibrational and proprioceptive sensory loss in ARSACS.  
Table 61: Comparison of age data and clinical rating scales for FRDA & ARSACS 
 FRDA ARSACS Mann-Whitney 
 Mean SD n Mean SD n Z p† 
AAO 13.7 9.6 167 15.0 17.4 26 -1.647 0.100 
AAE 34.3 13.2 167 43.3 13.7 26 -3.185 0.001 
DD 20.5 11.2 167 28.5 12.9 26 -3.006 0.003 
AAW 21.9 8.7 86 43.4 16.8 5 -2.881 0.004 
SARA 22.5 10.0 166 16.0 7.7 26 -3.280 0.001 
INAS 5.0 1.6 166 5.7 1.9 26 -2.075 0.038 
ADL 15.2 8.4 164 12.2 6.1 26 -1.677 0.094 
SDFS 5.0 1.3 167 4.4 1.2 26 -2.801 0.050 
AAO=Age at onset; AAE=age at examination; DD=disease duration; AAW=age at wheelchair-bound 
SARA=Total SARA; INAS=INAS count; ADL=total ADL 
SD=Standard deviation 
†Bonferroni correction reduces significant p value to 0.05/8=0.00625 
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Figure 89: Comparison of SARA subscore values between FRDA & ARSACS 
ARSACS patients are consistently less severely affected than FRD patients 
 
 
Figure 90: Comparison of components of the INAS count between FRDA & ARSACS 
Pyramidal features such as hyperreflexia, spasticity and extensor plantar reflexes are 
more prominent in ARSACS than FRDA patients; weakness, wasting and sensory loss 
are similar; brainstem oculomotor signs are commoner in FRDA than ARSACS 
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Figure 91: Comparison of eye movement abnormalities between FRDA & ARSACS 
SWJs, saccadic dysmetria and slowed saccades are commoner in FRDA than ARSACS; 
nystagmus is commoner in ARSACS than FRDA; broken pursuits are common in both 
FRDA and FRDA (GEN=gaze-evoked nystagmus; SWJ=square wave jerk) 
 
Figure 92: Comparison of muscle power between FRDA & ARSACS 
FRDA patients are consistently more severely affected than ARSACS. In both condition, 
the LLs are more affected than ULs, and distal muscles are more affected than 
proximal (UL=upper limb; LL=lower limb. For explanation of scale, see Chapter 2 
Method 2.2.2) 
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Figure 93: Comparison of sensory loss between FRDA & ARSACS 
Sensory loss is consistently more pronounced in FRDA than ARSACS; in both 
conditions, the LLs are more affected than the ULs. (UL=upper limb; LL=lower limb. For 
explanation of scale, see Chapter 2 Method 2.2.2) 
Thus, progression to loss of mobility is much less common in ARSACS than in FRDA. 
Speech, swallow and upper limb manual dexterity are also less commonly affected 
than in FRDA. Broken smooth pursuits and horizontal gaze-evoked nystagmus are 
almost universal in ARSACS, but square wave jerks are rarely observed. Broken smooth 
pursuits are also commonly seen in FRDA. The absence of square wave jerks and the 
lower frequency of slow saccades and saccadic dysmetria are clear differences from 
FRDA. The pattern of weakness is very similar between FRDA and ARSACS, although it 
is more severe in the FRDA patients. In both conditions, the lower limbs are more 
affected than the upper limbs, and the distal muscles more than the proximal. Sensory 
loss is much more prominent in FRDA. In particular, involvement of posterior column-
related sensory loss is much more common in FRDA, and this tends to involve both 
upper and lower limbs, as opposed to being much more restricted to the lower limbs in 
ARSACS. The greater frequency of pyramidal features in ARSACS, notably spasticity and 
hyperreflexia, is another distinguishing feature which is usually only seen in late-onset 
atypical forms of FRDA. In addition diabetes and cardiomyopathy are not features of 
ARSACS. 
In Chapter 6, the phenomenon of retinal nerve fibre (RNFL) thickening in ARSACS was 
investigated. Fundoscopic abnormalities were identified amongst the first descriptions 
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of ARSACS (Bouchard et al. 1978) but appeared to be less common in non-Québecois 
cases. Ocular coherence tomography (OCT) has proved to be a more sensitive tool for 
detecting this feature. However, it was unclear whether RNFL thickening was present 
in all cases of ARSACS and whether its presence was specific to ARSACS. There is a 
pressing need for a surrogate test for ARSACS as the genetic test is expensive, time-
consuming and not readily available. The advent of massively parallel sequencing 
panels has reduced the cost of genetic testing somewhat (Németh et al. 2013), but 
these tools remain expensive and are still restricted to specialist units. The present 
study found that RNFL thickening was present in all 17 cases studied (range 119.3-
174.8μm) and not present in 129 patients with other genetically diagnosed ataxic 
syndromes (range 35.1-106.3μm). The two groups did not overlap at all. It has 
previously been reported that asymptomatic heterozygous carriers of SACS gene 
mutations might also have RNFL thickening (Nethisinghe et al. 2011). None of the 
thirteen carriers in the present study had RNFL thickening (range 82.0-105.5μm). 
However, amongst the 45 cases with idiopathic ataxia studied (and no SACS gene 
mutations), two cases had RNFL thickness of greater than 109μm. Thus, amongst the 
very restricted population of patients with symptomatic ataxia under investigation in a 
tertiary hospital specialist ataxia clinic, this test has a sensitivity of 100% and a 
specificity of 99.4%.  
A further feature of this study which was not discussed at length in the thesis for 
pressures of time and space was the development of a massively parallel sequencing 
panel for the diagnosis of spastic ataxias. This was primarily used in Chapter 6 to 
determine whether any of the idiopathic ataxia cases had SACS gene mutations, and 
also to determine the genetic status of the asymptomatic carriers. However, the 
original pool of patients who had undergone OCT scanning as idiopathic cases from the 
ataxia clinic included the four cases of HSP7 and one case of ataxia with co-enzyme Q10 
deficiency (although she was known to have co-enzyme Q10 deficiency on biochemical 
testing). No other positive cases were found from the genes listed in the Method in 
Chapter 6. Thus, amongst 50 patients studied, four (8%) had HSP7 and one (2%) had 
ACoQ10D caused by an ADCK3 mutation. Ataxia is known to be common in HSP7, in one 
large series affecting 57% of patients (van Gassen et al. 2012). The present study 
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confirms several very recent studies showing that HSP7 is a common cause of 
undiagnosed ataxia (Pfeffer et al. 2015, Choquet et al. 2015). In the UK, the 
p.Ala510Val mutation is the commonest cause (Roxburgh et al. 2012). In the current 
study all four patients carried the mutation c.1529C>T/p.Ala510Val as two different 
compound heterozygotes. Three had the mutation c.1450_1457del/p.484_486del fs, 
and one had the mutation c.1904C>T/p.Ser635Lys (Ref Seq NM_003199). Thus, testing 
for HSP7 mutations should be considered in a patient with ataxia and spasticity and no 
other clear genetic explanation. This perhaps could be the topic of a further research 
project. 
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Appendix 
 Clinical Report Forms (EFACTS proforma) 
 Instructions for SARA, INAS count, ADL questionnaire & SCAFI 
EFACTS Pseudonimization Data 
The participant's unique pseudonym is created electronically from the identification data once and 
never stored permanently on an electronic hard drive. The pseudonym's creation is 
unique, secure and not invertible.  
Umlauts and other special characters are automatically converted into a unique spelling. 
Please print the data after creation of the pseudonym for your confidential medical documentation. 
That is the only way to re-identify the subject's personal data. 
First name : 
 
Last name at birth : 
 
Date of birth (dd.mm.yyyy) : 
 
Hospital no : 
 
City/place of birth : 
 
Mother’s maiden name : 
 
 
Pseudonym assigned : 
 
 
Date seen : 
Visit :     BL     FU1     FU2     FU3 
EFACTS  Pseudonym _____-_____-_____ 
Demographics  Baseline        Follow-up  
Demographics 
 
Date data obtained: _D_ _D_._M_ _M_._Y_ _Y_ _Y_ _Y_ 
 
Year of birth:  ___________ 
 
Country of birth:  _______________________________ 
 
Age:   _______ 
 
Sex:    male   female 
 
Children:   yes   no 
    
   If yes, how many: ________ 
 
Marital status:   
 single 
    married 
    widowed 
    divorced 
    separated 
    in a relationship 
 
Patient ethnic group:  
 Caucasian  
(Underline subgroup: North-Western European, Eastern European, Southern European, North American 
European, Other regions, Mixed, Unclassified) 
    South American 
    African 
(Underline subgroup: African African, North African, North American African, Afro-Caribbean, Other, 
Mixed, Unclassified) 
    Asian 
(Underline subgroup: South Asian, East Asian, Middle Eastern, Other, Mixed, Unclassified) 
    Australian   
(Underline subgroup: Australia, New Zealand, Other, Mixed, Unclassified) 
 Native American 
(Underline subgroup: Middle America, South America, Other, Mixed, Unclassified) 
 Jewish 
 Mixed 
 Unclassified 
 Other 
 
 
Education level and employment 
 
ISCED education level: 
Please see definitions for your country online   ISCED 0 
 ISCED 1 
      ISCED 2 
      ISCED 3 
      ISCED 4 
      ISCED 5 
      ISCED 6 
 
 
Years of education: ____________ 
 
Employment:   yes   no 
    
   If yes, is employment  Full time 
       Part time 
EFACTS  Pseudonym _____-_____-_____ 
Onset  Baseline        Follow-up  
Onset 
 
First symptoms of FA 
 
When: ___________ age 
 
Symptoms at onset: 
 Scoliosis   yes   no 
 Cardiomyopathy  yes   no 
 Instability   yes   no 
 Falls    yes   no 
 Diabetes mellitus  yes   no 
 Other    yes   no 
 
  If yes, please specify: __________________________________________ 
  ____________________________________________________________ 
 
 
Problems during neonatal period:    yes   no 
 
  If yes, please specify: __________________________________________ 
  ____________________________________________________________ 
 
 
Delayed motor milestones:    yes   no 
 
  If yes, please specify: __________________________________________ 
  ____________________________________________________________ 
 
   
Impaired physical abilities during infancy:   yes   no 
 
  If yes, please specify: __________________________________________ 
  ____________________________________________________________ 
 
 
Diagnosis 
 
When was FA suspected by a physician: ______________ age 
 
Genetic diagnosis established?    yes   no 
 
 When? ____________ age 
 
 Where: ____________________________________________________________ 
 
 Result: Allele 1: ___________/ Allele 2: ____________ GAA-repeats 
 
  Point mutation: _______________________________________________ 
  ____________________________________________________________ 
 
 
EFACTS  Pseudonym _____-_____-_____ 
Variable Items  Baseline        Follow-up  
Various Items 
General 
Date data obtained _D_ _D_._M_ _M_._Y_ _Y_ _Y_ _Y_ 
 
 
Severity Index 
Disability Stage:   No functional handicap but signs at examination 
    Mild, able to run, walking unlimited 
    Moderate, unable to run, limited walking without aid 
    Severe, walking with one stick 
    Walking with two sticks 
    Unable to walk, requiring wheelchair 
    Confined to bed 
 
 
Gait 
Permanently wheelchair bound:  yes   no 
     If yes, since when: ________ age 
 
Permanent support for walking:  yes   no 
     If yes, since when: ________ age 
 
Intermittent support for walking:  yes   no 
     If yes, since when: ________ age 
 
Falls:     yes   no 
     If yes, since when: ________ age 
 
 
Additional Symptoms/History 
Visual impairment:   yes   no 
    Glasses since when: ________ age 
 
    Glasses effective:   yes   no 
 
    Glasses ineffective since: ________ age 
 
Partial or complete hearing loss:  yes   no 
    Hearing aid since when: ________ age 
 
    Hearing aid effective:  yes   no 
 
    Hearing aid ineffective since: ________ age 
 
Dyspnoea:    yes   no 
    If yes, limitation:  Slight limitations of physical activity 
       Marked limitations of physical activity 
       Unable to carry out any physical activity 
 
    Since when: ________ age 
 
Palpitations:   yes   no 
Comments (start of palpitations, duration…) __________________________________ 
______________________________________________________________________ 
 
Since when: ________ age 
 
Chest pain:   yes   no 
   Comments (describe pain: site, duration,…): __________________________________ 
   ______________________________________________________________________ 
 
   Since when: ________ age 
 
 
 
EFACTS  Pseudonym _____-_____-_____ 
Variable Items  Baseline        Follow-up  
Additional Symptoms/History Continued 
Syncope:   yes   no 
   Comments (describe syncope, frequency,…): _________________________________ 
   ______________________________________________________________________ 
 
   Since when: ________ age 
 
 
Family History 
Are there any family members affected by FA?   yes  no 
If yes, list a) degree of relationship (spouse, child, sibling, parent, grandparent, aunt/uncle, niece/nephew, 
cousin), b) sex (m/f), c) blood relation (no, identical, first degree, second degree), d) year of birth, e) age at 
onset, f) age at death (if deceased), g) pseudonym (if relative is part of EFACTS). 
1. ____________________________________________________________________________________ 
2. ____________________________________________________________________________________ 
3. ____________________________________________________________________________________ 
4. ____________________________________________________________________________________ 
5. ____________________________________________________________________________________ 
 
 
Total no. of siblings: ______________ 
 
 
Are there any family members affected by other types of ataxias?   yes  no 
If yes, list a) degree of relationship (spouse, child, sibling, parent, grandparent, aunt/uncle, niece/nephew, 
cousin), b) sex (m/f), c) blood relation (no, identical, first degree, second degree), d) year of birth, e) age at 
onset, f) age at death (if deceased), g) pseudonym (if relative is part of EFACTS). 
1. ____________________________________________________________________________________ 
2. ____________________________________________________________________________________ 
3. ____________________________________________________________________________________ 
4. ____________________________________________________________________________________ 
5. ____________________________________________________________________________________ 
 
 
Laboratory 
Fasting glucose _____________ (include unit) 
 
HbA1c  _____________ (include unit) 
 
 
Other Medical Diagnosis 
Diabetes mellitus   yes  no  unknown Since: ________ age 
   Type 1  Type 2  
    
Metabolic/Endocrine  yes  no  unknown Since: ________ age 
   Specify: _______________________________________________________________ 
 
Cardiovascular disease  yes  no  unknown Since: ________ age 
   Specify: _______________________________________________________________ 
 
Hypertension   yes  no  unknown Since: ________ age 
 
Pulmonary Disease  yes  no  unknown Since: ________ age 
   Specify: _______________________________________________________________ 
 
Gastrointestinal Disease  yes  no  unknown Since: ________ age 
   Specify: _______________________________________________________________ 
 
Hepatobiliary Disease  yes  no  unknown Since: ________ age 
   Specify: _______________________________________________________________ 
 
Hemato/Lymphatic  yes  no  unknown Since: ________ age 
   Specify: _______________________________________________________________ 
 
 
EFACTS  Pseudonym _____-_____-_____ 
Variable Items  Baseline        Follow-up  
Other Medical Diagnosis Continued 
Allergy/Immunologic  yes  no  unknown Since: ________ age 
   Specify: _______________________________________________________________ 
 
Renal Disease   yes  no  unknown Since: ________ age 
   Specify: _______________________________________________________________ 
 
Gynecologic/Urologic  yes  no  unknown Since: ________ age 
Disease   Specify: _______________________________________________________________ 
 
Psychiatric Disorder  yes  no  unknown Since: ________ age 
   Specify: _______________________________________________________________ 
 
   Clinical depression within the past year:  yes  no  unknown 
 
   History of depressive disorder diagnosis:  yes  no  unknown 
 
   Depression first diagnosed: ________ age 
 
Neurologic (other than  yes  no  unknown Since: ________ age 
disease under study) Specify: _______________________________________________________________ 
 
ENT    yes  no  unknown Since: ________ age 
   Specify: _______________________________________________________________ 
 
Ophthalmological   yes  no  unknown Since: ________ age 
   Specify: _______________________________________________________________ 
 
Dermatological Disease  yes  no  unknown Since: ________ age 
   Specify: _______________________________________________________________ 
 
Musculoskeletal   yes  no  unknown Since: ________ age 
   Specify: _______________________________________________________________ 
 
Autoimmune Disease  yes  no  unknown Since: ________ age 
   Specify: _______________________________________________________________ 
 
Other    yes  no  unknown  
   Specify: ______________________________________________ Since: ________ age 
   Specify: ______________________________________________ Since: ________ age 
   Specify: ______________________________________________ Since: ________ age 
   Specify: ______________________________________________ Since: ________ age 
   Specify: ______________________________________________ Since: ________ age 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EFACTS  Pseudonym _____-_____-_____ 
Medication  Baseline        Follow-up  
Medication 
 
FA related Drugs 
  
     Drug  Since  Ongoing End  Dose  Timing                 Administration 
  [mm.yyyy]   [mm.yyyy]  [w. unit]  [per day/week/month]          [p.o.,i.v., s.c., i.a.] 
 
1. ________________________ ____.______  ____.______ ________ ______________  _________ 
 
2. ________________________ ____.______  ____.______ ________ ______________  _________ 
 
3. ________________________ ____.______  ____.______ ________ ______________  _________ 
 
4. ________________________ ____.______  ____.______ ________ ______________  _________ 
 
5. ________________________ ____.______  ____.______ ________ ______________  _________ 
 
Please use space at the bottom of this form for additional information. 
 
 
Concomitant Medication 
  
     Drug  Since  Ongoing End  Dose  Timing                 Administration 
  [mm.yyyy]   [mm.yyyy]  [w. unit]  [per day/week/month]          [p.o.,i.v., s.c., i.a.] 
 
1. ________________________ ____.______  ____.______ ________ ______________  _________ 
 
2. ________________________ ____.______  ____.______ ________ ______________  _________ 
 
3. ________________________ ____.______  ____.______ ________ ______________  _________ 
 
4. ________________________ ____.______  ____.______ ________ ______________  _________ 
 
5. ________________________ ____.______  ____.______ ________ ______________  _________ 
 
6. ________________________ ____.______  ____.______ ________ ______________  _________ 
 
7. ________________________ ____.______  ____.______ ________ ______________  _________ 
 
8. ________________________ ____.______  ____.______ ________ ______________  _________ 
 
9. ________________________ ____.______  ____.______ ________ ______________  _________ 
 
10. ________________________ ____.______  ____.______ ________ ______________  _________ 
 
Please use space at the bottom of this form for additional information. 
 
 
Vitamin Supplementation 
  
    Vitamin  Since  Ongoing End  Dose  Timing                 Administration 
  [mm.yyyy]   [mm.yyyy]  [w. unit]  [per day/week/month]          [p.o.,i.v., s.c., i.a.] 
 
1. ________________________ ____.______  ____.______ ________ ______________  _________ 
 
2. ________________________ ____.______  ____.______ ________ ______________  _________ 
 
3. ________________________ ____.______  ____.______ ________ ______________  _________ 
 
4. ________________________ ____.______  ____.______ ________ ______________  _________ 
 
5. ________________________ ____.______  ____.______ ________ ______________  _________ 
 
Please use space at the bottom of this form for additional information. 
 
 
 
 
 
 
 
 
EFACTS  Pseudonym _____-_____-_____ 
Medication  Baseline        Follow-up  
 
Participation in Drug Trials 
  
    Name of the study  FA related Start Date  Ongoing End Date   Start Dose  End Dose               
   [dd.mm.yyyy]  [dd.mm.yyyy]  [w. unit]  [w. unit]           
 
1. ________________________  ____.____.______      ____.____.______  ________ _____ ______________  
 
2. ________________________  ____.____.______      ____.____.______  ________ _____ ______________  
 
3. ________________________  ____.____.______      ____.____.______  ________ _____ ______________  
 
4. ________________________  ____.____.______      ____.____.______  ________ _____ ______________ 
  
5. ________________________  ____.____.______      ____.____.______  ________ _____ ______________ 
  
Please use space at the bottom of this form for additional information. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EFACTS  Pseudonym _____-_____-_____ 
Variable Items  Baseline        Follow-up  
Drug consumption 
Legal, recreational and illegal drugs:  yes   no 
 
 
Alcohol consumption:   yes  no 
 
If yes, number of alcohol units/week:  none   1-20   21-30   >30 
[see conversion table] 
 
 
Nicotine at present:   yes   no 
 
If yes, what:   Cigarettes  Pipe   Cigar 
 
Number per day: __________________ Since: ____________________ year 
 
 
Nicotine in the past:   yes   no 
 
If yes, what:   Cigarettes  Pipe   Cigar 
 
Since: _______________ year To: ____________________  Number per day: ____________________ 
 
 
Amphetamines:   yes   no 
[only at current consumption] 
Usage:   Occasional  Regular 
 
 
Cannabis/Marijuana:   yes   no 
 
If yes, usage:   Occasional  Regular 
 
 
Cocaine:   yes   no 
 
If yes, usage:   Occasional  Regular 
 
 
Ecstasy (MDMA):   yes   no 
 
If yes, usage:   Occasional  Regular 
 
Flunitrazepam (Rohyopnol ®):  yes   no 
 
If yes, usage:   Occasional  Regular 
 
 
GHB (Gamma-Hydroxybutyrate):  yes   no 
 
If yes, usage:   Occasional  Regular 
 
 
Ketamine:   yes   no 
 
If yes, usage:   Occasional  Regular 
 
 
LSD:   yes   no 
 
If yes, usage:   Occasional  Regular 
 
 
Opiates (e.g. Heroin):   yes   no 
 
If yes, usage:   Occasional  Regular 
 
 
Other:   yes   no 
 
If yes, which: ____________________________________________________________________________________________ 
 
Usage:    Occasional  Regular 
EFACTS  Pseudonym _____-_____-_____ 
Cardio  Baseline        Follow-up  
Cardio 
Which ancillary tests have been performed? 
 
Echocardiography 
 
 yes   no 
 
When:    ____________ age 
 
Septum thickness:   ____________ mm 
 
Intraventricular thickness:  ____________ mm 
 
Functional ejection fraction:  ____________ % 
 
 
Electrocardiogramm 
 
 yes   no 
 
When:    ____________ age 
 
Sinusal rhythm:    yes   no 
 
Repolarization abnormalities  yes   no 
 
Q-waves:    yes   no 
 
Arrhythmia:    yes   no 
 
    Diagnosis: ______________________________________________ 
      ______________________________________________ 
 
Left ventricular hypertrophy  yes   no 
 
Conduction abnormalities  yes   no 
 
    Diagnosis: ______________________________________________ 
      ______________________________________________ 
 
Pace maker:    yes   no 
 
    Since when: ____________ age 
 
Present cardiologic diagnosis 
 
Cardiac hypertrophy:   yes   no 
 
Arrhythmias:    yes   no 
 
Hypertension:    yes   no 
 
Ischemic cardiopathy:   yes   no 
 
Other cardiopathy 
(valvular disease, …):   yes   no 
 
    Specify: _____________________________________________________ 
     _____________________________________________________ 
     _____________________________________________________ 
 
EFACTS  Pseudonym _____-_____-_____ 
General  Baseline        Follow-up  
General 
 
Examination 
 
Scoliosis:   yes   no 
 
   If yes, is scoliosis  mild   moderate  pronounced 
 
 
   Operation:  yes   no 
 
     When: __________ age 
 
 
Pes cavus:  Right:  yes   no 
 
     ++  +  (+) 
 
 
   Operation:  yes   no 
 
     When: __________ age 
 
Left:  yes   no 
 
     ++  +  (+) 
 
 
   Operation:  yes   no 
 
     When: __________ age 
 
 
Blood pressure:   ___________ /___________ mmHg 
(after sitting for 5 minutes) 
 
 
Pulse rate:   ___________ /min 
 
 
Body weight:   ___________ kg 
 
 
Body height:   ___________ cm 
 
 
 
Neuropsychological testing 
 
Phonemic verbal fluency (Letter F) _______________________ No. of words 
 
 
Phonemic verbal fluency (LetterA) _______________________ No. of words 
EFACTS  Pseudonym _____-_____-_____ 
Activities of Daily Living  Baseline        Follow-up  
Activities of Daily Living 
 
Speech    normal 
    mildly impaired, no communication problems 
    moderately impaired, is asked to repeat from time to time 
    heavily impaired, is frequently asked to repeat 
    mostly incomprehensible 
 
Swallowing   normal 
    rare choking 
    frequent choking 
    soft food required 
    feeding tube/gastrostomy 
 
Cutting food/   normal 
Use of Cutlery   mildly slowed and clumsy, but no assistance required 
    can cut most dishes, but slowed and clumsy, some assistance required 
    dishes have to be cut by caregiver, can eat slowly 
    has to be fed 
 
Dressing   normal 
    mildly slowed and clumsy, but no assistance required 
    intermittent assistance in buttoning etc. Or: Alterations of the procedures: sits 
        down for getting dressed, does not wear ties anymore… 
    considerable assistance required, can still do some things by himself/herself 
    helpless 
 
Personal hygiene  normal 
    mildly slowed and clumsy, but no assistance required 
    assistance in showering and bathing required Or: considerably slowed, uses 
        special auxiliary devices 
    assistance in washing, brushing teeth, combing and using WC facilities 
        required 
    completely depending on help 
 
Falls    none 
    infrequent falls (< once a month) 
    intermittent falls (> once a month) 
    falls several times per week or requires devices 
    not capable to walk or stand 
 
Walking   normal 
    mild difficulties, experiences unsteadiness 
    moderate difficulties, needs little or no help 
    severe gait disturbances, needs help or devices (cane, walker, Zimmer frame) 
    incapable of walking even with support 
 
Sitting    normal 
    mild truncal imbalance, backrest not required 
    cannot sit without backrest 
    capable of sitting only with considerable support (special chair, fixation) 
    incapable of sitting 
 
Bladder function  normal 
    mild urinary retention or mild urge incontinence (< once a month) 
    moderate urinary retention or moderate urge incontinence (>= once a month) 
        or infrequent urinary incontinence (< once a week) 
    frequent urinary incontinence (>= once a week) 
    complete loss of bladder function, needs intermittent catheterization or 
        permanent catheter 
         
EFACTS  Pseudonym _____-_____-_____ 
INAS  Baseline        Follow-up  
INAS 
(Inventory of Non-Ataxia Symptoms) 
 
Clinical Findings 
 
Reflexes:  
   Normal   hyperreflexia  areflexia 
1. Biceps (BTR)         
2. Patellar (PTR)         
3. Achilles (ATR)          
 
4. Extensor plantar reflex:  none  unilateral  bilateral 
 
 
Motor symptoms: 
 
5. Spasticity  none  mild  mod  severe 
 Gait         
 Upper Limbs        
 Lower Limbs        
6. Paresis  none  mild  mod  severe 
 Face/tongue        
 UL proximal        
 UL distal        
 LL proximal        
 LL distal        
7. Muscle atrophy none  mild  mod  severe 
 Face/tongue        
 UL proximal        
 UL distal        
 LL proximal        
 LL distal        
8. Fasciculations  none  mild  mod  severe 
 Face/tongue        
 Upper limbs        
 Lower limbs        
9. Myoclonus  none  mild  mod  severe 
 Face/tongue        
 Trunk         
 Upper limbs        
 Lower limbs        
10. Rigidity  none  mild  mod  severe 
 Axial         
 Upper limbs        
 Lower limbs        
11. Chorea/Dyskinesia none  mild  mod  severe 
 Face/tongue        
 Neck         
 Trunk         
 Upper Limbs        
 Lower Limbs        
12. Dystonia  none  mild  mod  severe 
 Face/tongue        
 Neck         
 Trunk         
 Upper Limbs        
 Lower Limbs        
13. Resting tremor none  mild  mod  severe 
           
 
 
 
EFACTS  Pseudonym _____-_____-_____ 
INAS  Baseline        Follow-up  
Sensory symptoms: 
 
14. Impaired vibration sense none (8/8) mild (>5/8) mod (2-5/8) severe (<2/8) 
 Right foot         
 Left foot         
 
 
Ophthalmological findings: 
 
Testing of fixation and smooth pursuit  no  yes 
15. Broken up smooth pursuit      
16. Square wave jerks on fixation      
17. Downbeat-nystagmus on fixation     
18. Gaze evoked-nystagmus on  
horizontal testing       
19. Gaze evoked-nystagmus on  
vertical testing        
20. Ophthalmoparesis on horizontal gaze     
21. Ophthalmoparesis on vertical gaze     
Testing of fast saccades    no  yes 
22. Slowing of saccades         
23. Hypometric saccades       
24. Hypermetric saccades      
Testing of visual function   no  yes 
25. Impaired visual activity      
 
 
Reported Abnormalities 
 
26. Double vision  none  mild   mod   severe/constant 
27. Dysphagia   none  mild   mod   severe/tube feeding 
28. Urinary dysfunction  none  mild   mod   severe/catheter 
29. Cognitive impairment  none  mild   mod   severe 
 
30. Episodic vertigo   none 
     mild (< 1x/year) 
     mod (>= 1x/year) 
     severe (>= 1x/month) 
 
31. Speech problems   none 
     mild (only when tired or after moderate amounts of alcohol) 
     mod (spontaneously, but intermittent) 
     severe (permanent) 
 
32. Problems with handwriting  none 
     mild (a bit worse than used to be) 
     mod (definitely worse than used to  be, but legible) 
     severe (legibility impaired) 
 
33. Spontaneous cramps   none 
     mild (< 1x/month) 
     mod (>= 1x/month) 
     severe (>= 1x/week) 
 
34. Other abnormal clinical findings or reported abnormalities: ____________________________________ 
_______________________________________________________________________________________
_______________________________________________________________________________________
_______________________________________________________________________________________ 
 
   
EFACTS  Pseudonym _____-_____-_____ 
SARA  Baseline        Follow-up  
SARA 
(Scale for the assessment and rating of ataxia) 
PLEASE READ SOPs FOR SARA! 
 
 
Gait:  
 
 Normal, no difficulties in walking, turning and walking tandem (up to one misstep allowed) 
 Slight difficulties, only visible when walking 10 consecutive steps in tandem 
 Clearly abnormal, tandem walking > 10 steps is not possible 
 Considerable staggering, difficulties in half-turn, but without support 
 Marked staggering, intermittent support of the wall required 
 Severe staggering, permanent support of one cane or light support by one arm required 
 Walking > 10m only with strong support (two special canes or stroller or accompanying person) 
 Walking < 10m only with strong support (two special canes or stroller or accompanying person) 
 Unable to walk, even supported 
 
 
Stance: 
 
 Normal, able to stand in tandem for > 10s 
 Able to stand with feet together without sway, but not in tandem for > 10s 
 Able to stand with feet together for > 10s, but only with sway 
 Able to stand for > 10s without support in natural position, but not with feet together 
 Able to stand for > 10s in natural position only with intermittent support 
 Able to stand for > 10s in natural position only with constant support of one arm 
 Unable to stand for > 10s even with constant support of one arm 
 
 
Sitting: 
 
 Normal, no difficulties sitting > 10s 
 Slight difficulties, intermittent sway 
 Constant sway, but able to sit > 10s without support 
 Able to sit for > 10s only with intermittent support 
 Unable to sit for > 10s without continuous support 
 
 
Speech disturbance: 
 
 Normal 
 Suggestion of speech disturbance 
 Impaired speech, but easy to understand 
 Occasional words difficult to understand 
 Many words difficult to understand 
 Only single words understandable 
 Speech unintelligible/anarthria 
 
 
Finger chase: 
 
Right  Left 
    No dysmetria 
    Dysmetria, under/overshooting target < 5cm 
    Dysmetria, under/overshooting target < 15cm 
    Dysmetria, under/overshooting target > 15cm 
    Unable to perform 5 pointing movements 
 
 
 
 
EFACTS  Pseudonym _____-_____-_____ 
SARA  Baseline        Follow-up  
 
Nose-finger test: 
 
Right  Left 
    No tremor 
    Tremor with an amplitude < 2cm 
    Tremor with an amplitude < 5cm 
    Tremor with an amplitude > 5cm 
    Unable to perform 5 pointing movements 
 
 
Fast alternating hand movements: 
 
Right  Left 
    Normal, no irregularities (performs < 10s) 
    Slightly irregular (performs < 10s) 
    Clearly irregular, single movements difficult to distinguish or relevant 
    interruptions, but performs < 10s 
    Very irregular, single movements difficult to distinguish or relevant 
    interruptions, performs > 10s 
    Unable to complete 10 cycles 
 
 
Heel-shin slide: 
 
Right  Left 
    Normal 
    Slightly abnormal, contact to shin maintained 
    Clearly abnormal, goes off shin up to 3 times during 3 cycles 
    Severely abnormal, goes off shin 4 or more times during 3 cycles 
    Unable to perform the task 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
EFACTS  Pseudonym _____-_____-_____ 
SCAFI  Baseline        Follow-up  
SCAFI  
(Spinocerebellar Ataxia Functional Index) 
 
PLEASE READ THE SOPs of the timed walking test, 9-hole peg test and 
PATA rate test! 
 
Handedness 
Specify dominant hand:   Dominant LEFT, non-dominant right 
     Dominant RIGHT, non-dominant left 
 
 
Timed walking test: 8m (25-foot) walk  
8m walking test performed?  yes  no 
 
If test has been performed 
Assistive device:  none 
 one cane/crutch 
   two canes/crutches 
   wheeled walker 
   orthesis 
 
Did situations arise that necessitated repetition of a trial? ________________________________________ 
Other factors that might have affected performance? ____________________________________________ 
 
Times are only given for 2 successfully completed trials: 
 
    Trial 1: ___________ seconds (round to .1 second) 
 
    Trial 2: ___________ seconds (round to .1 second) 
 
 
Timed dexterity test: 9-hole peg test (9-HPT) 
9-hole peg test performed?  yes  no 
 
If test has been performed 
Did situations arise that necessitated repetition of a trial? ________________________________________ 
Other factors that might have affected performance? ____________________________________________ 
 
Dominant hand:  
Trial 1: ___________ seconds (round to .1 second) 
 
Trial 2: ___________ seconds (round to .1 second) 
 
Non-dominant hand:  
Trial 1: _____________ seconds (round to .1 second) 
 
Trial 2: _____________ seconds (round to .1 second) 
 
 
Timed speech task: PATA rate 
PATA rate test performed?  yes  no 
 
If test has been performed 
Did situations arise that necessitated repetition of a trial? ________________________________________ 
Other factors that might have affected performance? ____________________________________________ 
 
Counts are only given for 2 successfully completed trials: 
    Trial 1: _____________ times 
 
    Trial 2: _____________ times 
 
EFACTS  Pseudonym _____-_____-_____ 
CCFS  Baseline        Follow-up  
CCFS 
(Composite Cerebellar Functional Severity Score) 
 
PLEASE READ THE SOPs of the 9-hole peg test and the click test! 
 
 
Age:  _________ years 
 
 
Has test been performed? yes  no 
 
 
  If test has been performed 
 
  Dominant hand:  left   right 
 
  9-hole pegboard test: 
    Timing Dominant hand: ___________ seconds 
 
  Click test:  
    Timing Dominant hand: ___________ seconds 
 
 
Factors that might have affected performance: 
 
 
_______________________________________________________________________________________ 
 
 
EFACTS  Pseudonym _____-_____-_____ 
EQ-5D  Baseline        Follow-up  
EQ-5D 
 
Health 
Mobility:   I have no problems in walking about 
    I have some problems in walking about 
    I am confined to bed 
 
Self-care:   I have no problems with self-care 
    I have some problems washing or dressing myself 
    I am unable to wash or dress myself 
 
Usual activities:   I have no problems with performing my usual activities 
(e.g. work, study, housework,  I have some problems with performing my usual activities 
family or leisure activities)  I am unable to perform my usual activities 
 
Pain/Discomfort:  I have no pain or discomfort 
    I have moderate pain or discomfort 
    I have extreme pain or discomfort 
 
Anxiety/Depression:  I am not anxious or depressed 
    I am moderately anxious or depressed 
    I am extremely anxious or depressed 
 
Health State 
To help people say how good or bad a health state is, we have drawn a scale (rather like a thermometer) on which the best 
state you can imagine is marked 100 and the worst state you can imagine is marked 0.  
We would like you to indicate on this scale how good or bad your own health is today, in your opinion. Please do this by 
drawing a line from the box below to whichever point on the scale indicates how good or bad your health state is today. 
 
 
 
 
 
 
 
 
 
 
100 
Best imaginable 
health state 
 
Your own health state today 
 
0 
Worst imaginable 
health state 
 100 
EFACTS  Pseudonym _____-_____-_____ 
EQ-5D  Baseline        Follow-up  
 
Background 
 
Have you experienced serious illness? yes  no 
in you yourself       
in your family       
in caring for others      
 
What is your age in years? _________ 
 
Are you:   male  female 
 
Are you:   a current smoker  an ex-smoker  a never smoker 
 
Do you now, or did you  yes   no 
ever, work in health or     
social services? 
   If yes, 
   in what capacity? ____________________________________________________ 
 
Which of the following  in employment or self employment  
best describes your   retired 
main activity?   housework 
    student 
    seeking work 
    other 
   If other, please specify: _______________________________________________ 
 
Did your education   yes   no 
continue after the 
minimum school 
leaving age? 
 
Do you have a Degree  yes   no 
or equivalent professional  
qualification? 
 
If you know your postcode, would you please write it here: ___________________ 
Structured Neurological Examination (SNE)
Name
Date
Cranial Nerves Right Left Comments Grading
Pupils Light reaction
Normal/                  
Abnormal
Normal/                  
Abnormal
0 = normal ; 1 = abnormal 
(specify in free text)
RAPD
No  /  Yes No  /  Yes 0 = no ; 1 = yes
Snellen acuity
6 / 6 / Give value from 6m chart
Spectacles for Snellen
No  /  Yes No  /  Yes 0 = no ; 1 = yes
Fields Fields
Normal/                  
Abnormal
Normal/                  
Abnormal
Record nature of defect
Eye lids Ptosis
No  /  Yes No  /  Yes 0 =no ; 1 = yes
Eye mvts Ophthalmoparesis
No  /  Yes No  /  Yes 0 = no ; 1 = yes
Nature of paresis
1  2  3  4  5    n/a 1  2  3  4  5    n/a
1 = CN3 ; 2 = CN4 ; 3 = CN6 ; 4 = 
complex ; 5 = other
Pursuits, saccades, etc
See INAS
Trigeminal n. Facial sensation
Normal/                  
Abnormal
Normal/                  
Abnormal
0 = normal ; 1 = abnormal 
(specify in free text)
Mastication
Normal/                  
Abnormal
Normal/                  
Abnormal
0 = normal ; 1 = abnormal 
(specify in free text)
Facial n. Facial palsy
Normal/                  
Abnormal
Normal/                  
Abnormal
1 = UMN ; 2 = LMN ; 3 = other 
(specify in free text)
Vestibulococl. Hearing
Normal/                  
Abnormal
Normal/                  
Abnormal
0 = normal ; 1 = abnormal 
(specify in free text)
Palate Palatal movement
Normal/                  
Abnormal
Normal/                  
Abnormal
0 = normal ; 1 = abnormal 
(specify in free text)
Speech
As per SARA
Spinal acc. N. SCM
/ 5 / 5 MRC grade
Trapezii
/ 5 / 5 MRC grade
Tongue Atrophy
none / mild      
mod / severe
none / mild      
mod / severe
Atrophy grade
Tone
- -  /  -  /  NAD             
+  /  ++
- -  /  -  /  NAD             
+  /  ++
Tone grade
Other
Gait
As per SARA
Stance
As per SARA
Sitting
As per SARA
Parkinsonism
0 = no ; 1 = yes (specify)
Notes :
No  /  Yes
Upper Limbs
Right Left Comments Grading
Atrophy
none / mild      
mod / severe
none / mild      
mod / severe
Atrophy grade
Tone
- -  /  -  / 0 / +  / ++  
R / RC / G /oth
- -  /  -  / 0 / +  /  ++       
R / RC / G /oth
Tone grade
Power Shoulder abduction / 5 / 5 MRC grade
Shoulder adduction / 5 / 5 MRC grade
Elbow flexion / 5 / 5 MRC grade
Elbow extension / 5 / 5 MRC grade
Wrist extension / 5 / 5 MRC grade
Wrist flexion / 5 / 5 MRC grade
Finger extension / 5 / 5 MRC grade
Finger flexion / 5 / 5 MRC grade
1st dorsal interosseous / 5 / 5 MRC grade
Abductor digiti minini / 5 / 5 MRC grade
Abductor pollicis brevis / 5 / 5 MRC grade
Reflexes BJ
-  /  (+)  /  +  /  ++  /  
+++  /  ++++
-  /  (+)  /  +  /  ++  /  
+++  /  ++++
Reflex grade
SJ
-  /  (+)  /  +  /  ++  /  
+++  /  ++++
-  /  (+)  /  +  /  ++  /  
+++  /  ++++
Reflex grade
TJ
-  /  (+)  /  +  /  ++  /  
+++  /  ++++
-  /  (+)  /  +  /  ++  /  
+++  /  ++++
Reflex grade
FJ
-  /  (+)  /  +  /  ++  /  
+++  /  ++++
-  /  (+)  /  +  /  ++  /  
+++  /  ++++
Reflex grade
HJ
-  /  (+)  /  +  /  ++  /  
+++  /  ++++
-  /  (+)  /  +  /  ++  /  
+++  /  ++++
Reflex grade
Coordination Finger-nose test
As per SARA
Finger chase test As per SARA
Alternating hand mvts As per SARA
Sensation PP
0   1   2   3                   
4   5   6   7
0   1   2   3                   
4   5   6   7
UL Sensation grade
JPS
0   1   2   3                   
4   5   6   7
0   1   2   3                   
4   5   6   7
UL Sensation grade
Vibration
0   1   2   3                   
4   5   6   7
0   1   2   3                   
4   5   6   7
UL Sensation grade
Grading Scales
Atrophy : 0 = None ; 1 = Mild atrophy ; 2 = Moderate atrophy ; 3 = Severe atrophy
Tone : 1 = Highly flaccid (--) ; 2 = Flaccid (-) ; 3 = Normal ; 4 = Spastic (+) ; 5 = Highly spastic (++); 6 = Rigid (R) ;
7 = Rigid with cogwheeling (RC) ; 8 Gegenhalten (G) ; 9 = Other (specify in free text)
MRC Power :  0/5 = 0  ;  1/5 = 1  ;  2/5 = 2  ;  3/5 = 3  ;  4-/5 = 4  ;  4/5 = 5  ;  4+/5 = 6  ;  5/5 = 7
Reflexes : Absent [-] = 0  ;  Present with reinforcement [(+)] = 1  ;  Hyporeflexic [+] = 2  ;  Normal [++] = 3  ; 
Brisk [+++] -= 4 ; Brisk with clonus [++++] = 5
Plantars : 1 = down  ;  2 = up  ;  3 = null  ;  4 = withdrawal
UL Sensation: 0 = Normal ; 1 = fingertips ; 2 = knuckles ; 3 = wrists ; 4 = elbows ; 5 = shoulders ; 6 = other (specify, eg mononeuropathy, patchy)
(Record level where sensation is first normal)
Notes :
Lower Limbs
Right Left Comments Grading
Atrophy
none / mild      
mod / severe
none / mild      
mod / severe
Atrophy grade
Tone
- -  /  -  / 0 / +  / ++  
R / RC / G /oth
- -  /  -  / 0 / +  /  ++       
R / RC / G /oth
Tone grade
Power Hip flexion / 5 / 5
MRC grade
Hip extension / 5 / 5 MRC grade
Hip abduction / 5 / 5 MRC grade
Hip adduction / 5 / 5 MRC grade
Knee extension / 5 / 5 MRC grade
Knee flexion / 5 / 5 MRC grade
Ankle extension / 5 / 5 MRC grade
Ankle flexion / 5 / 5 MRC grade
Ankle inversion / 5 / 5 MRC grade
Ankle eversion / 5 / 5 MRC grade
Toe extension / 5 / 5 MRC grade
Toe flexion / 5 / 5 MRC grade
Reflexes KJ
-  /  (+)  /  +  /  ++  /  
+++  /  ++++
-  /  (+)  /  +  /  ++  /  
+++  /  ++++
Reflex grade
AJ
-  /  (+)  /  +  /  ++  /  
+++  /  ++++
-  /  (+)  /  +  /  ++  /  
+++  /  ++++
Reflex grade
Plantars
up / down      
mute/withdraw
up / down      
mute/withdraw
Plantar grade
Coordination Heel-shin test
As per SARA
Sensation PP
0   1   2   3                   
4   5   6   7
0   1   2   3                   
4   5   6   7
LL Sensation grade
JPS
0   1   2   3                   
4   5   6   7
0   1   2   3                   
4   5   6   7
LL Sensation grade
Vibration
0   1   2   3                   
4   5   6   7
0   1   2   3                   
4   5   6   7 LL Sensation grade
Pes cavus -    (+)    +    ++ -    (+)    +    ++
Talipes equinus -    (+)    +    ++ -    (+)    +    ++
Talipes varus -    (+)    +    ++ -    (+)    +    ++
Cold feet
Colour change?
Grading Scales
Atrophy : 0 = None ; 1 = Mild atrophy ; 2 = Moderate atrophy ; 3 = Severe atrophy
Tone : 1 = Highly flaccid (--) ; 2 = Flaccid (-) ; 3 = Normal ; 4 = Spastic (+) ; 5 = Highly spastic (++); 6 = Rigid (R) ;
7 = Rigid with cogwheeling (RC) ; 8 Gegenhalten (G) ; 9 = Other (specify in free text)
MRC Power :  0/5 = 0  ;  1/5 = 1  ;  2/5 = 2  ;  3/5 = 3  ;  4-/5 = 4  ;  4/5 = 5  ;  4+/5 = 6  ;  5/5 = 7
Reflexes : Absent [-] = 0  ;  Present with reinforcement [(+)] = 1  ;  Hyporeflexic [+] = 2  ;  Normal [++] = 3  ; 
Brisk [+++] -= 4 ; Brisk with clonus [++++] = 5
Plantars : 1 = down  ;  2 = up  ;  3 = mute  ;  4 = withdrawal
LL Sensation: 0 = Normal ; 1 = toes ; 2 = ankles ; 3 = knees ; 4 = hips ; 5 = lower costal margin ; 6 = sternum ; 7 = other (specify)
(Record level where sensation is first normal)
white / red / blue / purple / mottled
Yes / no
Rater: ____________________________date: ______________patient:_______________________ 
 1 
Scale for the assessment and rating of ataxia (SARA) 
 
1) Gait 
Proband is asked (1) to walk at a safe distance parallel to 
a wall including a half-turn (turn around to face the 
opposite direction of gait) and (2) to walk in tandem 
(heels to toes) without support.  
 
 
 
0 Normal, no difficulties in walking, turning and  
       walking tandem (up to one misstep allowed) 
   1     Slight difficulties, only visible when walking 10  
          consecutive steps in tandem 
   2     Clearly abnormal, tandem walking >10 steps not      
          possible 
   3     Considerable staggering, difficulties in half-turn, but  
          without support 
   4    Marked staggering, intermittent support of the wall  
          required 
   5     Severe staggering, permanent support of one stick or  
          light support by one arm required 
6 Walking > 10 m only with strong support (two  
        special sticks or stroller or accompanying person)  
7 Walking < 10 m only with strong support (two  
        special sticks or stroller or accompanying person)  
   8     Unable to walk, even supported 
2) Stance 
Proband is asked to stand (1) in natural position, (2) with 
feet together in parallel (big toes touching each other) and 
(3) in tandem (both feet on one line, no space between 
heel and toe). Proband does not wear shoes, eyes are 
open. For each condition, three trials are allowed. Best 
trial is rated. 
 
   0     Normal, able to stand in tandem for > 10 s 
   1     Able to stand with feet together without sway, but  
          not in tandem for > 10s 
   2     Able to stand with feet together for > 10 s, but only  
         with sway 
   3     Able to stand for > 10 s without support in natural  
         position, but not with feet together 
   4     Able to stand for >10 s in natural position only with  
          intermittent support 
   5     Able to stand >10 s in natural position only with  
         constant support of one arm  
   6     Unable to stand for >10 s even with constant support  
          of one arm 
 
  Score    Score  
3) Sitting 
Proband is asked to sit on an examination bed without 
support of feet, eyes open and arms outstretched to the 
front. 
 
   0     Normal, no difficulties sitting >10 sec 
   1     Slight difficulties, intermittent sway 
2 Constant sway, but able to sit > 10 s without support 
   3     Able to sit for > 10 s only with intermittent support 
   4     Unable to sit for >10 s without continuous support 
 
4) Speech disturbance 
Speech is assessed during normal conversation. 
 
 
 
   0     Normal 
   1     Suggestion of speech disturbance 
   2     Impaired speech, but easy to understand 
   3     Occasional words difficult to understand 
   4     Many words difficult to understand 
   5     Only single words understandable 
   6     Speech unintelligible / anarthria 
  Score     Score  
Rater: ____________________________date: ______________patient:_______________________ 
 2 
 
5) Finger chase  
Rated separately for each side 
Proband sits comfortably. If necessary, support of feet 
and trunk is allowed. Examiner sits in front of proband 
and performs 5 consecutive sudden and fast pointing 
movements in unpredictable directions in a frontal plane, 
at about 50 % of proband´s reach. Movements have an 
amplitude of 30 cm and a frequency of 1 movement 
every 2 s. Proband is asked to follow the movements 
with his index finger, as fast and precisely as possible. 
Average performance of last 3 movements is rated.  
 
   0     No dysmetria  
   1     Dysmetria, under/ overshooting target <5 cm 
   2     Dysmetria, under/ overshooting target < 15 cm  
   3     Dysmetria, under/ overshooting target > 15 cm 
   4     Unable to perform 5 pointing movements 
 
6) Nose-finger test  
Rated separately for each side 
Proband sits comfortably. If necessary, support of feet 
and trunk is allowed. Proband is asked to point repeatedly 
with his index finger from his nose to examiner’s finger 
which is in front of the proband at about 90 % of 
proband’s reach. Movements are performed at moderate 
speed. Average performance of movements is rated 
according to the amplitude of the kinetic tremor.  
 
 
 
   0     No tremor  
   1     Tremor with an amplitude < 2 cm 
   2     Tremor with an amplitude < 5 cm  
   3     Tremor with an amplitude > 5 cm  
   4     Unable to perform 5 pointing movements  
Score Right Left Score Right Left 
mean of both sides (R+L)/2  mean of both sides (R+L)/2  
7) Fast alternating hand movements  
Rated separately for each side  
Proband sits comfortably. If necessary, support of feet 
and trunk is allowed. Proband is asked to perform 10 
cycles of repetitive alternation of pro- and supinations of 
the hand on his/her thigh as fast and as precise as 
possible. Movement is demonstrated by examiner at a 
speed of approx. 10 cycles within 7 s. Exact times for 
movement execution have to be taken. 
 
   0     Normal, no irregularities (performs <10s) 
   1     Slightly irregular (performs <10s) 
   2     Clearly irregular, single movements difficult  
          to distinguish or relevant interruptions, but   
          performs <10s 
   3    Very irregular, single movements difficult  
          to distinguish or relevant interruptions,  
          performs >10s 
   4     Unable to complete 10 cycles 
  
8) Heel-shin slide  
Rated separately for each side 
Proband lies on examination bed, without sight of his 
legs. Proband is asked to lift one leg, point with the heel 
to the opposite knee, slide down along the shin to the 
ankle, and lay the leg back on the examination bed. The 
task is performed 3 times. Slide-down movements should 
be performed within 1 s. If proband slides down without 
contact to shin in all three trials, rate 4.  
 
   0     Normal 
   1     Slightly abnormal, contact to shin maintained  
2 Clearly abnormal, goes off shin up to 3 times   
       during 3 cycles 
3 Severely abnormal, goes off shin 4 or more times  
       during 3 cycles 
   4     Unable to perform the task 
 
      Score Right Left   Score Right Left 
  mean of both sides (R+L)/2    mean of both sides (R+L) / 2  
SOPs Scale for the assessment and rating of ataxia (SARA) 
 
Gait:  
Proband is asked  
1) to walk at a safe distance parallel to a wall including a half-turn (turn around to face 
the opposite direction of gait) and 
2) to walk in tandem (heels to toes) without support 
 
Stance: 
Proband is asked to stand 
1) in natural position 
2) with feet together in parallel (big toes touching each other) and 
3) in tandem (both feet on one line, no space between heel and toe). Proband does not 
wear shoes, eyes are open. For each condition, three trials are allowed. Best trial is 
rated. 
 
Sitting: 
Proband is asked to sit on an examination bed without support of feet, eyes open and arms 
outstretched to the front. 
 
Speech: 
Speech is assessed during normal conversation. 
 
Finger chase: 
Rated separately for each side.  
Proband sits comfortably. If necessary, support of feet and trunk is allowed. Examiner sits in 
front of proband and performs 5 consecutive sudden and fast pointing movements in 
unpredictable directions in a frontal plane, at about 50% of proband’s reach. Movements have 
an amplitude of 30cm and a frequency of 1 movement every 2s. Proband is asked to follow 
the movements with his index finger, as fast and precisely as possible. Average performance 
of last 3 movements is rated. 
 
Nose finger test: 
Rated separately for each side.  
Proband sits comfortably. If necessary, support of feet and trunk is allowed. Proband is asked 
to point repeatedly with his index finger from his nose to examiner’s finger which is in front 
of the proband at about 90% of proband’s reach. Movements are performed at moderate 
speed. Average performance of movements is rated according to the amplitude of the kinetic 
tremor. 
 
Fast alternating hand movements: 
Rated separately for each side. 
Proband sits comfortably. If necessary support of feet and trunk is allowed. Proband is asked 
to perform 10 cycles of repetitive alternation of pro- and supinations of the hand on his/her 
thigh as fast and as precisely as possible. Movement is demonstrated by examiner at a speed 
of approximately 10 cycles within 7s. Exact times for movement execution have to be taken. 
 
 
 
 
 
Heel-shin slide: 
Rated separately for each side. 
Proband lies on examination bed, without sight of his legs. Proband is asked to lift one leg, 
point with the heel to the opposite knee, slide down along the shin to the ankle, and lay the leg 
back on the examination bed. The task if performed 3 times. Slide-down movements should 
be performed within 1s. If proband slides down without contact to shin in all three trials, rate 
4.  
 
 
 
 
 
  
From Jacobi H et al (2013) Cerebellum, 12, 418-428 
  
 
ACTIVITIES OF DAILY LIVING QUESTIONNAIRE 
From FRIEDREICH’S ATAXIA RATING SCALE (FARS) 
Subramony SH et al. (2005) Neurology, 64, 1261-1262. 
 
1. Speech                                              
      
 0   -  Normal 
 1 - Mildly affected.  No difficulty being understood. 
 2 - Moderately affected.  Sometimes asked to repeat statements. 
 3 - Severely affected.  Frequently asked to repeat statements. 
 4 - Unintelligible most of the time. 
 
 
2. Swallowing 
  
 0 - Normal. 
 1 - Rare choking (< once a month). 
 2 - Frequent choking (< once a week, > once a month). 
 3 - Requires modified food or chokes multiple times a week. Or patient avoids  
  certain foods.  
 4 - Requires NG tube or gastrostomy feedings. 
 
 
3. Cutting Food and Handling Utensils 
   
 0 -  Normal. 
 1 -  Somewhat slow and clumsy, but no help needed. 
 2 -  Clumsy and slow, but can cut most foods with some help needed. Or needs assistance 
         when in a hurry. 
 3 -  Food must be cut by someone, but can still feed self slowly. 
 4 -  Needs to be fed. 
 
 
4. Dressing 
 
 0  -  Normal. 
 1  -  Somewhat slow, but no help needed. 
 2  -  Occasional assistance with buttoning, getting arms in sleeves, etc. or has to 
       modify activity in some way (e.g. Having to sit to get dressed; use velcro for 
        shoes, stop wearing ties, etc.). 
 3  -  Considerable help required, but can do some things alone. 
 4  -  Helpless. 
 
 
5. Personal Hygiene         
 
  0 -  Normal.         
  1 -  Somewhat slow, but no help needed. 
  2 -  Very slow hygienic care or has need for devices such as special grab bars, tub 
   bench, shower chair, etc. 
  3 -  Requires personal help with washing, brushing teeth, combing hair or using toilet. 
  4 -  Fully dependent 
  
 
 
6. Falling (assistive device = score 3) 
 
 0 -  Normal. 
 1 -  Rare falling (< once a month). 
 2 -  Occasional falls (once a week to once a month). 
 3 -  Falls multiple times a week or requires device to prevent falls. 
 4 -  Unable to stand or walk. 
 
 
7. Walking (assistive device = score 3) 
            
 0 -  Normal. 
 1 -  Mild difficulty, perception of imbalance. 
 2 -  Moderate difficulty, but requires little or no assistance. 
 3 -  Severe disturbance of walking, requires assistance or walking aids. 
 4 -  Cannot walk at all even with assistance (wheelchair bound). 
 
 
8. Quality of Sitting Position 
            
 0 -  Normal. 
 1 -  Slight imbalance of the trunk, but needs no back support. 
 2 -  Unable to sit without back support. 
 3 -  Can sit only with extensive support (Geriatric chair, posy, etc.). 
 4 -  Unable to sit. 
 
 
9. Bladder Function (if using drugs for bladder, automatic score of 3) 
           
 0 -  Normal. 
 1 -  Mild urinary hesitance, urgency or retention (< once a month). 
 2 -  Moderate hesitance, urgency, rare retention/incontinence  (> once a month, 
       but < once a week). 
 3 -  Frequent urinary incontinence (> once a week). 
 4 -  Loss of bladder function requiring intermittent catheterization/indwelling  
  catheter. 
 
 
 
 
    
 
   TOTAL ACTIVITIES OF DAILY LIVING SCORE:               
SCA Functional Index Instruction Manual 
General rules of application: 
• The SCAFI investigator may be a clinical investigator or technician, if training is 
provided. 
• The SCAFI should be administered close to the beginning of the study visit to 
obtain optimal results, definitely before any other motor testing (e.g. SARA 
rating) is performed. 
• The SCAFI components should be assessed in the order given below without 
major pauses (< 5 min) between the single trials. For discontinuation of a single 
component, follow the discontinue rules.  
• Instructions given to the proband should follow standardized procedures as 
indicated below. Practice trials are limited to those stated in the EFACTS 
instructions.  
• Efforts should be made to keep distractions during testing to a minimum 
(designated area for timed walk, separate room with only proband and 
investigator present for peg test and speech, phones turned off). 
• Discourage the proband from talking throughout the 8m-walk test and 9-hole 
peg test. 
It is important for data analysis to distinguish, if proband was unable to perform 
due to physical limitation or if a single component was not performed/rated due to 
other reason (time constraints, refusal by proband, no staff). 
Any deviation from standard instruction due to proband’s or examiner error or 
external interferences should be noted on the record form.  
The stopwatch used should be counterchecked for accuracy with a different reliable 
stopwatch before the first SCAFI assessment.  
Timed walking test: 8m walk (8MW)  
Equipment: 
• clearly marked 8 m line in designated unobstructed area to minimize external 
interference. 
• stopwatch 
• assistive device for walking, if needed by proband 
Instruction: 
The proband is directed to one end of the 8 m line and asked to walk the 8 m 
distance to the other end as quickly as possible but safely (Trial 1). Examiner walks 
along with the proband. Exact time is taken, recorded and stopwatch reset. The task 
is immediately administered again by having the proband walk back the same 
distance (Trial 2). Exact time is taken (excluding time for turning). The test is 
performed from standing start with both feet behind the start line (assistive device 
may be ahead of startline), but without stopping at the finish line. Timing begins 
when lead foot passes the starting line and stops when lead foot passes the finish 
line. Walk time is reported to within 0.1 second, rounded as needed. Maximal rest 
period between both trials is 5 minutes.  
Probands may use assistive devices, usually their customary device. For probands 
with significant gait impairment, the investigator should have the proband use a 
wheeled walker, even if this is not the customary device (decision on assistive device 
to be made by neurologist). In general, non-wheeled walkers should not be used. 
Assistance of another person or using the wall as support is not allowed. If such 
attempts are made more than twice, repeat the trial or reevaluate proband for use of 
assistive device. The same device should be used at follow-up if possible. 
Discontinue rules: 
1. if proband cannot complete a trial in 3 minutes. 
2. if proband cannot complete trial 2 of the timed walk after max. 5 –min rest 
period after trial 1, discontinue 8m-walk.  
Timsed dexterity test: 9-hole peg test (9HPT) 
Equipment: 
• stopwatch  
• solid table (not rolling bedside table) 
• Rolyan 9-hole peg test apparatus(plastic one-piece model)  
• (exactly) nine pegs in the peg container of the 9-hole peg board 
• extra pegs to replace fallen pegs in examiner’s hand 
• adhesive material to anchor the apparatus on the table, e.g. DycemTM obtained 
by suppliers of occupational therapy materials. 
 
Instruction: 
The pegboard is placed and secured on the table directly in front of the proband 
with the mould (peg container) in front of the hand that is going to be tested (i.e. to 
the right side, if right hand is tested). The dominant hand is tested first for two 
consecutive trials, immediately followed by two consecutive trials of the non-
dominant hand. Handedness here refers to the hand that is used or has been used 
for writing the majority of time.  
The following instruction is given to the proband:  
“On this test, I want you to pick up the pegs one at a time, using one hand only, and 
put them into the holes as quickly as you can in any order until all the holes are 
filled. Then, without pausing, remove the pegs one at a time and return them to the 
container as quickly as you can. We’ll have you do this two times with each hand. 
We’ll start with your (dominant) hand. You can hold the peg board steady with your 
(non-dominant) hand. If a peg falls onto the table, please retrieve it and continue 
with the task. If a peg falls on the floor, keep working and I will retrieve it for you. 
See how fast you can put all of the pegs in and take them out again.” 
Timing begins when proband touches the first peg and stops when the last peg is 
removed and hits the container. Time is reported to within 0.1 second, rounded as 
needed. After trial 1 of the dominant hand is completed, time is recorded and 
stopwatch reset. Then proband is asked to perform again with the same hand.  
If subject stops after having put all the pegs into the holes, examiner may prompt 
the subject (without interruption of timing) to continue directly with removing them 
one by one. If more than one is removed at a time, remind the proband to remove 
them one by one. Other communication throughout the test should be avoided and 
if proband starts talking she/he should be reminded not to talk.  
If pegs drop onto the table within proband’s arm reach, proband is to retrieve it. If it 
falls on the floor or onto the table beyond proband’s reach, examiner is to retrieve it 
and puts it back in the container. 
After trial 2 of the dominant hand, the pegboard is rotated 180° with the peg 
container towards the other hand and proband instructed as follows “Now I’d like 
you to switch and use your (non-dominant) hand. This time you may use your 
(dominant) hand to stabilize the peg board.”  
Two consecutive trials are performed with the non-dominant hand.  
No major pause (>5 min) between all four trials.  
Discontinue rule: 
1. if proband cannot complete one trial in 5 minutes (i.e. 300 seconds) with 
dominant hand, move on to the trials with non-dominant hand. 
2. if proband cannot complete one trial in 5 minutes (i.e. 300 seconds) with non-
dominant hand, discontinue 9-hole-peg test. 
Timed speech task: PATA rate  
Equipment:  
• stopwatch 
• tape recorder that can play at fast and slow speed. Recordings should be done at 
normal (2,4 cm/sec) speed, while counting is done by playing at slow speed.
 OR 
• standard PC equipped with microphone, using audio software to visualize 
vocalization (e.g. free download of www.audacity.sourceforge.net). In this case, 
time count is included in the software.  OR 
• standard PC and text software 
Instruction: 
The proband is asked to repeat “PATA” as quickly and distinctly as possible for 10 
seconds until told to stop. Say “go” and as soon as proband starts speaking, start 
timer and begin counting the number of PATA repeats. After 10 seconds, stop timer 
and stop counting.  
The test is performed two times without major pause (< 5min) inbetween. 
The count of PATA repeats usually needs a technical device and can be done by 
different means:  
1. record the test on a tape recorder and use playback at slower speed for counting 
the numbers of PATA between the “go” and “stop” signal. 
2. record the test on PC and count the numbers of PATA repeats within 10 seconds. 
Slow playback and time count is inherent in the software.  
3. press any key on the PC keyboard for each PATA repetition in any text software 
looking at the stopwatch. After 10 seconds, count the number of keystrings. 
4. paper and pencil: put a mark on paper for each PATA repetition. After 10 
seconds, count the number of marks. 
Discontinue rule:  
1. If PATA articulation is too difficult to distinguish for counting 
2. If proband cannot complete 10 seconds for two consecutive trials 
SOPs for Spinocerebellar Ataxia Functional Index (SCAFI) 
SCAFI (Schmitz-Hübsch, Neurology 2008) 
Components: 8 metre foot walk (8MW) + 9 hole peg board (9HPT) + PATA rate 
8 metre foot walk (8MW) is defined at the time needed to walk 8m with any device 
but without help of another person or wall ´as quickly as possible but safely´. The 
time is measured from standing start with feet behind the start line (whereas 
assistive device is allowed ahead of start line). The 8MW test has to be repeated 
resulting in two values. Stop criterion is 180 s. If the test is not performed, please 
indicate the reason as ´patient unable to perform the test due to physical limitation 
(unabke to perform) or ´other´(other reason) 
For the 9 hole peg board (9HPT), the patient is asked to complete a 9-hole peg 
board and to remove all pegs for each hand separately (dominant (D) and 
nondominant (ND) hand) with the writing hand as the dominant hand. Stop criterion 
is 300 s. The 9HPT test has to be repeated resulting in two values for each hand. If 
the test is not performed, please indicate the reason as ´patient unable to perform 
the test due to physical limitation (unable to perform) or ´other´(other reason). 
IMPORTANT: the 9HPT design differs between SCAFI and CCFS. 
For assessing the PATA rate, the proband is asked to repeat the syllable ´PATA´ 
within 10 seconds. The PATA rate test has to be repeated resulting in two values. If 
the test is not performed, please indicate the reason as ´patient unable to perform 
the test due to physical limitation (unable to perform)´ or ´other´(other reason). 
 
INTRODUCTION 
Verbal fluency requires the production of words within a time limit and under a specific  
constraint, e.g., words beginning with the letter "F" (Letter Fluency). This is an executive  
function task where strategies such as clustering can be implemented in order to  
facilitate word production. Our Letter Fluency test includes two two-minute trials using  
the letters F and A.  
 
LETTER FLUENCY ADMINISTRATION 
(1) Begin by reading the following instructions to the participant. 
I am going to say a letter of the alphabet, and I want you to say as quickly as you  
can, all the words you can think of which begin with that letter. You may say any  
words at all, except proper names such as the names of people or places, so you  
could not say 'Robert' or' Rhode Island.' Also, do not use the same word again,  
with a different ending, such as 'eat' and 'eating.' For example, if I say 'B,' you  
could say 'boy,' 'book,' 'blue,' and so on. Can you think of another word beginning  
with the letter 'B'?"  
   
Wait until the participant gives a word. If he succeeds, indicate that he is performing  
correctly and start with testing. - If the participant gives an inappropriate word, correct  
him, repeat the instructions, and ask him to try again.    
   
(2) Before administering the test, read the following instructions to the participant. 
"That's fine, now I am going to give you another letter and again you say all the  
words beginning with that letter that you can think of. Remember, no names of  
people or places, just ordinary words. Also, if you draw a blank, I want you to keep  
trying until the time limit is up. You will have two minutes for each letter." 
 
Get the stopwatch ready. Legibly record all responses. The participant is encouraged to  
go as fast as he can. If there are long pauses, or if he says "that's it," it's OK to encourage  
the participant with comments like, "Any other words that you can 
think of?," or, "You have some time left; see if you can think of a few more words." 
 
In general, you should never interrupt in the middle of a trial except to give encouragement.  
You may interrupt the participant if it is obvious that he has misunderstood the instructions  
(for example, if he begins the task by using the wrong letter). Also, if the participant 
responds  
with two proper names, remind him that proper names are not allowed after the second  
proper name is given. 
 If the participant gives a word that you may not have heard correctly or that you are not  
familiar with, spell the word as best you can with what you heard and mark the word with  
a question mark next to it. After the trial is over, you may ask the participant to repeat  
the word or to spell it for you. If you are unsure if a response is a real word, assume it is  
until the word can be looked up in a dictionary. 
 
It is possible that the participant may give responses at a rate too fast to legibly record all  
responses. If this occurs, write enough of the word (e.g., the first three to five letters)  
that will allow you to know what that word is when you go back to it later. Finish recording  
any unfinished words when you have time either during pauses within the trial or after  
the trial.  
   
Any word that the participant at least starts to say before the time is up is to be recorded  
as a response. If you say, "Stop," while the participant is saying a word, the participant  
may finish the word after the stopping point. 
 
When the participant is ready to begin, say,  
"Go as fast as you can. The first letter is 'F.' Ready? Go." 
Start the stopwatch immediately after you say "Go" for each letter.  
Allow 2 minutes seconds for each letter. After 2 minutes, say, "Stop." 
 
At the start of the second trial, say, "The next letter is 'A.' Go."  
After 2 minutes, say, "Stop." 
